0001412408-23-000023.txt : 20230323 0001412408-23-000023.hdr.sgml : 20230323 20230323160307 ACCESSION NUMBER: 0001412408-23-000023 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20230131 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phreesia, Inc. CENTRAL INDEX KEY: 0001412408 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38977 FILM NUMBER: 23756146 BUSINESS ADDRESS: STREET 1: 1521 CONCORD PIKE STREET 2: SUITE 301 PMB 221 CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 888-654-7473 MAIL ADDRESS: STREET 1: 1521 CONCORD PIKE STREET 2: SUITE 301 PMB 221 CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Phreesia Inc DATE OF NAME CHANGE: 20070914 10-K 1 phr-20230131.htm 10-K phr-20230131
false00014124082023FYP1DP2DP1DP2DP3YP3YP2DP3YP2Yhttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrenthttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrenthttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations00014124082022-02-012023-01-3100014124082022-07-31iso4217:USD00014124082023-03-17xbrli:shares00014124082023-01-3100014124082022-01-31iso4217:USDxbrli:shares0001412408phr:SubscriptionAndServicesMember2022-02-012023-01-310001412408phr:SubscriptionAndServicesMember2021-02-012022-01-310001412408phr:SubscriptionAndServicesMember2020-02-012021-01-310001412408phr:PaymentProcessingFeesMember2022-02-012023-01-310001412408phr:PaymentProcessingFeesMember2021-02-012022-01-310001412408phr:PaymentProcessingFeesMember2020-02-012021-01-310001412408phr:NetworkSolutionsMember2022-02-012023-01-310001412408phr:NetworkSolutionsMember2021-02-012022-01-310001412408phr:NetworkSolutionsMember2020-02-012021-01-3100014124082021-02-012022-01-3100014124082020-02-012021-01-310001412408us-gaap:CommonStockMember2020-01-310001412408us-gaap:AdditionalPaidInCapitalMember2020-01-310001412408us-gaap:RetainedEarningsMember2020-01-310001412408us-gaap:TreasuryStockMember2020-01-3100014124082020-01-310001412408us-gaap:RetainedEarningsMember2020-02-012021-01-310001412408us-gaap:AdditionalPaidInCapitalMember2020-02-012021-01-310001412408us-gaap:CommonStockMember2020-02-012021-01-310001412408us-gaap:TreasuryStockMember2020-02-012021-01-310001412408us-gaap:CommonStockMember2021-01-310001412408us-gaap:AdditionalPaidInCapitalMember2021-01-310001412408us-gaap:RetainedEarningsMember2021-01-310001412408us-gaap:TreasuryStockMember2021-01-3100014124082021-01-310001412408us-gaap:RetainedEarningsMember2021-02-012022-01-310001412408us-gaap:AdditionalPaidInCapitalMember2021-02-012022-01-310001412408us-gaap:CommonStockMember2021-02-012022-01-310001412408us-gaap:TreasuryStockMember2021-02-012022-01-310001412408us-gaap:CommonStockMember2022-01-310001412408us-gaap:AdditionalPaidInCapitalMember2022-01-310001412408us-gaap:RetainedEarningsMember2022-01-310001412408us-gaap:TreasuryStockMember2022-01-310001412408us-gaap:RetainedEarningsMember2022-02-012023-01-310001412408us-gaap:AdditionalPaidInCapitalMember2022-02-012023-01-310001412408us-gaap:CommonStockMember2022-02-012023-01-310001412408us-gaap:TreasuryStockMember2022-02-012023-01-310001412408us-gaap:CommonStockMember2023-01-310001412408us-gaap:AdditionalPaidInCapitalMember2023-01-310001412408us-gaap:RetainedEarningsMember2023-01-310001412408us-gaap:TreasuryStockMember2023-01-310001412408us-gaap:SubsequentEventMemberphr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember2023-03-100001412408us-gaap:SubsequentEventMemberphr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-03-100001412408phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember2022-02-012023-01-310001412408srt:MinimumMember2023-01-310001412408srt:MaximumMember2023-01-310001412408srt:MinimumMember2022-02-012023-01-310001412408srt:MaximumMember2022-02-012023-01-31phr:processor0001412408phr:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-02-012023-01-31xbrli:pure0001412408phr:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-02-012022-01-310001412408srt:MinimumMemberus-gaap:ComputerSoftwareIntangibleAssetMember2022-02-012023-01-310001412408us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2022-02-012023-01-31phr:segment0001412408us-gaap:EmployeeStockMember2022-02-012023-01-310001412408phr:PhreesiaPadsAndArrivalsStationsMember2022-02-012023-01-310001412408phr:PhreesiaPadsAndArrivalsStationsMember2023-01-310001412408phr:PhreesiaPadsAndArrivalsStationsMember2022-01-310001412408us-gaap:ComputerEquipmentMember2022-02-012023-01-310001412408us-gaap:ComputerEquipmentMember2023-01-310001412408us-gaap:ComputerEquipmentMember2022-01-310001412408srt:MinimumMemberphr:ComputerSoftwareMember2022-02-012023-01-310001412408phr:ComputerSoftwareMembersrt:MaximumMember2022-02-012023-01-310001412408phr:ComputerSoftwareMember2023-01-310001412408phr:ComputerSoftwareMember2022-01-310001412408phr:HardwareDevelopmentMember2022-02-012023-01-310001412408phr:HardwareDevelopmentMember2023-01-310001412408phr:HardwareDevelopmentMember2022-01-310001412408us-gaap:FurnitureAndFixturesMember2022-02-012023-01-310001412408us-gaap:FurnitureAndFixturesMember2023-01-310001412408us-gaap:FurnitureAndFixturesMember2022-01-310001412408us-gaap:LeaseholdImprovementsMember2022-02-012023-01-310001412408us-gaap:LeaseholdImprovementsMember2023-01-310001412408us-gaap:LeaseholdImprovementsMember2022-01-310001412408us-gaap:TechnologyBasedIntangibleAssetsMember2022-02-012023-01-310001412408us-gaap:TechnologyBasedIntangibleAssetsMember2023-01-310001412408us-gaap:TechnologyBasedIntangibleAssetsMember2022-01-310001412408srt:MinimumMemberus-gaap:CustomerRelationshipsMember2022-02-012023-01-310001412408us-gaap:CustomerRelationshipsMembersrt:MaximumMember2022-02-012023-01-310001412408us-gaap:CustomerRelationshipsMember2023-01-310001412408us-gaap:CustomerRelationshipsMember2022-01-310001412408us-gaap:LicenseMember2022-02-012023-01-310001412408us-gaap:LicenseMember2023-01-310001412408us-gaap:LicenseMember2022-01-310001412408us-gaap:TechnologyBasedIntangibleAssetsMember2021-02-012022-01-310001412408us-gaap:CustomerRelationshipsMember2022-02-012023-01-310001412408us-gaap:CustomerRelationshipsMember2021-02-012022-01-310001412408us-gaap:LicenseMember2021-02-012022-01-310001412408phr:QueueDrMember2021-02-012022-01-310001412408phr:SubscriptionAndRelatedServicesMember2022-02-012023-01-310001412408phr:SubscriptionAndRelatedServicesMember2021-02-012022-01-310001412408phr:SubscriptionAndRelatedServicesMember2020-02-012021-01-310001412408phr:FinancingArrangementsMember2023-01-310001412408phr:FinancingArrangementsMember2022-01-310001412408phr:AccruedInterestAndPaymentsMember2023-01-310001412408phr:AccruedInterestAndPaymentsMember2022-01-310001412408phr:TermLoanMember2019-02-280001412408phr:TermLoanMember2020-02-012021-01-310001412408phr:SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-05-050001412408phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-03-270001412408phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-03-280001412408phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-01-310001412408us-gaap:PrimeRateMemberphr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-02-012023-01-310001412408phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-02-012023-01-310001412408phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-05-050001412408phr:SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-01-310001412408phr:SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-01-3100014124082019-07-220001412408phr:FollowOnOfferingMember2021-04-122021-04-120001412408phr:FollowOnOfferingMember2021-04-120001412408phr:TwoThousandEighteenStockOptionPlanMember2018-01-310001412408phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember2019-06-300001412408phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember2019-06-012019-06-300001412408us-gaap:EmployeeStockMemberphr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember2019-06-300001412408us-gaap:EmployeeStockMemberphr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember2023-01-310001412408us-gaap:EmployeeStockMemberphr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember2021-02-012022-01-31phr:offering_period0001412408us-gaap:EmployeeStockMember2021-02-012022-01-310001412408us-gaap:RestrictedStockUnitsRSUMember2022-02-012023-01-310001412408us-gaap:RestrictedStockUnitsRSUMember2021-02-012022-01-310001412408us-gaap:RestrictedStockUnitsRSUMember2020-02-012021-01-310001412408phr:LiabilityAwardsMember2022-02-012023-01-310001412408phr:LiabilityAwardsMember2021-02-012022-01-310001412408phr:LiabilityAwardsMember2020-02-012021-01-310001412408us-gaap:PerformanceSharesMember2022-02-012023-01-310001412408us-gaap:PerformanceSharesMember2021-02-012022-01-310001412408us-gaap:PerformanceSharesMember2020-02-012021-01-310001412408us-gaap:EmployeeStockOptionMember2022-02-012023-01-310001412408us-gaap:EmployeeStockOptionMember2021-02-012022-01-310001412408us-gaap:EmployeeStockOptionMember2020-02-012021-01-310001412408us-gaap:EmployeeStockMember2020-02-012021-01-310001412408us-gaap:AdditionalPaidInCapitalMember2022-02-012023-01-310001412408us-gaap:AdditionalPaidInCapitalMember2021-02-012022-01-310001412408us-gaap:AdditionalPaidInCapitalMember2020-02-012021-01-310001412408us-gaap:AccruedLiabilitiesMember2022-02-012023-01-310001412408us-gaap:AccruedLiabilitiesMember2021-02-012022-01-310001412408us-gaap:AccruedLiabilitiesMember2020-02-012021-01-310001412408us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockUnitsRSUMember2020-12-312020-12-310001412408us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-12-312020-12-310001412408us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-12-312020-12-310001412408phr:ShareBasedPaymentArrangementTrancheFourMemberus-gaap:RestrictedStockUnitsRSUMember2020-12-312020-12-310001412408us-gaap:RestrictedStockUnitsRSUMember2020-12-312020-12-310001412408us-gaap:RestrictedStockUnitsRSUMemberphr:EmployeesOtherThanNamedExecutiveOfficersMember2021-01-012021-01-010001412408us-gaap:RestrictedStockUnitsRSUMembersrt:ExecutiveOfficerMember2022-01-012022-12-310001412408us-gaap:RestrictedStockUnitsRSUMembersrt:ExecutiveOfficerMember2023-01-022023-01-020001412408us-gaap:RestrictedStockUnitsRSUMember2020-01-310001412408us-gaap:RestrictedStockUnitsRSUMember2021-01-310001412408us-gaap:RestrictedStockUnitsRSUMember2022-01-310001412408us-gaap:RestrictedStockUnitsRSUMember2023-01-310001412408phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2022-02-012023-01-310001412408us-gaap:ShareBasedCompensationAwardTrancheOneMemberphr:TwoThousandAndNineteenStockOptionAndIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-02-012023-01-310001412408phr:ShareBasedPaymentArrangementTrancheFourMemberphr:TwoThousandAndNineteenStockOptionAndIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-02-012023-01-310001412408us-gaap:ShareBasedCompensationAwardTrancheTwoMemberphr:TwoThousandAndNineteenStockOptionAndIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-02-012023-01-310001412408srt:MinimumMemberus-gaap:PerformanceSharesMember2022-02-012023-01-310001412408us-gaap:PerformanceSharesMembersrt:MaximumMember2022-02-012023-01-310001412408us-gaap:PerformanceSharesMembersrt:MaximumMember2021-02-012022-01-310001412408us-gaap:PerformanceSharesMembersrt:MaximumMember2020-02-012021-01-310001412408us-gaap:PerformanceSharesMember2023-01-310001412408us-gaap:PerformanceSharesMember2022-01-310001412408us-gaap:PerformanceSharesMember2021-01-310001412408us-gaap:PerformanceSharesMember2020-01-310001412408us-gaap:EmployeeStockMember2023-01-310001412408us-gaap:RestrictedStockUnitsRSUMemberphr:A2022ShareSettledBonusAwardProgramMember2022-02-012023-01-310001412408us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-310001412408us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-310001412408us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-310001412408us-gaap:FairValueMeasurementsRecurringMember2023-01-310001412408us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-01-310001412408us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-01-310001412408us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-01-310001412408us-gaap:FairValueMeasurementsRecurringMember2022-01-310001412408srt:MinimumMemberus-gaap:ComputerEquipmentMember2023-01-310001412408us-gaap:ComputerEquipmentMembersrt:MaximumMember2023-01-310001412408us-gaap:DomesticCountryMember2023-01-310001412408us-gaap:DomesticCountryMember2022-01-310001412408us-gaap:ForeignCountryMember2023-01-310001412408us-gaap:StockCompensationPlanMember2022-02-012023-01-310001412408us-gaap:StockCompensationPlanMember2021-02-012022-01-310001412408us-gaap:StockCompensationPlanMember2020-02-012021-01-310001412408us-gaap:EmployeeStockMember2022-02-012023-01-310001412408us-gaap:EmployeeStockMember2021-02-012022-01-310001412408us-gaap:EmployeeStockMember2020-02-012021-01-310001412408phr:AffiliateOfDirectorMemberphr:AdvertisementsWithPharmaceuticalCompanyMember2022-02-012023-01-310001412408phr:AffiliateOfDirectorMemberphr:AdvertisementsWithPharmaceuticalCompanyMember2021-02-012022-01-310001412408phr:AffiliateOfDirectorMemberphr:AdvertisementsWithPharmaceuticalCompanyMember2023-01-310001412408phr:AffiliateOfDirectorMemberphr:AdvertisementsWithPharmaceuticalCompanyMember2022-01-310001412408phr:AffiliateOfDirectorMemberphr:SoftwareAgreementMember2022-02-012023-01-310001412408phr:AffiliateOfDirectorMemberphr:SoftwareAgreementMember2021-02-012022-01-310001412408us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberphr:AffiliateOfDirectorMemberphr:SoftwareAgreementMember2023-01-310001412408us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberphr:AffiliateOfDirectorMemberphr:SoftwareAgreementMember2022-01-310001412408us-gaap:OtherAssetsMemberphr:AffiliateOfDirectorMemberphr:SoftwareAgreementMember2022-01-310001412408phr:RevenueFromAffiliateOfStockholderMembersrt:AffiliatedEntityMember2020-02-012021-01-310001412408phr:InsigniaHealthLLCMember2021-12-030001412408phr:InsigniaHealthLLCMember2021-12-032021-12-030001412408us-gaap:LicenseMemberphr:InsigniaHealthLLCMember2021-12-032021-12-030001412408us-gaap:LicenseMemberphr:InsigniaHealthLLCMember2021-12-030001412408phr:InsigniaHealthLLCMemberus-gaap:CustomerRelationshipsMember2021-12-032021-12-030001412408phr:InsigniaHealthLLCMemberus-gaap:CustomerRelationshipsMember2021-12-030001412408phr:InsigniaHealthLLCMember2021-01-082021-01-080001412408phr:InsigniaHealthLLCMember2021-02-012022-01-310001412408phr:QueueDrMember2021-01-080001412408phr:QueueDrMember2021-01-082021-01-080001412408phr:QueueDrMember2020-02-012021-01-310001412408phr:QueueDrMember2022-01-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended January 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _ to _

Commission File Number: 001-38977


PHREESIA, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware20-2275479
(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)
1521 Concord Pike, Suite 301 PMB 221
Wilmington, DE1
19803
(Address of Principal Executive Offices)(Zip Code)

(888) 654-7473
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, $0.01 par value per sharePHRThe New York Stock Exchange


Securities registered pursuant to Section 12(g) of the Act:
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer ☐Non-accelerated filer ☐Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes No

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the common stock held by non-affiliates of the registrant, based on the closing price of a share of common stock on July 31, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, as reported by the New York Stock Exchange on such date was approximately $1,157,351,642. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.

As of March 17, 2023, there were 53,355,050 shares of the registrant’s common stock, par value $0.01 per share, outstanding.

1 Phreesia, Inc. is a fully remote company and no longer maintains its principal executive office. The address listed here is the mailing address that we maintain. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and
Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices should
be directed to the email address set forth in our proxy materials and/or identified on our investor relations website.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement relating to its 2023 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.



1

Table of Contents

PART I.
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.
PART III.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV.
Item 15.
Item 16.
Signatures

2

Table of Contents
Summary of Material Risks Associated with our Business


Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks and uncertainties include, but are not limited to, the following:

We have grown rapidly in recent periods, and as a result, our expenses have continued to increase. If we fail to manage our growth effectively, our revenue may not increase and we may be unable to implement our business strategy.
We operate in a highly competitive industry, and if we are not able to compete effectively, including with the electronic health records ("EHR") and practice management ("PM") systems with which we integrate, our business and results of operations will be harmed.
We have experienced net losses in the past and we may not achieve profitability in the future.
Privacy concerns or security breaches relating to our SaaS-based technology platform (the "Phreesia Platform" or our "Platform") could result in economic loss, damage to our reputation, deterring users from using our products, and our exposure to legal penalties and liability.
Business or economic disruptions or global health concerns have harmed and may continue to harm our business and increase our costs and expenses.
We typically incur significant upfront costs in our client relationships, and if we are unable to develop or grow these relationships over time, we are unlikely to recover these costs and our operating results may suffer.
As a result of our variable sales and implementation cycles, we may be unable to recognize revenue to offset expenditures, which could result in fluctuations in our quarterly results of operations or otherwise harm our future operating results.
We depend on our senior management team and certain key employees, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.
We are subject to health care laws and data privacy and security laws and regulations governing our collection, use, disclosure, or storage of personally identifiable information, including protected health information and payment card data, which may impose restrictions on us and our operations, require us to change our business practices and put in place additional compliance mechanisms, and subject us to fines, penalties, lawsuits, adverse publicity, reputational harm, loss of customer trust or government enforcement actions if we are unable to fully comply with such laws.
We rely on our third-party contractors, vendors and partners, including some outside of the United States, to execute our business strategy. Replacing them could be difficult and disruptive to our business. If we are unsuccessful in forming or maintaining such relationships on terms favorable to us, our business may not succeed.

The summary risk factors described above should be read together with the text of the full risk factors below in the section titled "Risk Factors" and in the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the U.S. Securities and Exchange Commission (the "SEC"). If any such risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, prospects, financial condition and results of operations.

3

Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, including the sections entitled “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:
 
our future financial performance, including our revenue, cash flows, costs of revenue and operating expenses;
the rapidly evolving industry and the market for technology-enabled services in healthcare in the United States being relatively immature and unproven;
our reliance on a limited number of clients for a substantial portion of our revenue;
our anticipated growth and growth strategies and our ability to effectively manage that growth;
our ability to achieve and grow profitability;
the sufficiency of our cash, cash equivalents and investments to meet our liquidity needs;
our potential competition with our customers or partners;
our existing clients not renewing their existing contracts with us, renewing at lower fee levels or declining to purchase additional applications from us;
our failure to adequately maintain our direct sales force, impeding our growth;
our ability to recover the significant upfront costs in our customer relationships;
liability arising from our collection, use, disclosure, or storage of sensitive data collected from or about patients;
our reliance on third-party vendors, manufacturers and partners such as Rayden Design Studio Private Limited (“Rayden”) and DataArt Solutions, Inc. ("DataArt") to execute our business strategy;
consolidation in the healthcare industry resulting in loss of clients;
the uncertainty and ongoing flux of the regulatory and political framework;
our ability to determine the size of our target market;
the impact of pandemics or epidemics, market volatility, including the recent high inflationary environment, economic slowdowns and recessions, and other global financial, economic and political events on our business and our ability to attract, retain and cross-sell to healthcare services clients;
our ability to obtain, maintain and enforce intellectual property for our technology and products;
our reliance on third-party vendors, manufacturers and partners to execute our business strategy;
our inability to implement our solutions for clients resulting in loss of clients and reputation;
our dependency on our key personnel, and our ability to attract, hire, integrate, and retain key personnel, including as a result of being a fully remote company;
the possibility that we may become subject to future litigation;
our future indebtedness and contractual obligations;
4

Table of Contents
our expectations regarding trends in our key metrics and revenue from subscription fees from our healthcare services clients, payment processing fees and fees charged to our life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health;
our ability to realize the intended benefits of our acquisitions; and
other risks and uncertainties, including those listed under the caption “Risk Factors.”

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K. You should not rely upon forward-looking statements as predictions of future events. We have based our forward-looking statements primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including, without limitation, those described in the section titled “Risk Factors” in this Annual Report on Form 10-K.

Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. We cannot assure you that the results, events and circumstances reflected in these forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements contained in this Annual Report on Form 10-K speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this Annual Report on Form 10-K to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements.

This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.

NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, the terms “Phreesia,” “the Company,” “we,” “us,” and “our” in this Annual Report on Form 10-K refer to Phreesia, Inc.
5

Table of Contents
PART I
Item 1. Business
Overview
We are a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through our SaaS-based technology platform, which we refer to as the Phreesia Platform or our Platform, we offer healthcare services clients a robust suite of integrated solutions that manage patient access, registration and payments. Our Platform also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. In fiscal 2023, we facilitated patient visits in over 2,800 healthcare services clients across all 50 states. We define a patient visit as an individual, in-person or telehealth visit to a healthcare services provider, which may include multiple encounters by the same patient. Additionally, our Platform processed nearly $3.3 billion in patient payments in fiscal 2023, of which 80% were credit and debit card patient payment volume that we processed as a payment facilitator. Payment facilitator volume is a major driver of our payment processing revenue.

Patient intake is a complex and time-consuming process involving numerous tasks, including registration, insurance verification, patient questionnaires, patient-reported outcomes ("PROs"), payments and scheduling. Inefficiencies during the intake process often result in lower satisfaction for patients and healthcare services organizations, wasted time, missed revenue opportunities and diminished health outcomes. Phreesia’s mission is to create a better, more engaging healthcare experience. We have created an integrated and streamlined system that automates data capture and activates patients before, during and after their interaction with their healthcare services provider. As evidenced in industry survey reports from healthcare IT research firm KLAS, we have been recognized as a market leader based on our integration capabilities with healthcare services organizations, the broad adoption of our software solutions, our response to the COVID-19 pandemic and by overall client satisfaction.

The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments and post-appointment patient surveys. The Phreesia Platform securely collects and analyzes each patient’s information and provides engagement tools to efficiently guide each patient through their healthcare journey. We deploy our Platform across a range of modalities, including through patients’ mobile devices (Phreesia Mobile), through a web-based dashboard for healthcare services clients (Phreesia Dashboard) and through our self-service intake tablets (PhreesiaPads) and on-site kiosks (Arrivals Kiosks), all of which provide an individualized experience for each patient based on age, gender, appointment type and other clinical and demographic factors. Our solutions are highly customizable and scalable to any size healthcare service organization and can seamlessly integrate within a client’s workflows and leading Practice Management, or PM, and Electronic Health Record, or EHR, systems. Our Platform additionally allows for secure time-of-service and post-explanation of benefits integrated payments.

We serve an array of healthcare services clients of all sizes across over 25 specialties, ranging from single-specialty practices, including internal and family medicine, urology, dermatology, and orthopedics, to large, multi-specialty groups, and health systems as well as regional and national payers and other organizations that provide other types of healthcare-related services. Our network solutions revenue (as described below) is generated from clients in the pharmaceutical, biotechnology, and medical device industries, as well as payers, patient advocacy, public interest and other not-for-profit organizations seeking to activate, engage and educate patients about topics critical to their health.
Our Platform
The Phreesia Platform has evolved to offer our clients a comprehensive range of technology applications and modules that address the growing needs of the healthcare market by activating patients in their care.
Our access solution provides a comprehensive appointment scheduling system to provide clients with applications for online appointments, reminders and referral tracking and management.
Our registration solution automates patient self-registration via Phreesia Mobile—either before or at the time of the patient’s visit—or through the use of a purpose-built PhreesiaPad or Arrivals Kiosk for on-site check-in. The solution also includes the Phreesia Dashboard, which healthcare services organization staff use to monitor and manage the intake process. The solution also collects clinical intake and PRO data for more than 25
6

Table of Contents
specialties, enabling our clients to ask the right clinical questions of the appropriate patients at the right time and gather key data that aligns with their quality-reporting goals.
Our revenue cycle solution provides insurance-verification processes, point-of-sale payments applications, post-visit payment collection and flexible payment options, which help healthcare services clients maximize the timely collection of patient payments.
Our network connect solution provides a channel to our life sciences and payer clients that leverages our large and growing network of over 2,800 healthcare services clients. We deliver clinically relevant content to patients and health plan members who voluntarily opt in, on behalf of our life sciences and payer clients. We believe life sciences clients value our network connect solutions because they allow patients to have more informed conversations with their providers. We believe payer clients value our network connect solutions because they help them attract new members and engage and better understand their existing membership.

Our market opportunity
The Phreesia Platform serves a range of healthcare services clients, including single-specialty practices, large multi-specialty groups and health systems. Through our network connect solutions, we provide services to large and small pharmaceutical, medical device and biotechnology companies as well as payer organizations. We believe the current addressable market for our Platform and services is approximately $10.0 billion and is derived from: (1) the potential subscription and related services revenue generated from the approximately 1.5 million U.S.-based healthcare services organizations who take medical appointments in ambulatory care settings and healthcare service providers who work in hospital settings, (2) consumer-related transaction and payment processing fees, which are based on a percentage of payments that can be processed via the Phreesia Platform and address approximately $95.0 billion of annual out of pocket patient spend in ambulatory healthcare related professional services, (3) a portion of the $6.0 billion spent by life sciences companies on direct-to-consumer prescription drug marketing, and (4) a portion of the $1.0 billion spent by health plans on member acquisition and retention. We estimate that our target client universe in the ambulatory and hospital markets is approximately 50,000 unique healthcare services clients. As we develop new products and services on the Phreesia Platform, we expect our total addressable market to grow.

Our value proposition
We are focused on creating a better, more engaging healthcare experience for patients, healthcare services organizations, life sciences companies and payer organizations by activating patients in their care. We believe our solutions provide a unique value proposition that is differentiated from what is offered by the traditional healthcare system.
Value proposition for patients
Improved patient experience. Our Platform streamlines the patient intake process and provides consumer-centric options for check-in. We pre-populate information from prior visits, minimizing the frustration of repetitive questions during the intake process and streamlining the information for review by a clinician by the time the patient reaches the exam room. We also offer patients a convenient, flexible, secure intake experience that saves time and reduces the confusion and anxiety around payments. Patients are also able to save time by making their appointments using our technology.
Flexible payment options. Our Platform provides patients with flexibility and choice in how they pay for healthcare services. Patients are able to pay upfront or set up an automated payment plan that adheres to our healthcare services clients' financial policies. Patients can also choose to pay online on their healthcare services organization’s website or place a card on file. Our Platform also removes the need for difficult payment-related conversations with staff and ensures a level of personal privacy throughout the transaction.
Activation in care. By leveraging the power of self-service and providing individualized and flexible software solutions, we activate patients early in their healthcare journey and provide them with relevant information to further educate them so they can take an active role in their healthcare decisions.
Value proposition for healthcare services clients
Simplify operations and enhance staff efficiency. We enable healthcare services clients to streamline operations through automated patient intake and payments that are integrated into existing workflows and PM and EHR
7

Table of Contents
systems. By automating the numerous tasks of the intake process, our healthcare services clients have been able to save time on patient check-ins.
Improve cash flow and profitability. We enable our healthcare services clients to increase collections and reduce costs. Based on client feedback received and our internal analysis, we believe that our flexible patient payment options, including card on file, have led to an increase in time-of-service collections for the majority of our healthcare services clients. Our automated eligibility and benefits verification solution also reduces the number of denied claims.
Enhance clinical and cost outcomes. We enable our healthcare services clients to more efficiently and effectively capture the right clinical information to meet their clinical goals and align with quality reporting initiatives. Our logic-driven delivery of PROs and other questionnaires help healthcare services clients identify at-risk patients in need of specific care and reduce errors by avoiding the need to manually gather the information. These PROs enable our healthcare services clients to close gaps in care, identify successful treatments and engage patients in their care. Through our subsidiary, Insignia Health, LLC ("Insignia"), we license the exclusive worldwide rights to the Patient Activation Measure ("PAM"®), which we believe is widely viewed as the gold standard of patient activation measures. Extensive research over the past decade suggests that the PAM could be a critical pathway in helping healthcare services clients achieve the goals of reducing costs and improving the health of their patients.
Improve patient experience. We activate patients through their journey from access to registration to drive higher patient satisfaction, retention and safety. Our streamlined intake and payments offering provides a consumer-friendly experience and activates patients to take control of their care. Through our patient surveys, healthcare services clients are able to conduct outreach to patients within 24 hours of visit and generate real-time feedback that informs and drives efforts to improve patient experience.
Value proposition for life sciences and payer organizations
Direct communications. We provide life sciences and payer organizations with a channel to activate patients by identifying, reaching, educating and communicating with patients who voluntarily opt in, when they are most receptive and actively seeking care. Our data-driven solutions provide direct patient and member outreach based on various demographic, clinical, environmental and social data, allowing our clients to activate patients and members with clinically or demographically relevant health content to help facilitate conversations with their providers about treatment and prevention options or to gain a better understanding of the health insurance products that best fit their individual needs.
Improve diagnosis and uptake of preventative health services. Our data and analytics capabilities identify patient populations that align with our life sciences clients’ audiences. Based on our ongoing analyses of client marketing and education campaigns conducted by data analytics companies, we believe patients exposed to such campaigns using the Phreesia Platform are more likely, on average, to receive a relevant diagnosis, undergo a preventative health screening, or receive a relevant treatment, than control patients.
Improve brand conversion, treatment, and adherence. Our data and analytics capabilities identify patient populations that align with our life sciences clients’ audiences. Based on our ongoing analyses of client marketing campaigns conducted by data analytics companies, we believe patients exposed to a brand campaign using the Phreesia Platform are more likely, on average, to take an action, such as having a prescription filled for that product, than control patients.
Feedback from patient voice. Our Patient and Member Insights solutions provide a channel for our life sciences and payer clients to deliver dynamic surveys to patients and members and capture direct feedback and access relevant population insights.
Member engagement: We provide payer organizations with a unique channel to identify seniors 64 years and older who are interested in learning more about different Medicare products available to them. Our platform and network enable us to connect eligible and interested seniors with health plan agents who can educate them about the Medicare products that may best suit their needs. We believe our solution delivers timely, actionable qualified leads to health plans for potential member engagement.
Our competitive landscape
We compete in a dynamic patient intake market with direct and indirect competitors that maintain varying degrees of resources and capabilities. We believe many direct competitors are focused on the basic aspects of electronic patient intake and are only starting to expand into the multiple adjacencies beyond patient registration such as access and clinical support. Some of our existing and potential service providers, particularly EHR providers, have developed their own patient intake solutions and have become direct competitors. The Phreesia Platform is
8

Table of Contents
integrated with a majority of the leading EHR systems. KLAS, an independent healthcare information technology research firm, evaluates Phreesia against many of these direct competitors and named Phreesia the top-ranked patient intake management vendor for four years in a row, based on direct feedback from healthcare organizations across the country.

We believe companies in the market for comprehensive software solutions, including patient intake, compete on the basis of several factors, including:
price;
breadth, depth, quality and reliability of product and service offerings;
ease of use;
ability to drive tangible return on investment;
client-focused implementation services and training programs;
healthcare domain expertise;
patient clinical content offerings;
client support and client services; and
ability to integrate with all of a client’s existing systems, including EHR and/or PM systems.

Life sciences marketing is highly competitive and rapidly evolving and consists of both traditional media platforms (e.g. television and print media) as well as more modern web-based and application-based platforms that provide direct-to-consumer marketing for the life sciences industries. Our direct marketing solutions are unique and compete at the point of care as well as pre- and post-visit across an array of digital devices backed by our commitment to transparency and third-party auditing. We compete on the basis of several factors, including price, quality, transparency and the ability to demonstrate meaningful return on investment.

Health plan member acquisition programs are competitive and highly regulated. Health plans are promoted through direct mailings, telemarketing, and advertising on radio, television, websites, and social media channels. Our direct marketing solutions are delivered at the point of care as well as pre-visit across an array of digital devices backed by our commitment to transparency and third-party auditing. We compete on the basis of several factors, including price, speed, quality, and the ability to demonstrate meaningful return on investment.
Our growth strategies
The success of our business depends on acquiring new clients and increasing utilization among our existing clients, which in turn drives growth across our Platform and solutions. We believe we are well-positioned to benefit from a number of prevailing industry tailwinds across our patient access, registration, revenue cycle and network connect solution areas. We intend to continue to proactively grow the business through the following strategies:

Expanding our Platform to new healthcare services organizations
The market for a technology-powered intake and payment platform in the U.S. healthcare industry is large and underserved, and we believe we have a substantial opportunity to grow our client base and market share. With the ability to support over 25 different medical specialties and existing agreements with leading PM and EHR providers, the Phreesia Platform is able to serve a large portion of the U.S. ambulatory and acute care market. The Phreesia Platform is currently used by a small percentage of ambulatory and acute care organizations, and we plan to continue to utilize our direct sales force to win new clients.

Deepening our relationship with existing healthcare services clients
We generate recurring fees from our healthcare services clients based on the number of subscriptions to our base Platform plus subscriptions for any add-on applications. As our healthcare services clients realize the value of the Phreesia Platform, they typically purchase additional subscriptions for their organizations. Our sales strategy is focused on expanding our revenue per average healthcare services client ("AHSC") and we believe there is a significant opportunity to sell new applications.

Continuing to innovate and leverage our Platform
We believe the depth, scalability and robust capabilities of our Phreesia Platform allow us to address key challenges facing providers, payers and life sciences organizations. As an innovative leader across these segments of healthcare, we intend to continue to invest in new value-added offerings for our clients. We have a well-defined technology roadmap to introduce new features and functionality to the Phreesia Platform that activate patients in their care. We intend to leverage our patient database and patient activation capabilities to eliminate gaps in care and increase care coordination among all key healthcare constituents. By expanding and continuously enhancing
9

Table of Contents
the Phreesia Platform, we believe we can drive incremental revenue from existing clients as well as broaden the appeal of the Phreesia Platform to potential new clients.

Pursuing opportunistic strategic investments, partnerships and acquisitions
Our strong growth has been mostly organic, as we have added healthcare services clients as well as life sciences and payer organizations to our Platform, while also expanding the solutions we offer those clients. Through our history, we have effectively contracted with leading PM and EHR solution providers and will continue to evaluate strategic and innovative investments and partnerships to accelerate growth. We also have acquired products and functionalities that complement our offering. We evaluate many investment, partnership and acquisition opportunities on an ongoing basis. We target opportunities that enhance the breadth or depth of our ability to activate patients in their care. Our acquisitions to date have all been consistent with this philosophy, and we will continue to evaluate growth opportunities that complement our internal initiatives.

Enhancing our margins through continued strategic growth
Our business model is based on developing and deploying new, value-added applications for our clients that increase revenue and enhance our attractive client unit economics. We have invested significantly and expect to continue investing significantly to create a comprehensive, scalable technology platform that allows us to gain operating leverage and enhance margins. Over time, we expect to increase profitability and margins by adding new clients to our Platform and by expanding our existing clients with minimal incremental investments in our Platform. Moreover, we continually aim to improve the effectiveness and efficiency of our Platform.

Our products and services
Our Platform and suite of solutions are specifically designed to cater to the needs of patients, healthcare services clients and life sciences and payer companies while improving healthcare engagement. Our robust analytics suite provides real-time operational, financial and clinical insights across our portfolio of products and services.

phr-20230131_g1.jpg

Access

Our Access solutions allow for convenient online appointment requests for patients, appointment tracking and appointment management in one place, and provide insight into past and upcoming appointments. Our Appointments solutions include:
Appointment reminders. Patients receive 24/7 access to book appointments on a practice’s website. Appointment requests populate into the Phreesia Appointments Hub for staff to track and schedule. Patients can confirm their appointment time and date via automated text or email.
10

Table of Contents
Integrated patient scheduling. Our integrated patient scheduling solution gives patients 24/7 access to request or schedule their own in-person or virtual appointments online, either through a link or by responding to patient-outreach by their provider. Once patients self-schedule or send an appointment request, their information automatically populates into the Phreesia Appointments Hub for staff to track and manage.
Automated appointment rescheduling. Our automated appointment rescheduling tool is an automated, text-based solution designed to fill open slots on a healthcare services client's schedule with clinically relevant patients. The tool leverages artificial intelligence and a custom-rules engine to offer earlier appointments for eligible patients as soon as a time slot becomes available.
Patient text messaging. Our patient text messaging product allows healthcare services clients to send and receive text messages from individual patients about their in-person or virtual visits. This capability helps to reduce face-to-face interactions, decrease phone-call volume and improve patient communication.

Registration
Our Registration applications facilitate mobile and on-site check-in, create a more complete patient record and increase patient convenience and satisfaction. Our Registration solutions include:
Mobile and in-office intake modalities. Our Phreesia Mobile intake platform allows patients to check in securely and conveniently on their computer or mobile device, either prior to their visit or when they arrive at the office. Patients can also update their clinical and demographic information, take a photo to store in their patient record, capture images of their driver’s license and insurance card, sign forms and policies and pay copays and outstanding balances—all from the privacy and ease of their own device.
Registration for virtual visits. Our registration for virtual visits offering supports healthcare services clients as they continue to shift visits to telehealth by allowing them to perform all the necessary intake tasks for each virtual visit, including gathering consents, at scale. Intake for telehealth also provides patients with information about how their telehealth visit will work.
Specialty-specific workflows. Our workflows leverage our proprietary logic to guide patients through a tailored list of questions, allowing them to efficiently enter and verify their demographics, insurance data and clinical information.
Consent management. Our automated consent forms streamline the process of collecting consents by ensuring that each patient receives the right forms. These forms can be customized by appointment type and can capture electronic signatures and send required forms directly to the PM or EHR system.
Self service patient-reported outcomes and screenings
We deliver clinical assessments to screen patients for common morbidities and the appropriate PROs and assessments for a wide range of medical specialties including orthopedics, gastroenterology, otolaryngology, or ENT, and urology. We also own the worldwide exclusive license to the PAM™, a measure that we believe is widely viewed as the gold standard for measuring patient activation.
Behavioral health screenings for primary care. Our wellness for primary care application supports primary care providers as they take on increasing responsibility for their patients’ mental health needs. It identifies and screens patients for common behavioral and mental health conditions, including depression, anxiety and substance abuse, using questionnaires such as PHQ-2 and PHQ-9.
Social determinants of health screening. We enable healthcare services clients to ask patients privately about their access to healthy food, safe housing and other social determinants that can have a critical impact on their health. The gathered information is automatically integrated within PM and EHR systems, giving healthcare services clients key data to better understand patients and connect them to needed services.

Revenue cycle
We are able to improve key revenue cycle metrics with our payment solutions, increasing time-of-service and post-visit collections as well as improving patient convenience with online payments and card on file. Our Revenue Cycle solutions include:
11

Table of Contents
Point-of-service payments. Our point-of-service payments solution offers self-service options on Phreesia Mobile, on the PhreesiaPad or at an Arrivals Kiosk. Healthcare services client staff can also process time-of-service or post-explanation of benefits payments on the Phreesia Dashboard. We are able to replace or support a client’s existing payment processor with a fast and secure way to process transactions, as we accept all major credit cards (Visa, MasterCard, American Express and Discover). Phreesia is a PCI DSS Level 1 Service Provider and offers PCI-compliant point-of-sale solutions that significantly reduce the client's PCI DSS reporting requirements.
Insurance verification. Our automated eligibility and benefits application streamlines verification, reduces staff’s manual workload and alerts staff when attention is needed. We can run eligibility and benefits checks in advance, so our clients know their patients’ primary and secondary insurance before their visit. We have achieved Coalition of Affordable Quality Healthcare ("CAQH") CORE Phase 1 Certification for seamless, secure healthcare administrative data exchange.
Payment plans. Our healthcare services clients can give patients the option to set up private, automated payment plans when they check in, or have the staff create payment plans for them on the Phreesia Dashboard. Each plan is configured according to the healthcare services client’s financial policies and managed automatically.
Online payments. Our online payments application allows practices to add a custom payment button to their website or send email reminders that direct patients to an online payment page.
Card on file and payment assurance. Patients may sign a financial policy that gives authorization to store their payment card on a secure platform, thus automatically collecting payments once claims are adjudicated.

Network connect
Our Phreesia network allows us to activate, engage and educate patients and members on behalf of life sciences and payer clients by presenting direct communications to patients and members about topics critical to their health. Our partnerships also provide insights to help clients better understand patient and member needs and perspectives.
Patient and member education and engagement. Our Patient Connect product enables clients to engage with relevant patients who voluntarily opt in and deliver pertinent content at the point at which they are actively seeking care. We believe our tools raise patient awareness and help them to start the right conversations with their providers. Our tools can be used for disease education to speed time-to-diagnosis, screening to aid in early detection and disease prevention, and vaccine and therapy awareness to promote treatment and immunization."Our Member Connect product helps health plans attract new members and engage and better understand their existing membership. Our tools allow us to measure member activation levels and connect eligible and interested seniors with health plan agents who can educate them about the Medicare products that may best suit their needs. We believe our solution delivers timely, actionable, qualified leads to health plans for potential member acquisition.
Referral management. Our Provider Connect tool tracks incoming referrals in a centralized list and allows referring healthcare services clients to send and check the status of each request.
Patient and member insights We leverage patient and member insights within our Platform to conduct primary research to understand patient sentiments and uncover unmet patient needs, which aid life sciences and payer clients in enhancing their existing products and services. Our surveys are designed to provide clients with a better understanding of their patients' and members' experiences as well as insights to drive improvements in health outcomes.

Our technology
We have continued to enhance and develop our proprietary SaaS-based technology platform with a focus on delivering reliability, performance, security and privacy. The Phreesia Platform operates as a single, unified, multi-tenant platform that has demonstrated scalability and robust integration within the operating infrastructure of our healthcare services clients. Our core technology capabilities include:
Robust integration. We integrate our technology into PMs, EHRs and ambulatory and acute system workflows for over 2,800 healthcare services clients. Data captured from the patient or generated by the use of our Platform automatically integrates into the PM and EHR systems of healthcare services clients. We currently contract with leading PM and EHR providers that collectively represent the majority of the total
12

Table of Contents
PM and EHR market. These providers of PM and EHR solutions and our healthcare services clients can leverage our expanding APIs to embed the functionality of the Phreesia Platform for their patients, while controlling the look and feel.
Embedded payments. The payment processing features of our Platform have been designed to operate seamlessly within the workflows of our healthcare services clients, and our revenue cycle solutions can connect directly to those making payments, to multiple clearinghouses and directly with PM, EHR and other systems.
Scalable at cost. We have developed a robust and scalable SaaS-based platform that allows us to iterate on existing technology and develop new solutions quickly and efficiently to meet the needs of our clients. Our unique architecture also allows new integrated applications to be quickly deployed to clients and allows real-time integration without expensive and difficult-to-manage VPN tunnels. This is particularly important in a regulatory environment and industry that continues to evolve.
Consumer-oriented. Through technological innovation, we have continued to ensure our products and services evolve to meet growing and increasingly consumer-centric demands. Our technological innovations include enhancements to our user interface, which we believe has improved user experience and satisfaction.
Reliable. Our technology is engineered to provide strong reliability and availability. The Phreesia Platform performs hundreds of thousands of transactions, including eligibility and benefits verifications, payment card processing and email and text messaging, quickly and reliably at a low cost every day.
Secure and private. We securely manage billions of data points for millions of patients using multiple devices. Maintaining the integrity of our Platform is critical to our business, our clients and the patients they treat. We continue to enhance and evolve our security program.

Privacy and security
Privacy and security are our top priorities. We maintain a comprehensive security program designed to safeguard the confidentiality, integrity and availability of our clients’ data. In particular, we deploy physical, administrative and technical controls to protect the security and privacy of patient information.

We operate a single, unified, multi-tenant platform that offers reliability, performance, security and privacy for our clients. We have infrastructure in place with three co-located data centers, and within Microsoft Azure and Amazon Web Service environments, to securely manage and maintain our clients’ patient information.

We use external security auditors and industry-leading vendors, such as Sikich, A-LIGN, and Bluefin to ensure we have the controls and procedures in place to protect our clients’ sensitive information. We have industry certifications, including HITRUST, PCI-DSS Level 1 Service Provider, Systems and Organization Controls 2 ("SOC 2") and PCI Point-to-Point Encryption. As a PCI-DSS Level 1 Service Provider, we are committed to upholding industry security standards to cardholder data.

We are committed to protecting the information and privacy of our clients and their patients.  We are a "Business Associate" as defined under the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information and Technology for Economic ad Clinical Health Act ("HITECH Act") and their implementing regulations, collectively referred to as HIPAA, and sign business associate agreements that govern our uses and disclosures of protected health information on behalf of our covered entity clients that engage us to provide our software solutions.
Sales and marketing
We market and sell our products and services to healthcare services clients throughout the United States using a direct sales organization. Our demand generation team develops content and identifies prospects that our sales development team researches and qualifies to generate high-grade, actionable sales programs. Our direct sales force executes on these qualified sales leads, partnering with client services to ensure prospects are educated on the breadth of our capabilities and demonstrable value proposition, with the goal of attracting and retaining clients and expanding their use of our Platform over time. Most of our Platform solutions are contracted pursuant to annual, auto-renewing agreements. Our sales typically involve competitive processes, and sales cycles have, on average, varied in duration from three months to six months, depending on the size of the potential client. In addition, through Phreesia University (Phreesia’s in-house training program), events, client conferences and webinars, we help our healthcare services clients optimize their businesses and, as a result, support client retention.
13

Table of Contents
We also sell products and services to life sciences and payer organizations as well as advertising agencies through our direct sales and marketing teams.

Subscriber services and support
Our operations and support organizations differentiate and enhance our clients’ and patients’ experience. Our teams have significant experience integrating with various EHR and PM systems, which can help take our healthcare services clients from sale to go-live much quicker than other platforms. Our client-focused operations are structured to provide a seamless process.
Client services. Our dedicated Client Services team is responsible for pre-sales engagement, new client onboarding and implementation, existing client implementation and on-site optimization. Our Client Services are organized by market specialization, ensuring that our teams provide deep expertise in the markets they support. In addition, our implementation teams have extensive knowledge of the PM and EHR systems that our healthcare services clients use. Through our designed implementation approach and expertise, we are able to take healthcare services clients live efficiently and quickly. Our Client Services teams are also able to demonstrate early return on investment in land-and-expand deals, enabling us to roll out to additional locations.
Client success. Our success is driven by our ability to retain and expand relationships with existing and new clients. Our dedicated Client Success team is focused on the retention of our client base, coordinating directly with Sales and Client Services to meet this objective. Furthermore, we are continuously expanding our business by offering additional products to our clients and driving adoption and utilization.
Client support. We provide technical support to our healthcare services clients through our dedicated Client Support team to directly resolve any product and/or service issues. We serve as the single starting point for client issues and offer a collaborative support model in contrast to tiered support models. This model has proven to help large companies continue to scale, while leveraging the benefits of smaller operations.

We are committed to providing quality services and support, with a focus on integration, implementation support and overall client satisfaction.

Regulatory Matters

Our business is subject to extensive, complex and rapidly changing federal and state laws and regulations. Various federal and state agencies have discretion to issue regulations and interpret and enforce healthcare laws. While we routinely evaluate our legal positions under applicable healthcare laws and regulations, these regulations can vary significantly from jurisdiction to jurisdiction, and interpretation and enforcement of existing laws and regulations can be uncertain or may change periodically. Moreover, in many jurisdictions in which we operate, neither our current nor our anticipated business model has been the subject of judicial or administrative interpretation. We cannot be assured that a review of our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that the healthcare regulatory environment will not change in a way that restricts our operations. Federal and state legislatures also may enact various legislative proposals that could materially impact certain aspects of our business. In addition, our consumer transactions business is subject to certain financial services laws, regulations and rules, such as the Payment Card Industry Data Security Standards.

U.S. state and federal health information privacy and security laws
There are numerous U.S. federal and state laws and regulations related to the privacy and security of personally identifiable information, including health information. In particular, the Health Insurance Portability and Accountability Act of 1996, or HIPAA, establishes privacy and security standards that limit the use and disclosure of protected health information, referred to as PHI, and require the implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form. Many of our customers are regulated as covered entities under HIPAA. As a service provider who creates, receives, maintains or transmits PHI on behalf of our covered entity customers, Phreesia is a “business associate” as defined under HIPAA, and certain HIPAA requirements are directly applicable to business associates.
Violations of HIPAA may result in civil and criminal penalties and a single breach incident can result in violations of multiple standards. We must also comply with HIPAA’s breach notification rule. Under the breach notification rule, business associates must notify covered entities of a breach, and those covered entities must notify affected individuals without unreasonable delay in the case of a breach of unsecured PHI, which may compromise the privacy, security or integrity of the PHI. In addition, notification must be provided to the U.S. Department of Health
14

Table of Contents
and Human Services, or HHS, and the local media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must be reported to HHS on an annual basis. In the event of a breach, our covered entity customers may require we provide assistance in the breach notification process and may seek indemnification and other contractual remedies.
State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would allow individuals to sue in civil court for a HIPAA violation, its standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. In light of the HIPAA Omnibus Final Rule, recent enforcement activity, and statements from HHS, we expect increased federal and state HIPAA privacy and security enforcement efforts.
There has been increasing focus on the application of HIPAA and other privacy laws to technology companies.

Other federal and state laws restrict the use and protect the privacy and security of personally identifiable information. For example, according to the Federal Trade Commission (FTC), failing to take appropriate steps to keep consumers’ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C. § 45(a). The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. In recent years, the FTC has paid increased attention to privacy and data security matters, and we expect them to continue to do so in the future.

Additionally, many states in which we operate and in which our patients reside also have laws that protect the privacy and security of sensitive and personal information, including health information, and are, in many cases, not preempted by HIPAA and may be subject to varying interpretations by courts and government agencies. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California, in which we operate, are more restrictive than HIPAA. The California Consumer Privacy Act, or CCPA, as amended by the California Privacy Rights Act, or CPRA, creates individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. Additionally, as of January 1, 2023, the effective date for the CPRA's amendments to the CCPA, California has a new state agency that is vested with authority to implement and enforce the CCPA. While any information we maintain in our role as a business associate may be exempt from the CCPA, other records and information we maintain may be subject to the CCPA.

Additionally, we expect that there will continue to be new proposed and amended laws, regulations and industry standards concerning privacy, data protection and information security in the U.S. Already in the U.S. we have witnessed significant developments at the state level. For example, on January 1, 2023, the Virginia Consumer Data Protection Act (the “CDPA”) became effective. Further, many additional US state privacy laws will go into effect throughout 2023: the Colorado Privacy Act (the “CPA”) (July 1, 2023); the Connecticut Data Privacy Act (the “CTDPA”) (July 1, 2023); and the Utah Consumer Privacy Act (the “UCPA”) (December 31, 2023). The CDPA, CPA, CTDPA, and UCPA are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including a general exemption for clinical trial data and limited obligations for entities regulated by HIPAA.

Where state laws are more protective than HIPAA, we must comply with these additional state laws. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some state laws, unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition, state laws are changing rapidly, and there is discussion of a new federal privacy law or federal breach notification law, to which we may be subject.

In addition to HIPAA, state health information privacy and state health information privacy laws, we may be subject to other state and federal privacy laws. Such laws, for example, could include state laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security and laws that place specific requirements on certain types of activities, such as data security and texting.

15

Table of Contents
In recent years, there have been a number of well publicized data breaches involving the improper use and disclosure of personally identifiable information and PHI. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals and state officials. In addition, under HIPAA and pursuant to the related contracts with our business associates, we must report breaches of unsecured PHI to our contractual partners following discovery of the breach. Notification must also be made in certain circumstances to affected individuals, federal authorities and others.

U.S. federal and state telecommunications laws

There are number of U.S. federal and state laws and regulations that concern telephone calls, text messages and other telephonic communications to patients, potential patients, clients, and potential clients. For example, the Telephone Consumer Protection Act (“TCPA”) is a federal statute that restricts certain calls and text messages to individuals. Some states, including Florida and Oklahoma, have mini-TCPA laws that restrict certain calls and text messages to their residents and mini-TCPA laws have been proposed in other state legislatures. Our call and text communications are or may be (or may become) subject to these laws.

U.S. federal contracting laws
Our subsidiary, Insignia, as a federal government contractor, is obligated to comply with applicable laws and regulations, including provisions of the Federal Acquisition Regulation ("FAR") and Section 508 of the Rehabilitation Act of 1973 (29 U.S.C. 794d), as amended by the Workforce Investment Act of 1998 ("Section 508"), in connection with its performance of its government contracts. Insignia’s obligations under the FAR include, for example, calculating overhead rates in accordance with the accounting procedures and internal controls required under the FAR standards. In addition, Insignia is obligated under Section 508 to ensure its services and products comply with federal accessibility standards. Consequences for violating the FAR and other laws and regulations applicable to government contracting include termination of contracts, suspension or debarment from doing future business with the government, criminal or civil remedies under the False Claims Act (as described below), and other penalties.

U.S. federal and state fraud and abuse laws
We are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. Such laws and regulations include:

the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation. In addition to a few statutory exceptions and regulatory safe harbors, the U.S. Department of Health and Human Services Office of Inspector General, or OIG, has published safe-harbor regulations that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute provided all applicable criteria are met. The failure of a financial relationship to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. Moreover, the government may assert that a claim including items
16

Table of Contents
or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act or federal civil monetary penalty laws;

the federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;

HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.

Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America’s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign
17

Table of Contents
laws, including for example the European Union General Data Protection Regulation, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Intellectual property
Our continued growth and success depend, in part, on our ability to protect our intellectual property and proprietary technology, including the Phreesia Platform. We primarily protect our intellectual property through a combination of trademarks, trade secrets and other contractual rights, including confidentiality, non-disclosure and assignment-of-invention agreements with our employees, independent contractors, consultants and companies with which we conduct business.
However, these intellectual property rights and procedures may not prevent others from creating a competitive SaaS platform or otherwise competing with us. We may be unable to obtain, maintain and enforce the intellectual property rights on which our business depends, and assertions by third parties that we violate their intellectual property rights could have a material adverse effect on our business, financial condition and results of operations.

Human Capital Resources

As of January 31, 2023, we had 1,546 full-time employees, including 325 in services and support, 607 in sales and marketing, 445 in research and development and 169 in general and administrative. As of January 31, 2023, we had 1,038 full-time employees in the United States and 538 full-time employees internationally. We also supplement our workforce with contractors and consultants, including a substantial number of contractors and consultants in international locations. For example, we have a strategic relationship with Rayden, pursuant to which Rayden’s India-based personnel exclusively support our business through various functions, including, but not limited to, finance and accounting, sales and marketing, customer operations, product management and support, and research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good, and we have not experienced any work stoppages.

Talent and Culture: The success and continued evolution of our company has been due in large part to the talent and engagement of the entire Phreesia team. Our team members are key pillars of our success and fostering and developing their talent is central to our culture. Attracting and retaining top talent is a high priority for us, and we look to hire smart, passionate, diverse and driven individuals who want to be a part of our mission. Our strong company culture and investment in long-term career growth for our people is evidenced by the long tenure of many of our team members with our organization. We believe our success is due in large part to the continued engagement of our talented and committed team. During our fiscal year ended January 31, 2023, Modern Healthcare magazine recognized Phreesia as one of the “Best Places to Work in Healthcare” for the sixth time, and Inc. magazine recognized Phreesia as one of the "Best Led Companies of 2022". Phreesia has also had representation on the Software Report's Top 50 Women Leaders in SaaS for the past five years. All of these achievements optimally position us to continue to attract top healthcare and technology talent.

Diversity and Inclusiveness: We are committed to hiring, developing and supporting a diverse and inclusive workplace. We employ strong recruiting practices that actively seek out and engage underrepresented groups. We strive to make career paths, career development opportunities and mentorships available to all employees. Additionally, we cultivate opportunities for diverse voices to be heard and supported. Our employee resource groups (ERGs) support our commitment to promoting and maintaining an inclusive culture for all employees by bringing together individuals from a wide range of backgrounds, experiences and perspectives. These groups seek to foster a sense of shared community and empowerment for employees who share a common social identity, such as gender, race, ethnicity, disability and sexual orientation. Phreesians can voluntarily join an ERG to network, discuss and exchange ideas and enhance their professional development.

We recognize that our ability to execute on our mission of creating a better, more engaging experience depends on our people. We are also committed to supporting gender equality in our organization, including through our inclusive culture, board representation, pathways to leadership for women, pay equity and strong family-leave policies.
We published our third Phreesia Gender Equality Report in 2022 based on the framework provided by the Bloomberg Gender Equality Index which has included Phreesia in January 2021, 2022 and 2023.
18

Table of Contents

Remote Workforce: We have operated as a fully remote company since 2020, as we believe this arrangement allows us access to the best talent and creates optimal flexibility for our employees.

Corporate Information

We are a fully remote company and no longer maintain our principal executive offices. Our mailing address is 1521 Concord Pike, Suite 301, PMB 221, Wilmington, DE 19803, and our telephone number is (888) 654-7473. Our website address is http://www.phreesia.com. We do not incorporate the information on or accessible through our website into this report, and you should not consider any information on, or that can be accessed through, our website as part of this report.

Available Information

Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to these filings, are available free of charge from our investor relations website at https://ir.phreesia.com as soon as reasonably practicable following our filing with or furnishing to the Securities and Exchange Commission, or SEC, of any of these reports. The SEC maintains an Internet website at https://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
Phreesia investors and others should note that we announce material information to the public about our company, products and services and other issues through a variety of means, including our website at https://www.phreesia.com, our investor relations website at https://ir.phreesia.com, press releases, SEC filings and public conference calls, in order to achieve broad, non-exclusionary distribution of information to the public. We also use the following social media channels as a means of disclosing information about the company, our platform, our planned financial and other announcements and attendance at upcoming investor and industry conferences, and other matters and for complying with our disclosure obligations under Regulation FD:
PHREESIA Twitter Account (https://twitter.com/phreesia)
PHREESIA Facebook Page (https://www.facebook.com/phreesia/)
PHREESIA LinkedIn Page (https://www.linkedin.com/company/phreesia)
PHREESIA Instagram Account (https://www.instagram.com/phreesia.co)
PHREESIA News Page (https://www.phreesia.com/news/)
PHREESIA Life Sciences Twitter Account (https://twitter.com/PhreesiaLifeSci)
PHREESIA Life Sciences Facebook Page (https://www.facebook.com/PhreesiaLifeSciences/)
PHREESIA Life Sciences LinkedIn Page (https://www.linkedin.com/company/phreesia-life-sciences/)
PHREESIA Life Sciences Page (https://lifesciences.phreesia.com)
INSIGNIA Health website (https://www.insigniahealth.com/)

We encourage our investors and others to review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.
The contents of any website referred to in this Annual Report on Form 10-K are not intended to be incorporated into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our websites are intended to be inactive textual references only.

ITEM 1A.    RISK FACTORS
Risk factors
A description of the risks and uncertainties associated with our business and industry is set forth below. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including our consolidated financial statements and notes thereto and the “Management’s discussion and analysis of financial condition and results of operations” section of Annual Report on Form 10-K, before deciding whether to purchase shares of our common stock. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, perhaps significantly. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business
19


operations. Certain statements in this Annual Report on Form 10-K are forward-looking statements. See the section of this Annual Report on Form 10-K titled “Special Note Regarding Forward-Looking Statements.”


Risks relating to our business and industry
We have grown rapidly in recent periods, and as a result, our expenses have continued to increase. If we fail to manage our growth effectively, our revenue may not increase, and we may be unable to implement our business strategy.
We have experienced significant growth in recent periods, which puts strain on our business, operations and employees. We anticipate that our operations will continue to expand. As we continue to grow, both organically and through acquisitions, we must effectively integrate, develop, and manage an increasingly distributed employee base in a fully remote working environment. We may find it challenging to maintain the same level of employee productivity while executing our growth plan, fostering collaboration, and maintaining the beneficial aspects of our culture, and any such failures could negatively affect our future success, including our ability to attract and retain highly qualified employees and to achieve our business objectives.

In addition, to manage our current and anticipated future growth effectively, we must continue to maintain and enhance our IT infrastructure, financial and accounting systems and controls and continue to build our qualified work force in key areas of our company. A key element of how we manage our growth is our ability to scale our capabilities and satisfactorily implement the Phreesia Platform for our clients’ needs. Our healthcare services clients often require specific features or functions unique to their organizational structure, which, at a time of significant growth or during periods of high demand, may strain our implementation capacity and hinder our ability to successfully implement the Phreesia Platform to our clients in a timely manner. If we are unable to address the needs of our healthcare services clients or our healthcare services clients are unsatisfied with the quality of the Phreesia Platform or our services due to our inability to manage our rapid growth, they may not renew their contracts, seek to cancel or terminate their relationship with us or renew on less favorable terms, any of which could adversely affect our business.

Failure to effectively manage our growth could also lead us to over-invest or under-invest in development and operations, result in weaknesses in our infrastructure, systems or controls, give rise to operational mistakes, financial losses, loss of productivity or business opportunities and result in loss of employees and reduced productivity of remaining employees. In addition, our growth has required and is expected to require significant capital expenditures and may divert financial resources from other projects such as the development of new applications and services. We may also need to make further investments in our technology and automate portions of the Phreesia Platform or our services to decrease our costs. If our management is unable to effectively manage our growth, our revenue may not increase (including sufficiently to offset our expenses) or may grow more slowly than expected and we may be unable to implement our business strategy.

We operate in a highly competitive industry, and if we are not able to compete effectively, including with the EHR and PM systems with which we integrate, our business and results of operations will be harmed.
The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, evolving regulatory requirements, changes in client needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities, including the EHR and PM systems with which we integrate. As costs fall and technology improves, increased market saturation may change the competitive landscape in favor of competitors with greater scale than we currently possess.

In order to remain competitive, we are continually involved in a number of projects to compete with new market entrants by developing new services, growing our client base and penetrating new markets. These projects carry risks, such as cost overruns, delays in delivery, performance problems and lack of acceptance by our clients.


The success of our business and growth strategy depend upon our continued ability to maintain and expand a network of healthcare services clients. If we are unable to attract and retain healthcare services clients, it would have a material adverse effect on our business and ability to grow and would adversely affect our results of operations. Our success also depends on providing high-quality products and services that healthcare services clients use to improve clinical, financial and operational performance and that are used and positively received by patients. If we cannot adapt to rapidly evolving industry standards and technology and increasingly sophisticated




20


and varied healthcare services organization and patient needs, our existing technology could become undesirable, obsolete or harm our reputation.

We believe demand for our products and services has been driven in large part by increasing patient responsibility, engagement and consumerism. Our ability to streamline the intake process and critical workflows in order to improve healthcare services organization, staff efficiency and patient engagement to allow for optimal allocation of resources will be critical to our business. Our success also depends on the ability of our Platform to increase patient engagement, and our ability to demonstrate the value of our Platform to healthcare services clients, patients and life sciences companies. If our existing clients do not recognize or acknowledge the benefits of our Platform or our Platform does not drive patient engagement, then the market for our products and services might develop more slowly than we expect, which could adversely affect our operating results.

In addition, as we and the EHR and PM solutions with which we integrate, grow and expand product offerings, the EHR and PM solutions with which we integrate could offer more competitive services. Some of these EHR and PM systems offer, or may begin to offer, services, including patient intake and engagement services, payment processing tools and direct patient communication services, in the same or similar manner as we do. Although there are many potential opportunities for, and applications of, these services, these EHR and PM systems may seek opportunities or target new clients in areas that may overlap with those that we have chosen to pursue. Such competition from these EHR and PM systems may adversely affect our business, market share and results from operations.
We compete on the basis of several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement through the use of products and services, quality and reliability of services, ease of use and convenience, brand recognition, price and the ability to integrate our Platform solutions with various EHR and PM systems and other technology. Some of our competitors have greater name recognition, longer operating histories and significantly greater resources than we do. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or client requirements. In addition, current and potential competitors have established, and may in the future establish, cooperative relationships with vendors of complementary products, technologies or services to increase the availability of their products to the marketplace. Accordingly, new competitors or providers of EHR and PM solutions may emerge that have greater market share, larger client bases, more widely adopted proprietary technologies, greater marketing expertise, greater financial resources and larger sales forces than we have, which could put us at a competitive disadvantage. We also may be subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of healthcare industry participants, practices of managed care organizations, government action and financial stress experienced by our clients. If our pricing experiences significant downward pressure, our business will be less profitable and our results of operations will be adversely affected. We cannot be certain that we will be able to retain our current clients or expand our client base in this competitive environment. If we do not retain current clients or expand our client base, or if we have to renegotiate existing contracts, our business, financial condition and results of operations will be harmed. Moreover, we expect that competition will continue to increase as a result of consolidation in both the healthcare information technology and healthcare industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could also adversely affect our ability to compete effectively and could harm our business, financial condition and results of operations.

We have experienced net losses in the past and we may not achieve profitability in the future.
We have incurred significant operating losses since our inception. For the years ended January 31, 2023 and January 31, 2022, we had net losses of $176.1 million and $118.2 million, respectively, and losses from operations of $176.6 million and $116.8 million, respectively. Our operating expenses may increase in the foreseeable future as we continue to invest to grow our business and build relationships with our clients and partners, develop the Phreesia Platform, develop new solutions and operate as a public company. In addition, to the extent we are successful in increasing our client base, we could incur increased losses because significant costs associated with entering into client agreements are generally incurred up front, while revenue is generally recognized ratably over the term of the agreement. As a result, we may need to raise additional capital through equity and debt financings in order to fund our operations, which may not be available to us on favorable terms or at all. If we are unable to effectively manage these risks and difficulties as we encounter them or effectively access the capital markets, our business, financial condition and results of operations may suffer.

Our operating results have in the past and may continue to fluctuate significantly and if we fail to meet the




21


expectations of analysts or investors, our stock price and the value of your investment could decline substantially.
Our operating results are likely to fluctuate, and if we fail to meet or exceed the expectations of securities analysts or investors, the trading price of our common stock could decline. Moreover, our stock price may be based on expectations of our future performance that may be unrealistic or that may not be met. Some of the important factors that could cause our revenues and operating results to fluctuate from quarter to quarter include:
the extent to which our products and services achieve or maintain market acceptance;
our ability to introduce new products and services and enhancements to our existing products and services on a timely basis;
new competitors and the introduction of enhanced products and services from new or existing competitors;
the length of our contracting and implementation cycles;
the financial condition of our current and potential clients;
our ability to integrate our Platform with the systems utilized by our healthcare services clients, including but not limited to, EHR and PM systems;
changes in client budgets and procurement policies;
patients' desires to receive communications from Phreesia and/or our partners, and the extent to which they opt-in to such communications;
amount and timing of our investment in research and development activities and other areas of our business;
technical difficulties or interruptions in our services;
our ability to hire and retain qualified personnel, including the rate of expansion of our sales force;
changes in the regulatory environment related to healthcare;
regulatory compliance costs;
the timing, size and integration success of potential future acquisitions;
unforeseen legal expenses, including litigation and settlement costs; and
buying patterns of our clients and the related seasonality impacts on our business.

Many of these factors are not within our control, and the occurrence of one or more of them might cause our operating results to vary widely. As such, we believe that quarter-to-quarter comparisons of our revenues and operating results may not be meaningful and should not be relied upon as an indication of future performance.

A significant portion of our operating expense is relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls may decrease our margins and could cause significant changes in our operating results from quarter to quarter.
Privacy concerns or security breaches relating to our Platform could result in economic loss, damage to our reputation, deterring users from using our products, and our exposure to legal penalties and liability.

We collect, process and store significant amounts of sensitive, confidential and proprietary information, including personally identifiable information, such as payment data and protected health information, of patients received in connection with the utilization of our Platform. Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized groups and individuals with a wide range of motives and expertise. In addition to extracting sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. The prevalent use of mobile devices also increases the risk of data security incidents. While we believe we have taken reasonable steps to protect such data, techniques used to gain unauthorized access to data and systems, disable or degrade service, or sabotage systems, are constantly evolving, and we may be unable to anticipate such techniques or implement adequate preventative measures to avoid unauthorized access or other adverse impacts to such data or our systems. In addition, some of our third-party service providers and partners also collect and/or store our sensitive information and our clients' data on our behalf, and these service providers and partners are subject to similar threats of cyber attacks and other malicious internet-based activities, which could also expose us to risk of loss, litigation, and potential liability. The risk of state-supported and geopolitical-related cyber-attacks may increase in connection with the war in Ukraine and any related political or economic responses and counter-responses. We may not discover all such incidents or activity or be able to respond or otherwise address them promptly, in sufficient respects or at all.

We may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by




22


HIPAA. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our business and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals’ health information. Patients about whom we obtain health information, as well as the healthcare services clients who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals’ privacy rights, violated applicable privacy laws and regulations or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.

Like all internet services, our service is vulnerable to software bugs, computer viruses, internet worms, break-ins, phishing attacks, attempts to overload servers with denial-of-service, or other attacks or similar disruptions from unauthorized use of our and third-party computer systems, any of which could lead to system interruptions, delays, or shutdowns, causing loss of critical data or the unauthorized access of data. Though it is difficult to determine what, if any, harm may directly result from any specific interruption or attack, any failure to maintain performance, reliability, security and availability of our products, or failure to prevent software bugs, to the satisfaction of our clients or the health and safety of their patients, such events may harm our reputation and our ability to retain existing clients, and negatively affect our clients and their patients. We have in place systems and processes that are designed to protect our data, prevent data loss, disable undesirable accounts and activities on our Platform and prevent or detect security breaches, however, we cannot assure you that such measures will provide absolute security.

Further, the security systems in place at our employees’ and service providers’ offices and homes may be less secure than those used in our offices, and while we have implemented technical and administrative safeguards to help protect our systems as our employees and service providers work from their offices, homes and other remote locations, we may be subject to increased cybersecurity risk, which could expose us to risks of data or financial loss, and could disrupt our business operations. There is no guarantee that the data security and privacy safeguards we have put in place will be completely effective or that we will not encounter risks associated with employees and service providers accessing company data and systems remotely. If an actual or perceived breach of security occurs to our systems or a third-party’s systems, we also could be required to expend significant resources to mitigate the breach of security, pay any applicable fines and address matters related to any such breach, including notifying users or regulators, and address reputational harm.

Business or economic disruptions or global health concerns could harm our business and increase our costs and expenses.
Broad-based business or economic disruptions or global health concerns, such as the COVID-19 pandemic and recent high inflationary environment, could materially and adversely impact our business and results of operations due to, among other factors:

a general decline in business activity, including the impact of our clients’ office closures earlier in the COVID-19 pandemic;
a potentially disproportionate impact on the healthcare services clients with whom we contract;
disruptions to our supply chains and our third-party vendors, partners, and suppliers;
difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions that could affect our access to capital necessary to fund business operations or address maturing liabilities on a timely basis; and
social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate.

In addition, market volatility, the high inflationary environment and economic uncertainty remain widespread, making it potentially very difficult for our clients and us to accurately forecast and plan future business activities. During challenging economic times, our clients and patients may have difficulty gaining timely access to sufficient credit or obtaining credit on reasonable terms and may face increased costs or other negative financial impacts, each of which could impair their ability to make timely payments to us and adversely affect our revenue. If that were to occur, our financial results could be harmed. Further, challenging economic conditions may impair the ability of our clients to pay for the applications and services they already have purchased from us and, as a result, our write-offs of accounts receivable could increase.





23


We are a fully remote company that does not maintain a physical office presence, which subjects us to unique operational risks.

Being a fully remote company subjects us to unique operational risks. For example, technologies in our employees’ homes may not be as robust as in our offices and could cause the networks, information systems, applications, and other tools available to employees and service providers to be more limited or less reliable than in our offices. Further, the security systems in place at our employees’ homes may be less secure than those used in our offices, and while we have implemented technical and administrative safeguards to help protect our systems as our employees and service providers work from home, we may be subject to increased cybersecurity risk, which could expose us to risks of data or financial loss and could disrupt our business operations. There is no guarantee that the data security and privacy safeguards we have put in place will be completely effective or that we will not encounter risks associated with employees accessing company data and systems remotely. In addition, operating remotely may negatively impact our corporate culture, including employee engagement and productivity.

If our internal controls over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.

As a public company, we are required to maintain internal control over financial reporting and disclosure controls and procedures. Section 404 of the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act") requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on the internal control over financial reporting. Our testing, or the subsequent testing by our independent public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses. If we are not able to comply with the requirements of Section 404 in a timely manner, or if we or our accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock would likely decline and we could be subject to lawsuits, sanctions or investigations by regulatory authorities, including SEC enforcement actions, and we could be required to restate our financial results, any of which would require additional financial and management resources.

If material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results, which could materially and adversely affect our business, results of operations and financial condition, restrict our ability to access the capital markets, require us to expend significant resources to correct the material weakness, subject us to fines, penalties or judgments, harm our reputation or otherwise cause a decline in investor confidence.

We continue to invest in more robust technology and resources to manage those reporting requirements. Implementing the appropriate changes to our internal controls may distract our officers and employees, result in substantial costs and require significant time to complete. Any difficulties or delays in implementing these controls could impact our ability to timely report our financial results. For these reasons, we may encounter difficulties in the timely and accurate reporting of our financial results, which would impact our ability to provide our investors with information in a timely manner. As a result, our investors could lose confidence in our reported financial information, and our stock price could decline.

In addition, any such changes do not guarantee that we will be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy could prevent us from accurately reporting our financial results.

We typically incur significant upfront costs in our client relationships, and if we are unable to develop or grow these relationships over time, we are unlikely to recover these costs and our operating results may suffer.
We devote significant resources to establish relationships with new clients and deepen relationships with existing clients. Our efforts involve educating our clients and patients about the use, technical capabilities and benefits of our products and services. We do not provide access to our Platform and do not charge fees during this initial sales period. For clients that decide to enter into a contract with us, most of these contracts may provide for a preliminary trial period where a subset of healthcare services locations from the client is granted access to our Platform. Following any such trial period, we aim to increase the number of healthcare services locations within the client that utilize our Platform. Accordingly, our operating results depend in substantial part on our ability to deliver a successful client and patient experience and persuade our clients and patients to grow their relationship with us over time. As we expect to grow rapidly, our client acquisition costs could outpace revenue growth, and we may be




24


unable to reduce our total operating costs through economies of scale such that we are unable to achieve profitability. Any increased or unexpected costs or unanticipated delays, including delays caused by factors outside of our control, could cause our operating results to suffer.
As a result of our variable sales and implementation cycles, we may be unable to recognize revenue to offset expenditures, which could result in fluctuations in our quarterly results of operations or otherwise harm our future operating results.
The sales cycle for our services can be variable, typically ranging from three to six months from initial contact to contract execution. During the sales cycle, we expend time and resources, and we do not recognize any revenue to offset such expenditures. Our implementation cycle is also variable, typically ranging from one to 24 months from contract execution to completion of implementation. The variability of our sales and implementation cycle is dependent on numerous factors, including the discretionary nature of potential clients' purchasing and budget decisions and the size and complexity of the applicable client. Some of our new-client set-up projects are complex and require a lengthy delay and significant implementation work, including to educate prospective clients about the uses and benefits of our Platform. Each customer’s situation is different, and unanticipated difficulties and delays may arise as a result of failure by us or by the client to meet our respective implementation responsibilities. During the implementation cycle, we expend substantial time, effort and financial resources implementing our service, but accounting principles do not allow us to recognize the resulting revenue until the service has been implemented, at which time we begin recognition of subscription and related implementation revenue over the life of the contract. This could harm our future operating results. If implementation periods are extended, our revenue cycle will be delayed and our financial condition may be adversely affected. In addition, cancellation of any implementation after it has begun may involve loss to us of time, effort and expenses invested in the cancelled implementation process and lost opportunity for implementing paying clients in that same period of time.
These factors may contribute to substantial fluctuations in our quarterly operating results, particularly in the near term and during any period in which our sales volume is relatively low. As a result, in future quarters our operating results could fall below the expectations of securities analysts or investors, in which event our stock price would likely decrease.
The growth of our business relies, in part, on the growth and success of our clients and certain revenues from our engagements, which is difficult to predict and is subject to factors outside of our control.
We enter into agreements with our healthcare services clients, under which a significant portion of our fees are variable, including fees which are dependent upon the number of add-on features to the Phreesia Platform subscribed for by our clients and the number of patients utilizing our payment processing tools. If there is a general reduction in spending by healthcare services organizations on healthcare technology solutions, it may result in a reduction in fees generated from our healthcare services clients or a reduction in the number of add-on features subscribed for by our healthcare services clients. This could lead to a decrease in our revenue, which could harm our business, financial condition and results of operations.
In addition, the number of patients utilizing our payment processing tools, and the amounts those patients pay directly to our healthcare services clients for services, is often impacted by factors outside of our control, such as the number of patients with high deductible health plans. Accordingly, revenue under these agreements can be uncertain and unpredictable. If the number of patients utilizing our payment systems, or the aggregate amounts paid by such patients directly to our healthcare services clients through the Phreesia Platform, were to be reduced by a material amount, such decrease would lead to a decrease in our revenue, which could harm our business, financial condition and results of operations.
We also generate network solutions revenue through fees charged to our life sciences and payer clients by delivering direct communications to help activate, engage and educate patients who authorize the delivery of, or "opt-in" to, such communications about topics critical to their health. The growth of our revenue stream from life sciences and payer clients is driven, in part, by our ability to grow our network of healthcare services clients and available population of patients to engage, our ability to achieve adequate patient opt-in rates, the number of newly approved drugs and the success of newly launched drugs, each of which is impacted by factors outside of our control. If there is a reduction in newly approved drugs, or newly launched drugs are not successful, this could negatively affect the ability of our life sciences clients to deliver relevant messages to patients who would have otherwise been candidates to receive such drugs, and accordingly may reduce patient opt-in rates. A reduction in the available population of patients to engage or a decline in patient opt-in rates could lead to a decrease in our network solutions revenue, which could harm our business, financial condition and results of operations.




25


If our existing clients are not satisfied with our services, it could have a material adverse effect on our business, financial condition, results of operations and reputation.
We depend on our existing clients’ satisfaction with our products and services. We expect to derive a significant portion of our revenue from renewal of existing clients’ contracts and sales of additional applications and services to existing clients. As part of our growth strategy, we have recently focused on expanding our services amongst current clients. As a result, achieving a high client retention rate, expanding within clients and selling additional applications and services are critical to our future business, revenue growth and results of operations. We also believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing clients and the patients that they serve and to our ability to attract new clients. The promotion of our brand may require us to make substantial investments, and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. In addition, the loss or dissatisfaction of any client could substantially harm our brand and reputation, inhibit widespread adoption of the Phreesia Platform and impair our ability to attract new clients.
Factors that may affect our client satisfaction and our ability to sell additional applications and services include, but are not limited to, the following:
the price, performance and functionality of our Platform;
patient acceptance and adoption of services and utilization of our payment processing tools;
the availability, price, performance and functionality of competing solutions;
our ability to develop and sell complimentary applications and services;
the stability, performance and security of our hosting infrastructure and hosting services;
changes in healthcare laws, regulations or trends;
the business environment of our clients including healthcare staffing shortages and headcount reductions by our clients; and
our ability to maintain and enhance our reputation and brand recognition.
We typically enter into annual contracts with our clients, which have a stated initial term of one year and automatically renew for one-year subsequent terms. Most of our clients have no obligation to renew their subscriptions for our Platform solution after the initial term expires. In addition, our clients may negotiate terms less advantageous to us upon renewal, which may reduce our revenue from these clients and may decrease our annual revenue. If our clients fail to renew their contracts, renew their contracts upon less favorable terms or at lower fee levels or fail to purchase new products and services from us, our revenue may decline or our future revenue growth may be constrained. Should any of our clients terminate their relationship with us after implementation has begun, we would not only lose our time, effort and resources invested in that implementation, but we would also have lost the opportunity to leverage those resources to build a relationship with other clients over that same period of time.

The estimates and assumptions we use to determine the size of our target market may prove to be inaccurate, and even if the markets in which we compete meet our size estimates and forecasted growth, our business may not grow at similar rates, or at all.
Market estimates and growth forecasts that we disclose are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. The estimates and forecasts relating to the size and expected growth of the market for our services may prove to be inaccurate. These estimates and forecasts may be impacted by economic uncertainty that is outside our control, including international conflicts that may impact international trade and global economic performance and other macroeconomic trends, such as international and domestic supply chain risks, inflationary pressure, interest rate increases and declines in consumer confidence that impact our customers.
The principal assumptions relating to our market opportunity include the number of healthcare services organizations currently taking appointments, the amount of annual out of pocket consumer spend for healthcare-related services, and the amount of annual spend by life sciences and payer companies on direct communications with patients at the point of care. Our market opportunity is also based on the assumption that the strategic approach that the Phreesia Platform enables for our potential clients will be more attractive in creating efficiencies in patient care than competing solutions.
If these assumptions prove inaccurate, our business, financial condition and results of operations could be adversely affected.

If we cannot implement the Phreesia Platform for clients or resolve any technical issues in a timely manner, we may incur costs in the form of service credits or other remedial steps and/or lose clients, and our reputation may be harmed.




26


Our clients utilize a variety of data formats, applications and infrastructure and the Phreesia Platform must support our clients’ data formats. Furthermore, the healthcare industry has shifted towards digitalized record keeping, and accordingly, many of our healthcare services clients have developed their own software, or utilize third-party software, for practice management and secure storage of electronic medical records. Our ability to develop and maintain logic-based and scalable technology for patient intake management and engagement and payment processing that successfully integrates with our clients’ software systems for practice management and storage of electronic medical records is critical. If our Platform does not currently support a client’s required data format or appropriately integrate with clients’ systems, then we must configure our Platform to do so, which could increase our expenses. Additionally, we do not control our clients’ implementation schedules. As a result, if our clients do not allocate the internal resources necessary to meet their implementation responsibilities or if we face unanticipated implementation difficulties, the implementation may be delayed. If the client implementation process is not executed successfully or if execution is delayed, we could incur significant costs, clients could become dissatisfied and decide not to increase utilization of the Phreesia Platform or not to implement the Phreesia Platform beyond an initial period prior to their term commitment or, in some cases, revenue recognition could be delayed. In addition, competitors with more efficient operating models with lower implementation costs could jeopardize our client relationships.
Our clients and patients depend on our support services to resolve any technical issues relating to the Phreesia Platform and our services, and we may be unable to respond quickly enough to accommodate short-term increases in demand for support services, particularly as we increase the size of our client bases (including healthcare services clients and the number of patients that they serve). We also may be unable to modify the format of our support services to compete with changes in support services provided by competitors. It is difficult to predict client and patient demand for technical support services, and if client or patient demand increases significantly, we may be unable to provide satisfactory support services to our clients. Further, if we are unable to address the needs of our clients and their patients in a timely fashion or further develop and enhance the Phreesia Platform, or if a client or patient is not satisfied with the quality of work performed by us or with the technical support services rendered, then we could incur additional costs to address the situation or be required to issue credits or refunds for amounts related to unused services, and our profitability may be impaired and clients’ or patients’ dissatisfaction with the Phreesia Platform could damage our ability to expand the number of applications and services purchased by such clients. These clients may not renew their contracts, seek to terminate their relationships with us or renew on less favorable terms. Moreover, negative publicity related to our client and patient relationships, or regarding patient confidentiality and privacy in the context of technology-enabled healthcare, regardless of its accuracy, may further damage our business by affecting our reputation or ability to compete for new business with current and prospective clients. If any of these were to occur, our revenue may decline and our business, financial condition and results of operations could be adversely affected.

We historically derive a significant portion of our revenues from our largest clients.
Historically, we have relied on a limited number of clients for a substantial portion of our total revenue and accounts receivable. The sudden loss of any of our larger clients, or the renegotiation of any of their contracts on less favorable terms, could adversely affect our operating results. Because we rely on a limited number of clients for a significant portion of our revenues, we depend on the creditworthiness of these clients. If the financial condition of our larger clients declines, our credit risk could increase. Should one or more of our significant clients declare bankruptcy, it could adversely affect the collectability of our accounts receivable and affect our bad debt reserves and net income.

Consolidation in the healthcare industry could have a material adverse effect on our business, financial condition and results of operations.
Many healthcare industry participants are consolidating to create larger and more integrated healthcare delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the healthcare industry in the future. As consolidation accelerates, the economies of scale of our clients’ organizations may grow. If a client experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as healthcare services organizations and life sciences companies consolidate to create larger and more integrated healthcare delivery systems with greater market power, these healthcare services organizations may try to use their market power to negotiate fee reductions for our products and services. Finally, consolidation may also result in the acquisition or future development by our healthcare services clients and life sciences clients of products and services that compete with our products and services. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.





27


We depend on our senior management team and certain key employees, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.
Our success depends, in part, on the skills, working relationships and continued services of our founders, Chaim Indig (Chief Executive Officer) and Evan Roberts (Chief Operating Officer), and senior management team and other key personnel. From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives, which could disrupt our business. In addition, our shift to a remote work environment could make it increasingly difficult to manage our business and adequately oversee our employees and business functions, potentially resulting in harm to our company culture, increased employee attrition, and the loss of key personnel.
In addition, we must attract, train and retain a significant number of highly skilled employees, including sales and marketing personnel, client support personnel, professional services personnel, software engineers, technical personnel and management personnel, and the availability of such personnel, in particular software engineers, may be constrained. We also believe that our future growth will depend on the continued development of our direct sales force and its ability to obtain new clients and to manage our existing client base. If we are unable to hire and develop sufficient numbers of productive direct sales personnel or if new direct sales personnel are unable to achieve desired productivity levels in a reasonable period of time, sales of our services will suffer and our growth will be impeded.

Competition for qualified management and employees in our industry is intense, and identifying and recruiting qualified personnel and training them requires significant time, expense and attention. Many of the companies with which we compete for personnel have greater financial and other resources than we do. While we have entered into offer letters or employment agreements with certain of our executive officers, all of our employees are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason and without notice, subject, in certain cases, to severance payment rights. The departure and replacement of one or more of our executive officers or other key employees would likely involve significant time and costs, may significantly delay or prevent the achievement of our business objectives and could materially harm our business. In addition, volatility or lack of performance in our stock price may affect our ability to attract replacement should key personnel depart.

We may make future acquisitions and investments which may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.
We have in the past acquired, and we may in the future acquire or invest in, businesses, products or technologies that we believe could complement or expand our products and services, enhance our technical capabilities or otherwise offer growth opportunities.
There are inherent risks in integrating and managing acquisitions, and the pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses related to identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We cannot assure you that we will realize the anticipated benefits of these or any future acquisitions. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including, without limitation:
difficulty integrating the purchased operations, products or technologies and maintaining the quality and security standards consistent with our brand;
the need to integrate or implement additional controls, procedures and policies;
unanticipated costs or liabilities associated with the acquisition;
our inability to comply with the regulatory requirements applicable to the acquired business;
assimilation of the acquired businesses, which may divert significant management attention and financial resources from our other operations and could disrupt our ongoing business;
use of substantial portions of our available cash or the incurrence of debt to consummate the acquisition;
the loss of key employees, particularly those of the acquired operations;
difficulty retaining or developing the acquired business’ customers;
adverse effects on our existing business relationships;
failure to realize the potential cost savings or other financial benefits or the strategic benefits of the acquisitions, including failure to consummate any proposed or contemplated transaction; and
liabilities from the acquired businesses for infringement of intellectual property rights or other claims and failure to obtain indemnification for such liabilities or claims.
Acquisitions also increase the risk of unforeseen legal liability, including for potential violations of applicable law or industry rules and regulations, arising from prior or ongoing acts or omissions by the acquired businesses which are




28


not discovered by due diligence during the acquisition process. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our business, results of operations or financial condition. Even if we are successful in completing and integrating an acquired business, it may not perform as we expect or enhance the value of our business as a whole.
Certain of our operating results and financial metrics, including the key metrics included in this report, may be difficult to predict as a result of seasonality.
We believe there are significant seasonal factors that may cause us to record higher revenue in some quarters compared with others. We believe this variability is largely due to our focus on the healthcare industry. For example, with respect to our healthcare services clients, we receive a disproportionate increase in payment processing revenue from such clients during the first two to three months of the calendar year relative to the other months of the year, which is driven, in part, by the resetting of patient deductibles at the beginning of each calendar year. Sales for our life sciences solutions are also seasonal, primarily due to the annual spending patterns of our clients. This portion of our sales is usually the highest in the fourth quarter of each calendar year. While we believe we have visibility into the seasonality of our business, our rapid growth rate over the last several years may have made seasonal fluctuations more difficult to detect. If our rate of growth slows over time, seasonal or cyclical variations in our operations may become more pronounced, and our business, results of operations and financial position may be adversely affected.

Our risk management policies and procedures may not be fully effective in mitigating our risk exposure in all market environments or against all types of risk.
We operate in a rapidly changing industry. Accordingly, our risk management policies and procedures may not be fully effective to identify, monitor and manage all risks our business encounters. If our policies and procedures are not fully effective or we are not successful in identifying and mitigating all risks to which we are or may be exposed, we may suffer uninsured liability, harm to our reputation or be subject to litigation or regulatory actions that could adversely affect our business, financial condition or results of operations.

Our ability to limit our liabilities by contract or through insurance may be ineffective or insufficient to cover our future liabilities.
We attempt to limit, by contract, our liability for damages arising from our negligence, errors, mistakes or security breaches. Contractual limitations on liability, however, may not be enforceable or may otherwise not provide sufficient protection to us from liability for damages and we are not always able to negotiate meaningful limitations. We maintain liability insurance coverage, including coverage for cyber security and errors and omissions. It is possible, however, that claims could exceed the amount of our applicable insurance coverage, if any, or that this coverage may not continue to be available on acceptable terms or in sufficient amounts. Even if these claims do not result in liability to us, investigating and defending against them could be expensive and time-consuming and could divert management’s attention away from our operations. In addition, negative publicity caused by these events may delay market acceptance of our products and services, any of which could materially and adversely affect our reputation and our business.

We may become subject to litigation, which could have a material adverse effect on our business, financial condition and results of operations.
We may become subject to litigation in the future. Some of these claims may result in significant defense costs and potentially significant judgments against us, some of which we are not, or cannot be, insured against. We generally intend to defend ourselves vigorously; however, we cannot be certain of the ultimate outcomes of any claims that may arise in the future. Resolution of these types of matters against us may result in our having to pay significant fines, judgments or settlements, which, if uninsured, or if the fines, judgments and settlements exceed insured levels, could adversely impact our earnings and cash flows, thereby having a material adverse effect on our business, financial condition, results of operations, cash flow and per share trading price of our common stock. Certain litigation or the resolution of certain litigation may affect the availability or cost of some of our insurance coverage, which could adversely impact our results of operations and cash flows, expose us to increased risks that would be uninsured and adversely impact our ability to attract directors and officers.





29


Risks relating to our payments business

If our payments platform is limited, restricted, curtailed or degraded in any way, or if we fail to continue to grow and develop our payments platform, our business may be materially and adversely affected.
Our payments platform is a core element of our business. For the fiscal year ended January 31, 2023, our payments platform generated 28% of our total revenue. Our future success depends in part on the continued growth and development of our payments platform. If such activities are limited, restricted, curtailed or degraded in any way, or if we fail to continue to grow and develop our payments platform, our business may be materially and adversely affected. The utilization of our payment processing tools may be impacted by factors outside of our control, such as disruptions in the payment processing industry generally. If the number of patients utilizing our payments platform, or the aggregate amounts paid by such patients directly to our healthcare services clients through our payments platform, were to be reduced as a result of disruptions in the payment processing industry or other factors, it could result in a decrease to our revenue, which could harm our business, financial condition and results of operations. In addition, some potential or existing clients may not desire to use our payment processing services or to switch from their existing payment processing vendors for a variety of reasons, such as transition costs, business disruption, and loss of accustomed functionality. There can be no assurance that our efforts to overcome these factors will be successful, and this resistance may adversely affect our growth.

The attractiveness of our payment processing services may also depend on our ability to integrate emerging payment technologies, including crypto-currencies, other emerging or alternative payment methods, and credit card systems that we or our processing partners may not adequately support or for which we or they do not provide adequate processing rates. In the event such methods become popular among consumers, any failure to timely integrate emerging payment methods (such as ApplePay) into our software, anticipate client behavior changes, or contract with payment processing partners that support such emerging payment technologies could reduce the attractiveness of our payment processing services, potentially resulting in a corresponding loss of revenue.

Increases in card network fees and other changes to fee arrangements may result in the loss of clients who use our payment processing services or a reduction in our earnings.
From time to time, card networks, including Visa, MasterCard, American Express and Discover, increase the fees that they charge acquirers, which would be passed down to processors, payment facilitators and merchants. We could attempt to pass these increases along to our clients, but this strategy might result in the loss of clients to competitors who do not pass along the increases. If competitive practices prevent us from passing along the higher fees to our clients in the future, we may have to absorb all or a portion of such increases, which may increase our operating costs and reduce our earnings.

If we fail to comply with the applicable requirements of card networks, they could seek to fine us, suspend us or terminate our payment facilitator status. If our clients or sales partners incur fines or penalties that we cannot collect from them, we may have to bear the cost of such fines or penalties.
We provide a payments solution for the secure processing of patient payments. Our payment processing tools can connect to multiple clearinghouses and can also connect directly with patients. We have developed partnerships with primary credit card processors in the United States to facilitate payment processing, and we are registered with Visa, MasterCard, American Express, Discover and other card networks as a service provider (payment facilitator or the equivalent) for acquiring member institutions. These card networks set the operating rules and standards with which we must comply. The termination of our status as a certified service provider, a decision by the card networks to disallow payment facilitators or bar us from serving as such, or any changes in network rules or standards, including interpretation and implementation of the operating rules or standards, that increase the cost of doing business or limit our ability to provide transaction processing services to our clients or partners, could adversely affect our business, financial condition or results of operations.
We and our clients are subject to card network rules that could subject us or our clients to a variety of fines or penalties that may be levied by card networks for certain acts or omissions by us or our clients. If a client or sales partner fails to comply with the applicable requirements of card networks, we could be subject to a variety of fines or penalties that may be levied by card networks. We may have to bear the cost of such fines or penalties if we cannot collect them from the applicable client or sales partner, resulting in lower earnings or losses for us. Our violation of the network rules may result in the termination or suspension of our registration with the affected network. The termination of our registration, including a card network barring us from acting as a payment facilitator, or any changes in card network rules that would impair our registration, could require us to stop providing payment




30


processing services relating to the affected card network, which would adversely affect our ability to conduct our business.

In addition, the rules of card networks are set by their boards, which may be influenced by card issuers. Many banks directly or indirectly sell processing services to clients in competition with us. These banks could attempt, by virtue of their influence on the networks, to alter the networks’ rules or policies to the detriment of non-members, including us.

Changes in laws and regulations relating to interchange fees on payment card transactions would adversely affect our revenue and results of operations.

We pay interchange fees to the card networks or the card issuers for each transaction we process. The card networks may increase, from time to time, the fees that they charge members or service providers. Although we may attempt to pass these increases along to our clients, this may result in the loss of clients to our competitors that do not pass along the increases. A provision of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the "Dodd-Frank Act") known as the Durbin Amendment empowered the Federal Reserve Board, ("FRB"), to establish and regulate a cap on the interchange fees that merchants pay banks for electronic clearing of debit card transactions. The final rule implementing the Durbin Amendment established standards for assessing whether debit card interchange fees received by debit card issuers were reasonable and proportional to the costs incurred by issuers for electronic debit transactions, and it established a maximum permissible interchange fee that an issuer may receive for an electronic debit transaction, limiting the fee revenue to debit card issuers and payment processors. To the extent that HSA-linked payment cards and other exempt payment cards used on our Platform (or their issuing banks) lose their exempt status under the current rules or if the current interchange rate caps applicable to other payment cards used on our Platform are increased, any such amendment, rule making, or legislation could impact interchange rates applicable to payment card transactions processed through our Platform. As a result, this could decrease our revenue and profit and could have a material adverse effect on our financial condition and results of operations.

Risk relating to our data and intellectual property
If our intellectual property is not adequately protected, we may not be able to build name recognition, protect our technology and products, and our business may be adversely affected.
Our business depends on proprietary technology and content, including software, databases, confidential information and know-how, the protection of which is crucial to the success of our business. We rely on a combination of trademark, trade-secret and copyright laws, confidentiality procedures and contractual provisions to protect our intellectual property rights in our proprietary technology, content and brand. We may, over time, increase our investment in protecting our intellectual property through additional trademark, patent and other intellectual property filings that could be expensive and time-consuming. Effective trademark, trade-secret and copyright protection is expensive to develop and maintain, both in terms of initial and ongoing registration requirements and the costs of defending our rights. These measures, however, may not be sufficient to offer us meaningful protection. If we are unable to protect our intellectual property and other proprietary rights, our brand, competitive position and business could be harmed, as third parties may be able to dilute our brand or commercialize and use technologies and software products that are substantially the same as ours without incurring the development and licensing costs that we have incurred. Any of our owned or licensed intellectual property rights could be challenged, invalidated, circumvented, infringed or misappropriated, our trade secrets and other confidential information could be disclosed in an unauthorized manner to third parties, or our intellectual property rights may not be sufficient to permit us to take advantage of current market trends or otherwise provide us with competitive advantages, which could result in costly redesign efforts, discontinuance of certain offerings or other competitive harm.
Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors’ products and services, and may in the future seek to enforce our rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent infringement or misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our brand or our ability to compete and reduce demand for our technology and products. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our products and services rely on technologies and software developed by or licensed from third parties. Any disruption or disturbance in such third-party products or services, which we have experienced in the past, could interrupt the operation of our Platform. We may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms or at all.




31


We may also be required to protect our proprietary technology and content in an increasing number of jurisdictions, a process that is expensive and may not be successful, or which we may not pursue in every location. In addition, effective intellectual property protection may not be available to us in every country, and the laws of some foreign countries may not be as protective of intellectual property rights as those in the United States. Additional uncertainty may result from changes to intellectual property legislation enacted in the United States and elsewhere, and from interpretations of intellectual property laws by applicable courts and agencies. Accordingly, despite our efforts, we may be unable to obtain and maintain the intellectual property rights necessary to provide us with a competitive advantage. Our failure to obtain, maintain and enforce our intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.

Our use of “open source” software could adversely affect our ability to offer our services and subject us to possible litigation.
We may use open source software in connection with our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the use of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to such software and/or make available any derivative works of the open source code, which could include valuable proprietary code of the user, on unfavorable terms or at no cost. While we monitor the use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, in part because open source license terms are often ambiguous. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations and could help our competitors develop products and services that are similar to or better than ours.

Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.
We depend upon licenses from third parties for some of the technology and data used in our applications, and for some of the technology platforms upon which these applications are built and operate. We expect that we may need to obtain additional licenses from third parties in the future in connection with the development of our products and services. In addition, we obtain a portion of the data that we use from government entities, public records and our partners for specific partner engagements. We believe that we have all rights necessary to use the data that is incorporated into our products and services. However, we cannot assure you that our licenses for information will allow us to use that information for all potential or contemplated applications and products. In addition, our ability to use data to support existing products and services and to develop new products and services is largely dependent upon the contractual rights we secure. For example, certain of our products depend on maintaining our data and analytics platform, which is populated with data disclosed to us by healthcare services clients, life sciences companies and their respective patients and other partners with their consent. If these clients, patients or partners revoke their consent for us to maintain, use, de-identify and share this data, consistent with applicable law, our data assets could be degraded.
In the future, data providers could withdraw their data from us or restrict our usage for any reason, including if there is a competitive reason to do so, if legislation is passed restricting the use of the data or if judicial interpretations are issued restricting use of the data that we currently use in our products and services. In addition, data providers could fail to adhere to our quality control standards in the future, causing us to incur additional expense to appropriately utilize the data. If a substantial number of data providers were to withdraw or restrict their data, or if they fail to adhere to our quality control standards, and if we are unable to identify and contract with suitable alternative data suppliers and integrate these data sources into our service offerings, our ability to provide products and services to our partners would be materially adversely impacted, which could have a material adverse effect on our business, financial condition and results of operations.
We also integrate into our proprietary applications and use third-party software to maintain and enhance, among other things, content generation and delivery, and to support our technology infrastructure. Some of this software is proprietary and some is open source software. Our use of third-party technologies and open source software exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into the Phreesia Platform, the diversion of our resources from development of our own proprietary technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and




32


maintenance costs. These technologies may not be available to us in the future on commercially reasonable terms or at all and could be difficult to replace once integrated into our own proprietary applications. Most of these licenses can be renewed only by mutual consent and may be terminated if we breach the terms of the license and fail to cure the breach within a specified period of time. Our inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and integrated, which would harm our business, financial condition and results of operations.
Most of our third-party licenses are non-exclusive and our competitors may obtain the right to use any of the technology covered by these licenses to compete directly with us. If our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.

Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business, financial condition and results of operations.
Our commercial success depends on our ability to develop and commercialize our services and use our proprietary technology without infringing the intellectual property or proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. As the market for healthcare in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our products and technology of which we are not aware or that we must challenge to continue our operations as currently contemplated. Whether merited or not, we may face allegations that we, our partners, our licensees or parties indemnified by us have infringed or otherwise violated the patents, trademarks, copyrights or other intellectual property rights of third parties. Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties. Additionally, in recent years, individuals and groups have begun purchasing intellectual property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. We may also face allegations that our employees have misappropriated the intellectual property or proprietary rights of their former employers or other third parties. It may be necessary for us to initiate litigation to defend ourselves in order to determine the scope, enforceability and validity of third-party intellectual property or proprietary rights, or to establish our respective rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, such claims can be time-consuming, divert management’s attention and financial resources and can be costly to evaluate and defend. Results of any such litigation are difficult to predict and may require us to stop commercializing or using our products or technology, obtain licenses, modify our services and technology while we develop non-infringing substitutes or incur substantial damages, settlement costs or face a temporary or permanent injunction prohibiting us from marketing or providing the affected products and services. If we require a third-party license, it may not be available on reasonable terms or at all, and we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services. We may also have to redesign our products or services so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our technology and products may not be available for commercialization or use. Even if we have an agreement to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot or do not obtain a third-party license to the infringed technology, license the technology on reasonable terms or obtain similar technology from another source, our revenue and earnings could be adversely impacted.
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. We are not currently subject to any claims from third parties asserting infringement of their intellectual property rights. Some third parties may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Moreover, any uncertainties resulting from the initiation and continuation of any legal proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations. Assertions by third parties that we violate their intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.

Interruption or failure of our information technology and communications systems could impair our ability to effectively deliver our products and services, which could cause us to lose clients and harm our operating results.




33


Our business depends on the continuing operation of our technology infrastructure and systems. Proprietary software development is time-consuming, expensive and complex, and may involve unforeseen difficulties. We may encounter technical obstacles in enhancing our existing software and developing new software, and it is possible that we may discover additional problems that prevent our proprietary applications from operating properly. In addition, any damage to or failure of our existing systems could result in interruptions in our ability to deliver our products and services. Interruptions in our service could reduce our revenue and profits, and our reputation could be damaged if people believe our systems are unreliable.
Our systems and operations are vulnerable to damage or interruption from natural disasters or man-made problems, such as earthquakes, floods, fires, political unrest, acts of terrorism, armed conflict or war (such as the current Russian invasion of Ukraine), power loss, break-ins, hardware or software failures, telecommunications failures, computer viruses or other attempts to harm our systems and similar events. Any unscheduled interruption in our service would result in an immediate loss of revenue. Frequent or persistent system failures that result in the unavailability of our Platform or slower response times could reduce our clients’ ability to access our Platform, impair our delivery of our products and services and harm the perception of our Platform as reliable, trustworthy and consistent. Our insurance policies provide only limited coverage for service interruptions and may not adequately compensate us for any losses that may occur due to any failures or interruptions in our systems.

If our services fail to provide accurate and timely information, or if our content or any other element of our service is associated with errors or malfunctions, we could have liability to clients or patients which could adversely affect our results of operations.
Our software, content and services are used to assist medical groups, health systems and payers with managing the patient intake process and to empower patients and healthcare organizations as they navigate the challenges of an evolving healthcare system. If our software, content or services fail to provide accurate and timely information or are associated with errors or malfunctions, then healthcare services clients or patients could assert claims against us that could result in substantial costs to us, harm our reputation in the industry and cause demand for our services to decline.
Our proprietary service is utilized in patient intake and engagement and to help healthcare services organizations better understand patients through medical histories, insurance benefits and socio-economic indicators. If our service fails to provide accurate and timely information, or if our content or any other element of our service is associated with errors or malfunctions, we could have liability to healthcare services clients or patients. We attempt to limit by contract our liability for damages and to require that our clients assume responsibility for medical care and approve key system rules, protocols and data. Despite these precautions, the allocations of responsibility and limitations of liability set forth in our contracts may not be enforceable, may not be binding upon patients or may not otherwise protect us from liability for damages.
Our proprietary software may contain errors or failures that are not detected until after the software is introduced or updates and new versions are released. It is challenging for us to test our software for all potential problems because it is difficult to simulate the wide variety of computing environments or methodologies that our clients may deploy or rely upon. From time to time we have discovered defects or errors in our software, and such defects or errors can be expected to appear in the future. Defects and errors that are not timely detected and remedied could expose us to risk of liability to healthcare services clients and patients and cause delays in introduction of new services, result in increased costs and diversion of development resources, require design modifications or decrease market acceptance or client satisfaction with our services. If any of these risks occur, they could materially adversely affect our business, financial condition or results of operations.

We may be liable for use of incorrect or incomplete data we provide which could harm our business, financial condition and results of operations.

We collect, store and display data, including patient health information, for use by healthcare services clients in handling patient intake and engagement. Our clients, their patients, or third parties provide us with most of this data. If this data is incorrect or incomplete or if we make mistakes in the capture or input of this data, adverse consequences may occur and give rise to product liability and other claims against us. In addition, a court or government agency may take the position that our storage and display of health information exposes us to liability arising out of our intake, storage and display of erroneous health information. While we maintain insurance coverage, we cannot be certain that this coverage will prove to be adequate or will continue to be available on acceptable terms, if at all. Even unsuccessful claims could result in substantial costs and diversion of management resources. A claim brought against us that is uninsured or under-insured could harm our business, financial condition and results of operations.




34



Risks relating to laws and regulations applicable to our industry

We are subject to health care laws and data privacy and security laws and regulations governing our collection, use, disclosure, storage and transmission of personally identifiable information, including protected health information and payment card data, which may impose restrictions on us and our operations, require us to change our business practices and put in place additional compliance mechanisms, and subject us to fines, penalties, lawsuits, adverse publicity, reputational harm, loss of customer trust or government enforcement actions if we are unable to fully comply with such laws.
Numerous complex federal and state laws and regulations govern the collection, use, disclosure, storage and transmission of personally identifiable information, including protected health information. State laws may be even more restrictive and not preempted by HIPAA, and may be subject to varying interpretations by the courts and government agencies. These laws and regulations, including their interpretation by governmental agencies, are subject to frequent change and could have a negative impact on our business. Further, these varying interpretations could create complex compliance issues for us and our partners and potentially expose us to additional expense, liability, penalties, negatively impact our client relationships, and lead to adverse publicity, and all of these risks could adversely affect our business in the short and long term. In addition, contractual obligations and in the future, legislation may limit, forbid or regulate the use or transmission of health information outside of the United States or across other national borders. These developments, if adopted, could render our use of Canadian employees and other non-U.S. resources for work related to such data impracticable or substantially more expensive.

We are a “Business Associate” as defined under the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act ("HITECH Act") and their implementing regulations, collectively referred to as HIPAA. The U.S. Department of Health and Human Services, ("HHS"), Office for Civil Rights, may impose civil penalties on a Business Associate for a failure to comply with HIPAA requirements. The U.S. Department of Justice is responsible for criminal prosecutions under HIPAA. Penalties can vary significantly depending on a number of factors, such as whether the Business Associate’s failure to comply was due to willful neglect. State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would allow individuals to sue in civil court for HIPAA violations, its standards have been used as the basis for the duty of care in state civil suits, such as those for recklessness in misusing individuals’ health information. If we are subject to investigation or litigation related to an alleged violation of HIPAA, then we may elect to resolve the matter through a settlement. Such settlement could require payment of a civil penalty or damages, corrective action and/or monitoring of our business by a third party.

The security measures that we and our third-party vendors and subcontractors have in place to ensure compliance with privacy and data protection laws may not protect our facilities and systems from security breaches, acts of vandalism or theft, computer viruses, misplaced or lost data, malfeasance, programming and human errors or other similar events. Under the HITECH Act, as a Business Associate we may also be liable for privacy and security breaches and failures of our subcontractors. Even though we provide for appropriate protections through our agreements with our subcontractors, we still have limited control over their actions and practices. A breach of privacy or security of individually identifiable health information by a subcontractor may result in an enforcement action, including criminal and civil liability, against us. We are not able to predict the extent of the impact such incidents may have on our business. Our failure to comply may result in criminal and civil liability because the potential for enforcement action against Business Associates is now greater. Enforcement actions against us could be costly and could interrupt regular operations, which may adversely affect our business. While we have not received any notices of violation of the applicable privacy and data protection laws and believe we are in compliance with such laws, there can be no assurance that we will not receive such notices in the future.

Even when HIPAA does not apply, according to the Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers’ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C. § 45(a). The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC’s current guidance for appropriately securing consumers’ personal information is similar to what is required by the HIPAA security regulations, but this guidance may change in the future, resulting in increased complexity and the need to expend additional resources to ensure we are complying with the FTCA.





35


Other federal and state laws restrict the use and protect the privacy and security of personally identifiable information are, in many cases, are not preempted by HIPAA and may be subject to varying interpretations by the courts and government agencies. These varying interpretations can create complex compliance issues for us and our partners and potentially expose us to additional expense, adverse publicity and liability, any of which could adversely affect our business.

Federal and state consumer protection laws are increasingly being applied by the United States Federal Trade Commission and states’ attorneys general to regulate the collection, use, storage and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.

There is ongoing concern from privacy advocates, regulators and others regarding data privacy and security issues, and the number of jurisdictions with data privacy and security laws has been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identification, anonymization or pseudonymization of health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. We expect that there will continue to be new proposed and amended laws, regulations and industry standards concerning privacy, data protection and information security in the United States, such as the CCPA, as amended by the California Privacy Rights Act, or CPRA, which amendments went into effect on January 1, 2023, The CCPA creates specific obligations with respect to processing and storing personal information, and the CPRA amendments created a new state agency that is vested with authority to implement and enforce the CCPA. Additionally, a similar law went into effect in Virginia on January 1, 2023, and further US-state comprehensive privacy laws are set to go into effect throughout 2023, including laws in Colorado, Connecticut, and Utah. We cannot yet determine the full impact these laws or other such future laws, regulations and standards may have on our current or future business. Any of these laws may broaden their scope in the future, and similar laws have been proposed on both a federal level and in more than half of the states in the U.S. A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.

We also expect that there will continue to be new or amended laws, regulations, standards and obligations proposed and enacted in various jurisdictions. Many countries around the world have enacted comprehensive privacy and data protection laws that can impact our business. For example, in May 2018, the General Data Protection Regulation, or GDPR, went into effect in the European Union, or EU. The GDPR imposes more stringent data protection requirements and requires businesses subject to it to give more detailed disclosures about how they collect, use, and share personal information; contractually commit to data protection measures in contracts; maintain adequate data security measures; notify regulators and affected individuals of certain data breaches; obtain consent to collect sensitive personal information such as health information; meet extensive privacy governance and documentation requirements; and honor individuals’ data protection rights, including their rights to access, correct, and delete their personal information. The GDPR also imposes strict rules on the transfer of personal information to countries outside of the European Economic Area, or EEA, including the United States. A recent judicial decision from the EU and recent announcements from European regulators regarding transfers of personal information outside of the EEA have increased the legal risks and liabilities, and compliance and operational costs, of lawfully making such transfers. Companies that violate the GDPR can face private litigation, restrictions, or prohibitions on data processing, and fines of up to the greater of 20 million Euros or 4% of worldwide annual revenue.

In addition, further to the UK’s exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK’s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK’s data protection regime, which is independent from but aligned to the EU’s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to £17.5 million or 4% of worldwide revenue, whichever is higher. Although the GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the GDPR. The UK government has announced plans to reform the data protection legal framework in the UK in its Data Reform Bill but those have been put on hold. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of EU personal




36


information and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EU.

Although the UK is regarded as a third country under the EU’s GDPR, the European Commission (the “EC”), has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC’s new standard contractual clauses but has published the UK International Data Transfer Agreement and International Data Transfer Addendum to the new standard contractual clauses (the “IDTA”), which enable transfers from the UK. For new transfers, the IDTA already needs to be in place, and must be in place for all existing transfers from the UK from March 21, 2024. Following a ruling from the Court of Justice of the EU, in Data Protection Commissioner v Facebook Ireland Limited and Maximillian Schrems, Case C-311/18 ("Schrems II"), companies relying on standard contractual clauses to govern transfers of personal data to third countries (in particular the United States) will need to assess whether the data importer can ensure sufficient guarantees for safeguarding the personal data under GDPR. This assessment includes assessing whether third-party vendors can also ensure these guarantees. The same assessment is required for transfers governed by the IDTA. We will be required to implement these new safeguards when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost.

On March 25, 2022, the European Commission and the U.S. White House announced that an agreement on Privacy Shield 2.0 has been reached. However, it is too soon to tell how the future of Privacy Shield 2.0 will evolve and what impact it will have on our cross-border activities.

Insignia Health, LLC, which we acquired in December 2021, is subject to additional laws and regulations, including those in the EEA and UK, such as the GDPR and UK GDPR. Compliance with such laws and regulations requires resources and could be more costly and take more time than we anticipate and could involve new fines or penalties for non-compliance, all of which could adversely affect our business.

The UK has additional privacy and consumer protection laws, such as the Privacy and Electronic Communications Regulations, to which our marketing messages to actual or potential UK-based customers may be subject.

We have operations in Canada, where our collection, use, disclosure, and management of personal information must comply with both federal and provincial privacy laws, which impose separate requirements, but may overlap in some instances. The Personal Information Protection and Electronic Documents Act ("PIPEDA"), applies in all Canadian provinces except Alberta, British Columbia and Québec, as well as to the transfer of consumer data across provincial borders. PIPEDA imposes stringent consumer data protection obligations, requires privacy breach reporting, and limits the purposes for which organizations may collect, use, and disclose consumer data. The provinces of Alberta, British Columbia, and Québec have enacted separate data privacy laws that are substantially similar to PIPEDA, but all three additionally apply to our handling of our own employees’ personal data within their respective provinces. Notably, Québec’s Act respecting the protection of personal information in the private sector, or the Private Sector Act, was amended by Bill 64, an Act to modernize legislative provisions as regards the protection of personal information, which introduced major amendments to the Private Sector Act, notably, to impose significant and stringent new obligations on Québec businesses while increasing the powers of Quebec’s supervisory authority. We may incur additional costs and expenses related to compliance with these laws and may incur significant liability if we are not able to comply with these laws. We are also subject to Canada’s anti-spam legislation, or CASL, which includes rules governing commercial electronic messages, which include marketing emails, text messages, and social media advertisements. Under these rules, we must follow certain standards when sending marketing communications, are prohibited from sending them to customers without their consent, and can be held liable for violations.

Internationally, virtually every jurisdiction in which we operate has established its own data security and privacy legal framework with which we or our customers must comply. Cross-border data transfers and other future developments regarding local data residency and access could increase the cost and complexity of delivering our services in some markets and may lead to governmental enforcement actions, litigation, fines, and penalties or adverse publicity, which could adversely affect our business and financial position could greatly increase our cost of




37


providing our products and services, require significant changes to our operations or even prevent us from offering certain services in specific jurisdictions. In addition, any limitation on our ability to use or transmit health information outside of the U.S. could impose restrictions on our ability to recruit and maintain employees residing outside of the U.S., which could, in turn, adversely affect our business.

Future laws, regulations, standards, obligations amendments, and changes in the interpretation of existing laws, regulations, standards and obligations could impair our or our clients’ ability to collect, use or disclose information relating to consumers, which could decrease demand for our Platform, increase our costs and impair our ability to maintain and grow our client base and increase our revenue. New laws, amendments to or re-interpretations of existing laws and regulations, industry standards and contractual obligations could impair our or our customers’ ability to collect, use or disclose information relating to patients or consumers, which could decrease demand for our platform offerings, increase our costs and impair our ability to maintain and grow our client base and increase our revenue. Accordingly, we may find it necessary or desirable to fundamentally change our business activities and practices or to expend significant resources to modify our software or Platform and otherwise adapt to these changes.

We are also subject to self-regulatory standards and industry certifications that may legally or contractually apply to us. These include the Payment Card Industry Data Security Standards ("PCI-DSS") and AICPA Security Organization Control 2 ("SOC 2"), with which we are currently compliant, and HITRUST certification, which we currently maintain. In the event we fail to comply with the PCI-DSS or fail to maintain our SOC 2 or HITRUST certification, we could be in breach of our obligations under customer and other contracts, fines and other penalties could result, and we may suffer reputational harm and damage to our business. Further, our clients may expect us to comply with more stringent privacy, data storage and data security requirements than those imposed by laws, regulations or self-regulatory requirements, and we may be obligated contractually to comply with additional or different standards relating to our handling or protection of data.

Any failure or perceived failure by us to comply with domestic or foreign laws or regulations, industry standards or other legal obligations, or any actual or suspected privacy or security incident, whether or not resulting in unauthorized access to, or acquisition, release or transfer of personally identifiable information or other data, may result in governmental enforcement actions and prosecutions, private litigation, fines and penalties or adverse publicity and could cause our clients to lose trust in us, which could have an adverse effect on our reputation and business. We may be unable to make such changes and modifications in a commercially reasonable manner or at all, and our ability to develop new products and features could be limited. Any of these developments could harm our business, financial condition and results of operations. Privacy and data security concerns, whether valid or not valid, may inhibit retention of our Platform or services by existing clients or adoption of our Platform or services by new clients.

Existing laws regulate our ability to engage in direct marketing and changes in privacy laws could adversely affect our ability to market our products effectively and could impact our results from operations or result in costs and fines.
We rely on a variety of direct marketing techniques, including email marketing. These activities are regulated by legislation such as the Controlling the Assault of Non-Solicited Pornography and Marketing (CAN-SPAM) Act of 2003. Any failure by us to comply fully with the CAN-SPAM Act may leave us subject to substantial fines and penalties. In addition, any future restrictions in laws such as the CAN-SPAM Act, and various United States state laws, or new federal laws regarding marketing and solicitation or international data protection laws that govern these activities could adversely affect the continuing effectiveness of our marketing efforts and could force changes in our marketing strategies. If this occurs, we may not be able to develop adequate alternative marketing strategies, which could have a material adverse impact on our results of operations.

Any failure by us to comply fully with website accessibility standards could result in us being subject to considerable fines and penalties.
We conduct business through various Internet websites and web-based applications that are subject to accessibility requirements. Courts have ruled that the Americans with Disabilities Act (ADA) applies to Internet websites and other digital experiences and litigation related to ADA website accessibility has soared in recent years. Failing to comply with those requirements could leave our Company subject to claims, litigation, lawsuits and, ultimately, substantial fines and penalties.

The healthcare regulatory and political framework is uncertain and evolving.




38


Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. For example, in March 2010, the Patient Protection and Affordable Care Act ("ACA") was adopted, which is a healthcare reform measure that provides healthcare insurance for millions of Americans. The ACA includes a variety of healthcare reform provisions and requirements that became effective at varying times through 2018 and substantially changes the way healthcare is financed by both governmental and private insurers, which may significantly impact our industry and our business. Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.

Further, on March 9, 2020, the HHS, Office of the National Coordinator for Health Information Technology ("ONC") and CMS promulgated final rules aimed at supporting seamless and secure access, exchange, and use of electronic health information ("EHI"), by increasing innovation and competition by giving patients and their healthcare service providers secure access to health information and new tools, allowing for more choice in care and treatment. The final rules are intended to clarify and operationalize provisions of the 21st Century Cures Act ("Cures Act"), regarding interoperability and “information blocking,” and create significant new requirements for health care industry participants. Information blocking is defined as activity that is likely to interfere with, prevent, or materially discourage access, exchange, or use of EHI, where a health information technology developer, health information network or health information exchange knows or should know that such practice is likely to interfere with access to, exchange or use of EHI.

The final CMS rule focuses on patients enrolled in Medicare Advantage plans, Medicaid and Children's Health Insurance Program ("CHIP") fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and qualified health plans on the federally-facilitated exchanges, and enacts measures to enable patients to have both their clinical and administrative information travel with them.
Recent regulatory reform constitutes a significant departure from previous regulations regarding patient data. While these rules benefit us in that certain EHR vendors will no longer be permitted to interfere with our attempts at integration, they may also make it easier for other similar companies to enter the market, creating increased competition and reducing our market share. It is unclear at this time what the costs of compliance with the final rules will be, and what additional risks there may be to our business.
In addition, we are subject to various other laws and regulations, including, among others, anti-kickback laws, antitrust laws and the privacy and data protection laws described below.

We conduct business in a heavily regulated industry, and any failure to comply with applicable healthcare laws and government regulations, could result in financial penalties, exclusion from participation in government healthcare programs and adverse publicity, or could require us to make significant operational changes, any of which could harm our business.

Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws, HIPAA and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs, and other interactions with healthcare professionals. For more information regarding the risks related to these laws and regulations please see “Business – Regulatory Matters – U.S. Federal and State Fraud and Abuse Laws.”

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Because of the breadth of these laws and the narrowness of their statutory or regulatory exceptions and safe harbors, some of our business activities may be subject to challenge under one or more of them.

Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. Achieving and sustaining compliance requires us to implement controls across our entire organization which may prove costly and challenging to monitor and enforce.




39


The risk of our being found in violation of healthcare laws and regulations is increased by the fact that their provisions are sometimes complex and open to a variety of interpretations.

It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Likewise, if any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment as well. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.
The U.S. Food and Drug Administration may in the future determine that our technology solutions are subject to the Federal Food, Drug, and Cosmetic Act and we may face additional costs and risks as a result.
The FDA may promulgate a policy or regulation that affects our products and services. FDA regulations govern among other things, product development, testing, manufacture, packaging, labeling, storage, clearance or approval, advertising and promotion, sales and distribution and import and export for regulated drugs, biologics and devices. Non-compliance with applicable FDA requirements can result in, among other things, public warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure of the FDA to grant marketing approvals, withdrawal of marketing approvals, a recommendation by the FDA to disallow us from entering into government contracts and criminal prosecutions. The FDA also has the authority to request repair, replace or refund of the cost of any device.
Individuals may claim our calling or text messaging services are subject to, and are not compliant with the Telephone Consumer Protection Act or similar state laws.
Our clients may use our products to place various short message service, or SMS, text messages and calls to patients. The Telephone Consumer Protection Act ("TCPA") is a federal statute that protects consumers from unwanted telephone calls, faxes and text messages. There are a number of federal and state statutes and regulations that govern such telecommunications, the use of automatic telephone dialing systems (“ATDS”) or other automated systems to make such telecommunications, and the use of artificial voice or pre-recorded messages in certain telecommunications. These laws include the Telephone Consumer Protection Act (TCPA), Telemarketing Sales Rule (TSR), and various other state laws. The U.S. Federal Communications Commission (FCC), and the Federal Trade Commissions have responsibility for regulating various aspects of some of the TCPA, TSR and other federal laws. Among other requirements, the TCPA requires callers to obtain prior express written consent for certain telemarketing calls and to adhere to “do-not-call” registry requirements which, in part, mandate that callers maintain and regularly update lists of consumers who have chosen not to be called and restrict calls to consumers who are on the national do-not-call list. Florida, Oklahoma and other states also have mini-TCPA and other similar consumer protection laws regulating calls and texts directed to their residents. As currently construed, the TCPA does not distinguish between voice and data, and, as such, text and SMS/MMS messages are also “calls” for the purpose of TCPA (and, in some cases, state mini-TCPA) obligations and restrictions.

For violations of the TCPA, the law provides for a private right of action under which a plaintiff may recover monetary damages of $500 for each call or text made in violation of the prohibitions on certain calls made using an artificial or pre-recorded voice or an ATDS and certain calls made to numbers properly registered on the federal “do-not-call” list. A court may treble the $500 amount upon a finding of a willful or knowing violation. There is no statutory cap on maximum aggregate exposure (although some courts have applied in TCPA class actions constitutional limits on excessive penalties). An action may be brought by the FCC, a state attorney general, an individual, or a class of individuals. As with the TCPA, Florida’s mini-TCPA, for example, restricts certain calls and calls and texts made using an automated system to Florida residents without prior consent, allows a plaintiff to obtain $500 for each call or text made in violation of its prohibitions, and permits a court to treble the $500 amount for willful or knowing violations of the statute. The TCPA, TSR, mini-TCPA laws and other similar state laws are subject to interpretations that may change. We regularly evaluate how they may apply to our business. The FCC, FTC, a state attorney general or other regulator, or a court, however, may disagree with our interpretation of these




40


laws and conclude that we are not in compliance and impose damages, civil penalties and other consequences upon us for noncompliance. Determination by a court or regulatory agency that our services did not comply also invalidate all or portions of some of our client contracts, could require us to change or terminate some portions of our business, could require us to refund portions of our services fees, and could have an adverse effect on our business. Further, we could be subject to putative class action lawsuits alleging violations of the TCPA, state mini-TCPA laws and other similar state laws. Our call and SMS texting services are potential sources of risk for class action lawsuits and liability for our Company. Numerous class-action suits under federal and state laws have been filed in recent years against companies who conduct call and SMS texting programs, with many resulting in multi-million-dollar settlements to the plaintiffs. Even an unsuccessful challenge by consumers or regulatory authorities of our activities could result in adverse publicity and could require a costly response from us. If in the future we are found to have violated such laws in a class action, the amount of damages and potential liability could be extensive and adversely impact our business. Accordingly, were such a class certified or if we are unable to successfully defend such a suit, then the damages could have a material adverse effect on our results of operations and financial condition.

Our employees in Canada are subject to the laws and regulations of the government of Canada and its subdivisions.

Certain of our employees are based in Canada and are subject to additional laws and regulations by the government of Canada, as well as its provinces. These include Canadian federal and local corporation requirements, restrictions on exchange of funds, employment-related laws and qualification for tax status. If we fail to comply with Canadian laws and regulations, or if the government of Canada or its provinces determines that our corporate actions do not comply with applicable Canadian law, we could face sanctions or fines, which could have a material adverse effect on our business.

Due to the particular nature of certain services we provide or the manner in which we provide them, we may be subject to additional government regulation and foreign government regulation.

While our Platform is primarily subject to government regulations pertaining to healthcare, certain aspects of our Platform may require us to comply with regulatory schema from other areas. Examples of such regulatory schema include:
Foreign Corrupt Practices Act ("FCPA") and foreign anti-bribery laws. The FCPA makes it illegal for U.S. persons, including U.S. companies, and their subsidiaries, directors, officers, employees, and agents, to promise, authorize or make any corrupt payment, or otherwise provide anything of value, directly or indirectly, to any foreign official, any foreign political party or party official, or candidate for foreign political office to obtain or retain business. Violations of the FCPA can also result in violations of other U.S. laws, including anti-money laundering, mail and wire fraud, and conspiracy laws. There are severe penalties for violating the FCPA. In addition, the Company may also be subject to other non-U.S. anti-corruption or anti-bribery laws, such as the U.K. Bribery Act 2010. If our employees, contractors, vendors, or partners fail to comply with the FCPA and/or foreign anti-bribery laws, we may be subject to penalties or sanctions, and our ability to develop new prospects and retain existing customers could be adversely affected.
Economic sanctions and export controls. Economic and trade sanctions programs that are administered by the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) prohibit or restrict transactions to or from, and dealings with specified countries and territories, their governments, and in certain circumstances, with individuals and entities that are located in or nationals of those countries, and other sanctioned persons, including specially designated nationals, narcotics traffickers and terrorists or terrorist organizations. As federal, state and foreign legislative regulatory scrutiny and enforcement actions in these areas increase, we expect our costs to comply with these requirements will increase as well. Failure to comply with any of these requirements could result in the limitation, suspension or termination of our services, imposition of significant civil and criminal penalties, including fines, and/or the seizure and/or forfeiture of our assets.

Further, our Platform incorporates encryption technology. The U.S. Export Administration Regulations require authorization for the export of certain encryption items, including by a license, a license exception or other appropriate government authorizations. Such solutions may also be subject to certain regulatory reporting requirements. While we believe our products meet certain exceptions that reduce the scope of export control restrictions applicable to such products, these exceptions may be determined not to apply to our products and our products and underlying technology may become subject to export control restrictions.


Risks relating to our dependence on third parties




41



We rely on our third-party contractors, vendors and partners, including some outside of the United States, to execute our business strategy. Replacing them could be difficult and disruptive to our business. If we are unsuccessful in forming or maintaining such relationships on terms favorable to us, our business may not succeed.
We have entered into contracts with third-party contractors and vendors to provide critical services relating to our business, including initial software development and cloud hosting. We also rely on third-party providers to enable automated eligibility and benefits verification through our Platform, and we outsource certain of our software development and design, quality assurance and operations activities to third-party contractors that have employees and consultants in international locations that may be subject to political and economic instability, including India, Russia and Ukraine. For example, we have entered into a Master Services Agreement with Rayden, pursuant to which Rayden's India-based personnel exclusively support our business through various functions including, but not limited to finance and accounting, sales and marketing, customer operations, product management and support, and research and development. We are also a party to a Consulting and Development Agreement with DataArt, pursuant to which we primarily outsource certain software development services to DataArt.

Our dependence on Rayden, DataArt and other third-party contractors to support key functions of our business creates numerous risks, in particular, the risk that we may not maintain service quality, control or effective management with respect to these operations. In the event that these service providers fail to maintain adequate levels of support, do not provide high quality service, increase the fees they charge us, discontinue their lines of business, terminate our contractual arrangements or cease or reduce operations, we may suffer additional costs and be required to pursue new third-party relationships, which could materially disrupt our operations and our ability to provide our products and services, and could divert management’s time and resources. Our reputation and our customers’ willingness to purchase our products and partners’ willingness to use our products depend, in part, on our third-party contractors’ compliance with ethical employment practices, such as with respect to child labor, wages and benefits, forced labor, discrimination, safe and healthy working conditions, and with all legal and regulatory requirements relating to the conduct of their businesses. If our third-party contractors fail to comply with applicable laws, regulations, safety codes, employment practices, human rights standards, quality standards, environmental standards, production practices, or other obligations, norms, or ethical standards, our reputation and brand image could be harmed and we could be exposed to litigation and additional costs that would harm our business, reputation, and results of operations.

The ability of our third-party contractors to effectively satisfy our business requirements could be impacted by financial difficulty of our third-party contractors or damage to their operations caused by fire, terrorist attack, natural disaster, or other events. It would be difficult to replace some of our third-party contractors and third-party vendors in a timely manner if they were unwilling or unable to provide us with these services in the future, and our business and operations could be adversely affected. If these services fail or are of poor quality, our business, reputation and operating results could be harmed. For example, the continued Russian invasion of Ukraine has, and may continue to, impact macroeconomic conditions, give rise to regional instability, increase the threat of cyberwarfare and result in heightened economic sanctions from the U.S. and the international community in a manner that adversely affects us and our third-party contractors that have employees and consultants located in Russia and Ukraine. Further, although the length and impact of the continuing conflict are highly unpredictable, individuals located in these areas have been and could continue to be forced to evacuate or voluntarily choose to relocate, making them unavailable to provide services, such as software engineering, to support our business. It could also disrupt or delay our communications with such resources or the flow of funds to support their operations, or otherwise render some of our resources unavailable. While we have risk mitigation efforts in place, the realization of any these risks could adversely affect our product development, operations, business and/or financial results and may require us to shift some of our development activities to other jurisdictions and/or third-party contractors, which may result in significant disruption, including delays in releases of new versions or updates of our software and incurrence of additional costs. We anticipate that we will continue to depend on these and other third-party relationships in order to grow our business for the foreseeable future. If we are unsuccessful in maintaining existing and, if needed, establishing new relationships with third parties, our ability to efficiently operate existing services or develop new services could be impaired, and, as a result, our competitive position or our results of operations could suffer.
We also depend on our third-party processing partners to perform payment processing services, which generate almost all of our payments revenue. Our processing partners may go out of business or otherwise be unable or unwilling to continue providing such services, which could significantly and materially reduce our payments revenue and disrupt our business. A number of our processing contracts require us to assume liability for any losses our processing partners may suffer as a result of losses caused by our healthcare services clients and their patients, including losses caused by chargebacks and fraud. Thus, in the event of a significant loss by our processing partners, we may be required to pay-out a large amount of cash in one or two business days following such event




42


and, if we do not have sufficient cash on hand, may be deemed in breach of such contracts. A contractual dispute with our processing partners could adversely impact our revenue. Certain contracts may expire or be terminated, and we may not be able to enter into a new payment processor relationship that replicates the associated revenue for a considerable period of time.
In addition, we have entered into contracts with providers of EHR and PM solutions, and we intend to pursue such agreements in the future. These contracts are typically structured as commercial and technical agreements, pursuant to which we integrate certain of our Platform solutions into the EHR and PM systems that are utilized by many of our clients, for agreed payments or provision of services to such providers of EHR and PM solutions. Our ability to form and maintain these agreements in order to facilitate the integration of our Platform into the EHR and PM systems used by our healthcare services clients and their patients is important to the success of our business. If providers of EHR or PM solutions amend, terminate or fail to perform their obligations under their agreements with us, we may need to seek other ways of integrating our Platform with the EHR and PM systems of our healthcare services clients, which could be costly and time consuming, and could adversely affect our business results.
We or the providers of EHR and PM solutions with which we contract may terminate or seek to amend our agreements in order to incorporate new final rules promulgated on March 9, 2020 by the HHS, ONC, and CMS, which are further described above and are aimed at supporting seamless and secure access, exchange, and use of EHI by increasing innovation and competition by giving patients and their healthcare service providers secure access to health information and new tools, allowing for more choice in care and treatment.
We may also seek to enter into new agreements in the future, and we may not be successful in entering into future agreements on terms favorable to us. Any delay in entering agreements with providers of EHR or PM solutions or other technology providers could either delay the development and adoption of our products and services and reduce their competitiveness. Any such delay could adversely affect our business.

We rely on a limited number of third-party suppliers and contract manufacturers to support our products, and a loss or degradation in performance of these suppliers and contract manufacturers could have a negative effect on our business, financial condition and results of operations.
We rely on third-party suppliers and contract manufacturers for the materials and components used to operate our Phreesia Platform and product offerings, and to manufacture and assemble our hardware, including the PhreesiaPad and our on-site kiosks, which we refer to as Arrivals Kiosks. We rely on a sole supplier, for example, as the manufacturer of our PhreesiaPads and Arrivals Kiosks, which help drive our business and support our subscription, payment processing and life sciences offerings. In connection with these services, our supplier builds new hardware for us and refurbishes and maintains existing hardware.
Any of our other suppliers or third-party contract manufacturers may be unwilling or unable to supply the necessary materials and components or manufacture and assemble our products reliably and at the levels we anticipate or that are required by the market. Our ability to supply our products commercially and to develop any future products depends, in part, on our ability to obtain these materials, components and products in accordance with regulatory requirements and in sufficient quantities for commercialization. If we are required to change contract manufacturers due to any change in or termination of our relationships with these third parties, or if our manufacturers are unable to obtain the materials they need to produce our products at consistent prices or at all, (including, without limitation, because of the effect of tariffs or other trade restrictions), we may lose sales, experience manufacturing or other delays, incur increased costs or otherwise experience impairment to our client relationships. We cannot guarantee that we will be able to establish alternative relationships on similar terms, without delay or at all.
If our third-party suppliers fail to deliver the required quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the supply of our products to clients and the development of any future products will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.





43


We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our clients, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with clients, adversely affecting our brand and our business.
Our ability to deliver our products and services, particularly our cloud-based solutions, is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network connection with the necessary speed, data capacity and security for providing reliable Internet access and services and reliable telephone and facsimile services. Our services are designed to operate without interruption in accordance with our service level commitments.
However, we have experienced limited interruptions in these systems in the past, including server failures that temporarily slow down the performance of our services, and we may experience more significant interruptions in the future. We rely on internal systems as well as third-party suppliers, including bandwidth and telecommunications equipment providers, to provide our services. We do not maintain redundant systems or facilities for some of these services. Interruptions in these systems, whether due to system failures, computer viruses, physical or electronic break-ins or other catastrophic events, could affect the security or availability of our services and prevent or inhibit the ability of our partners to access our services. In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could result in substantial costs to remedy those problems or negatively impact our relationship with our clients, our business, results of operations and financial condition.
Any disruption in the network access, telecommunications or co-location services provided by third-party providers or any failure of or by third-party providers’ systems or our own systems to handle current or higher volume of use could significantly harm our business. We exercise limited control over our third-party suppliers, which increases our vulnerability to problems with services they provide. We have experienced failures by third-party providers’ systems which resulted in a limited interruption of our system, although this failure did not result in any claims against us. Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with clients and adversely affect our business and could expose us to third-party liabilities.
The reliability and performance of our Internet connection may be harmed by increased usage or by denial-of-service attacks. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services.

Risks relating to taxes and accounting standards
Changes in tax regulations and accounting standards, or changes in related judgments or assumptions could materially impact our financial position and results of operation.
We are subject to federal and state income, sales, use, value added and other taxes in the United States and other countries in which we conduct business, and such laws and rates vary by jurisdiction. We are now registered in all states that assess sales taxes on our services. Although we believe our tax practices and provisions are reasonable, the final determination of tax audits and any related litigation, changes in the taxation of our activities and proposed changes in tax laws could cause the ultimate settlement of our tax liabilities to be materially different from our historical tax practices, provisions and accruals. If we receive an adverse ruling as a result of an audit, or we unilaterally determine that we have misinterpreted provisions of the tax regulations to which we are subject, there could be a material effect on our tax provision, net income or cash flows in the period or periods for which that determination is made, which could materially impact our financial results. Further, any changes in the taxation of our activities, including certain proposed changes in U.S. tax laws, may increase our effective tax rate and adversely affect our financial position and results of operations. In addition, liabilities associated with taxes are often subject to an extended or indefinite statute of limitations period. Therefore, we may be subject to additional tax liability (including penalties and interest) for a particular year for extended periods of time.
Furthermore, changes in accounting rules and interpretations or in our accounting assumptions and/or judgments could significantly impact our consolidated financial statements. In some cases, we could be required to delay the filing of our consolidated financial statements, or to apply a new or revised standard retroactively, resulting in restating prior period consolidated financial statements. Any of these circumstances could have a material adverse effect on our business, prospects, liquidity, financial condition and results of operations.




44



Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
As of January 31, 2023, we had U.S. federal and state net operating loss carryforwards, or NOLs, of $493.3 million due to prior period losses, which, subject to the following discussion, are generally available to be carried forward to offset a portion of our future taxable income, if any, until such NOLs are used or expire. In general, under Section 382 ("Section 382") of the Internal Revenue Code of 1986, as amended (the "Code"), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-ownership change NOLs to offset future taxable income. Similar rules may apply under state tax laws. We have completed a Section 382 study and as a result of the analysis, it is more likely than not that we have experienced an "ownership change." In addition, it is more likely than not that our existing NOLs are subject to limitations arising from previous ownership changes. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. In addition, under the Tax Cuts and Jobs Act of 2017, as amended by The Coronavirus Aid, Relief, and Economic Security Act of 2020, the amount of post 2017 NOLs that we are permitted to utilize in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs. We have a valuation allowance related to our NOLs to recognize only the portion of the deferred tax asset that is more likely than not to be realized.

Risks relating to our financing needs

Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.

We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance limit. If any such depositary institution fails to return our deposits, or if a depository institution is subject to other adverse conditions in the financial or credit markets, this could further impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.

In order to support the growth of our business, we may need to incur additional indebtedness under our current credit facilities or seek capital through new equity or debt financings, which sources of additional capital may not be available to us on acceptable terms or at all.

Our operations have consumed substantial amounts of cash since inception and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new applications and services, enhance our existing solution and services, enhance our operating infrastructure and potentially acquire complementary businesses and technologies. For the year ended January 31, 2023 our net cash used in operating activities was $90.1 million. As of January 31, 2023, we had $176.7 million of cash and cash equivalents, which are held for working capital purposes. We are party to a credit facility with Silicon Valley Bank ("SVB") pursuant to which we have the ability to borrow up to $100.0 million under a revolving line of credit. The credit facility contains a covenant limiting our ability to retain certain levels of cash in accounts outside SVB. As of January 31, 2023, we were in compliance with all covenants in the credit facility. However, in connection with the closure of SVB, we transferred substantially all of our cash and cash equivalents from SVB to other financial institutions. On Friday March 10, 2023, we obtained consent from SVB to retain up to $165 million of cash outside SVB until May 15, 2023 provided we do not borrow against the credit facility. As a result, we are unable to borrow against our credit facility until we return sufficient cash and cash equivalents to SVB to comply with the covenant discussed above and maintain compliance with the other covenants in the credit facility.

Borrowings under the facility are secured by substantially all of our properties, rights and assets, excluding intellectual property. As of January 31, 2023, we had no outstanding borrowings under our revolving line of credit.

Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:

finance unanticipated working capital requirements;
develop or enhance our technological infrastructure and our existing products and services;
fund strategic relationships, including joint ventures and co-investments;
fund additional implementation engagements;
respond to competitive pressures; and




45


acquire complementary businesses, technologies, products or services.

Accordingly, we may need to engage in equity or debt financings or collaborative arrangements to secure additional funds. Additional financing may not be available on terms favorable to us, or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, during times of economic instability, it has been difficult for many companies to obtain financing in the public markets or to obtain debt financing, and we may not be able to obtain additional financing on commercially reasonable terms, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us, it could have a material adverse effect on our business, financial condition and results of operations.

Restrictive covenants in the agreements governing our credit facility may restrict our ability to pursue our business strategies.

The credit agreement governing our credit facility with SVB contains, and any future credit agreements we may enter into may contain, restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, create subsidiaries, enter into certain transactions with affiliates, and transfer or dispose of assets as well as financial covenants requiring us to maintain a specified level of recurring revenue growth, a specified maximum funded debt to recurring revenue ratio and a specified amount of minimum liquidity.

Our ability to comply with these covenants may be affected by events beyond our control, and we may not be able to meet those covenants. A breach of any of any such covenants could result in a default under the applicable loan agreement, which could cause all of the outstanding indebtedness under such credit facility to become immediately due and payable and terminate all commitments to extend further credit. These covenants could also limit our ability to seek capital through the incurrence of new indebtedness or, if we are unable to meet our obligations, require us to repay any outstanding amounts with sources of capital we may otherwise use to fund our business, operations and strategy.

Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.
Adverse developments that affect financial institutions, transactional counterparties or other third parties, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. The U.S. Department of the Treasury, the Federal Reserve and the FDIC released a statement that indicated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. We had a minimal amount of exposure to the SVB closure and did not experience any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations. However, uncertainty remains over liquidity concerns in the broader financial services industry, and there may be additional impacts to our business and our industry that we cannot predict. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.

Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.





46


Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have banking relationships, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:

delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;
loss of access to revolving existing credit facilities or other working capital sources and/or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources; or
potential or actual breach of financial covenants in our credit agreements or credit arrangements.

In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.

In addition, a partner or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on the Company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any partner or supplier bankruptcy or insolvency, or the failure of any partner to make payments when due, or any breach or default by a partner or supplier, or the loss of any significant supplier relationships, may have a material adverse impact on our business.

Risks relating to ownership of our common stock

Our share price has been and may in the future be volatile, and you could lose all or part of your investment.
The trading price of our common stock has been and may be volatile and subject to wide price fluctuations in response to various factors, including, but not limited to:
market conditions in the broader stock market in general, or in our industry in particular, which create highly variable and unpredictable pricing of equity securities;
actual or anticipated fluctuations in our quarterly financial reports and results of operations;
changes in the financial projections we provide to the public or our failure to meet these projections;
our ability to satisfy our ongoing capital needs and unanticipated cash requirements;
indebtedness incurred in the future;
actual or anticipated developments in our business, our competitors' businesses, or the competitive landscape generally, including introduction of new products and services by us or our competitors;
issuance of new or changed securities analysts’ reports or recommendations;
additions or departures of key personnel;
new laws or regulations or new interpretations of existing laws or regulations applicable to our business;




47


regulatory developments;
litigation and governmental investigations;
the impact of COVID-19 on the economy, our company, our customers, suppliers or employees;
macroeconomic conditions, such as rising interest and inflation rates and economic slowdowns and recessions, and political conditions or events, including those resulting from geopolitical uncertainty and instability or war, such as the ongoing military conflict between Russia and Ukraine; and
our sale of common stock or other securities in the future.

In addition, on March 10, 2023, the FDIC took control and was appointed receiver of SVB. At the time SVB entered into receivership, a large number of companies, including many technology companies, held cash deposits with SVB. Although such companies had access to their deposits as of March 13, 2023, companies may continue to face financing uncertainty as a result of SVB’s entry into receivership, which may cause significant volatility with respect to technology company stocks. This, in turn, could negatively impact the trading price of our common stock.

These and other factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business.
The trading market for our common stock is also influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more securities or industry analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. If one or more of the analysts who cover us downgrades our common stock or provides more favorable recommendations about our competitors, or if our results of operations do not meet their expectations, our stock price could decline.
We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

We have never declared or paid any cash dividends on our common stock and do not currently intend to do so for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future and the success of an investment in shares of our common stock will depend upon any future appreciation in its value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.

Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.

Adverse developments that affect financial institutions, transactional counterparties or other third parties, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. The U.S. Department of the Treasury, the Federal Reserve and the FDIC released a statement that indicated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. We had a minimal amount of exposure to the SVB closure and did not experience any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations. However, uncertainty remains over liquidity concerns in the broader financial services industry, and there may be additional impacts to our business and our industry that we cannot predict. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.

48


Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.

Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have banking relationships, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:

delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;
loss of access to revolving existing credit facilities or other working capital sources and/or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources; or
potential or actual breach of financial covenants in our credit agreements or credit arrangements.

In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.

In addition, a partner or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on the Company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any partner or supplier bankruptcy or insolvency, or the failure of any partner to make payments when due, or any breach or default by a partner or supplier, or the loss of any significant supplier relationships, may have a material adverse impact on our business.

Risks relating to our bylaws and certificate of incorporation

Anti-takeover provisions under our incorporation documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
49


Our amended and restated certificate of incorporation ("certificate of incorporation") and our third amended and restated by-laws ("bylaws") contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:
a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;
a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;
a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;
advance notice requirements for stockholder proposals and nominations for election to our board of directors;
a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than 75% of all outstanding shares of our voting stock then entitled to vote in the election of directors;
a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and
the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.
In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law ("DGCL"), which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our certificate of incorporation and our bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors or cause us to take other corporate actions. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.
Our bylaws designate certain specified courts as the sole and exclusive forums for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (the "Chancery Court") will be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws, (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine (the "Delaware Forum Provision"). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, as amended (the "Securities Act"), or Securities Exchange Act of 1934, as amended, (the "Exchange Act"). Our bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the "Federal Forum Provision"). Our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other states courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts
50


will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable in an action, we may incur additional costs associated with resolving such an action. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Chancery Court or the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties
We are a fully remote company and no longer maintain physical corporate offices. Our employees work remotely, from home or at shared co-working office spaces. We believe these arrangements support our current needs. During the year ended January 31, 2023, we ceased using our office spaces in Raleigh, North Carolina and Kanata, Ontario. Each of these leases expires during the year ended January 31, 2024. We maintain a mailing address at 1521 Concord Pike, Suite 301, PMB 221, Wilmington, DE 19803. For purposes of compliance with applicable requirements of the Securities Act and the Exchange Act, stockholder communications required to be sent to our principal executive offices may be directed to the email address set forth in our proxy materials and/or identified on our investor relations website.

Item 3. Legal Proceedings

From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.

Item 4. Mine Safety Disclosures

Not applicable.
51


PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market for Our Common Stock

Our common stock began trading on the New York Stock Exchange, or NYSE, under the symbol "PHR" on July 18, 2019. Prior to that time, there was no public market for our common stock.

Stock Performance Graph

The following performance graph shall not be deemed “soliciting material” or to be “filed” with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Phreesia, Inc. under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act.
The following graph shows a comparison from July 18, 2019, the date on which our common stock first began trading the NYSE, through January 31, 2023 of the cumulative total stockholder return on our common stock, the NYSE Composite Index, S&P 500, and the S&P 1500 Composite Software and Services Index, each of which assumes an initial investment of $100 and reinvestment of all dividends. Such returns are based on historical results and are not intended to suggest future performance.
The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.


phr-20230131_g2.jpgphr-20230131_g2.jpg
52




Stockholders

We had approximately 49 stockholders of record as of March 17, 2023; however, because many of our outstanding shares are held in accounts with brokers and other institutions, we believe we have more beneficial owners. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend Policy
We have never declared or paid any cash dividends on our common stock. We anticipate that we will retain all available funds and any future earnings, if any, for use in the operation of our business and do not anticipate declaring or paying cash dividends in the foreseeable future. In addition, future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, restrictions that may be imposed by applicable law and our contracts and other factors the board of directors deems relevant. Additionally, our ability to pay dividends on our common stock is limited by restrictions under the terms of the Third SVB Facility.

Securities Authorized for Issuance Under Equity Compensation Plans
Information about our equity compensation plans in Item 12 of Part III of this Annual Report on Form 10-K is incorporated herein by reference.

Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities

Not applicable.
Use of Proceeds from Sales of Registered Securities
Not applicable.


Item 6. Reserved

Not applicable.
53



Item 7. Management’s discussion and analysis of financial condition and results of operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Our fiscal year ends January 31. References to fiscal 2023 and 2022 refer to the fiscal years ended January 31, 2023 and 2022, respectively.

Basis of Presentation

This management's discussion and analysis discusses our financial condition and results of operations for the years ended January 31, 2023 and 2022. Please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended January 31, 2022 for a comparison of the year ended January 31, 2022 to the year ended January 31, 2021.

Financial Highlights
Fiscal 2023
Total revenue increased 32% to $280.9 million in fiscal 2023 compared with $213.2 million in fiscal 2022.
Net loss was $176.1 million in fiscal 2023 compared with $118.2 million in fiscal 2022.
Adjusted EBITDA was negative $92.5 million in fiscal 2023 compared with negative $59.0 million in fiscal
    2022.
Cash used in operating activities was $90.1 million in fiscal 2023 compared with cash used in operating activities of $74.7 million in fiscal 2022.
Free cash flow was negative $116.3 million in fiscal 2023 compared with negative $105.5 million in fiscal 2022.
Cash and cash equivalents was $176.7 million as of January 31, 2023 compared with $313.8 million as of January 31, 2022.
For a reconciliation of Adjusted EBITDA to net loss and a reconciliation of free cash flow to net cash used in operating activities, and for more information as to how we define and calculate such measures, see the section below titled “Non-GAAP financial measures.”

Overview

We are a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. As evidenced in industry survey reports from KLAS, we have been recognized as a leader based on our integration capabilities with healthcare services client organizations, the broad adoption of our patient intake functionalities and by overall client satisfaction. Through our SaaS-based technology platform, which we refer to as the Phreesia Platform or our Platform, we offer healthcare services clients a robust suite of integrated solutions that manage patient access, registration and payments. Our Platform also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients.
We serve an array of healthcare services clients of all sizes across over 25 specialties, ranging from single-specialty practices, including internal and family medicine, urology, dermatology, and orthopedics, to large, multi-specialty
54


groups, and health systems as well as regional and national payers and other organizations that provide other types of healthcare-related services. Our network solutions revenue (as described below) is generated from clients in the pharmaceutical, biotechnology, and medical device industries, as well as payers, patient advocacy, public interest and other not-for-profit organizations seeking to activate, engage and educate patients about topics critical to their health.
We derive revenue from (i) subscription fees from healthcare services clients for access to the Phreesia Platform and related professional services fees, (ii) payment processing fees based on levels of patient payment volume processed through the Phreesia Platform and (iii) fees from life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health using the Phreesia Platform. We have strong visibility into our business as the majority of our revenue is derived from recurring subscription fees and re-occurring payment processing fees.
We market and sell our products and services to healthcare services clients throughout the United States using a direct sales organization. Our demand generation team develops content and identifies prospects that our sales development team researches and qualifies to generate high-grade, actionable sales programs. Our direct sales force executes on these qualified sales leads, partnering with client services to ensure prospects are educated on the breadth of our capabilities and demonstrable value proposition, with the goal of attracting and retaining clients and expanding their use of our Platform over time. Most of our Platform solutions are contracted pursuant to annual, auto-renewing agreements. Our sales typically involve competitive processes, and sales cycles have, on average, varied in duration from three months to six months, depending on the size of the potential client. In addition, through Phreesia University (Phreesia’s in-house training program), events, client conferences and webinars, we help our healthcare services clients optimize their businesses and, as a result, support client retention.
We also sell products and services to life sciences and payer organizations as well as advertising agencies through our direct sales and marketing teams.

Since our inception, we have focused substantially all of our sales efforts within the United States. Accordingly, substantially all of our revenue from historical periods has come from the United States, and our current strategy is to continue to focus substantially all of our sales efforts within the United States.
Our revenue growth has been primarily organic and reflects our significant addition of new healthcare services clients. New healthcare services clients are defined as clients that go live in the applicable period and existing healthcare services clients are defined as clients that go live in any period before the applicable period.

Investments in Growth

During the fiscal year ended January 31, 2022, we accelerated hiring and overall investments across all areas of Phreesia to prepare for our anticipated growth in clients and use of our platform. Results for the fiscal year ended January 31, 2023 reflect a full year run rate of expenditures related to those investments. In fiscal 2024 and thereafter, we expect growth in our team and compensation to moderate.
Recent developments and current economic conditions
Closure of Silicon Valley Bank ("SVB")
See "Liquidity and Capital Resources - Silicon Valley Bank facility - Closure of SVB" below for additional discussion regarding the closure of SVB and its impact on our cash and cash equivalents, liquidity and sources of funds available for our material cash requirements.
Macroeconomic environment and geopolitical conditions
Our business is directly and indirectly affected by macroeconomic conditions, geopolitical conditions and the state of global financial markets. Recent geopolitical uncertainty resulting, in part, from military conflict between Russia and Ukraine as well as other macro-economic conditions, such as the impact of pandemics, increased interest rates, inflation in the cost of goods, services and labor, or a recession or an economic slowdown in the U.S. or internationally have contributed to significant volatility and decline in global financial markets during fiscal 2023. The uncertainty over the extent and duration of the ongoing conflict and these macroeconomic conditions continues to cause disruptions to businesses and markets worldwide. While none of these factors individually has had a material impact on our business to date, it is difficult to predict the potential impact these factors may have on our future business results, and each could adversely impact our business operations, financial performance and results of operations.
55


Key Metrics
We regularly review the following key metrics to measure our performance, identify trends affecting our business, formulate financial projections, make strategic business decisions and assess working capital needs.
For the fiscal years ended January 31,Change
20232022Amount%
Key Metrics:
Average healthcare services clients ("AHSCs")2,856 2,074 782 38 %
Healthcare services revenue per AHSC$72,599 $77,478 $(4,879)(6)%
Total revenue per AHSC$98,358 $102,812 $(4,454)(4)%

We remain focused on building secure and reliable products that derive a strong return on investment for our clients and implementing them with speed and ease. This strategy continues to enable us to grow our network of healthcare services clients. We believe the investments we make to grow, strengthen and sustain our network of healthcare services clients lead to growth in all of our revenue categories. As a result, we are relabeling and expanding our key metrics related to revenue and AHSCs to more clearly depict the value of our network of healthcare services clients.

During the fourth quarter of the year ended January 31, 2023, we relabeled our key metric “Average revenue per healthcare services client” to “Healthcare services revenue per AHSC”. We did not make any changes to the calculation of this metric in connection with relabeling this metric, and we have not changed any previously reported amounts.

During the fourth quarter of the year ended January 31, 2023, we have added a key metric for Total revenue per AHSC. The definitions of our key metrics are presented below.

AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment processing revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our Platform to healthcare services organizations that are not yet clients. While growth in AHSCs is an important indicator of expected revenue growth, it also informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our Platform and software for our healthcare services clients and their patients.
Healthcare services revenue per AHSC. We define Healthcare services revenue as the sum of subscription and related services revenue and payment processing revenue. We define Healthcare services revenue per AHSC as healthcare services revenue in a given period divided by AHSCs during that same period. We are focused on continually delivering value to our healthcare services clients and believe that our ability to increase healthcare services revenue per AHSC is an indicator of the long-term value of the Phreesia Platform. Healthcare services revenue per AHSC was $72,599 for the year ended January 31, 2023 compared to $77,478 for the year ended January 31, 2022, a decrease of $4,879. The decline was primarily driven by AHSC growth significantly outpacing payment processing volume and payment processing revenue growth. Additionally, the mix of solutions used by new clients across the Patient Access, Registration and Revenue Cycle offerings has been a contributing factor to the declining trends in this metric.
Total Revenue per AHSC. We define Total revenue per AHSC as Total revenue in a given period divided by AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment processing revenue. Additionally, our relationships with healthcare services clients who subscribe to the Phreesia Platform give us the opportunity to engage with life sciences companies, health plans and other payer organizations, patient advocacy, public interest and other not-for-profit organizations who deliver direct communication to patients through our Platform. As a result, we believe that our ability to increase Total revenue per AHSC is an indicator of the long-term value of the Phreesia Platform. Total revenue per AHSC was $98,358 for the year ended January 31, 2023 compared to $102,812 for the year ended January 31, 2022,
56


a decrease of $4,454. The decline was primarily driven by healthcare services client growth significantly outpacing growth in payment processing volume and payment processing revenue.

Additional Information
For the fiscal years ended January 31,Change
20232022Amount%
Patient payment volume (in millions)$3,284 $2,769 $515 19 %
Payment facilitator volume percentage80 %79 %%%

Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our healthcare services clients’ businesses and the continuing shift of healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors.

Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payment volume that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing revenue.


57


Results of operations

The following tables set forth our results of operations for the periods presented and as a percentage of revenue for those periods:
For the fiscal years ended January 31,For the fiscal years ended January 31,
(in thousands)2023202220232022
Revenue
Subscription and related services$128,975 $95,514 46 %45 %
Payment processing fees78,368 65,201 28 %31 %
Network solutions73,567 52,518 26 %25 %
Total revenue280,910 213,233 100 %100 %
Expenses
Cost of revenue (excluding depreciation and amortization)58,944 42,669 21 %20 %
Payment processing expense50,323 38,719 18 %18 %
Sales and marketing151,263 106,421 54 %50 %
Research and development91,244 52,265 32 %25 %
General and administrative80,384 68,674 29 %32 %
Depreciation17,988 14,985 %%
Amortization7,316 6,317 %%
Total expenses457,462 330,050 163 %155 %
Operating loss(176,552)(116,817)(63)%(55)%
Other expense, net(175)(78)— %— %
Interest income (expense), net1,064 (1,084)— %(1)%
Total other income (expense), net889 (1,162)— %(1)%
Loss before provision for income taxes(175,663)(117,979)(63)%(55)%
Provision for income taxes(483)(182)— %— %
Net loss$(176,146)$(118,161)(63)%(55)%

Components of statements of operations
Revenue
We generate revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. We derive revenue from subscription fees and related services generated from our healthcare services clients for access to the Phreesia Platform, payment processing fees based on the levels of patient payment volume processed through the Phreesia Platform, and from fees from life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health using the Phreesia Platform.
Our total revenue consists of the following:
Subscription and related services. We primarily generate subscription fees from our healthcare services clients based on the number of healthcare services clients that subscribe to and utilize the Phreesia Platform. Our healthcare services clients are typically billed monthly in arrears, though in some instances, healthcare services clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from healthcare services clients’ accounts every month. As we target and add larger enterprise healthcare services clients, these clients may choose to contract differently than our typical per healthcare services client subscription model. To the extent we charge in an alternative manner with larger enterprise healthcare services clients, we expect that such a pricing model will recur and, combined with our per healthcare services client subscription fees, will increase as a percentage of our total revenue.
58


In addition, we receive certain fees from healthcare services clients for professional services associated with our implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training.
Payment processing fees. We generate revenue from payment processing fees based on the number of transactions and the levels of patient payment volume processed through the Phreesia Platform. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. Credit and debit patient payment volume processed through our payment facilitator model represented 80% and 79% of our patient payment volume in fiscal 2023 and 2022, respectively. The remainder of our patient payment volume is composed of credit and debit transactions for which Phreesia acts as a gateway to another payment processor, and cash and check transactions. Utilization trends have been dynamic through the pandemic, diverging from our pre-pandemic seasonality. We expect the environment to remain dynamic through fiscal year 2024.
Network solutions. We generate revenue from life sciences and payer clients for delivering direct communications to patients. As we expand our healthcare services client base, we increase the number of new patients we can reach to deliver our direct communications that help activate, engage and educate patients about topics critical to their health on behalf of life sciences and payer clients.
Cost of revenue (excluding depreciation and amortization)
Our cost of revenue primarily consists of personnel costs, including salaries, stock-based compensation, benefits and bonuses for implementation and technical support, and infrastructure costs to operate our Platform such as hosting fees and fees paid to various third-party providers for access to their technology, as well as costs to verify insurance eligibility and benefits.
Payment processing expense
Payment processing expense consists primarily of interchange fees set by payment card networks and that are ultimately paid to the card-issuing financial institution, assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways. Payment processing expense may increase as a percentage of payment processing revenue if card networks raise pricing for interchange and assessment fees or if we reduce pricing to our clients.
Sales and marketing
Sales and marketing expense consists primarily of personnel costs, including salaries, stock-based compensation, commissions, bonuses and benefits costs for our sales and marketing personnel. Sales and marketing expense also includes costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales and lead generation. Advertising is expensed as incurred.
Research and development
Research and development expense consists of costs to develop our products and services that do not meet the criteria for capitalization as internal-use software. These costs consist primarily of personnel costs, including salaries, stock-based compensation, benefits and bonuses for our development personnel. Research and development expense also includes third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
General and administrative
General and administrative expense consists primarily of personnel costs, including salaries, stock-based compensation, bonuses and benefits for our executive, finance, legal, security, human resources, information technology and other administrative personnel. General and administrative expense also includes software costs to support our finance, legal and human resources operations, insurance costs as well as fees to third-party providers for accounting, legal and consulting services, costs for various non income-based taxes and allocated overhead.
Depreciation
Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks, data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.
59


Amortization
Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
Other income (expense), net
Our other income and expense line items consist of the following:
Other (expense) income, net. Other (expense) income, net consists of foreign currency-related losses and gains and other miscellaneous (expense) income.
Interest income. Interest income consists of interest earned on our cash and cash equivalent balances.
Interest expense. Interest expense consists primarily of the interest incurred on our financing obligations as well as amortization of discounts and deferred financing costs.
Provision for income taxes
Based upon our cumulative pre-tax losses in recent years and available evidence, we have determined that it is more likely than not that certain deferred tax assets as of January 31, 2023 will not be realized in the near term. Consequently, we have established a valuation allowance against our net deferred tax assets totaling approximately $143.1 million and $97.3 million as of January 31, 2023 and 2022, respectively, to recognize only the portion of our deferred tax asset that is more likely than not to be realized. In future periods, if we conclude we have future taxable income sufficient to realize the deferred tax assets, we may reduce or eliminate the valuation allowance.
Comparison of fiscal 2023 versus fiscal 2022
Revenue (in thousands)
Fiscal years ended January 31,
20232022$ Change% Change
Subscription and related services$128,975 $95,514 $33,461 35 %
Payment processing fees78,368 65,201 13,167 20 %
Network solutions73,567 52,518 21,049 40 %
Total revenue$280,910 $213,233 $67,677 32 %
Subscription and related services. Our subscription and related services revenue from healthcare services organizations increased $33.5 million to $129.0 million for fiscal 2023, as compared to $95.5 million for fiscal 2022, primarily due to new healthcare services clients added in fiscal 2023 as well as expansion of and cross-selling to existing healthcare services clients.
Payment processing fees. Our revenue from patient payments processed through the Phreesia Platform increased $13.2 million to $78.4 million for fiscal 2023, as compared to $65.2 million for fiscal 2022, due to the addition of more healthcare services clients, which drove increases in patient visits and patient payments processed through the Phreesia Platform.
Network solutions. Our revenue from life science and payer clients increased $21.0 million to $73.6 million for fiscal 2023, as compared to $52.5 million for fiscal 2022 due to an increase in new activation, engagement and education programs and deeper patient outreach among the existing programs.
Cost of revenue (excluding depreciation and amortization)
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Cost of revenue (excluding depreciation and amortization)
$58,944 $42,669 $16,275 38 %
Cost of revenue (excluding depreciation and amortization) increased $16.3 million to $58.9 million for fiscal 2023, as compared to $42.7 million for fiscal 2022. The increase resulted primarily from a $6.8 million increase in employee compensation costs driven by higher compensation for existing employees and higher average headcount, as well as a $2.5 million increase in outside services costs and a $1.2 million increase in software costs, each driven by growth in revenue.
60


Stock compensation incurred related to cost of revenue was $3.7 million and $2.1 million for fiscal 2023 and fiscal 2022, respectively.
Payment processing expense
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Payment processing expense$50,323 $38,719 $11,604 30 %
Payment processing expense increased $11.6 million to $50.3 million in fiscal 2023, as compared to $38.7 million for fiscal 2022. The increase resulted primarily from an increase in payment processing fees revenue and patient payments processed through the Phreesia Platform, each driven by an increase in patient visits over the prior year.
Sales and marketing
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Sales and marketing
$151,263 $106,421 $44,842 42 %
Sales and marketing expense increased $44.8 million to $151.3 million for fiscal 2023, as compared to $106.4 million for fiscal 2022. The increase was primarily attributable to a $37.6 million increase in total compensation costs driven by higher compensation for existing employees and higher average headcount, as well as a $3.8 million increase in outside services costs, a $1.5 million increase in travel and entertainment costs and $1.3 million increase in software costs.
Stock compensation incurred related to sales and marketing expense was $22.2 million and $12.5 million for fiscal 2023 and fiscal 2022, respectively.
Research and development
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Research and development
$91,244 $52,265 $38,979 75 %
Research and development expense increased $39.0 million to $91.2 million for fiscal 2023, as compared to $52.3 million for fiscal 2022. The increase resulted primarily from a $26.8 million increase in total compensation costs driven by higher compensation for existing employees and higher average headcount, as well as a $6.8 million increase in outside services costs and higher software expenses.
Stock compensation incurred related to research and development expense was $11.8 million and $6.0 million in fiscal 2023 and fiscal 2022, respectively.
General and administrative
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
General and administrative
$80,384 $68,674 $11,710 17 %
General and administrative expense increased $11.7 million to $80.4 million for fiscal 2023, as compared to $68.7 million for fiscal 2022. The increase resulted primarily from a $11.0 million increase in total compensation and benefits costs driven by higher average headcount as well as a $2.2 million increase in outside services costs, partially offset by decreases in other third-party general and administrative expenses.
Stock compensation incurred related to general and administrative expense was $21.2 million and $15.7 million in fiscal 2023 and fiscal 2022, respectively.
61


Depreciation
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Depreciation
$17,988 $14,985 $3,003 20 %
Depreciation expense increased $3.0 million to $18.0 million for fiscal 2023, as compared to $15.0 million for fiscal 2022. The increase was primarily attributable to higher data center and computer equipment depreciation.
Amortization
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Amortization
$7,316 $6,317 $999 16 %
Amortization expense increased $1.0 million to $7.3 million for fiscal 2023, as compared to $6.3 million for fiscal 2022. The increase was primarily driven by higher amortization of acquired intangible assets.

Other expense, net
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Other expense, net$(175)$(78)$(97)124 %
Other expense, net increased by $0.1 million to $0.2 million for fiscal 2023 as compared to $0.1 million for fiscal 2022. Other expense, net is comprised primarily of foreign exchange losses.
Interest income (expense), net
Fiscal years ended January 31,
(in thousands)
20232022$ Change% Change
Interest income (expense), net$1,064 $(1,084)$2,148 (198 %)
Interest income (expense), net changed by $2.1 million to $1.1 million of income for fiscal 2023, as compared to $1.1 million of expense for fiscal 2022. The change is primarily attributable to higher interest income earned from our money market mutual funds, partially offset by higher commitment fees related to the Third SVB Facility as well as interest expense related to finance leases we entered into during fiscal 2023 and fiscal 2022.
Provision for income taxes
Fiscal years ended January 31,
(in thousands)20232022$ Change% Change
Provision for income taxes$(483)$(182)$(301)165 %
Provision for income taxes increased by $0.3 million to $0.5 million for fiscal 2023, as compared to $0.2 million for fiscal 2022. Provision for income taxes relates primarily to change in Canadian net operating loss carryforwards and state income taxes.
Non-GAAP financial measures
Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We define Adjusted EBITDA as net income or loss before interest (income) expense, net, provision for income taxes, depreciation and
62


amortization, and before stock-based compensation expense, change in fair value of contingent consideration liabilities and other expense, net.
We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this Annual Report on Form 10-K because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.
Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:
Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; or (4) interest (income) expense, net; and
Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.
Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss for each of the periods indicated:

For the fiscal years ended January 31,
(in thousands)20232022
Net loss$(176,146)$(118,161)
Interest (income) expense, net(1,064)1,084 
Provision for income taxes483 182 
Depreciation and amortization25,304 21,302 
Stock-based compensation expense58,775 36,234 
Change in fair value of contingent consideration liabilities— 258 
Other expense, net175 78 
Adjusted EBITDA$(92,473)$(59,023)

We calculate free cash flow as net cash used in operating activities less capitalized internal-use software development costs and purchases of property and equipment.
Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic investments, partnerships and acquisitions and strengthening our financial position.
63


The following table presents a reconciliation of free cash flow from net cash used in operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:
For the fiscal years ended January 31,
(in thousands)20232022
Net cash used in operating activities$(90,123)$(74,710)
Less:
Capitalized internal-use software(21,471)(12,385)
Purchases of property and equipment(4,732)(18,420)
Free cash flow$(116,326)$(105,515)

Liquidity and capital resources
In April 2021, we completed a follow-on offering of our common stock. In connection with this offering, we issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share resulting in net proceeds of $245,813, after deducting underwriting discounts and commissions.
As of January 31, 2023 and 2022, we had cash and cash equivalents of $176.7 million and $313.8 million, respectively. Cash and cash equivalents consist of money market funds and cash on deposit.
We believe that our existing cash and cash equivalents, along with cash generated in the normal course of business, will be sufficient to meet our needs for at least the next 12 months.
In addition, we also have potential borrowing capacity under our credit agreement subject to certain restrictive covenants. See Subsequent Event - Closure of SVB below and Note 17 - Subsequent Event within Item 8 - Financial Statements and Supplementary Data for additional information regarding our credit agreement with SVB.
Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under “Risk Factors.”
In the event that additional financing is required from outside sources, we may be unable to raise the funds on acceptable terms, if at all. If we are unable to raise additional capital when desired, our business, operating results and financial condition could be adversely affected.
Silicon Valley Bank facility
Second Amended and Restated Loan and Security Agreement
On May 5, 2020, we entered into the Second SVB Facility. The Second SVB Facility provided for a revolving line of credit of up to $50.0 million (with options to increase up to $65.0 million). We transferred the $20.0 million outstanding balance on a previous SVB Facility, the First SVB Facility term loan, plus related prepayment fees, into the revolving credit borrowings outstanding under the Second SVB Facility. As of January 31, 2022, the interest rate on the Second SVB Facility was 4.5%. Borrowings under the Second SVB Facility were payable on May 5, 2025. We repaid the outstanding balance on the Second SVB Facility in January 2021.
Third SVB Facility
On March 28, 2022, we entered into the Third SVB Facility to increase the borrowing capacity from $50.0 million to $100.0 million. The Third SVB Facility also reduced the interest rate to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%, amended the annual commitment fees to approximately $0.3 million per year and amended the quarterly fee to 0.15% per annum of the average unused revolving line under the facility. Borrowings under the Third SVB Facility are payable on May 5, 2025. As of January 31, 2023, the interest rate on the Third SVB Facility was 7%. As of January 31, 2023, we had no outstanding balance on the Third SVB Facility and $100.0 million of available borrowings under the facility.
In the event that we terminate the Third SVB Facility prior to the Maturity Date and do not replace the facility with another SVB facility, we are required to pay a termination fee equal to $0.2 million plus a percent of total borrowing capacity, both of which would be reduced based on the amount of time elapsed before the termination.
Any of our obligations under the Third SVB Facility are secured by a first priority security interest in substantially all of our assets, other than intellectual property. The Third SVB Facility includes financial covenants including, but not
64


limited to requiring us to maintain a minimum Adjusted Quick Ratio and limiting the amount of cash and cash equivalents we hold outside SVB, each as defined in the Third SVB Facility. We were in compliance with all covenants related to the Third SVB Facility as of January 31, 2023.
Closure of SVB
On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, we transferred a substantial portion of our cash and cash equivalents from SVB to other financial institutions. We had total cash and cash equivalents of approximately $170 million as of March 10, 2023.
On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of our actions to move a substantial portion of our cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, we have determined that all of our cash and cash equivalents continue to be available for our use.
We are also party to the Third SVB Facility which contains certain restrictive covenants including a covenant that limits our ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of our cash and cash equivalents from SVB to other financial institutions, we obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit us to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as we remain in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted our financial position or our operations.
We believe that our cash and cash equivalents along with cash generated in the normal course of business, are sufficient to fund our operations for at least the next 12 months.
The following table summarizes our sources and uses of cash for each of the periods presented:
Fiscal years ended
January 31,
(in thousands)
20232022
Net cash used in operating activities$(90,123)$(74,710)
Net cash used in investing activities(26,203)(65,228)
Net cash (used in) provided by financing activities(20,803)234,969 
Net (decrease) increase in cash and cash equivalents$(137,129)$95,031 
Operating activities
The primary sources of cash from operating activities are cash received from our customers and interest earned on our money market mutual funds. The primary uses of cash for operating activities are for payroll, payments to suppliers and employees, payments for operating leases, as well as cash paid for interest on our finance leases and other borrowings and cash paid for various sales, property and income taxes.

During the fiscal year ended January 31, 2023, net cash used in operating activities was $90.1 million, as our cash paid to employees and suppliers exceeded our cash received from customers in connection with our normal operations.

During the fiscal year ended January 31, 2022, net cash used in operating activities was $74.7 million, as our cash paid to employees and suppliers exceeded our cash received from customers in connection with our normal operations.

The change in net cash used in operating activities was driven primarily by higher employee compensation costs, primarily due to higher average employee headcount as well as an increase in compensation costs for existing employees, and higher outside services costs, partially offset by an increase in cash received from customers driven by higher revenues as well as higher interest income on money market mutual funds we held during the year ended January 31, 2023.
65


Investing activities
During the fiscal year ended January 31, 2023, net cash used in investing activities was $26.2 million, principally resulting from capital expenditures, the majority of which consisted of $21.5 million of cash paid for capitalized internal-use software, as well as $4.7 million of purchases of property and equipment, including hardware used by clients and data center equipment.
During the fiscal year ended January 31, 2022, net cash used in investing activities was $65.2 million, principally resulting from $34.4 million of net cash paid for the acquisition of Insignia, $18.4 million of purchases of property and equipment, principally driven by the purchase of data center equipment, as well as $12.4 million of cash paid for capitalized internal-use software.
Financing activities
During the fiscal year ended January 31, 2023, net cash used in financing activities was $20.8 million, primarily consisting of $19.4 million used for treasury stock to satisfy tax withholdings on stock compensation awards and $5.9 million used for principal payments on finance leases and financing arrangements, partially offset by $4.9 million in proceeds from our equity compensation plans.
During the fiscal year ended January 31, 2022, cash provided by financing activities was $235.0 million, primarily consisting of $245.8 million in proceeds from the April 2021 offering of our common stock, net of underwriters' discounts and commissions, and $6.9 million in proceeds from our equity compensation plans, partially offset by $9.0 million used for treasury stock to satisfy tax withholdings on stock compensation awards, $5.3 million used for principal payments on finance leases and financing arrangements and $3.3 million used for payments of acquisition-related liabilities.
Material Cash Requirements
Our material cash requirements relate to leases, financing arrangements, contractual purchase commitments and human capital. Refer to Note 4 - Composition of certain financial statement accounts in Part II - Item 8 of this Annual Report on Form 10-K for additional information on accrued payroll related liabilities. Refer to Note 6 - Finance leases and other debt, Note 10 - Leases and Note 11 - Commitments and contingencies in Part II - Item 8 of this Annual Report on Form 10-K for additional information on cash requirements for leases, financing arrangements and contractual purchase commitments.
See "Liquidity and Capital Resources - Silicon Valley Bank facility - Closure of SVB" above for information regarding the closure of SVB and its impact on our cash and cash equivalents, liquidity and sources of funds available for our material cash requirements.
Critical accounting policies and estimates
The preparation of the consolidated financial statements in conformity with GAAP requires us to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. Our most significant estimates and judgments involve revenue recognition, the fair value of assets acquired in business combinations, capitalized internal-use software, income taxes, and valuation of our stock-based compensation. Actual results may differ from these estimates. To the extent that there are differences between our estimates and actual results, our future financial statement presentation, financial condition, results of operations, and cash flows will be affected.
We believe that the accounting policies described below involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of operations.

Revenue recognition
We account for revenue from contracts with clients by applying the requirements of Topic 606, which includes the following steps:
Identification of the contract, or contracts, with a client
Identification of the performance obligations in a contract
Determination of the transaction price
66


Allocation of the transaction price to the performance obligations in the contract
Recognition of revenue when, or as, performance obligations are satisfied
Revenues are recognized when control of these services is transferred to our clients, in an amount that reflects the consideration we expect to be entitled to in exchange for those services.
We believe the areas in which we apply the most critical judgements when determining revenue recognition relate to the identification of distinct performance obligations, the assessment of the standalone selling price (“SSP”) for each performance obligation identified, the determination of the amount of variable consideration to include in the transaction price of our contracts with customers and the determination of whether we are the principal or the agent for certain performance obligations.

Determination of Performance Obligations
A performance obligation is a promise in a contract with a customer to transfer products or services that are distinct. Our contracts with customers may include multiple promises to transfer services to a customer. Determining whether products and services are distinct performance obligations that should be accounted for separately or combined as a single performance obligation may require significant judgment that requires us to assess the nature of the promise and the value delivered to the customer.
Our subscription and related services revenue includes certain fees from clients for professional services associated with implementation services.
In determining whether professional services for implementation are distinct, we consider the following factors for each professional services agreement: availability of the services from other vendors, the nature of the professional services and the complexity of interfaces created between systems.
We determined that the majority of implementation services were not distinct from the related subscription service because they are proprietary such that they cannot be performed by another entity, because we generally do not sell professional services on a stand-alone basis, and because they are integral to the customer’s ability to derive the intended benefit of the subscription service, indicating that the implementation services and related subscription are inputs to a combined output.
Determination of Standalone Selling Prices

We allocate the transaction price of our customer contracts to the performance obligations within those contracts based on the relative SSP of the performance obligations.

The SSP is the price that we would sell a product separately to a customer. The best evidence of this is an observable price from stand-alone sales of that product to similarly situated customers. However, as we do not typically transfer our performance obligations on a standalone basis, but rather we transfer bundles of performance obligations, we use an adjusted market assessment approach to estimate the price a customer would be willing to pay for our performance obligations using historical price information as priced in previous bundled contracts.

In determining SSPs, we stratify the population of customer transactions by product, type, size of customer and geographic area. We typically establish a range of SSPs for each of our performance obligations.

The prices we charge for digital messaging solutions provided to life sciences companies have historically been highly variable. We consider pricing to be highly variable if we have a history of selling the services at a wide range of prices to similar customers in similar geographic areas within the same time periods. As the pricing of our digital messaging solutions has historically been highly variable, we use the residual method to estimate the SSP of performance obligations for digital messaging solutions. We estimate the residual SSP of our digital messaging solutions as the total transaction price of the customer contract less the SSPs of the remaining performance obligations pursuant to the contract.

Variable Consideration

We estimate the transaction price at contract inception, including any variable consideration, and we update the estimate each reporting period for any changes in circumstances. When determining the transaction price, we assume the products will be transferred to the customer based on the terms of the existing contract and our assumption does not take into consideration the possibility of a contract being canceled, renewed, or modified.

67


We occasionally provide credits to customers representing adjustments to the transaction price. Known and estimable credits and adjustments represent a form of variable consideration, which are estimated at contract inception and generally result in reductions to revenues recognized for a particular contract. These estimates are updated at the end of each reporting period as additional information becomes available. We estimate the amount of variable consideration based on its expected probability-weighted value or its most likely amount. We include variable consideration in the transaction price to the extent it is probable there will not be a significant reversal of revenue when the uncertainty with respect to the variable consideration is resolved. We believe that there will not be significant changes to our estimates of variable consideration as of January 31, 2023.

Principal vs Agent Considerations
As part of our revenue recognition process, we evaluate whether we are the principal or agent for the performance obligations in our contracts with customers. When we determine that we are the principal for a performance obligation, we recognize revenue for that performance obligation on a gross basis. When we determine that we are an agent for a performance obligation, we recognize revenue for that performance obligation net of the related costs. In determining whether we are the principal or the agent, we evaluate whether we have control of the services before we transfer the services to the customer by considering whether we are primarily obligated for transferring the services to the customer, whether we have inventory risk for the services before the services are transferred to the customer, and whether we have latitude in establishing prices. We recognize payment processing fees collected from customers as revenue on a gross basis because, as the merchant of record, we control the services before delivery to the customer, we are primarily responsible for the delivery of the services to our customers, we have latitude in establishing pricing with respect to the customer and other terms of service, we have sole discretion in selecting the third-party to perform the settlement, and we assume the credit risk for the transaction processed. We also have the unilateral ability to accept or reject a transaction based on our established criteria.
Business combinations
We use our best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. With the assistance of third-party appraisers, we assess the fair value of the assets acquired in business combinations. The fair value of the acquired licenses and technology was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, we used cash flows discounted at a rate considered appropriate given the inherent risks associated with each client grouping. Our estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. We continue to collect information and reevaluate these estimates and assumptions quarterly and record any adjustments to our preliminary estimates to goodwill provided that we are within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
Where applicable, the consideration transferred for business combinations includes the acquisition date fair value of contingent consideration. In connection with the QueueDr acquisition, we recorded contingent consideration liabilities within accrued expenses for amounts payable to the selling shareholders based on collections from QueueDr customers. The fair value of our contingent consideration liabilities was determined using a Monte-Carlo simulation which uses estimated cash flows and likelihoods of contract cancellation to estimate the expected payout based on collections and active status of the underlying customer contracts. The fair value of our contingent consideration liabilities was determined based on inputs which are not readily available in public markets. Therefore, we categorized the liabilities as Level 3 in the fair value hierarchy. In connection with the acquisition of QueueDr, we recorded contingent consideration liabilities with an acquisition-date fair value of $2,240. During the fiscal years ended January 31, 2021 and 2022, we paid a total of $2,574 to settle the contingent consideration liabilities, which represented the maximum amount payable for the contingent consideration liabilities. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.
Capitalized internal-use software
We capitalize certain costs incurred for the development of computer software for internal use pursuant to ASC Topic 350-40, Intangibles—Goodwill and Other—Internal use software. These costs relate to the development of our Phreesia Platform. We capitalize the costs during the development of the project, when it is determined that it
68


is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three to five years. We evaluate the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. We exercise judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that we change the manner in which we develop and test new features and functionalities related to our solutions, assess the ongoing value of capitalized assets or determine the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs we capitalize and amortize could change in future periods.
Income taxes
An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. We follow ASC 740, Accounting for Uncertainty in Income Taxes. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a company’s consolidated financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, disclosure, and transition.
We have accumulated U.S. federal and state net operating loss carryforwards of approximately $493.3 million, and $332.5 million as of January 31, 2023 and 2022, respectively. These carryforwards will begin to expire in 2025. As of January 31, 2023, our foreign branch had net operating loss carryforwards of approximately $0.7 million, which may be available to offset future income tax liabilities and will expire beginning in 2034.
In assessing the realizability of the net deferred tax asset we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards.
Due to uncertainty regarding the ability to realize the benefit of U.S. deferred tax assets primarily relating to net operating loss carryforwards, we have established valuation allowances to reduce deferred the U.S. deferred tax assets to an amount that is more likely than not to be realized. On the basis of this evaluation, we have recorded valuation allowances of $143.1 million and $97.3 million as of January 31, 2023 and 2022.
Under Section 382 of the Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2023, we have U.S. net operating loss carryforwards of approximately $493.3 million. We have completed a Section 382 study and, as a result of the analysis, it is more likely than not that we have experienced an "ownership change". We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. Accordingly, if we earn net taxable income, it is more likely than not that our ability to use our pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability.
We review and evaluate tax positions in major jurisdictions and determine whether we record unrecognized tax benefits as reductions of deferred tax assets or as liabilities in accordance with ASC 740 and adjust these unrecognized tax benefits when our judgment changes as a result of the evaluation of new information not previously available. We recognize interest and penalties related to uncertain tax positions in income tax expense. There was no outstanding balance for unrecognized tax benefits as of January 31, 2023.
Stock-based compensation for market-based performance stock units ("PSUs")
We recognize the grant-date fair value of stock-based awards issued as compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We granted market-based PSUs during fiscal 2021, 2022 and 2023.
69



PSUs vest in between 0% and 220% of the number of PSUs originally granted based on our total stockholder return ("TSR"), relative to a peer group of companies on the Russell 3000 stock index. PSUs granted during fiscal 2023, 2022 and 2021 vest in a maximum of 220%, 200% and 200% of the number of PSUs originally granted, respectively. We estimate the fair value of the PSUs using a Monte Carlo Simulation model which projects TSR for Phreesia and each member of the peer group over a performance period of approximately three years. The most critical and judgmental assumptions used in the Monte Carlo Simulation to estimate the fair value of the PSUs are set forth below:

Correlation coefficient: The correlation coefficient measures the correlation of our stock to the stock of the companies in the peer group. This coefficient is used to project the performance of our stock against our peers to estimate projected performance under the plan.
Expected volatility: For PSUs granted during the year ended January 31, 2023, the expected volatility is based on the historical volatility of our stock price over a term commensurate with the simulation term assumption. For PSUs granted during the fiscal years ended January 31, 2022 and 2021, the expected volatility was based on historical volatilities of peer companies within our industry which were commensurate with the simulation term assumption.
Recent accounting pronouncements
There are no recently issued accounting pronouncements that we have not yet adopted that will materially impact our consolidated financial statements.

See Note 3 to our Consolidated financial statements of this Annual Report on Form 10-K for a discussion of recent accounting pronouncements.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

We have operations both within the United States and in Canada, and we are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate and foreign exchange risks.

Interest rate risk

As of January 31, 2023, our cash and cash equivalents consisted primarily of money market funds and cash on deposit. The primary objective of our investment activities is to preserve principal while maximizing income without significantly increasing risk. Because our cash equivalents have a short maturity, our portfolio’s fair value is relatively insensitive to interest rate changes. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on our financial condition. Changes in interest rates impact the amount of interest income we record on our cash equivalents. In future periods, we will continue to evaluate our investment policy in order to ensure that we continue to meet our overall objectives.

As of January 31, 2023, we had no debt outstanding under the Third SVB Facility. See Note 17 - Subsequent Event and Note 6 - Finance Leases and Other Debt within Item 8 - Financial Statements and Supplementary Data for additional information regarding the Third SVB Facility, the closure of SVB and its impact on the Third SVB Facility.

Although we had no debt outstanding under the Third SVB Facility as of January 31, 2023, changes in interest rates would affect interest expense if we borrow against the Third SVB Facility in the future. Additionally, changes in interest rates will impact the discount rate and resulting interest expense for any new finance leases.

Foreign currency exchange risk

We have foreign currency risks related to our expenses denominated in Canadian dollars, which are subject to fluctuations due to changes in foreign currency exchange rates. Additionally, fluctuations in foreign currency exchange rates may cause us to recognize transaction gains and losses in our statements of operations. To date, foreign currency transaction gains and losses have not been material to our financial statements.

70


Item 8. Consolidated Financial Statements and Supplementary Data

PHREESIA, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firm (KPMG LLP, Pittsburgh, PA, Auditor Firm ID: 185)
Consolidated Balance Sheets as of January 31, 2023 and 2022
Consolidated Statements of Operations for the years ended January 31, 2023, 2022 and 2021
Consolidated Statements of Stockholders’ Equity (Deficit) for the years ended January 31, 2023, 2022 and 2021
Consolidated Statements of Cash Flows for the years ended January 31, 2023, 2022 and 2021
Notes to Consolidated Financial Statements


71





Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors
Phreesia, Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Phreesia, Inc. and subsidiaries (the Company) as of January 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the three-year period ended January 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of January 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended January 31, 2023, in conformity with U.S. generally accepted accounting principles.

We also were engaged to audit, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of January 31, 2023, based on criteria established in
Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 23, 2023 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

Identification of performance obligations for larger enterprise healthcare services contracts

As discussed in Note 5 to the consolidated financial statements, the Company executes contracts that may include various combinations of performance obligations related to software, hardware, and services comprised of customized solutions, on-site support and training, as well as different contract terms. When these contracts are executed or modified, the Company performs a detailed evaluation to identify the performance obligations in the contract. During the year ended January 31, 2023, the Company recognized $128,975 thousand of subscription and
72


related services revenue, a portion of which related to larger enterprise healthcare services clients that may choose to contract differently than typical customers that use a per provider subscription model.

We identified the evaluation of the Company’s identification of performance obligations for larger enterprise healthcare services contracts that were entered into or modified during the year as a critical audit matter. Specifically, for contracts with larger enterprise healthcare services clients that were entered into or modified during the year, evaluating the Company’s determination of distinct performance obligations required challenging auditor judgment due to the varying nature of the underlying promises and the associated contract terms.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s revenue recognition process, including an internal control related to the Company’s identification of performance obligations in larger enterprise healthcare services contracts entered into or modified during the year.

For larger enterprise healthcare services contracts that were entered into or modified during the year ended January 31, 2023, we (1) read the contracts to understand their terms and conditions and (2) evaluated the identification of performance obligations in each arrangement by considering the nature of the promises within the contract and whether they were distinct from other promised goods and services. For a sample of sales items, we compared the sales item to a performance obligation identified in the contract by the Company.

/s/ KPMG LLP

We have served as the Company’s auditor since 2019.

Pittsburgh, Pennsylvania
March 23, 2023

73



Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors
Phreesia, Inc.:

Opinion on Internal Control Over Financial Reporting
We have audited Phreesia, Inc. and subsidiaries' (the Company) internal control over financial reporting as of January 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of January 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the three-year period ended January 31, 2023, and the related notes (collectively, the consolidated financial statements), and our report dated March 23, 2023 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

74


Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Pittsburgh, Pennsylvania
March 23, 2023

75


Phreesia, Inc.
Consolidated Balance Sheets
(in thousands, except share data)
January 31,
20232022
Assets
Current:
Cash and cash equivalents$176,683 $313,812 
Settlement assets22,599 19,590 
Accounts receivable, net of allowance for doubtful accounts of $1,053 and $863 as of January 31, 2023 and 2022, respectively
51,394 40,262 
Deferred contract acquisition costs1,056 1,642 
Prepaid expenses and other current assets10,709 11,043 
Total current assets262,441 386,349 
Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively
21,670 34,645 
Capitalized internal-use software, net of accumulated amortization of $37,236 and $31,139 as of January 31, 2023 and 2022, respectively
35,150 17,643 
Operating lease right-of-use assets569 2,337 
Deferred contract acquisition costs1,754 2,437 
Intangible assets, net of accumulated amortization of $2,549 and $1,178 as of January 31, 2023 and 2022, respectively
11,401 12,772 
Deferred tax asset81 515 
Goodwill33,736 33,621 
Other assets3,255 4,157 
Total Assets$370,057 $494,476 
Liabilities and Stockholders’ Equity
Current:
Settlement obligations$22,599 $19,590 
Current portion of finance lease liabilities and other debt5,172 5,821 
Current portion of operating lease liabilities934 1,281 
Accounts payable10,836 5,119 
Accrued expenses21,810 20,128 
Deferred revenue17,688 16,493 
Total current liabilities79,039 68,432 
Long-term finance lease liabilities and other debt2,725 7,423 
Operating lease liabilities, non-current349 1,276 
Long-term deferred revenue125 65 
Total Liabilities82,238 77,196 
Commitments and contingencies (Note 11)


Stockholders’ Equity:
Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2023 and 2022; 54,187,172 and 52,095,964 shares issued as of January 31, 2023 and 2022, respectively
542 521 
Additional paid-in capital926,957 860,657 
Accumulated deficit(606,084)(429,938)
Treasury stock, at cost, 971,236 and 301,003 shares as of January 31, 2023 and 2022, respectively
(33,596)(13,960)
Total Stockholders’ Equity287,819 417,280 
Total Liabilities and Stockholders’ Equity$370,057 $494,476 
See notes to consolidated financial statements.
76


Phreesia, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share data)
For the fiscal years ended January 31,
202320222021
Revenue:
Subscription and related services$128,975 $95,514 $69,042 
Payment processing fees78,368 65,201 49,900 
Network solutions73,567 52,518 29,735 
Total revenue280,910 213,233 148,677 
Expenses:
Cost of revenue (excluding depreciation and amortization)58,944 42,669 23,461 
Payment processing expense50,323 38,719 28,925 
Sales and marketing151,263 106,421 42,972 
Research and development91,244 52,265 22,622 
General and administrative80,384 68,674 40,460 
Depreciation17,988 14,985 9,770 
Amortization7,316 6,317 6,138 
Total expenses457,462 330,050 174,348 
Operating loss(176,552)(116,817)(25,671)
Other (expense) income, net(175)(78)1 
Interest income (expense), net1,064 (1,084)(1,573)
Total other income (expense), net889 (1,162)(1,572)
Loss before provision for income taxes(175,663)(117,979)(27,243)
Provision for income taxes(483)(182)(49)
Net loss(176,146)(118,161)(27,292)
Net loss per share attributable to common stockholders, basic and diluted$(3.36)$(2.37)$(0.69)
Weighted-average common shares outstanding, basic and diluted52,440,067 49,888,436 39,519,640 
See notes to consolidated financial statements.
77


Phreesia, Inc.
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
Stockholders’ equity
Common stock
SharesAmountAdditional
paid-in
capital
Accumulated
deficit
Treasury stockTotal
Balance, January 31, 202036,610,763 $366 $386,383 $(284,485)$(399)$101,865 
Net loss — — — (27,292) — (27,292)
Stock-based compensation expense — — 13,489 —  — 13,489 
Exercise of stock options and vesting of restricted stock units 2,459,782 25 5,275 —  — 5,300 
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings — — — —  (4,566)(4,566)
Issuance of common stock in follow-on public offering, net of issuance costs of $290
 5,750,000 57 174,453 —  — 174,510 
Cashless exercise of common stock warrants 60,338 1 (1)—  —  
Balance, January 31, 2021 44,880,883 $449 $579,599 $(311,777) $(4,965)$263,306 
Net loss— — — (118,161)— (118,161)
Stock-based compensation expense— — 29,668 — — 29,668 
Exercise of stock options and vesting of restricted stock units1,997,551 204,123 — — 4,143 
Issuance of common stock for employee stock purchase plan42,530 — 1,506 — — 1,506 
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings— — — — (8,995)(8,995)
Issuance of common stock in follow-on public offering, net5,175,000 52 245,761 — — 245,813 
Balance, January 31, 202252,095,964 $521 $860,657 $(429,938)$(13,960)$417,280 
Net loss— — — (176,146)— (176,146)
Stock-based compensation expense— — 52,506 — — 52,506 
Exercise of stock options and vesting of restricted stock units1,626,123 16 1,515 — — 1,531 
Issuance of common stock for employee stock purchase plan162,154 2 3,470 — — 3,472 
Issuance of stock for share-settled bonus awards302,931 3 8,809 — — 8,812 
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings— — — — (19,636)(19,636)
Balance, January 31, 202354,187,172 $542 $926,957 $(606,084)$(33,596)$287,819 
See notes to consolidated financial statements
78


Phreesia, Inc.
Consolidated Statements of Cash Flows
(in thousands)
For the fiscal years ended January 31,
202320222021
Operating activities:
Net loss$(176,146)$(118,161)$(27,292)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization25,304 21,302 15,908 
Non-cash stock-based compensation expense58,775 36,144 13,489 
Amortization of deferred financing costs and debt discount310 288 389 
Cost of Phreesia hardware purchased by customers1,598 672 762 
Deferred contract acquisition costs amortization1,696 2,211 2,025 
Non-cash operating lease expense1,768 1,004 1,766 
Change in fair value of contingent consideration liabilities 258  
Deferred tax asset434 143 (65)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable(11,132)(10,216)(6,619)
Prepaid expenses and other assets250 (7,192)(1,600)
Deferred contract acquisition costs(427)(3,349)(1,652)
Accounts payable4,774 2,881 (3,821)
Accrued expenses and other liabilities2,720 (2,983)6,004 
Lease liability(1,302)(1,060)(1,786)
Deferred revenue1,255 3,348 5,382 
Net cash (used in) provided by operating activities(90,123)(74,710)2,890 
Investing activities:
Acquisitions, net of cash acquired (34,423)(6,510)
Capitalized internal-use software(21,471)(12,385)(7,334)
Purchases of property and equipment(4,732)(18,420)(11,241)
Net cash used in investing activities(26,203)(65,228)(25,085)
Financing activities:
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 245,813 174,800 
Proceeds from issuance of common stock upon exercise of stock options1,603 4,889 4,385 
Treasury stock to satisfy tax withholdings on stock compensation awards(19,383)(8,995)(4,965)
Payment of offering costs  (290)
Proceeds from employee stock purchase plan3,321 1,979  
Insurance financing agreement  2,009 
Finance lease payments(5,731)(4,267)(2,630)
Principal payments on financing agreements(216)(1,039)(1,691)
Debt issuance costs and facility fees(397)(125)(294)
Financing payments of acquisition-related liabilities (3,286) 
Payments of revolving line of credit  (20,663)
Net cash (used in) provided by financing activities(20,803)234,969 150,661 
Net (decrease) increase in cash and cash equivalents(137,129)95,031 128,466 
Cash and cash equivalents—beginning of year313,812 218,781 90,315 
Cash and cash equivalents—end of year$176,683 $313,812 $218,781 
79


Supplemental information of non-cash investing and financing activities:
Right-of-use assets recorded in exchange for operating lease liabilities$ $81 $4,359 
Property and equipment acquisitions through finance leases$526 $7,394 $8,885 
Capitalized software acquired through vendor financing$ $ $174 
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities$2,345 $1,124 $3,359 
Cashless transfer of term loan and related accrued fees into increase in debt balance$ $ $20,257 
Cashless transfer of lender fees through increase in debt balance$ $ $406 
Receivables for cash in-transit on stock option exercises$97 $169 $915 
Cashless exercise of common stock warrants$ $ $3,060 
Capitalized stock based compensation$1,372 $489 $ 
Issuance of stock to settle liabilities for stock-based compensation$12,284 $ $ 
Cash paid for:
Interest$763 $802 $1,465 
Income taxes$39 $49 $64 
See notes to consolidated financial statements
80


Phreesia, Inc.
Notes to Consolidated Financial Statements
(in thousands, except share and per share data)
1. Background and liquidity
(a) Background
Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through the SaaS-based technology platform (the "Phreesia Platform" or "Platform"), the Company offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration and payments. The Company’s Platform also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. In connection with the patient intake and registration process, Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005.
During the fiscal year ended January 31, 2023, the Company ceased using its Raleigh, North Carolina office as its principal executive offices.
b) Liquidity
Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year.
On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023.
On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company.
The Company is also party to the Second Amended and Restated Loan and Security Agreement with SVB, as amended by the First Loan Modification Agreement (the “Third SVB Facility”), which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations. See Note 6 - Finance Leases and Other Debt and Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.
Management believes that the Company’s cash and cash equivalents at January 31, 2023, along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months.
The Company will seek to obtain additional financing, if needed, to successfully implement its long-term strategy.
2. Basis of presentation
(a) Consolidated Financial Statements
81


The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company").
(b) Fiscal year
The Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
(c) Network solutions revenue
During the year ended January 31, 2023, the Company relabeled its Life sciences category of revenue presented on its Consolidated Statements of Operations to Network solutions revenue. The Company's Network solutions revenue includes fees from life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health using the Phreesia Platform. Prior to the year ended January 31, 2023, the Company's Network solutions revenue was generated by its life sciences clients. There have been no changes to previously reported revenues.
3. Summary of significant accounting policies

(a) Use of estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.
(b) Revenue recognition

The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers, as well as for additional details about the Company's products and service lines.
(c) Concentrations of credit risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor.
The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2023 and January 31, 2022. As of both January 31, 2023 and January 31, 2022, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable.
See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.
(d) Risks and uncertainties
The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. Certain of the Company's
82


service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and Contingencies, for a summary of our contractual commitments as of January 31, 2023. See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.
(e) Cost of revenue (excluding depreciation and amortization)
Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
(f) Payment processing expense
Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways.
(g) Sales and marketing
Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $2,634, $4,007 and $558 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
(h) Research and development
Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
(i) General and administrative
General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
(j) Depreciation
Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.
(k) Amortization
Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
83


(l) Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents.
(m) Settlement assets
Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one to two business days of the transaction date.
(n) Settlement obligations
Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
(o) Accounts receivable
Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2023 and 2022, the Company has reserved $1,053 and $863, respectively, for the allowance for doubtful accounts.
Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5).
(p) Property and equipment
Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three and seven years. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.
Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
(q) Capitalized internal-use software
The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software. These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period.
(r) Business combinations
The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date,
84


the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations.
When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.
(s) Goodwill and intangible assets
Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.
The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.
All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
(t) Long-lived assets
Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
(u) Income taxes
An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure.
The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
85


(v) Segment information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements.
(w) Stock-based compensation
The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718, Compensation — Stock Compensation, which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.
The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield.

During fiscal 2022, the Company activated the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date.

For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares.
See Note 8 - Equity-Based Compensation, for additional information on stock-based compensation.
(x) Fair value of financial instruments
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
86


Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.
Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
(y) Equity offering costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations.
(z) Foreign currency
The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net.
(aa) New accounting pronouncements
Impact of recently adopted accounting pronouncements
During the year ended January 31, 2023, the Company did not adopt any accounting pronouncements.
Recent accounting pronouncements not yet adopted
There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.
87


4. Composition of certain financial statement captions
(a) Accrued expenses
Accrued expenses at January 31, 2023 and 2022 are as follows:
January 31,
20232022
Payroll-related expenses and taxes$10,345 $10,780 
Payment processing fees liability4,796 3,502 
Acquisition-related liabilities96 96 
Tax liabilities1,491 2,093 
Information technology services2,249 1,266 
Other2,833 2,391 
Total$21,810 $20,128 
(b) Property and equipment
Property and equipment at January 31, 2023 and 2022 are as follows:
Useful life
(years)
January 31,
20232022
PhreesiaPads and Arrivals Kiosks3$17,932 $26,387 
Computer equipment
354,485 53,957 
Computer software
3 to 5
8,571 5,311 
Hardware development
3529 1,024 
Furniture and fixtures
7 539 
Leasehold improvements
2 748 
Total property and equipment
$81,517 $87,966 
Less accumulated depreciation(59,847)(53,321)
Property and equipment — net$21,670 $34,645 
Depreciation expense related to property and equipment amounted to $17,988, $14,985 and $9,770 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
Assets acquired under finance leases included in computer equipment were $27,813 and $27,310 at January 31, 2023 and 2022, respectively. Accumulated amortization of assets under finance leases was $20,657 and $15,025 at January 31, 2023 and 2022, respectively.
88


(c) Capitalized internal-use software
For the fiscal years ended January 31, 2023, 2022 and 2021, the Company capitalized $23,604, $12,830 and $7,663 of costs related to the Phreesia Platform, respectively.
During the fiscal years ended January 31, 2023, 2022 and 2021 amortization expense related to capitalized internal-use software was $5,945, $5,664 and $5,884, respectively.
(d) Intangible assets and goodwill
The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022.
Useful LifeJanuary 31,
(years)20232022
Acquired technology5$1,410 $1,410 
Customer relationship
7 to 10
6,340 6,340 
License156,200 6,200 
Total intangible assets, gross carrying value$13,950 $13,950 
Less accumulated amortization(2,549)(1,178)
Net carrying value$11,401 $12,772 
The remaining useful life for acquired technology in years is 2.7 and 3.5 as of January 31, 2023 and 2022, respectively. The remaining useful life for customer relationships in years is 8.3 and 9.2 as of January 31, 2023 and 2022, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years is 13.8 and 14.8 as of January 31, 2023 and 2022, respectively. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes.
Amortization expense associated with intangible assets for the fiscal years ended January 31, 2023, 2022 and 2021 was $1,371, $653 and $254, respectively.
The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023:
January 31, 2023
2024$1,358 
20251,273 
20261,242 
2027949 
Thereafter6,579 
Total$11,401 
The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023:
Balance at January 31, 2021$8,307 
Goodwill acquired during the year ended January 31, 202225,314 
Balance at January 31, 202233,621 
Measurement period adjustments to goodwill during the year ended January 31, 2023115 
Balance at January 31, 2023$33,736 
The Company did not record any impairments of goodwill during the years ended January 31, 2023, 2022 or 2021. Additions to goodwill during the year ended January 31, 2022 are net of a $96 measurement period adjustment for the QueueDr acquisition. Additions to goodwill during the year ended January 31, 2023 represent measurement period adjustments for the Insignia acquisition. Substantially all of the Company's goodwill is amortizable for tax purposes.
89


(e) Accounts receivable
Accounts Receivable as of January 31, 2023 and 2022 are as follows:
January 31,
20232022
Billed$51,458 $40,733 
Unbilled989 392 
Total accounts receivable, gross52,447 41,125 
Less accounts receivable allowances(1,053)(863)
Total accounts receivable$51,394 $40,262 

Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022:
Balance, January 31, 2021$699 
Bad debt expense212 
Write-offs and adjustments(48)
Balance, January 31, 2022863 
Bad debt expense587 
Write-offs and adjustments(397)
Balance, January 31, 2023
$1,053 

The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible.

(f) Prepaid and other current assets
Prepaid and other current assets as of January 31, 2023 and 2022 are as follows:
January 31,
20232022
Prepaid software and business systems$3,426 $3,738 
Prepaid data center expenses2,389 3,230 
Prepaid insurance1,552 1,924 
Other prepaid expenses and other current assets3,342 2,151 
Total prepaid and other current assets$10,709 $11,043 

(g) Cloud computing implementation costs

The Company enters into cloud computing service contracts to support its sales and marketing, product development and administrative activities. The Company capitalizes certain implementation costs for cloud computing arrangements that meet the definition of a service contract. The Company includes these capitalized implementation costs within Prepaid expenses and other current assets and within other assets on its consolidated balance sheets. Once placed in service, the Company amortizes these costs over the remaining subscription term to the same caption in the consolidated statements of operations as the related cloud subscription. Capitalized implementation costs for cloud computing arrangements accounted for as service contracts were $1,532 as of January 31, 2023. Accumulated amortization of capitalized implementation costs for these arrangements was $610 as of January 31, 2023.

(h) Other (expense) income, net

Other (expense) income, net for the year ended January 31, 2023 and 2022 was expense of $175 and $78, respectively, driven by foreign exchange losses, partially offset by other miscellaneous income.
90


5. Revenue and Contract Costs
The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Phreesia Platform, payment processing fees based on patient payment volume, and fees from life sciences and payer clients for delivering direct communications to patients using the Phreesia Platform.
The Company accounts for revenue from contracts with customers by applying the requirements of ASC 606. Accordingly, the Company determines revenue recognition through the following steps:
identification of the contract, or contracts, with a customer;
identification of the performance obligations in the contract;
determination of the transaction price;
allocation of the transaction price to the performance obligations in the contract; and
recognition of revenue when, or as, the Company satisfies a performance obligation.
Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services.
The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. We typically establish a range of SSPs for each of our performance obligations. We use the residual method to the estimate the SSP for certain performance obligations with highly variable pricing.
(a) Subscription and related services
In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other applications. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. The Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 842, Leases.
The amount of subscription and related services revenues recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $10,197, $6,489 and $6,312 for the years ended January 31, 2023, 2022 and 2021, respectively.
In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from Phreesia’s Platform and are therefore recognized over the term of the contract. Revenue from sales of Phreesia hardware and training are recognized in the period they are delivered to clients.
(b) Payment processing fees
The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions.
91


The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees.
The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers.
The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company.
As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations.
(c) Network solutions
The Company's Network solutions revenue includes fees from life sciences companies and payers for direct communications to activate, engage and educate patients about topics critical to their health using the Phreesia platform.
The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered.
The Company generates revenue from sales of qualified leads to health plans and other payer organizations which is based largely on the delivery of qualified leads to health plans and other payer organizations at a contracted price per lead. The Company identifies the qualified leads based on direct communications delivered to patients. Revenue for leads is recognized based on our estimate of leads accepted by health plans and other payer organizations.
(d) Disaggregation of revenue
Revenue from the Company’s contracts with its customers are disaggregated by service offering on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees, digital marketing solutions sold to life sciences companies and qualified leads sold to health plans and other payer organizations. In addition, substantially all of the Company’s revenue is derived from customers in the United States.
(e) Remaining performance obligations
The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue).
(f) Contract balances
Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred
92


revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying balance sheets.
The following table represents a roll-forward of contract assets:
January 31,
20232022
Beginning Balance$392 $1,287 
Amount transferred to receivables from beginning balance of contract assets(392)(1,287)
Increases in contract assets due to acquisitions 243 
Contract asset additions, net of reclassification to receivables989 149 
Ending Balance$989 $392 
The following table represents a roll-forward of deferred revenue:
 January 31,
20232022
Beginning Balance$16,558 $10,838 
Revenue recognized that was included in deferred revenue at the beginning of the period(16,005)(10,838)
Increases in deferred revenue due to acquisitions 2,372 
Other current year activity in deferred revenue17,260 14,186 
Ending Balance$17,813 $16,558 
(g) Cost to obtain a contract
The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three to five years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $1,696 and $2,211 for the years ended January 31, 2023 and 2022, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.
The following table represents a roll-forward of deferred contract acquisition costs:
January 31,
20232022
Beginning balance$4,079 $2,941 
Additions to deferred contract acquisition costs427 3,349 
Amortization of deferred contract acquisition costs(1,696)(2,211)
Ending balance$2,810 $4,079 
Deferred contract acquisition costs, current (to be amortized in next 12 months)$1,056 $1,642 
Deferred contract acquisition costs, non-current1,754 2,437 
Total deferred contract acquisition costs$2,810 $4,079 

93


6. Finance leases and other debt
As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt:
January 31,
20232022
Finance leases$7,651 $12,884 
Financing arrangements46 266 
Accrued interest and payments200 94 
Total finance lease liabilities and other debt$7,897 $13,244 
Less - current portion of finance lease liabilities and other debt(5,172)(5,821)
Long-term finance leases and other debt$2,725 $7,423 
(a) Finance leases

See Note 10 - Leases for more information regarding finance leases.

(b) Amended and Restated Loan and Security Agreement

On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. In connection with the transaction, the Company recorded a $1,073 loss on extinguishment of debt within other (expense) income, net for the settlement of previously outstanding loans payable.

On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility. The Second SVB Facility modified the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. The borrowing capacity could be increased to $65,000 at the sole discretion of Silicon Valley Bank. Upon entering into the Second SVB Facility, the Company borrowed $20,663 against the revolving credit facility and used the proceeds to repay all amounts due under the First SVB Facility term loan. The Company repaid the balance on the Second SVB Facility during the fiscal year ended January 31, 2021.

On March 28, 2022 (the "Third SVB Effective Date"), the Company entered into a First Loan Modification Agreement
to the Second SVB Facility (as amended, the "Third SVB Facility") to increase the borrowing capacity from $50,000
to $100,000 and to reduce the interest rate on the facility. Borrowings under the Third SVB Facility are payable on May 5, 2025. Borrowings under the Third SVB Facility bear interest, which is payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%. As of January 31, 2023, the interest rate on the Third SVB Facility was 7%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual commitment fee of approximately $250 per year and a quarterly fee of 0.15% per annum of the average unused revolving line under the facility. The Company had $100,000 of availability under the facility as of January 31, 2023.

In the event that the Company terminates the Third SVB Facility prior to May 5, 2024, the Company will be required to pay a termination fee of up to 1.5% of borrowing capacity based on the length of time between termination and maturity. Any Company obligations under the Third SVB Facility are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The Third SVB Facility includes a financial covenant that requires the Company to maintain a minimum Adjusted Quick Ratio as defined in the Third SVB Facility. The Third SVB Facility also includes a financial covenant that requires the Company to achieve certain profitability and liquidity thresholds. The financial covenant will not be effective if the Company maintains certain levels of liquidity as defined. Additionally, the Third SVB facility contains a covenant limiting the amount of cash and cash equivalents the Company can hold outside SVB. The Third SVB Facility also contains customary events of default. The Company was in compliance with all covenants related to the Third SVB Facility as of January 31, 2023.

As of January 31, 2023 and 2022, there was no debt outstanding related to the Third SVB Facility and the Second SVB Facility, respectively. As a result, the Company presented all unamortized deferred costs within other assets as of January 31, 2023 and 2022, respectively. The Company is amortizing the remaining unamortized costs over the remaining term of the Third SVB Facility.

94


Maturities of finance leases and other debt in each of the next five years and thereafter are as follows:
 TotalFinance LeasesOther Debt
Fiscal year ending January 31:
2024$5,172 $4,926 $246 
20252,518 2,518  
2026207 207  
Total maturities of finance leases and other debt$7,897 $7,651 $246 
The following table presents the components of interest income (expense), net:
Fiscal years ended January 31,
 202320222021
Interest expense (1)
$(1,411)$(1,163)$(1,695)
Interest income2,475 79 122 
Interest income (expense), net$1,064 $(1,084)$(1,573)
(1) Includes amortization of deferred financing costs and original issue discount
7. Stockholders' Equity
(a) Common stock
The Company closed an IPO on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share.
On April 12, 2021, the Company completed a follow-on offering of its common stock. In connection with this offering, the Company issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share.
(b) Treasury stock
The Company's equity-based compensation plan allows for the grant of non-vested stock options, RSUs and TSR PSUs to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Under the provision of the plans, for RSU and PSU awards, unless otherwise elected, participants fulfill their related income tax withholding obligation by having shares withheld at the time of vesting. On the date of vesting of the RSU or PSU, the Company divides the participant's estimated income tax obligation in dollars by the closing price of its common stock and withholds the resulting number of vested shares. The shares withheld are then transferred to the Company's treasury stock at cost.
8. Equity-based compensation
(a) Equity award plans
In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock.
In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2023, 2022 and 2021 were made pursuant to the 2019 plan, respectively.
In June 2019, the Board of Directors also adopted the ESPP, which became effective immediately prior to the
95


effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares.
In August 2021, the Company amended its fiscal 2022 incentive bonus to allow eligible employees to elect to receive all or a portion of their fiscal 2022 year end incentive compensation in the form of immediately vested restricted stock units instead of cash. The Company's fiscal 2023 incentive bonus allows eligible employees to elect to receive all or a portion of their fiscal 2023 incentive compensation in the form of immediately vested restricted stock units instead of cash.
As of January 31, 2023, there are 3,408,720 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase which occurs on February 1 of each fiscal year, as well as an additional 576,304 shares available for future grant pursuant to the ESPP. During fiscal 2022, the Company activated its ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions.
(b) Summary of stock-based compensation

The following table sets forth stock-based compensation by type of award:

For the fiscal years ended
January 31,
 202320222021
RSUs$42,214 $24,222 $10,693 
Liability awards7,641 7,055  
PSUs7,282 2,389 93 
Stock options1,489 2,294 2,703 
ESPP1,521 763  
Total stock-based compensation$60,147 $36,723 $13,489 

The following table sets forth the presentation of stock-based compensation in the Company's financial statements:


For the fiscal years ended
January 31,
 202320222021
Stock-based compensation expense recorded to additional paid-in capital(1)
$52,506 $29,668 $13,489 
Stock-based compensation expense recorded to accrued expenses7,641 7,055  
Total stock-based compensation60,147 36,723 13,489 
Less stock-based compensation expense capitalized as internal-use software(1,372)(489) 
Stock-based compensation expense per consolidated statements of operations(2)
$58,775 $36,234 $13,489 
(1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts.
(2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.

The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense.

96


(c) Restricted stock units

The Company has issued restricted stock units to employees and independent directors that vest based on a time-based condition. For RSUs granted to employees prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The restricted stock units expire seven years from the grant date.

During the year ended January 31, 2022, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its 2022 proxy statement ("2022 NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than 2022 NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For 2022 NEOs and other members of the Company's executive management team, RSUs granted from January 1, 2022 through December 31, 2022 vest 6.25% each quarter over four years based on continued service. Beginning January 2023, all RSUs granted vest 25% each year over four years based on continued service.

Additionally, the Company provides certain employees the option to settle their incentive bonus in immediately vested RSUs. RSUs granted to settle bonus awards are included in RSUs granted and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards.
  Restricted stock units
Unvested, January 31, 20201,447,418 
Granted during year
972,271 
Vested(242,049)
Forfeited and expired(124,602)
Unvested, January 31, 20212,053,038 
Granted during year
1,836,534 
Vested(559,767)
Forfeited and expired(195,966)
Unvested, January 31, 20223,133,839 
Granted during year
2,907,838 
Vested(1,626,679)
Forfeited and expired (497,245)
Unvested, January 31, 2023
3,917,753 

As of January 31, 2023, there is $112,482 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.8 years.
For the years ended January 31, 2023, 2022 and 2021, the weighted average grant date fair value of restricted stock units granted was $26.79, $46.60 and $32.78 respectively.
(d) Stock options
Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis.
97


Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows:
Number of
options
Weighted-
average
exercise price
Weighted-
average
remaining
contractual life
(in years)
Aggregate Intrinsic
value
Outstanding—January 31, 20205,516,452 $3.80 
Granted during the year $ 
Exercised(2,216,368)$2.39 
Forfeited(88,730)$7.45 
Outstanding and expected to vest — January 31, 2021
3,211,354 $4.67 5.99$194,676 
Outstanding—January 31, 20213,211,354 $4.67 
Granted during the year $ 
Exercised(1,439,186)$2.88 
Forfeited and expired(67,018)$9.02 
Outstanding and expected to vest — January 31, 2022
1,705,150 $6.01 5.94$42,938 
Outstanding—January 31, 20221,705,150 $6.01 
Granted during the year $ 
Exercised(311,743)$4.92 
Forfeited and expired(8,214)$4.68 
Outstanding and expected to vest — January 31, 2023
1,385,193 $6.26 5.06$43,341 
Exercisable — January 31, 2023
1,362,903 $6.12 5.03$42,750 
Amount vested during year ended January 31, 2023
258,735 $8.27 

The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2023, 2022 and 2021 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $6,970, $73,624 and $33,575, respectively.
As of January 31, 2023, there is $45 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 0.33 years.
For the year ended January 31, 2023, stock-based compensation expense for stock options includes $322 related to the modification of stock options.
(e) TSR performance-based restricted stock units (PSUs)

The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Peer Group. Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. PSUs granted during the years ended January 31, 2023, 2022 and 2021 vest in a maximum of 220%, 200% and 200% of the number of PSUs originally granted, respectively. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%.

The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period.

98


The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions:

Fiscal years ended
January 31,
 202320222021
Correlation coefficient0.4957 0.3878 0.4230 
Valuation date stock price$35.41 $36.03 $62.96 
Simulation term3.00 Years2.99 Years3.00 Years
Volatility64.98 %44.32 %43.71 %
Risk-free rate3.84 %1.23 %0.20 %
Dividend yield % % %
Weighted average fair value of grants
$56.52 $48.47 $84.38 


Market based PSU activity for the years ended January 31, 2023, 2022 and 2021 are as follows:
Performance
stock units
Outstanding February 1, 2020 
Granted during the year ended January 31, 202170,806 
Outstanding, February 1, 202170,806 
Granted during the year ended January 31, 2022325,410 
Vested 
Forfeited and expired 
Outstanding, February 1, 2022396,216 
Granted during the year ended January 31, 2023
255,572 
Vested 
Forfeited and expired(3,555)
Outstanding, January 31, 2023
648,233 
As of January 31, 2023, unrecognized compensation cost for the PSUs was $26,128, to be recognized over a weighted average remaining vesting period of 2.4 years, subject to the participants' continued employment with the Company.

(f) Employee stock purchase plan
The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986.

The fair value of shares granted under the ESPP during the year ended January 31, 2023 was estimated using a Black-Scholes pricing model with the following assumptions:
Year ended
January 31, 2023
Year ended
January 31, 2022
Risk-free interest rate
3.68 %0.17 %
Expected dividends
nonenone
Expected term (in years)
0.47 years0.49 years
Volatility
74.8 %55.7 %

During the fiscal years ended January 31, 2023 and 2022, the Company issued 162,154 and 42,530 shares of common stock, respectively, for the ESPP. In connection with these issuances, during the years ended January 31, 2023 and 2022, the Company recorded increases of $3,470 and $1,506, respectively, to additional paid-in capital
99


within stockholders' equity. As of January 31, 2023, unrecognized compensation cost related to the ESPP was $605, to be recognized over the next five months.

(g) Liability awards
The Company's amended fiscal 2022 incentive bonus and the Company's fiscal 2023 incentive bonus allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the bonuses converted. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities, within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. During the year-ended January 31, 2023, the Company settled $8,812 of share-settled bonus awards by issuing 302,931 immediately vested RSUs. See (c) Restricted Stock Units above for additional discussion regarding RSUs.
9. Fair Value Measurements
The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands):
 Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2023
 
Money market mutual funds$163,563 $ $ $163,563 
Total assets$163,563 $ $ $163,563 

The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands):
 Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2022
 
Money market mutual funds$197,601 $ $ $197,601 
Total assets$197,601 $ $ $197,601 

The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of January 31, 2023, the carrying value of the Company's debt approximated fair value because the interest rates approximated market rates and the debt maturities were relatively short-term.

The Company did not have any transfers of assets and liabilities between levels of the fair value measurements hierarchy during both the years ended January 31, 2023 and 2022.

10. Leases
(a) Phreesia as Lessee
The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option
100

Table of Contents
date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two to three years and are secured by the underlying equipment.
During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada
and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to
cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company
shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The
financial impact of the change in useful lives of the related right of use assets was not significant.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:
January 31,
20232022
Operating leases:
Lease right-of-use assets$569 $2,337 
Lease liabilities, current934 1,281 
Lease liabilities, non-current349 1,276 
Total operating lease liabilities$1,283 $2,557 
Finance leases:
Property and equipment, at cost$27,813 $27,310 
Accumulated depreciation(20,657)(15,025)
Property and equipment, net$7,156 $12,285 
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)4,926 5,600 
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)2,725 7,284 
Total finance lease liabilities$7,651 $12,884 

For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.
As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.



101

Table of Contents
The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:
Fiscal years ended
January 31,
202320222021
Operating leases:
Operating lease cost$1,835 $1,096 $1,766 
Variable lease cost62 223 257 
Total operating lease cost$1,897 $1,319 $2,023 
Finance leases:
Amortization of right-of-use assets$5,632 $4,636 $2,876 
Interest on lease liabilities368 378 326 
Total finance lease cost$6,000 $5,014 $3,202 

The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:
January 31, 2023
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2024$958 $5,102 
2025225 2,566 
202686 209 
202742  
Thereafter7  
Total future minimum lease payments$1,318 $7,877 
Less: interest(35)(226)
Present value of lease liabilities$1,283 $7,651 

As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.

Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:
Fiscal years ended
January 31,
202320222021
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,347 $1,206 $1,629 
Operating cash used for finance leases396 377 326 
Financing cash used for finance leases5,731 4,267 2,630 
Total$7,474 $5,850 $4,585 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and


102

Table of Contents
do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.
During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less.
11. Commitments and contingencies
(a) Indemnifications
The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third-party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued any liabilities related to such obligations in its consolidated financial statements.
In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions.
(b) Legal proceedings
In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.
(c) Other contractual commitments

Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below.
Purchase obligations
Year ending January 31,
2024$11,646 
20258,115 
20263,530 
2027598 
Total$23,889 
12. Income taxes
The Company recorded a tax provision of $483, $182 and $49, for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's provision for income taxes was 0.3%, 0.2% and 0.2% of loss before income taxes for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against the


103

Table of Contents
majority of its deferred tax assets, and due to foreign income tax expense recorded for the Company's Canada branch related to the use of net operating loss carry forwards to offset current income.
Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2023 and 2022.
The Company’s loss before income taxes was primarily generated in the United States for fiscal 2023, fiscal 2022 and fiscal 2021.
The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021:
Fiscal years ended January 31,
202320222021
Current tax
Federal$ $ $ 
State49 39 114 
Foreign   
Deferred tax
Federal109  (116)
State  (65)
Foreign325 143 116 
Total provision for income taxes$483 $182 $49 
A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows:
Fiscal years ended January 31,
202320222021
Federal income tax benefit at statutory rate21 %21 %21 %
State and local tax, net of federal benefit5 %9 %10 %
Permanent differences % % %
Equity compensation %6 %44 %
Foreign taxes % % %
Other % %(4)%
Change in valuation allowance(26)%(36)%(71)%
Effective income tax rate % % %


104

Table of Contents

The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2023 and 2022 are as follows:
January 31,
Deferred tax assets (liabilities)20232022
Net operating loss carryforwards$131,574 $88,979 
Stock based compensation7,765 5,374 
Accruals, reserves, and other expenses2,7633,697
Reserve for bad debts530 521 
Disallowed interest expense1,9341,934
Total deferred tax assets144,566 100,505 
Less valuation allowance(143,135)(97,279)
Net deferred tax assets1,431 3,226 
Depreciation and amortization(295)(1,250)
Intangible assets(305)(373)
Deferred contract acquisition costs(750)(1,088)
Total deferred tax liabilities(1,350)(2,711)
Deferred taxes, net$81 $515 

The Company has accumulated a Federal net operating loss carryforward of approximately $493,333 and $332,544 as of January 31, 2023 and 2022, respectively. This carryforward may be available to offset future income tax liabilities and will expire beginning in 2025. As of January 31, 2023, the Company's foreign branch had net operating loss carryforwards of approximately $716, which may be available to offset future income in Canada and will expire beginning in 2034.
Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized.
On the basis of this evaluation, as of January 31, 2023 and 2022, the Company recorded a valuation allowance of $143,135 and $97,279, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $45,856 increase in the valuation allowance recorded during the fiscal year ended January 31, 2023 relates primarily to deferred tax assets established and recorded during the fiscal year ended January 31, 2023. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced.
Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2023, the Company has U.S. net operating loss carryforwards of approximately $493.3 million. The Company has completed a Section 382 study and as a result of the analysis, it is more likely than not that the Company has experienced an “ownership change”. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership. Accordingly, if the Company earns net taxable income, it is more likely than not that the Company's ability to use its pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability.
The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2018 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2023 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets in accordance with ASC 740 and adjusts these balances when its judgement changes as a result of the evaluation of new information previously not available. The Company recognized interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2023 and for the years ended January


105

Table of Contents
31, 2023, 2022 and 2021, the Company did not have a balance of unrecognized tax benefits. As of January 31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions.
13. Net loss per share attributable to common stockholders
(a) Net loss per share attributable to common stockholders
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
Fiscal years ended January 31,
202320222021
Numerator:
Net loss$(176,146)$(118,161)$(27,292)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted52,440,067 49,888,436 39,519,640 
Net loss per share attributable to common stockholders$(3.36)$(2.37)$(0.69)
(b) Potential dilutive securities
The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock awards, and grants under the Company's ESPP, our employee stock purchase plan, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Fiscal years ended January 31,
202320222021
Stock options to purchase common stock, restricted stock units and performance stock awards6,745,591 5,632,823 5,406,004 
Employee stock purchase plan74,685 75,370  
Total6,820,276 5,708,193 5,406,004 
14. Retirement savings plan
On February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in the years ended January 31, 2023, 2022 or 2021.
15. Related party transactions
For the years ended January 31, 2023 and 2022, the Company recognized revenue totaling $775 and $482 for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of January 31, 2023 and 2022, accounts receivable from the pharmaceutical company totaled $339 and $173, respectively.
For the years ended January 31, 2023 and 2022, the Company recognized general and administrative expenses totaling $374 and $182 for software agreements with a software company, respectively. One of the Company's independent members of its board of directors serves as the chief executive officer and on the board of directors for this software company. As of January 31, 2023 and 2022, prepaid expenses and other current assets include approximately $51 and $374 of payments to this software company, respectively. As of January 31, 2022, other assets included $51 of payments to this software company. This software company has been a related party since October 2021 when this software company's chief executive officer and board member became an independent member of the Company's board of directors, and the disclosures above represent transactions occurring while the software company was a related party.


106

Table of Contents


The Company recognized revenue totaling approximately $2,425 from an affiliate of a stockholder of the Company for the year ended January 31, 2021. The revenue presented above includes revenue earned while the entity was a related party. The entity was a related party for a portion of the year ended January 31, 2021 and was no longer a related party during the years ended January 31, 2022 and 2023.
One of the Company's independent members of its board of directors has served as the chief financial officer of a
software company since April 2022. The Company recognized de minimis expenses during the year ended January 31, 2023 for software agreements with this software company.
16. Acquisitions
Acquisition of Insignia Health, LLC

On December 3, 2021, the Company entered into an agreement to acquire 100% of the outstanding equity of Insignia, a founder-led and mission-oriented company for cash consideration of $37,208. Insignia provides coaching and education solutions in conjunction with Insignia's exclusive worldwide license to the PAM. The PAM is a survey measuring a patient's knowledge, skills and ability to manage their care. The Company acquired Insignia to enable the Company to understand and engage patients in more personalized ways based on their level of activation. The acquisition of Insignia was accounted for as a business combination.
The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:
Cash consideration paid to sellers$37,112 
Liabilities incurred to sellers96 
Total fair value of acquisition consideration$37,208 

The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022.
Cash consideration paid to sellers$37,112 
Less: Cash acquired(2,689)
Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows$34,423 
The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations.

The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition:
Cash$2,689 
Accounts receivable994 
Prepaid expenses and other assets358 
Operating lease right-of-use assets606 
Intangibles10,700 
Goodwill25,410 
Total assets acquired40,757 
Accounts payable(84)
Accrued liabilities(487)
Deferred revenue(2,372)
Operating lease liabilities(606)
Total purchase price$37,208 


107

Table of Contents
The components of intangible assets acquired were as follows:
Estimated Useful Life
(in Years)
Fair Value
PAM license15$6,200 
Customer relationships104,500 
Total identifiable intangible assets acquired$10,700 
The weighted average amortization period for acquired intangible assets as of the date of acquisition is 13 years.
The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Insignia. The fair value of the acquired PAM license was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset.
The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes.
The goodwill recognized in the acquisition of Insignia is primarily attributable to expected synergies of the combined businesses driven by integrating the PAM into the Phreesia Platform and engaging with patients in more personalized ways based on their level of activation, as well as the acquisition of an assembled workforce. The goodwill is expected to be deductible for tax purposes.

During the fiscal year ended January 31, 2022, the Company incurred $720 of acquisition related costs for the acquisition of Insignia. These costs are primarily included within general and administrative expenses in our consolidated statement of operations.


Acquisition of QueueDr
On January 8, 2021, the Company entered into a stock purchase agreement with QueueDr to acquire 100% of the outstanding equity of QueueDr, an early-stage software company that automates the process of rescheduling cancellations and no-shows. We acquired QueueDr to enhance our appointments solution. The acquisition of QueueDr was accounted for as a business combination.
The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:
Cash consideration paid on acquisition date$5,773 
Liabilities incurred2,111 
Contingent consideration2,240 
Total fair value of acquisition consideration$10,124 
The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021:
Cash consideration paid on acquisition date$5,773 
Payments of acquisition date fair value of contingent consideration954 
Less cash acquired(217)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows$6,510 
During the fiscal year ended January 31, 2021, the Company incurred $282 of acquisition related costs for the acquisition of QueueDr. During the fiscal year ended January 31, 2022, the Company incurred $258 of expenses to remeasure the acquisition-date fair value of contingent consideration to its ultimate settlement amount of $1,544. Each of these costs were included within general and administrative expenses in our consolidated statements of operations.
During the years ended January 31, 2023 and, 2022, the Company recorded certain measurement period adjustments related to the acquisitions of Insignia and QueueDr. The financial impact of measurement period adjustments was not material.


108

Table of Contents
17. Subsequent event
On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023.

On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company.

The Company is also party to the Third SVB Facility which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations.

Management believes that the Company’s cash and cash equivalents along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of January 31, 2023 of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Management believes that the consolidated financial statements included in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented, in accordance with GAAP.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act.

Our internal control over financial reporting includes those policies and procedures that:



109

Table of Contents
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and disposition of our assets;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorization of our management and directors of the Company; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of January 31, 2023, based on the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and has concluded that we maintained effective internal control over financial reporting as of January 31, 2023.

Our independent registered public accounting firm, KPMG LLP, has issued an audit report with respect to our internal control over financial reporting, which appears in Part II, Item 8 of this Form 10-K.

Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the quarter ended January 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

On March 21, 2023, our Board of Directors approved the Third Amended and Restated By-Laws (as amended and restated, the “By-laws”), which became effective as of the same date. The amendments effected by the By-laws, among other things:

1.Add informational and procedural requirements with respect to stockholder proposals and stockholder director nominations, including to address matters relating to Rule 14a-19 under the Exchange Act, the SEC’s universal proxy rule (Article I, Section 2 and Section 6); 
2.Modify the provisions related to availability of lists of stockholders entitled to vote at a stockholder meeting to reflect recent amendments to the Delaware General Corporation Law (Article I, Section 8); 
3.Address adjournment of stockholder meetings relying on remote communication due to a technical failure to reflect recent amendments to the Delaware General Corporation Law (Article I, Section 4(e)); 
4.Clarify the powers of the chair of a stockholder meeting, including with respect to the chair’s ability to prescribe rules and regulations for the conduct of the meeting (Article I, Section 9); 
5.Revise the exclusive forum provision to indicate that the forum for claims under the Securities Act shall be the federal district courts of the United States (Article VI, Section 8); and
6.Make various updates throughout to conform to the Delaware General Corporation Law, to make ministerial changes, clarifications, and other conforming revisions, and to clarify the Company’s ability to conduct business by means of remote communication.

The By-laws also include various other updates, including certain technical, conforming and clarifying changes. The foregoing description of the By-laws is qualified in its entirety by reference to the full text of the Third Amended and Restated By-laws, a copy of which is filed as Exhibit 3.2 to this Annual Report on Form 10-K and is incorporated by reference herein.


Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not Applicable.


110

Table of Contents
PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2023 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 11. Executive Compensation

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2023 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2023 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2023 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.
Item 14. Principal Accountant Fees and Services

The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2023 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.


111

PART IV

Item 15. Exhibits, Financial Statement Schedules

The following documents are filed as part of this report:

(1) Consolidated Financial Statements. Reference is made to these consolidated financial statements included in this Annual Report on Form 10-K in Item 8, Consolidated Financial Statements and Supplementary Data.

(2) Financial Statement Schedules. All financial statement schedules have been omitted because they are not required, not applicable or the information required is shown in the consolidated financial statements or notes thereto.

(3) Exhibits. The following exhibits are filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.
Incorporated by Reference
Exhibit No.Exhibit IndexFormFile No.Exhibit No.Date Filed
3.110-Q001-389773.1September 10, 2019
3.2Filed herewith
4.1S-1333-2322644.1June 21, 2019
4.2S-1333-2322644.2June 21, 2019
4.310-K001-389774.4April 23, 2020
10.1#S-1333-23226410.1June 21, 2019
10.2#S-1333-23226410.2June 21, 2019
10.3#10-K001-3897710.3March 31, 2022
10.4#S-1/A333-23226410.4July 8, 2019
10.5#10-Q001-3897710.1September 8, 2022
10.6#S-1333-23226410.19June 21, 2019
10.7#S-1333-23226410.6June 21, 2019
10.8#8-K001-3897710.1January 28, 2021
10.9#8-K001-3897710.3January 28, 2021
10.10#8-K001-3897710.1May 4, 2021
10.11#10-Q001-3897710.3June 4, 2021
112

10.12#10-Q001-3897710.4June 4, 2021
10.13#S-1333-23226410.21June 21, 2019
10.14#S-1333-23226410.12June 21, 2019
10.158-K001-3897710.1May 11, 2020
10.168-K001-3897710.1March 30, 2022
10.17#8-K001-3897710.1March 22, 2023
21.1Filed herewith
23.1Filed herewith
24.1Power of Attorney (included on signature page hereto).Filed herewith
31.1Filed herewith
31.2Filed herewith
32.1+Filed herewith
32.2+Filed herewith
101.INSInline XBRL Instance Document.Filed herewith
101.SCHInline XBRL Taxonomy Extension Schema Document.Filed herewith
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.Filed herewith
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.Filed herewith
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document.Filed herewith
113

101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.Filed herewith
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).Filed herewith

#Indicates a management contract or any compensatory plan, contract or arrangement.
+



The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference.

Item 16. Form 10-K Summary

Not applicable.





SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHREESIA, INC.
Date: March 23, 2023By:/s/ Chaim Indig
Name: Chaim Indig
Title: Chief Executive Officer

114


POWER OF ATTORNEY AND SIGNATURES

Each individual whose signature appears below hereby constitutes and appoints each of Chaim Indig and Randy Rasmussen as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
NameTitleDate
/s/ Chaim IndigChief Executive Officer and Director (Principal Executive Officer)March 23, 2023
Chaim Indig
/s/ Randy RasmussenChief Financial Officer
(Principal Financial and Accounting Officer)
March 23, 2023
Randy Rasmussen
/s/ Michael WeintraubChairman and DirectorMarch 23, 2023
Michael Weintraub
/s/ Edward CahillDirectorMarch 23, 2023
Edward Cahill
/s/ Lainie GoldsteinDirectorMarch 23, 2023
Lainie Goldstein
/s/ Gillian MunsonDirectorMarch 23, 2023
Gillian Munson
/s/ Ramin SayarDirectorMarch 23, 2023
Ramin Sayar
/s/ Mark Smith, M.D.DirectorMarch 23, 2023
Mark Smith, M.D.

115
EX-3.2 2 ex32-phrthirdamendedandres.htm EX-3.2 Document
Exhibit 3.2
THIRD AMENDED AND RESTATED
BY-LAWS
OF
PHREESIA, INC.
(the “Corporation”)
ARTICLE 1

Stockholders
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subsequently be changed at any time by vote of the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). If no Annual Meeting has been held for a period of thirteen (13) months after the Corporation’s last Annual Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these By-laws or otherwise, all the force and effect of an Annual Meeting. Any and all references hereafter in these By-laws to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof.
SECTION 2. Notice of Stockholder Business and Nominations.
(a) Annual Meetings of Stockholders.

(1) Nominations of persons for election to the Board of Directors of the Corporation and the proposal of other business to be considered by the stockholders may be brought before an Annual Meeting (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice provided for in this By-law, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this By-law as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii) shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters properly brought under Rule 14a-8 (or any successor rule) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section 2(a)(2) and (3) of this By-law to bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this By-law, for any proposal of business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law.

(2) For nominations or other business to be properly brought before an Annual Meeting by a stockholder pursuant to clause (ii) of Article I, Section 2(a)(1) of this By-law, the stockholder must (i) have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation, (ii) have provided any updates or supplements to such notice at the times and in the forms required by this By-law and (iii) together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this By-law. To be timely, a stockholder’s written notice shall be received by the Secretary at the principal executive offices (with a copy via email to proxy@phreesia.com) of the Corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the one-year anniversary of the preceding year’s Annual Meeting; provided, however, that in the event the Annual Meeting is first convened more than thirty (30) days before or more than sixty (60) days after such anniversary date, or if no Annual Meeting were held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than the close of business on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as “Timely Notice”). Such stockholder’s Timely Notice shall set forth:



(A) as to each person whom the stockholder proposes to nominate for election or reelection as a director, (i) the name, age, business address and residence address of the nominee, (ii) the principal occupation or employment of the nominee, (iii) the class and number of shares of capital stock of the Corporation that are held of record or are beneficially owned by the nominee or their affiliates or associates and any Synthetic Equity Interest (as defined below) held or beneficially owned by the nominee or their affiliates or associates, (iv) a description of all arrangements or understandings between or among the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder or concerning the nominee’s potential service on the Board of Directors, (v) a questionnaire with respect to the background and qualifications of the nominee completed by the nominee in the form provided by the Corporation (which questionnaire shall be provided by the Secretary upon written request), (vi) a representation and agreement in the form provided by the Corporation (which form shall be provided by the Secretary upon written request) that: (a) such proposed nominee is not and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation; (b) such proposed nominee is not and will not become a party to any agreement, arrangement, or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement, or indemnification in connection with service or action as a director that has not been disclosed to the Corporation; (c) such proposed nominee would, if elected as a director, comply with all applicable rules and regulations of the exchanges upon which shares of the Corporation’s capital stock trade, each of the Corporation’s corporate governance, ethics, conflict of interest, confidentiality, stock ownership and trading policies and guidelines applicable generally to the Corporation’s directors and, if elected as a director of the Corporation, such person currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (d) such proposed nominee intends to serve as a director for the full term for which he or she is to stand for election; and (e) such proposed nominee will promptly provide to the Corporation such other information as it may reasonably request; (vii) a description of any position of such person as an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, within the three years preceding the submission of the notice; and (viii) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected);
(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text, if any, of any resolutions or Bylaw amendment proposed for adoption, the reasons for conducting such business at the meeting, and any material interest in such business of each Proposing Person (as defined below);
(C) (i) the name and address of the stockholder giving the notice, as they appear on the Corporation’s books, and the names and addresses of the other Proposing Persons (if any) and (ii) as to each Proposing Person, the following information: (a) the class or series and number of all shares of capital stock of the Corporation which are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its affiliates or associates (as such terms are defined in Rule 12b-2 promulgated under the Exchange Act), including any shares of any class or series of capital stock of the Corporation as to which such Proposing Person or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future (whether or not such right is exercisable immediately or only after the passage of time or upon the satisfaction of any conditions or both) pursuant to any agreement, arrangement or understanding (whether or not in writing), (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its affiliates or associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (x) whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person, or any of their affiliates or associates, (y) whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares and (z) whether or not such Proposing Person or any of their affiliates or associates and/or, to the extent known, the counterparty to such Synthetic Equity Interest has entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c) any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in




accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person or any of their affiliates or associates has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the Corporation, (d) any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person or any of their affiliates or associates that are separated or separable from the underlying shares of the Corporation, (e) any performance-related fees (other than an asset based fee) that such Proposing Person or any of their affiliates or associates, directly or indirectly, is entitled to receive based on any increase or decrease in the value of shares of any class or series of capital stock of the Corporation, or any Synthetic Equity Interests, (f)(1) if such Proposing Person is not a natural person, the identity of the natural person or persons associated with such Proposing Person responsible for (i) the formulation of and decision to propose the director nomination or business to be brought before the meeting and (ii) making voting and investment decisions on behalf of the Proposing Person (irrespective of whether such person or persons have “beneficial ownership” for purposes of Rule 13d-3 of the Exchange Act of any securities owned of record or beneficially by the Proposing Person) (such person or persons, the “Responsible Person”), the manner in which such Responsible Person was selected, any fiduciary duties owed by such Responsible Person to the equity holders or other beneficiaries of such Proposing Person and, the qualifications and background of such Responsible Person or (2) if such Proposing Person is a natural person, the qualifications and background of such natural person, (g) any equity interests or any Synthetic Equity Interests in any principal competitor of the Corporation beneficially owned by such Proposing Person or any of their affiliates or associates, (h) any direct or indirect interest of such Proposing Person or any of their affiliates or associates in any contract with the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation (including, without limitation, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), (i) any pending or threatened litigation in which such Proposing Person or any of their affiliates or associates is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation, (j) any material transaction occurring during the prior twelve months between such Proposing Person or any of their affiliates or associates, on the one hand, and the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation, on the other hand, and (k) any other information relating to such Proposing Person or any of their affiliates or associates that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (a) through (k) are referred to, collectively, as “Material Ownership Interests”) provided, however, that the Material Ownership Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these Bylaws on behalf of a beneficial owner;
(D) (i) a description of all agreements, arrangements or understandings to which any Proposing Person or any of their affiliates or associates is a party (whether the counterparty or counterparties are a Proposing Person or any affiliate or associate thereof, on the one hand, or one or more other third parties, on the other hand, (including any proposed nominee(s))) (a) pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders or (b) entered into for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (ii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support such nominations or other business proposal(s), and to the extent known the class and number of all shares of the Corporation’s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and
(E) a statement (i) that the stockholder is a holder of record of capital stock of the Corporation entitled to vote at such meeting, a representation that such stockholder intends to appear in person or by proxy at the meeting to propose such business or nominees and an acknowledgement that, if such stockholder (or a qualified representative of such stockholder) does not appear to present such business or proposed nominees, as applicable, at such meeting, the Corporation need not present such business or proposed nominees for a vote at such meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation, (ii) whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, (a) will deliver a proxy statement and form of proxy to




holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least 67 percent of the voting power of all of the shares of capital stock of the Corporation entitled to vote on the election of directors or (b) otherwise solicit proxies or votes from stockholders in support of such proposal or nomination, as applicable, (iii) providing a representation as to whether or not such Proposing Person intends to solicit proxies in support of director nominees other than the Corporation’s director nominees in accordance with Rule 14a-19 promulgated under the Exchange Act, and (iv) that the stockholder will provide any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (such statement, the “Solicitation Statement”).
For purposes of this Article I of these By-laws, the term “Proposing Person” shall mean the following persons: (i) the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders’ meeting, and (ii) the beneficial owner(s), if different, on whose behalf the nominations or business proposed to be brought before a stockholders’ meeting is made. For purposes of this Section 2 of Article I of these By-laws, the term “Synthetic Equity Interest” shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or so-called “stock borrowing” or securities lending agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a) give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit, or share in any profit, or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the Corporation, (b) mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, (c) otherwise provide in any manner the opportunity to profit, or share in any profit, or avoid a loss from any decrease in the value of any shares of any class or series of capital stock of the Corporation, or (d) increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation.
(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this By-law shall be true and correct as of the record date for the meeting and as of the date that is ten (10) business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the Corporation (with a copy via email to proxy@phreesia.com) not later than the close of business on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the record date), and not later than the close of business on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting). For the avoidance of doubt, the obligation to update as set forth in this Section 2(a)(3) shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the stockholders. Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its representation pursuant to Article I, Section 2(a)(2)(E), such Proposing Person shall inform the Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation (with a copy via email to proxy@phreesia.com) no later than two (2) business days after making the determination not to proceed with a solicitation of proxies. A Proposing Person shall also update its notice so that the information required by Article I, Section 2(a)(2)(C) is current through the date of the meeting or any adjournment, postponement, or rescheduling thereof, and such update shall be delivered in writing to the secretary at the principal executive offices of the Corporation (with a copy via email to proxy@phreesia.com) no later than two (2) business days after the occurrence of any material change to the information previously disclosed pursuant to Article I, Section 2(a)(2)(C).




(4) Notwithstanding anything in the second sentence of Article I, Section 2(a)(2) of this By-law to the contrary, in the event that the number of directors to be elected to the Board of Directors of the Corporation is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section 2(a)(2), a stockholder’s notice required by this By-law shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation.
(b) General.
(1) Only such persons who are nominated in accordance with the provisions of this By-law shall be eligible for election and to serve as directors and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this By-law or in accordance with Rule 14a-8 under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this By-law. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this By-law, the presiding officer of the Annual Meeting shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of this By-law. If the Board of Directors or a designated committee thereof or the presiding officer, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this By-law, such proposal or nomination shall be disregarded and shall not be presented for action at the Annual Meeting.
(2) Except as otherwise required by law, nothing in this Article I, Section 2 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.
(3) Notwithstanding the foregoing provisions of this Article I, Section 2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I, Section 2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders.
(4) For purposes of this By-law, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.
(5) Notwithstanding the foregoing provisions of this By-law, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder, including, but not limited to, Rule 14a-19 of the Exchange Act, with respect to the matters set forth in this By-law. If a stockholder fails to comply with any applicable requirements of the Exchange Act, including, but not limited to, Rule 14a-19 promulgated thereunder, such stockholder’s proposed nomination or proposed business shall be deemed to have not been made in compliance with this By-law and shall be disregarded. Nothing in this By-law shall be deemed to affect any rights of (i) stockholders to have proposals included in the Corporation’s proxy statement pursuant to Rule 14a-8 (or any successor rule), as applicable, under the Exchange Act and, to the extent required by such rule, have such proposals




considered and voted on at an Annual Meeting or (ii) the holders of any series of Undesignated Preferred Stock to elect directors under specified circumstances.
(6) Further notwithstanding the foregoing provisions of this By-law, unless otherwise required by law, (i) no Proposing Person shall solicit proxies in support of director nominees other than the Corporation’s nominees unless such Proposing Person has complied with Rule 14a-19 promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder with timely notice, and (ii) if any Proposing Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder with timely notice, and (C) no other Proposing Person has provided notice pursuant to, and in compliance with, Rule 14a-19 under the Exchange Act that it intends to solicit proxies in support of the election of such proposed nominee in accordance with Rule 14a-19(b) under the Exchange Act, then such proposed nominee shall be disqualified from nomination, the Corporation shall disregard the nomination of such proposed nominee and no vote on the election of such proposed nominee shall occur. Upon request by the Corporation, if any Proposing Person provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, such Proposing Person shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting date, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act.
(7) The number of nominees a stockholder may nominate for election at the Annual Meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the Annual Meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such Annual Meeting.
SECTION 3. Special Meetings. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. Nominations of persons for election to the Board of Directors of the Corporation and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section 1 of these By-laws, in which case such special meeting in lieu thereof shall be deemed an Annual Meeting for purposes of these By-laws and the provisions of Article I, Section 2 of these By-laws shall govern such special meeting.
SECTION 4. Notice of Meetings; Adjournments.
(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given not less than ten (10) days nor more than sixty (60) days before the Annual Meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation’s stock transfer books. Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.
(b) Notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice of all special meetings shall state the purpose or purposes for which the meeting has been called.
(c) Notice of an Annual Meeting or special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting, unless such attendance is for the express purpose of




objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened.
(d) The Board of Directors may postpone and reschedule any previously scheduled Annual Meeting or special meeting of stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section 2 of this Article I of these By-laws or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder’s notice under this Article I of these By-laws.
(e) When any meeting is convened, the presiding officer or the stockholders present or represented by proxy at such meeting may adjourn the meeting from time to time for any reason, regardless of whether a quorum is present , to reconvene at any other time and at any place at which a meeting of stockholders may be held under these By-laws. When any Annual Meeting or special meeting of stockholders is adjourned to another hour, date or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with this Section 4; provided, however, that if the adjournment is for more than thirty (30) days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the “Certificate”) or these By-laws, is entitled to such notice.
SECTION 5. Quorum. A majority of the shares entitled to vote, present in person or by remote communication, or represented by proxy, shall constitute a quorum at any meeting of stockholders. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section 4 of this Article I. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.
SECTION 6. Voting and Proxies.
(a) Stockholders shall have one vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i) in person, (ii) by written proxy or (iii) by a transmission permitted by Section 212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section 212(c) of the DGCL may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. Except as otherwise limited therein or as otherwise provided by law, proxies authorizing a person to vote at a specific meeting shall entitle the persons authorized thereby to vote at any adjournment of such meeting, but they shall not be valid after final adjournment of such meeting. A proxy with respect to stock held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. In the event the Corporation receives proxies for disqualified or withdrawn nominees for the Board of Directors, such votes for such disqualified or withdrawn nominees in the proxies will be treated as abstentions.




(b) Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board of Directors.
SECTION 7. Action at Meeting. When a quorum is present at any meeting of stockholders, any matter before any such meeting (other than an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the Certificate or by these By-laws. Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors.
SECTION 8. Stockholder Lists. The Corporation shall prepare, no later than the tenth (10th) day before each Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of ten (10) days, ending on the day before the meeting date in the manner provided by law.
SECTION 9. Conduct of Meeting. The Board of Directors may adopt by resolution such rules, regulations, and procedures for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with rules, regulations, and procedures adopted by the Board of Directors, the chair of the meeting shall have the right to prescribe such rules, regulations, and procedures and to do all such acts, as, in the judgment of such chair, are necessary, appropriate, or convenient for the proper conduct of the meeting. Such rules, regulations, or procedures, whether adopted by the Board of Directors or the chair of the meeting, may include, without limitation, the following: (a) the establishment of an agenda for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present at the meeting; (c) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, or such other persons as the chair of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; (e) the determination of the circumstances in which any person may make a statement or ask questions and limitations on the time allotted to questions or comments; (f) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (g) the exclusion or removal of any stockholders or any other individual who refuses to comply with meeting rules, regulations, or procedures; (h) restrictions on the use of audio and video recording devices, cell phones, and other electronic devices; (i) rules, regulations, and procedures for compliance with any federal, state, or local laws or regulations (including those concerning safety, health, or security); (j) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and (k) rules, regulations, or procedures regarding the participation by means of remote communication of stockholders and proxy holders not physically present at a meeting, whether such meeting is to be held at a designated place or solely by means of remote communication. Unless and to the extent determined by the Board of Directors or the chair of the meeting, the chair of the meeting shall not be obligated to adopt or follow any technical, formal, or parliamentary rules or principles of procedure.
SECTION 10. Inspectors of Elections. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the presiding officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of such person’s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such person’s ability. The inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. The presiding officer may review all determinations made by the inspectors, and in so doing the presiding officer shall be entitled to exercise such presiding officer’s sole judgment and discretion and such presiding officer shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the presiding officer, shall be subject to further review by any court of competent jurisdiction.




ARTICLE II

Directors
SECTION 1. Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided by the Certificate or required by law.
SECTION 2. Number and Terms. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The directors shall hold office in the manner provided in the Certificate.
SECTION 3. Qualification. No director need be a stockholder of the Corporation.
SECTION 4. Vacancies. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate.
SECTION 5. Removal. Directors may be removed from office only in the manner provided in the Certificate.
SECTION 6. Resignation. A director may resign at any time by giving written notice to the Chair of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides.
SECTION 7. Regular Meetings. Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined by the Board of Directors.
SECTION 8. Special Meetings. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a majority of the directors, the Chair of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place thereof.
SECTION 9. Notice of Meetings. Notice of the hour, date and place of all special meetings of the Board of Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chair of the Board, if one is elected, or the President or such other officer designated by the Chair of the Board, if one is elected, or the President. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of electronic communication, sent to such director’s business or home address, at least twenty-four (24) hours in advance of the meeting, or by written notice mailed to such director’s business or home address, at least forty-eight (48) hours in advance of the meeting. Such notice shall be deemed to be delivered when hand-delivered to such address, read to such director by telephone, deposited in the mail so addressed, with postage thereon prepaid if mailed, dispatched or transmitted if sent by facsimile transmission or by electronic mail or other form of electronic communications. A written waiver of notice signed or electronically transmitted before or after a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these By-laws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting.
SECTION 10. Quorum. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business which might have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this section, the total number of directors includes any unfilled vacancies on the Board of Directors.




SECTION 11. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these By-laws.
SECTION 12. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the records of the meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the Board of Directors for all purposes.
SECTION 13. Manner of Participation. Directors may participate in meetings of the Board of Directors by means of video conference, conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall constitute presence in person at such meeting for purposes of these By-laws.
SECTION 14. Presiding Director. The Board of Directors shall designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is absent, then the Chair of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chair of the Board, if one is elected, are unable to preside or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors.
SECTION 15. Committees. The Board of Directors, by vote of a majority of the directors then in office, may elect one or more committees, including, without limitation, a Compensation Committee, a Nominating & Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers except those which by law, by the Certificate or by these By-laws may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these By-laws for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings and shall report its action to the Board of Directors.
SECTION 16. Compensation of Directors. Directors shall receive such compensation for their services as shall be determined by a majority of the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees and who receive compensation for their services as such, shall not receive any salary or other compensation for their services as directors of the Corporation.
ARTICLE III
Officers
SECTION 1. Enumeration. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other officers, including, without limitation, a Chair of the Board of Directors, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine.
SECTION 2. Election. At the regular annual meeting of the Board of Directors following the Annual Meeting, the Board of Directors shall elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors at such regular annual meeting of the Board of Directors or at any other regular or special meeting.




SECTION 3. Qualification. No officer need be a stockholder or a director. Any person may occupy more than one office of the Corporation at any time.
SECTION 4. Tenure. Except as otherwise provided by the Certificate or by these By-laws, each of the officers of the Corporation shall hold office until the regular annual meeting of the Board of Directors following the next Annual Meeting and until such officer’s successor is elected and qualified or until such officer’s earlier resignation or removal.
SECTION 5. Resignation. Any officer may resign by delivering a written resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise provides.
SECTION 6. Removal. Except as otherwise provided by law, the Board of Directors may remove any officer with or without cause by the affirmative vote of a majority of the directors then in office.
SECTION 7. Absence or Disability. In the event of the absence or disability of any officer, the Board of Directors may designate another officer to act temporarily in place of such absent or disabled officer.
SECTION 8. Vacancies. Any vacancy in any office may be filled for the unexpired portion of the term by the Board of Directors.
SECTION 9. President. The President shall, subject to the direction of the Board of Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate.
SECTION 10. Chair of the Board. The Chair of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.
SECTION 11. Chief Executive Officer. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.
SECTION 12. Vice Presidents and Assistant Vice Presidents. Any Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.
SECTION 13. Treasurer and Assistant Treasurers. The Treasurer shall, subject to the direction of the Board of Directors and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all funds, securities, and valuable documents of the Corporation. The Treasurer shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.
SECTION 14. Secretary and Assistant Secretaries. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In the Secretary’s absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by the Secretary’s signature or that of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform the Secretary’s duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.




SECTION 15. Other Powers and Duties. Subject to these By-laws and to such limitations as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief Executive Officer.

ARTICLE IV

Capital Stock
SECTION 1. Certificates of Stock. Each stockholder shall be entitled to a certificate of the capital stock of the Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by the Chair of the Board, the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary. The Corporation seal and the signatures by the Corporation’s officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these Bylaws, the Board of Directors of the Corporation may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of these Bylaws the Board of Directors has determined that all classes or series of the Corporation’s stock may be uncertificated, whether upon original issuance, re-issuance, or subsequent transfer.
SECTION 2. Transfers. Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate theretofore properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its transfer agent may require.
SECTION 3. Record Holders. Except as may otherwise be required by law, by the Certificate or by these By-laws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these By-laws.
SECTION 4. Record Date. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a) in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting and (b) in the case of any other action, shall not be more than sixty (60) days prior to such other action. If no record date is fixed: (i) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is




held; and (ii) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.
SECTION 5. Replacement of Certificates. In case of the alleged loss, destruction or mutilation of a certificate of stock of the Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe.
ARTICLE V

Indemnification
SECTION 1. Definitions. For purposes of this Article:
(a) “Corporate Status” describes the status of a person who is serving or has served (i) as a Director of the Corporation, (ii) as an Officer of the Corporation, (iii) as a Non-Officer Employee of the Corporation, or (iv) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the Corporation. For purposes of this Section 1(a), a Director, Officer or Non-Officer Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, “Corporate Status” shall not include the status of a person who is serving or has served as a director, officer, employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person’s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders of the Corporation;
(b) “Director” means any person who serves or has served the Corporation as a director on the Board of Directors of the Corporation;
(c) “Disinterested Director” means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding;
(d) “Expenses” means all attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding;
(e) “Liabilities” means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement;
(f) “Non-Officer Employee” means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer;
(g) “Officer” means any person who serves or has served the Corporation as an officer of the Corporation appointed by the Board of Directors of the Corporation;
(h) “Proceeding” means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and
(i) “Subsidiary” shall mean any corporation, partnership, limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the




Corporation) either (i) a general partner, managing member or other similar interest or (ii) (A) fifty percent (50%) or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B) fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity.
SECTION 2. Indemnification of Directors and Officers.
(a) Subject to the operation of Section 4 of this Article V of these By-laws, each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section 2.
(1) Actions, Suits and Proceedings Other than By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe such Director’s or Officer’s conduct was unlawful.
(2) Actions, Suits and Proceedings By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this Section 2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery of the State of Delaware (the “Chancery Court”) or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.
(3) Survival of Rights. The rights of indemnification provided by this Section 2 shall continue as to a Director or Officer after such Director or Officer has ceased to be a Director or Officer and shall inure to the benefit of such Director’s or Officer’s heirs, executors, administrators and personal representatives.
(4) Actions by Directors or Officers. Notwithstanding the foregoing, the Corporation shall indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized in advance by the Board of Directors of the Corporation, unless such Proceeding was brought to enforce such Officer’s or Director’s rights to indemnification or, in the case of Directors, advancement of Expenses under these By-laws in accordance with the provisions set forth herein.
SECTION 3. Indemnification of Non-Officer Employees. Subject to the operation of Section 4 of this Article V of these By-laws, each Non-Officer Employee may, in the discretion of the Board of Directors of the Corporation, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such Non-Officer Employee or on such Non-Officer Employee’s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such Non-Officer Employee’s Corporate Status, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee reasonably believed to be in or not opposed to the best interests of the




Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe such Non-Officer Employee’s conduct was unlawful. The rights of indemnification provided by this Section 3 shall exist as to a Non-Officer Employee after such Non-Officer Employee has ceased to be a Non-Officer Employee and shall inure to the benefit of such Non-Officer Employee’s heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only if such Proceeding was authorized in advance by the Board of Directors of the Corporation.
SECTION 4. Determination. Unless ordered by a court, no indemnification shall be provided pursuant to this Article V to a Director, to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe such conduct was unlawful. Such determination shall be made by (a) a majority vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b) a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d) by the stockholders of the Corporation.
SECTION 5. Advancement of Expenses to Directors Prior to Final Disposition.
(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such Director is involved by reason of such Director’s Corporate Status within thirty (30) days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i) authorized by the Board of Directors of the Corporation, or (ii) brought to enforce such Director’s rights to indemnification or advancement of Expenses under these By-laws.
(b) If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30) days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be on the Corporation.
(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL.
SECTION 6. Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition.
(a) The Corporation may, at the discretion of the Board of Directors of the Corporation, advance any or all Expenses incurred by or on behalf of any Officer or any Non-Officer Employee in connection with any Proceeding in which such person is involved by reason of such person’s Corporate Status as an Officer or Non-Officer Employee upon the receipt by the Corporation of a statement or statements from such Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or Non-Officer Employee




and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses.
(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable standard for indemnification set forth in the DGCL.
SECTION 7. Contractual Nature of Rights.
(a) The provisions of this Article V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to the benefits hereof at any time while this Article V is in effect, in consideration of such person’s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of this Article V nor the adoption of any provision of the Certificate of Incorporation inconsistent with this Article V shall eliminate or reduce any right conferred by this Article V in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article V shall continue notwithstanding that the person has ceased to be a director or officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributes of such person.
(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60) days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation.
(c) In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL.
SECTION 8. Non-Exclusivity of Rights. The rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right which any Director, Officer, or Non-Officer Employee may have or hereafter acquire under any statute, provision of the Certificate or these By-laws, agreement, vote of stockholders or Disinterested Directors or otherwise.
SECTION 9. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any Director, Officer or Non-Officer Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or Non-Officer Employee, or arising out of any such person’s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article V.
SECTION 10. Other Indemnification. The Corporation’s obligation, if any, to indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the “Primary Indemnitor”). Any indemnification or advancement of Expenses under this




Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies.
ARTICLE VI
Miscellaneous Provisions
SECTION 1. Fiscal Year. The fiscal year of the Corporation shall be determined by the Board of Directors.
SECTION 2. Seal. The Board of Directors shall have power to adopt and alter the seal of the Corporation.
SECTION 3. Execution of Instruments. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chair of the Board, if one is elected, the President or the Treasurer or any other officer, employee or agent of the Corporation as the Board of Directors or the executive committee of the Board may authorize.
SECTION 4. Voting of Securities. Unless the Board of Directors otherwise provides, the Chair of the Board, if one is elected, the President or the Treasurer may waive notice of and act on behalf of the Corporation, or appoint another person or persons to act as proxy or attorney in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or shareholders of any other corporation or organization, any of whose securities are held by the Corporation.
SECTION 5. Resident Agent. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or proceeding against the Corporation.
SECTION 6. Corporate Records. The original or attested copies of the Certificate, By-laws and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the amount of stock held by each, may be kept outside the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or at such other place or places as may be designated from time to time by the Board of Directors.
SECTION 7. Certificate. All references in these By-laws to the Certificate shall be deemed to refer to the Seventh Amended and Restated Certificate of Incorporation of the Corporation, as amended and/or restated and in effect from time to time.
SECTION 8. Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the Certificate or these By-laws (including the interpretation, validity or enforceability thereof) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) any action asserting a claim governed by the internal affairs doctrine; provided, however, that this sentence will not apply to any causes of action arising under the Securities Act of 1933, as amended, or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Exchange Act, or the respective rules and regulations promulgated thereunder. To the fullest extent permitted by law, any person or




entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 8.
SECTION 9. Amendment of By-laws.
(a) Amendment by Directors. Except as provided otherwise by law, these By-laws may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the directors then in office.
(b) Amendment by Stockholders. These By-laws may be amended or repealed at any Annual Meeting, or special meeting of stockholders called for such purpose in accordance with these By-Laws, by the affirmative vote of at least seventy-five percent (75%) of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class. Notwithstanding the foregoing, stockholder approval shall not be required unless mandated by the Certificate, these By-laws, or other applicable law.
SECTION 10. Notices. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.
SECTION 11. Waivers. A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver.
Adopted March 21, 2023 and effective as of March 21, 2023.



EX-21.1 3 phrfy2023-exhibit211.htm EX-21.1 Document
                        
Exhibit 21.1

Subsidiaries of the Registrant

As of January 31, 2023 Phreesia, Inc. had no significant subsidiaries as defined in Rule 1-02(w) of Regulation S-X.

EX-23.1 4 phr-fy2023xex231x10xkconse.htm EX-23.1 Document

                         Exhibit 23.1


Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the registration statements (No.333-249541) on Form S-3ASR and registration statements (Nos. 333-264022, 333-254925, 333-237806 and 333-232832) on Form S-8 of our reports dated March 23, 2023, with respect to the consolidated financial statements of Phreesia, Inc. and subsidiaries and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP

Pittsburgh, Pennsylvania
March 23, 2023

EX-31.1 5 phr-fy2023xex311x10xkxceo3.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATIONS
I, Chaim Indig, certify that:
1.I have reviewed this Annual Report on Form 10-K of Phreesia, Inc. (the "registrant");
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and



b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 23, 2023
/s/ Chaim Indig
Chaim Indig
   Chief Executive Officer and Director
   (Principal Executive Officer)

EX-31.2 6 phr-fy2023xex312x10xkxcfo3.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATIONS
I, Randy Rasmussen, certify that:
1.I have reviewed this Annual Report on Form 10-K of Phreesia, Inc. (the "registrant");
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and



b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 23, 2023




/s/ Randy Rasmussen

Randy Rasmussen

   Chief Financial Officer
   (Principal Financial Officer and Principal Accounting Officer)

EX-32.1 7 phr-fy2023xex321x10xkxceo1.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Chaim Indig, Chief Executive Officer of Phreesia, Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
  
the Annual Report on Form 10-K of the Company for the fiscal year ended January 31, 2023 (the "Annual Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

• the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Date: March 23, 2023
 
By:
/s/ Chaim Indig
   Chaim Indig
   Chief Executive Officer and Director
   (Principal Executive Officer)



EX-32.2 8 phr-fy2023xex322x10xkcfo13.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Randy Rasmussen, Chief Financial Officer of Phreesia, Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
the Annual Report on Form 10-K of the Company for the fiscal year ended January 31, 2023 (the "Annual Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

• the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Date: March 23, 2023
 
By:
/s/ Randy Rasmussen
   Randy Rasmussen
   Chief Financial Officer
   (Principal Financial Officer and Principal Accounting Officer)









EX-101.SCH 9 phr-20230131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Background and liquidity link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Composition of certain financial statement captions link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Revenue and Contract Costs link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Finance leases and other debt link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Equity-based compensation link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Net loss per share attributable to common stockholders link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Retirement savings plan link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Subsequent event link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Composition of certain financial statement captions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Revenue and Contract Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Finance leases and other debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Equity-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Commitment and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Income taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Net loss per share attributable to common stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Background and liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Composition of certain financial statement captions - Schedule of accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Composition of certain financial statement captions - Schedule of property and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Composition of certain financial statement captions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Composition of certain financial statement captions - Schedule of intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Composition of certain financial statement captions - Schedule of future amortization expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Composition of certain financial statement captions - Schedule of accounts receivable (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Revenue and Contract Costs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Finance leases and other debt - Schedule of outstanding loan balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Finance leases and other debt - Schedule of outstanding loan balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Finance leases and other debt - Amended and restated loan and security agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Finance leases and other debt - Schedule of long-term debt maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Finance leases and other debt - Schedule of long-term debt maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Finance leases and other debt - Schedule of interest income (expense), net (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Equity-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Equity-based compensation - Stock-based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Equity-based compensation - Stock-based compensation in our financial statements (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Equity-based compensation - Performance-based restricted stock units (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Equity-based compensation - Weighted average assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Equity-based compensation - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Leases - Schedule of operating and finance leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Leases - Schedule of lease expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Leases - Schedule of maturing lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Leases - Schedule of maturing lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Leases - Schedule of supplemental cash flow information (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Income taxes - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Income taxes - Components of tax (benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Income taxes - Effective tax rate reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Income taxes - Company's deferred tax assets and deferred tax liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Net loss per share attributable to common stockholders - Schedule of computation (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Retirement savings plan (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Related party transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Acquisitions - Schedule of consideration paid (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Subsequent event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 phr-20230131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 phr-20230131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 phr-20230131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Stockholders’ equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Foreign Current Foreign Tax Expense (Benefit) Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Foreign currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Related Party Transactions [Abstract] Related Party Transactions [Abstract] Deferred tax asset Deferred Income Tax Assets, Net Long term debt Long-Term Debt, Gross Operating lease cost Operating Lease Cost, Excluding Variable Lease Cost Operating Lease Cost, Excluding Variable Lease Cost Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additions to deferred contract acquisition costs Deferred Contract Acquisition Costs Deferred Contract Acquisition Costs Property and equipment, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Schedule of Finite-Lived Intangible Assets [Table] Composition Of Certain Financial Statement [Table] Composition Of Certain Financial Statement Interest income Interest Income, Operating Deferred tax Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] 2025 Long-Term Debt, Maturity, Year Two Business combinations Business Combinations Policy [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Finance leases Total finance lease liabilities Finance Lease, Liability Line of credit borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Current portion of finance lease liabilities and other debt Less - current portion of finance lease liabilities and other debt Long-Term Debt and Lease Obligation, Current Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Prepaid expenses and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Depreciation and amortization Deferred Tax Liabilities, Property, Plant and Equipment Lease income Lease Income Fair value of financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Contract With Customer Liability [Roll Forward] Contract With Customer Liability [Roll Forward] Contract With Customer Liability Total Long-term Debt And Finance Lease Obligations, Fiscal Year Maturity [Abstract] Long-term Debt And Finance Lease Obligations, Fiscal Year Maturity 2027 Finance Lease, Liability, to be Paid, Year Four Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Exercise of stock options and vesting of restricted stock units (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Deferred taxes, net Deferred Tax Assets, Net Operating lease, weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Valuation date stock price (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Schedule of purchase price considerations at acquisition date Schedule of Business Acquisitions, by Acquisition [Table Text Block] Domestic Tax Authority Domestic Tax Authority [Member] QueueDr QueueDr [Member] QueueDr Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively Property and equipment — net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization State Current State and Local Tax Expense (Benefit) Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Income taxes Income Taxes Paid Amount transferred to receivables from beginning balance of contract assets Contract with Customer, Asset, Reclassified to Receivable 2026 Finance Lease, Liability, to be Paid, Year Three Net loss Net loss Net Income (Loss) Attributable to Parent Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of ESPP valuation assumptions Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Leases Lessee, Finance Leases [Text Block] Schedule of long-term debt and finance lease maturities Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Operating Lessee, Operating Lease, Liability, to be Paid [Abstract] Other (as a percent) Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Total accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss, Current Prepaid insurance Prepaid Insurance Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Total assets Assets, Fair Value Disclosure Percentage of vest option (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Leases Lessee, Operating Leases [Text Block] Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Debt issuance costs and facility fees Payments of Financing Costs Capitalized computed software amortization Capitalized Computer Software, Amortization Related Party [Domain] Related Party [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Incremental expense associated with the modification of stock options Share-Based Payment Arrangement, Plan Modification, Incremental Cost Plan Name [Axis] Plan Name [Axis] Beginning balance - Contract assets (unbilled accounts receivable) Ending balance - Contract assets (unbilled accounts receivable) Contract with Customer, Asset, after Allowance for Credit Loss Cost of Phreesia hardware purchased by customers Cost Of Phreesia Hardware Purchased By Others Cost Of Phreesia Hardware Purchased By Others Termination fee percentage (up to) (as a percent) Debt Instrument, Termination Fee, Percentage Debt Instrument, Termination Fee, Percentage Total finance lease liabilities and other debt Long-Term Debt and Lease Obligation, Including Current Maturities Supplemental information of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] NEOs and Other Members of Executive Management Executive Officer [Member] Number of operating segment Number of Operating Segments Unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Capitalized contract costs at beginning of period Capitalized contract costs at end of period Total deferred contract acquisition costs Capitalized Contract Cost, Net Contract asset additions, net of reclassification to receivables Contract with Customer, Asset, Purchase Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] ESPP Employee stock purchase plan Employee Stock [Member] Issue price per share (in dollars per share) Shares Issued, Price Per Share Scheduled reduction in interest rate (as a percent) Debt Instrument, Interest Rate, Increase (Decrease) Award Type [Axis] Award Type [Axis] Quarterly vesting rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage, Quarterly Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage, Quarterly 2018 Stock Option Plan Two Thousand Eighteen Stock Option Plan [Member] Two thousand eighteen stock option plan. Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liabilities Lease liabilities, current Operating Lease, Liability, Current Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Expenses: Costs and Expenses [Abstract] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Advertisements with Pharmaceutical Company Advertisements With Pharmaceutical Company [Member] Advertisements With Pharmaceutical Company Document Annual Report Document Annual Report Interest rate (as a percent) Line of Credit Facility, Interest Rate During Period Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset Total Liabilities Liabilities Operating lease, weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Goodwill adjustments during the year Measurement period adjustments to goodwill during the year Goodwill, Purchase Accounting Adjustments Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Percentage of equity acquired (as a percent) Business Acquisition, Percentage of Voting Interests Acquired Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Acquired technology Technology-Based Intangible Assets [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Accruals, reserves, and other expenses Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences Revolving credit facility Revolving Credit Facility [Member] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Schedule of operating and finance leases Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Current tax Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Document Type Document Type Weighted- average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Useful life (in years) Useful life (in years) Property, Plant and Equipment, Useful Life Restricted Stock Unit Activity: Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Forfeited and expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finance leases and other debt Debt Disclosure [Text Block] Finance Leases Finance Finance Lease, Liability, to be Paid [Abstract] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Accounts receivable from related parties Accounts Receivable, Related Parties, Current 2026 Long-Term Debt, Maturity, Year Three Affiliated Entity Affiliated Entity [Member] Percentage increase in number of shares reserved (as a percent) Percentage Increase In Number of Shares Reserved For Future Issuance Percentage Increase In Number of Shares Reserved For Future Issuance Revenue Benchmark Revenue Benchmark [Member] Subsequent event Subsequent Event [Member] Schedule of rollforward of contract assets and contract liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Share-based Payment Arrangement, Year 1 Share-Based Payment Arrangement, Tranche One [Member] Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Number of third party payment processors Number of Third-Party Payment Processors Number of Third-Party Payment Processors Total Assets Assets Write-offs and adjustments Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Accounts receivable Accounts Receivable [Policy Text Block] Share-based Payment Arrangement, Year 3 Share-Based Payment Arrangement, Tranche Three [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] PSUs Performance Shares [Member] Beginning balance, stockholders' equity (in shares) Ending balance, stockholders' equity (in shares) Shares, Issued Accrued expenses Total Accrued Liabilities, Current Settlement obligations Settlement Liabilities, Current Number of months with sufficient funds to operate (in months) Estimated Number Of Months The Company Have Sufficient To Fund Its Operations Estimated Number Of Months The Company Have Sufficient To Fund Its Operations Insignia Insignia Health, LLC [Member] Insignia Health, LLC Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Share settled bonuses Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid Accounting Policies [Abstract] Accounting Policies [Abstract] Payroll-related expenses and taxes Employee-related Liabilities, Current Variable lease cost Variable Lease, Cost Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ Equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Total prepaid and other current assets Prepaid Expense and Other Assets, Current Foreign taxes (as a percent) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Deferred tax asset Deferred Income Taxes and Tax Credits Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts Net loss per share attributable to common stockholders Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] 2022 Share Settled Bonus Award Program 2022 Share Settled Bonus Award Program [Member] 2022 Share Settled Bonus Award Program Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) Finance Lease, Liability, Noncurrent Schedule of stock based compensation by type of award Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Schedule of income tax (benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Award Type [Domain] Award Type [Domain] Change in valuation allowance (as a percent) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 2019 Stock Option And Incentive Plan Two Thousand And Nineteen Stock Option And Incentive Plan [Member] Two Thousand And Nineteen Stock Option And Incentive Plan [Member] Weighted average term for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Weighted-average remaining contractual life of options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Payment processing fees liability Accrued Processing Fee, Current Accrued processing fee. Schedule of intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Proceeds from employee stock purchase plan Proceeds from Stock Plans Cash consideration paid on acquisition date Cash consideration paid on acquisition date Payments to Acquire Businesses, Gross Computer equipment Computer Equipment [Member] Third SVB Facility Third Amended And Restated Loan And Security Agreement (Third SVB Facility) [Member] Third Amended And Restated Loan And Security Agreement (Third SVB Facility) Basis of presentation Basis of Accounting [Text Block] Entity Registrant Name Entity Registrant Name Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Subsequent event Subsequent Events [Text Block] Dividend yield (as a percent) Expected dividends (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Customer relationship Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Retirement savings plan Retirement Benefits [Text Block] Leases [Abstract] Leases [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Computer software Computer Software [Member] Computer Software [Member] Minimum Minimum [Member] Settlement obligations Settlement Obligations Policy [Policy Text Block] Settlement Obligations Policy [Text Block] 2025 Finance Lease, Liability, Payments, Due Year Two, Discounted Obligation Finance Lease, Liability, Payments, Due Year Two, Discounted Obligation Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Second SVB Facility Second Amended And Restated Loan And Security Agreement (Second SVB Facility) [Member] Second Amended And Restated Loan And Security Agreement (Second SVB Facility) Accumulated amortization of capitalized internal-use software Capitalized Computer Software, Accumulated Amortization Common stock, par value (in dollars per share) Common stock par value Common Stock, Par or Stated Value Per Share Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Auditor Name Auditor Name Fair Value Measurements Fair Value Disclosures [Text Block] Operating lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Accumulated federal net operating loss carryforward Operating Loss Carryforwards Trading Symbol Trading Symbol Entity File Number Entity File Number Acquisition related costs incurred Business Acquisition, Transaction Costs Treasury stock (in shares) Treasury Stock, Common, Shares 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Long-term deferred revenue Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Foreign Deferred Foreign Income Tax Expense (Benefit) Composition of Certain Financial Statement Captions [Abstract] Composition Of Certain Financial Statement [Abstract] Composition of Certain Financial Statement [Abstract] Title of Individual [Axis] Title of Individual [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Effective tax rate (as a percent) Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Contingent consideration Business Combination, Consideration Transferred, Contingent Consideration Business Combination, Consideration Transferred, Contingent Consideration Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Due from related parties, current Due from Related Parties, Current Number of options outstanding at beginning of period (in shares) Number of options outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of estimates Use of Estimates, Policy [Policy Text Block] Money market mutual funds Cash and Cash Equivalents, Fair Value Disclosure Acquisitions Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Prime Rate Prime Rate [Member] Concentration risk (as a percent) Concentration Risk, Percentage Subsequent Events [Abstract] Subsequent Events [Abstract] Total revenue Revenues Additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Capitalized contract cost, amortization period (in years) Capitalized Contract Cost, Amortization Period Liabilities incurred Business Combination, Consideration Transferred, Liabilities Incurred Annual commitment fee Debt Instrument, Fee Amount Liability awards Liability Awards [Member] Liability Awards Income taxes Income Tax Disclosure [Text Block] Recognized revenue from related parties Revenue from Related Parties State Deferred State and Local Income Tax Expense (Benefit) Amortization of intangible assets Amortization of Intangible Assets Schedule of goodwill Schedule of Goodwill [Table Text Block] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Net loss per share attributable to common stockholders - basic (in dollars per share) Earnings Per Share, Basic Disallowed interest expense Deferred Tax Assets Disallowed Interest Expense Deferred Tax Assets Disallowed Interest Expense 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three ESPP offering period (in months) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Insurance financing agreement Proceeds From Insurance Financing Arrangement Proceeds From Insurance Financing Arrangement Other assets Other Assets [Member] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Concentration Risk Type [Domain] Concentration Risk Type [Domain] Treasury stock Treasury Stock [Member] Sales and marketing Selling and Marketing Expense Total Stockholders’ Equity Beginning balance, stockholders' equity Ending balance, stockholders' equity Stockholders' Equity Attributable to Parent Vesting [Domain] Vesting [Domain] Accrued interest and payments Accrued Interest And Payments [Member] Accrued Interest And Payments Finite-Lived Intangible Assets [Line Items] Composition Of Certain Financial Statement [Line Items] Composition Of Certain Financial Statement Acquisitions, net of cash acquired Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows Payments To Acquire Businesses Including Contingent Consideration, Net Of Cash Acquired Payments To Acquire Businesses Including Contingent Consideration, Net Of Cash Acquired Capitalized Contract Cost [Roll Forward] Capitalized Contract Cost [Roll Forward] Capitalized Contract Cost Entity Interactive Data Current Entity Interactive Data Current Deferred contract acquisition costs amortization Capitalized contract cost, amortization Amortization of deferred contract acquisition costs Capitalized Contract Cost, Amortization Accumulated amortization of intangible assets Less accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Total finance lease cost Finance Lease, Cost Finance Lease, Cost Prepaid and other current assets Prepaid Expenses and Other Current Assets [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Payment processing fees Payment Processing Fees [Member] Payment processing fees. Numerator: Net Income (Loss) Attributable to Parent [Abstract] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Accumulated deficit Retained Earnings [Member] Unrecognized compensation cost to stock option Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Common stock Common Stock [Member] Schedule of stock based compensation in financial statements Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of lease expense and cash flow information Lease, Cost [Table Text Block] Deferred contract acquisition costs Increase (Decrease) in Deferred Charges Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Income taxes Income Tax, Policy [Policy Text Block] Revenue recognition Revenue [Policy Text Block] 2024 Finance Lease, Liability, Payments, Due Year One, Discounted Obligation Finance Lease, Liability, Payments, Due Year One, Discounted Obligation Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Statement [Table] Statement [Table] Principal payments on financing agreements Repayments of Other Long-Term Debt Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Furniture and fixtures Furniture and Fixtures [Member] Current: Assets, Current [Abstract] Operating lease liabilities, non-current Lease liabilities, non-current Operating Lease, Liability, Noncurrent Schedule of measurement inputs and valuation techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Company contributions Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Composition of certain financial statement captions Additional Financial Information Disclosure [Text Block] Financing payments of acquisition-related liabilities Payment for Contingent Consideration Liability, Financing Activities Related Party Transaction [Axis] Related Party Transaction [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable, net of allowance for doubtful accounts of $1,053 and $863 as of January 31, 2023 and 2022, respectively Total accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Reserve for bad debts Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Fair value, recurring Fair Value, Recurring [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related party transactions Related Party Transactions Disclosure [Text Block] Segment information Segment Reporting, Policy [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Schedule of intangible assets acquired Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Cost of revenue (excluding depreciation and amortization) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Information technology services Accrued Information Technology Services Expenses, Current Accrued Information Technology Services Expenses, Current Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Finance lease payments Financing cash used for finance leases Finance Lease, Principal Payments Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Equity offering costs Deferred Charges, Policy [Policy Text Block] Non-cash operating lease expense Noncash Operating Lease Expense Noncash Operating Lease Expense Total other income (expense), net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Total intangible assets, gross carrying value Finite-Lived Intangible Assets, Gross Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings Treasury Stock From Vesting Of Share-Based Awards Treasury Stock From Vesting Of Share-Based Awards Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Permanent differences (as a percent) Effective Income Tax Rate Reconciliation, Deduction, Percent Other prepaid expenses and other current assets Other Prepaid Expenses And Other Current Assets Other Prepaid Expenses And Other Current Assets Operating lease right-of-use assets Lease right-of-use assets Operating Lease, Right-of-Use Asset Long-lived assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Cash paid for: Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Weighted- average exercise price outstanding at beginning of period (in dollars per share) Weighted- average exercise price outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Foreign Tax Authority Foreign Tax Authority [Member] Local Phone Number Local Phone Number Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating loss Operating Income (Loss) New accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Payment processing expense Payment Service Obligations [Policy Text Block] Payment Service Obligations [Policy Text Block] Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Four Finite-Lived Intangible Assets, Amortization Expense, after Year Four Stock based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Goodwill Goodwill balance at beginning of period Goodwill balance at end of period Goodwill Goodwill Settlement assets Settlement Assets, Current Software Agreement Software Agreement [Member] Software Agreement Depreciation and amortization Depreciation, Depletion, and Amortization [Policy Text Block] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] General and administrative expenses from transactions with related party Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for income taxes Provision for income taxes Total provision for income taxes Income Tax Expense (Benefit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Allowable cash hold outside of facility Debt Instrument, Covenant, Cash Hold Outside Of Facility Debt Instrument, Covenant, Cash Hold Outside Of Facility 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Federal Deferred Federal Income Tax Expense (Benefit) Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Cash settled stock based compensation expense Share-Based Payment Arrangement, Cash Used to Settle Award Weighted-average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Billed Billed Contracts Receivable Simulation term (in years) Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Capitalized internal-use software Internal Use Software, Policy [Policy Text Block] Bonus settlement in shares (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Bonus Settlement In Shares, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Bonus Settlement In Shares, Percentage Capitalized implementation costs Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, before Accumulated Amortization Network solutions Network Solutions [Member] Network Solutions Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2023 and 2022; 54,187,172 and 52,095,964 shares issued as of January 31, 2023 and 2022, respectively Common Stock, Value, Issued Cashless transfer of term loan and related accrued fees into increase in debt balance Debt Conversion, Original Debt, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Follow-on Offering Follow-On Offering [Member] Follow-On Offering Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Deferred tax assets Deferred Tax Assets, Gross [Abstract] Cashless exercise of common stock warrants Cashless Exercise of Common Stock Warrants, Supplemental Cash Flow Information Cashless Exercise of Common Stock Warrants, Supplemental Cash Flow Information Affiliate of Director Affiliate of Director [Member] Affiliate of Director Schedule of shares excluded from computation of diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of fair value, assets and liabilities measured on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Financing arrangements Financing Arrangements [Member] Financing Arrangements Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Cash and cash equivalents—beginning of year Cash and cash equivalents—end of year Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Current: Liabilities, Current [Abstract] Audit Information [Abstract] Audit Information [Abstract] Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted-average remaining contractual life of options outstanding and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue Contract with Customer, Liability, Current Cashless exercise of common stock warrants (in shares) Stock Issued Upon Cashless Exercise of Common Stock Warrants Stock issued upon cashless exercise of common stock warrants. 2024 Purchase Obligation, to be Paid, Year One Interest on lease liabilities Finance Lease, Interest Expense Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Schedule of deferred contract acquisition costs Capitalized Contract Cost [Table Text Block] Acquisition related costs Business Combination, Acquisition Related Costs Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) Finance Lease, Liability, Current Amendment Flag Amendment Flag Estimated useful life (in years) Useful life (in years) Estimated Useful Life (in Years) Finite-Lived Intangible Asset, Useful Life Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Total operating lease cost Operating Lease, Cost Debt instrument, face amount Debt Instrument, Face Amount Finite-lived intangible assets, remaining amortization period (in years) Finite-Lived Intangible Assets, Remaining Amortization Period Issuance of common stock for employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Goodwill additions during the year Goodwill, Acquired During Period Deferred contract acquisition costs Deferred contract acquisition costs, current (to be amortized in next 12 months) Capitalized Contract Cost, Net, Current Other current year activity in deferred revenue Contract With Customer, Liability, Other Contract With Customer, Liability, Other Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies [Line Items] Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Goodwill and intangible assets Goodwill and Intangible Assets, Policy [Policy Text Block] Other Debt Long-Term Debt, Fiscal Year Maturity [Abstract] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Revenue from Affiliate of Stockholder Revenue From Affiliate Of Stockholder [Member] Revenue From Affiliate Of Stockholder 2024 Finance Lease, Liability, to be Paid, Year One Depreciation and amortization Depreciation, Depletion and Amortization Employee purchase price of common stock (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Unused capacity, commitment fee (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Federal income tax benefit at statutory rate (as a percent) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Deferred contract acquisition costs Deferred contract acquisition costs, non-current Capitalized Contract Cost, Net, Noncurrent Purchase obligation 2025 Purchase Obligation, to be Paid, Year Two Issuance of common stock for employee stock purchase plan (in shares) Purchase of ESPP settlement (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of allocation of purchase price of assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of components of interest income (expense) Interest Income and Interest Expense Disclosure [Table Text Block] Equity compensation (as a percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Fair Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Deferred contract acquisition costs Deferred Tax Liabilities, Deferred Expense, Other Capitalized Costs Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code State and local tax, net of federal benefit (as a percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent 2025 Finance Lease, Liability, to be Paid, Year Two Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Prepaid data center expenses Prepaid Data Center Expenses, Current Prepaid Data Center Expenses, Current Property and equipment acquisitions through finance leases Lease Obligation Incurred Operating cash used for operating leases Operating Lease, Payments Schedule of estimated amortization expense for intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Accordion feature, potential new maximum borrowing capacity Line Of Credit Facility, Accordion Feature, Potential Maximum Borrowing Capacity Line Of Credit Facility, Accordion Feature, Potential Maximum Borrowing Capacity Stock options Share-Based Payment Arrangement, Option [Member] Treasury stock, at cost, 971,236 and 301,003 shares as of January 31, 2023 and 2022, respectively Treasury Stock, Value Title of Individual [Domain] Title of Individual [Domain] Volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Finance Lease, Liability, to be Paid, After Year Four Finance Lease, Liability, to be Paid, After Year Four Finance Lease, Liability, to be Paid, After Year Four Accounts receivable, allowance for doubtful accounts Allowance for doubtful accounts Less accounts receivable allowances Allowance for doubtful accounts at beginning of period Allowance for doubtful accounts at end of period Accounts Receivable, Allowance for Credit Loss, Current Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Exercise of stock options and vesting of restricted stock units Stock Issued During Period, Value, Stock Options Exercised Forfeited and expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Total long-term debt maturities Long-Term Debt Other (expense) income, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, shares authorized (in shares) Common stock authorized (up to) (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Acquisition-related liabilities Acquisition Related Liabilities, Current Acquisition Related Liabilities, Current Tax liabilities Accrued Income Taxes, Current Payment processing expense Payment Processing Expense Payment processing expense. Maximum Maximum [Member] Increases in deferred revenue due to acquisitions Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Stock options to purchase common stock, restricted stock units and performance stock awards Share-Based Payment Arrangement [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Fiscal year Fiscal Period, Policy [Policy Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Revenue recognized that was included in deferred revenue at the beginning of the period Contract with Customer, Liability, Revenue Recognized Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Revenue: Revenues [Abstract] Intangible assets, net of accumulated amortization of $2,549 and $1,178 as of January 31, 2023 and 2022, respectively Net carrying value Finite-Lived Intangible Assets, Net Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Cost of revenue (excluding depreciation and amortization) Cost of Goods and Service [Policy Text Block] Summary of significant accounting policies Significant Accounting Policies [Text Block] Computer software Computer Software, Intangible Asset [Member] Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Schedule of Minimum Payments Under Purchase Commitments Contractual Obligation, Fiscal Year Maturity [Table Text Block] Schedule of market-based performance stock unit activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] 2027 Purchase Obligation, to be Paid, Year Four Cashless exercise of common stock warrants Cashless Exercise of Common Stock Warrants Cashless exercise of common stock warrants. Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Background and liquidity Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Measurement Of Lease Liabilities [Abstract] Cash Paid For Measurement Of Lease Liabilities ESPP, number of offering periods per year Employee Stock Purchase Plan, Number Of Offering Periods Per Year Employee Stock Purchase Plan, Number Of Offering Periods Per Year Operating leases: Operating leases: Lessee, Operating Lease, Description [Abstract] Assets under finance lease, accumulated amortization Accumulated depreciation Finance Lease, Right-of-Use Asset, Accumulated Amortization Total expenses Costs and Expenses Capitalized implementation costs, accumulated amortization Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Accumulated Amortization ESPP, employee common stock purchase discount (as a percent) ESPP, Employee Common Stock Purchase Discount, Percent of Discount ESPP, Employee Common Stock Purchase Discount, Percent of Discount Subsequent Event [Line Items] Subsequent Event [Line Items] Correlation coefficient Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Correlation Coefficient Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Correlation Coefficient Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Capitalized contract cost, impairment loss Capitalized Contract Cost, Impairment Loss Class of Stock [Line Items] Class of Stock [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Stock-based compensation Share-Based Payment Arrangement [Policy Text Block] Total future minimum lease payments Finance Lease, Liability, to be Paid Schedule of maturing lease commitments of finance leases Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Finance lease, term of contract (in years) Lessee, Finance Lease, Term of Contract Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Forfeited and expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Aggregate intrinsic value outstanding and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Customer One Customer One [Member] Customer One Accumulated depreciation and amortization, property and equipment Less accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Auditor Location Auditor Location Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Liabilities Entity Filer Category Entity Filer Category Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions Proceeds from Issuance of Common Stock Weighted-average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Hardware development Hardware Development [Member] Hardware development [Member] PhreesiaPads and Arrivals Kiosks Phreesia Pads and Arrivals Stations [Member] Phreesia pads and arrivals stations [Member] Federal Current Federal Tax Expense (Benefit) Term loan Term Loan [Member] Term Loan Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 11) Commitments and Contingencies Security Exchange Name Security Exchange Name License License [Member] Weighted average amortization period (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 2026 Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Three Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Three Issuance of stock to settle liabilities for stock-based compensation Stock Issued Issuance of stock for share-settled bonus awards Stock Issued During Period, Value, Issued for Services Tax examination, penalties and interest accrued Income Tax Examination, Penalties and Interest Accrued Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Amount vested at the end of the period (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price Subscription and related services Subscription And Related Services [Member] Subscription And Related Services Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Cashless transfer of lender fees through increase in debt balance Debt Conversion, Cashless Transfer Of Lender Fees Debt Conversion, Cashless Transfer Of Lender Fees Employees Other than NEOs Employees Other Than Named Executive Officers [Member] Employees Other Than Named Executive Officers Common stock reserve for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover page. Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Entity Voluntary Filers Entity Voluntary Filers 2024 Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year One Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year One Impairment of goodwill Goodwill, Impairment Loss Equity-based compensation Share-Based Payment Arrangement [Text Block] Finance lease, weighted average discount rate (as a percent) Finance Lease, Weighted Average Discount Rate, Percent Revenue and Contract Costs Revenue from Contract with Customer [Text Block] Less cash acquired Cash Acquired from Acquisition Increases in contract assets due to acquisitions Increase (Decrease) in Contract with Customer, Asset Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Risk-free rate (as a percent) Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Due from related parties, noncurrent Due from Related Parties, Noncurrent Contract With Customer Asset [Roll Forward] Contract With Customer Asset [Roll Forward] Contract With Customer Asset Interest income (expense), net Interest income (expense), net Interest Income (Expense), Net Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Treasury stock to satisfy tax withholdings on stock compensation awards Payment, Tax Withholding, Share-Based Payment Arrangement Total Liabilities and Stockholders’ Equity Liabilities and Equity Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Related Party [Axis] Related Party [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Payments of revolving line of credit Repayments of Long-Term Lines of Credit Payments of acquisition date fair value of contingent consideration Payment for Contingent Consideration Liability, Investing Activities 2025 Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Two Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total deferred tax assets Deferred Tax Assets, Gross Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Vesting [Axis] Vesting [Axis] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Net loss per share attributable to common stockholders - diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Prepaid software and business systems Prepaid Software And Business Systems, Current Prepaid Software And Business Systems, Current Share-based Payment Arrangement, Year 2 Share-Based Payment Arrangement, Tranche Two [Member] Vesting term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payment of offering costs Payments of Stock Issuance Costs Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Amount vested at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Finance leases: Finance leases: Lessee, Finance Lease, Description [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Property and equipment, at cost Finance Lease, Right-of-Use Asset, before Accumulated Amortization Total stock based compensation Total stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount Schedule of accounts receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Receivables for cash in-transit on stock option exercises Receivables For Cash In-Transit On Stock Option Exercise Receivables For Cash In-Transit On Stock Option Exercise Settlement period (in days) Settlement Assets, Settlement Period Settlement Assets, Settlement Period Customer Concentration Risk Customer Concentration Risk [Member] Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Intangible assets Deferred Tax Liabilities, Intangible Assets Capitalized cost of computer software Capitalized Computer Software, Additions Schedule of restricted stock unit activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Capitalized internal-use software Payments to Develop Software Issuance of stock for share-settled bonus awards (in shares) Stock Issued During Period, Shares, Issued for Services Expiration period / maximum term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Schedule of allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Amortization Amortization Schedule of maturing lease commitments of operating leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Beginning balance - Contract liabilities (deferred revenue) Ending balance - Contract liabilities (deferred revenue) Contract with Customer, Liability Capitalized stock based compensation Less stock-based compensation expense capitalized as internal-use software Share-Based Payment Arrangement, Amount Capitalized Lease liability Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities 2026 Finance Lease, Liability, Payments, Due Year Three, Discounted Obligation Finance Lease, Liability, Payments, Due Year Three, Discounted Obligation Product and Service [Axis] Product and Service [Axis] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Finance lease, weighted average remaining lease term (in years) Finance Lease, Weighted Average Remaining Lease Term Unbilled Unbilled Contracts Receivable Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Interest expense Interest Expense Long-term finance lease liabilities and other debt Long-term finance leases and other debt Long-Term Debt and Lease Obligation Schedule of accrued expenses Schedule of Accrued Liabilities [Table Text Block] Schedule of long-term debt instruments Schedule of Long-Term Debt Instruments [Table Text Block] Equity [Abstract] Equity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Awards vested during period (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Number of shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized 2026 Purchase Obligation, to be Paid, Year Three Advertising expense Advertising Expense Capitalized software acquired through vendor financing Capitalized Software Obtained Through Financing Capitalized Software Obtained Through Financing Total deferred tax liabilities Deferred Tax Liabilities, Gross Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Total property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Operating cash used for finance leases Finance Lease, Interest Payment on Liability Schedule of effective tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Customer payment period Contract With Customer, Payment Period Contract With Customer, Payment Period Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total cash paid in measurement of lease liabilities Lease, Payments Lease, Payments Accrued expenses Accrued Liabilities [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and development Research and Development Expense, Policy [Policy Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Consideration transferred Total fair value of acquisition consideration Business Combination, Consideration Transferred Concentrations of credit risk and risks and uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Other Accrued Liabilities, Current Capitalized internal-use software, net of accumulated amortization of $37,236 and $31,139 as of January 31, 2023 and 2022, respectively Capitalized Computer Software, Net Share-based Payment Arrangement, Year 4 Share-Based Payment Arrangement, Tranche Four [Member] Share-Based Payment Arrangement, Tranche Four City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] General and administrative Selling, General and Administrative Expenses, Policy [Policy Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Total maturities of finance leases and other debt Long-term Debt And Lease Obligations, Gross, Including Original Issue Discount Long-term Debt And Lease Obligations, Gross, Including Original Issue Discount Total Purchase Obligation Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Sales and marketing Advertising Cost [Policy Text Block] Settlement assets Settlement Assets Policy [Policy Text Block] Settlement Assets Policy [Text Block] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Schedule of prepaid and other current assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] 2024 Long-Term Debt, Maturity, Year One Non-cash stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Subscription and related services Subscription And Services [Member] Subscription and related services. Weighted average fair market value of grants (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Less: interest Finance Lease, Liability, Undiscounted Excess Amount Leases Lessor, Operating Leases [Text Block] Asset impairment charges Asset Impairment Charges Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use assets recorded in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Customer [Domain] Customer [Domain] EX-101.PRE 13 phr-20230131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 phr-20230131_g1.jpg GRAPHIC begin 644 phr-20230131_g1.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@"(02. P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHJI9ZKI^HR M2QZ??VUT\)Q*L$RN8SSPP!XZ'KZ4[,5TMRW152ZU73[&XA@OK^VMIISB*.:9 M4:0YQ\H)YY(Z5;HL[7"ZO8****0PHHHH **J6.JZ?J?F?V;?VUWY1 D^SS+) ML)['!XZ&K=-IK1B335T%%%%(84444 %%%% !1110 456M-2L;^29+&]M[EX& MVRK#*KF,\\-@\'@]?2FWVJZ=I:JVI7]K9AONFXF6//TR:=G>Q/,K7OH6Z*CM M[B&[@6>UFCFB<962-@RL/8BJUSK6EV5TMM>:E9V\[XVQ2SJK-] 3FBS;L/F2 M5R[14%W>VNGVS7-_!R>*CL-5T_5$=],O[:\5#AVMYED"GT M."<46=KBYE>U]2W16?>^(-&TZX\C4-6L;2; /ESW*(V#WP3FKX(905(((R". M]%FE<:DF[)BT4UY8XR@D=5+G:H8XW'T'K5:?5=/M;V*SNK^VANIL>5!),JO) MDX&U2E64WG7% MFBM.4P50DD;<_P!X8Y':FDWL)R2W-.BBBD,**** "BBB@ HHHH **** "BBB M@ HHHH **** "BHKFZ@LK9[B\GCMX(QEY97"JH]23P*2SO;74+5+FPN8;JW? M.V6"0.C8.#@C@\C% [.UR:BJD6K:=/J,FGPZA:R7L0S);),ID0<YO[F&UMX\;Y9I B+DX&2>!R0* W)J*BM;JWO;9 M+FRGBN()!E)8G#JP]B.#4-YJVG:?/##J&H6MK+<'$,<\RHTAR!A03SR1T]:= MG>P[,MT444A!1110 44WS8_.$6]?,*[@F><=,X]*=0 4444 %%%% !1110 4 M45'<7,%I;O/=S1P0QC+R2L%51ZDG@4 2454L-5T[58VDTN_M;U$.&:VF60*? MQMGN+VXBMX$&6EF<(J_4G M@5%8:G8:I"9=,O;:\C4X+V\JR 'TR":=F.SMO IU !115"]UW2=-N%@U'5+*TF<96.>X1&8>P)S1N-)O8OT51OMV3S56[\4Z5::WIVDFY66]U')ACB(;"A2V]N>%., M ]STZ'#46]@Y6S8HHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR MKX/?\C#XK_Z[I_Z')7JM>)^#?$EAX'\;^(K/Q"9+=;B?Y9?++!=K,1D $X(; M.179ATY0J1CO;]4>?C)*%2E.6B3_ $9K_%/_ )'SPC_UW'_HU*Z'Q-\1$T77 M/[&TK1[K6=15 \D-OD; 1GL&)..>G>N)\2^(;'QM\2O#<#BMU!*%.% M1=)::]]+];',ZK=2M4HR6\==.VMKZ7-WPEXZ?Q+?3V-WHE[I=U ,L)5+(/8M MM&#ST(K-U?XI);:S<:=X?T.[UR2U)%P\!(5,'!QA6) /&>!6?X6\;:T_C9?# M6H:A8ZY%+&Q6_LP/D(4MR5 4CC!XZGK7*^")+O3]2UFS?Q=!X9N5G_>K=6D3 M^<02/O.1@CT]\TEAXCN[J:2T\.:C/I,+8EOXU+;!ZE M0N ._+=*R=*\/6Y\,>++K0_$D6N3WULWG1PVWDL'RS9V[N_S <#VJ[\-_%OA M[3/AR+;4+^WMY[8RF:&1@KR98D;5ZMD$#C/2IE1II3E%^NCO;YV]2'X'N)!X@=>5::(CZ?/7IFJ:G::-I<^H:A*(K>!=SM_0> MI/2O,?@8RM%KS1C:IEB*CT'SUO\ Q?M;BY^'\QM@S"&9))0/[@R#^1(-+%14 ML5RO2]OR1>"J.."YUJUS/\69O_"X6*_;5\*ZB=(W8^W9XZXZ;=N?;=6YXA^( M$.D^%;/Q!I=G_:EC&5^$Z0M?VWF+IPMS9[ MAYGF;-N-G7KWZ=ZJ>!/#4^J?!N\T^]4J+]Y);8-VX&T_]]+FJG3IQ3DXV46E MUU7^?H13K5IN,8SNY1;V7NOI\NFIU_BCQC:^'/"D>MI%]L2;9Y$8DV>9N&1S M@]LGI536OB!;>'_#VGWNI64@O]0C#Q:?$^Y@2 <%L#ID#IU[5Y=H<]UXQO?# M7A2[1_*TN20W08=54YP?HHV_C70?%-9[3XA:!?-=_8+<(JQW9A$JP,')+;3P M<9!Q3^K0C4C3ENVW\EM]]B7C*LJ4ZT=DDO\ MY[_ '7.FT'XF1ZCKD6D:YHU MWH=Y/_J%N,D/Z#E5()[<8]Z9K_Q/30?%=QH9T>6ZDCC4PM#+EIG8 A NWCKU MR>G2N>N],M==\2Z5_:7Q)L=0O+:59+98[*--9/VD4W M#.V+QEI+PYQ;KG&<]%^I_ 9KM* M0_=/TK@YU&7-RZ=CU'3DZ?)S:]^IY1\#59(]>5SN82Q G/4_/6HOPS_M7Q;J M6K^,IHK^WFS]FACF=?+7/&<8Q@8Z''6L[X)?>\1?]=X__9Z9X[\8RZYKS>$M M'U&VTZV!*7U]<3"->/O*"2.!TP.2>.F:]&K[1XJ2IZ-I:]E9'DT?8PP4?:JZ M4G9=WS.R*GP[O?['UKQ;'I,KS:-9Q231%CE=RD[+?!6K MZ[K0EGU.>24PS^:1L*J#G .#DD]<\#BNVT+2/#EKX/OO#_AK4K._N)K:0RM% M<(\DC%=NXA3P,D =A7*?#_Q5IFB_#C5;+4KR&VO+:2;;!(V'?*C& >IW9''2 MB4Y-3E3O?W5Y^OS%"G"+I1K6Y6Y.W1;:?+6Q135I]4_9\O$NG:1[*Z2W5F.2 M5#HR_D&Q] *F^#L[:5XA^Q2-^[U:Q%Q'GNR.PP/PW?E5.SL);3]GS49IE*B[ MO5ECSW7>BY_-32:TUQH'A3P5XBLL>=%;O"3[,"0/R+5T2LU.G'[4FOGRW_,X MX3 U\UI#[A%'],?G7T=:?\>4'_7- M?Y5X%XATPV'P@\.R.N)+JZDN')ZG>#@_]\@5[[:?\>4'_7-?Y5RXNWLHQ71M M?=8[\!=UIS>\DG][;/%/$GB;5(_C%;W0T:\F>Q+1V]B&;,XPPWJ-O (.> >G M6NHUS6=,D\=>%O[5\.,VI7<4$DP^/FE7-] M-';P);J6EE8*JY60-IH[CXO\ A*:"198I!"R.ARK RD@@]Q6D5&7L ME;H^_F8S/_#?\$VM2^*::=XKOM#_ +$N;J:W^6#[,^]YWP#C M9MX&">5O3[H(([@C\ZS_#ZAOV@]:) M )6%R,]CB,?UHT=%/[1.JY4?+"2..A\M.?U-9JE2LDX_8YMS65?$)]6N-*N],GTO4(%+F&5MV0" >H!!&1P15'5?BHL&KW%CX? MT*[UO[(2+B6 D*F.N,*V1[G K'TL,W[0>LJAPQMF /H?+CKG? -NPQWSV/\ +FN:_P"%NWAB6\'@[43I MKL MWN.&!../DVD^VZJ_AC0?#D6A^(;B\\56^IZ?J 47;K#]G\EMS$-C<<$D M\#';BLPZA<^%M#-QX6^(-C?64 W1Z?=JOF$ _< .6_+;2C2H\\DE?;>_^6_J M5*OB/9Q;=M[VY6_)ZNUN]NI[!I]ZFHZ=!>1Q31+,@<1SQE'7/8@]#7$_%>_T MFPTO3VUO1?[7C:=@B?:W@V';URO6NB\&Z]-XE\)V>JW-NMO+,&#(N=I*L5R, M]CC-<1\=/^0'I7_7RW_H-8486Q*@^_\ 6IU8BIS8-U(ZZ=OT9T7B_P ?P^#K M_3+>XL#-!>*2\JRX,2@@$A=IW=?45F6_Q:0:];6.K>'[[3+>[8""XN"06!. MQ4J..>H)K*^**J_C3P@K@,K2J""."/,2G?&X_GR<_P#?%;T:5*2IJ2UE M?KVNO7BZLHRLH*+M;NDV>KUX=XD\3:I'\8K>Z&C7DSV):.WL0S9G&&&]1 MMX!!SP#TZU[C7DGB:ZM[#X^:5'1M7T*\TB2Y8+ UP3EB?N[E*@C/3C/-8GBMX;OXU>&)8V2:&2.)T=2&5A MN8@@]^QI_P 2ACXF^$2.OGQ\_P#;9:Z8QA45.$ENG\MSDG.K2E5J0ELX]-]$ MOZL=)XH^(D&@ZNFD:=IMQK&IL-QM[?(VC&<9 )SCG '2K'A#QY:>*9Y[*2TF MT[4K89EM)^H&<$@X&<<9R >:\ZG-UIWQFU<2:_'X>DN%8QWD]NDJNIVD+\Y M7@=?]G%=#X4TJSNOB&VL+XVMM:U"-&2:**T6+S5V[<@JV"!QR >E9NC25)-[ MVO?7?[K6-%B:\J[2V4K6TV[[WOUV/37;8C-UP,UYE:?&*2_@E6P\+WEW>1N< MP6\AD 08^,8_&O2YO]2_\ NG^5>.?"#Q#H^D?VQ;ZI=V]E-)*LBR3N M$#J,C )[@]O>L,/",HSDU>UCJQ52<)TXQER\U[OY'>^&/'VF>)-%N[XAK)[% M=UU#*%+B71$/3WKE M?"NLFQUWQKXGTN'SK.*-VB7!"NS297/M@$_0T_4[O5M?^%USK^N>)2L<^5AT MZWC2-"P?&UCU;IG'ZUT>P@IWMIIO?2_33KZG(L54E"W-JN;5):I===$O0[_4 MOB%I&G^#K;Q#B66&[^6"$ !V;G*GL,8.?IWK$MOBG>B_MX=6\':I8Q7#;8Y MKNS>X4H,_@363I]EX>U#X*Z1#XEU$:>BO(T$P/S!Q(_1>2W!Y%5-1\6:UX/@ MMY[+QGIGB6UW!/LSA3+C'4[26_$M^%.-"GS2@E=W:UO^:_44L56Y(5'*RY4W M:WSNF[V]!?C1K%Z=2T_3Q9W$=K$?-6;+!+ACCY<8QE?J>O:O4/#>K7>MZ*E[ MJ&ES:5,S,IMI\[E . >54\_2O-_C%<_:M+\,WCQM")6:1D;JF50X/N*]6LKZ MTU&V%QI]U#=0,2!)#('4D=>1652RPT%;J_S_ %-Z-WC*CYM+1_7\OUU.=;QI MY/Q#7PO=Z?Y(FC\R"[\[(D^7.-NWCHPZ]O>C6_&ATOQCIGAVTT_[;<7V"[>? ML\E<]<;3G@,>W2L#XMV4MG'I7BBR'^D:9*X/$%[%:2FX@AM1"7Q@[AAL8RHY QS5RHTHTO.U[Z[_= M:WS,X8FM.O;IS6MIM]][_*QJM\3+RZL[S4M#\,3W^DV;%9+QKI8LXY)"8)(P M<\5JOX\M)/A_+XIL+9YXXA\UO(^Q@VX*5)P?7-+/ >KZ[K/B3[%:( M)(UL+2-$!.WA68Y;DG&.X[U!HYS^SOJF.TS9_P"^TIRH02VU32Z]>_\ P!0Q M51S5G=--[);=NOWG7>'?B/<>)]2M+>P\-W9M)AMN+S>3% V,E<[,''U&<]*U MM/M8+/Q]=P6<$<$*:9%MCB0*JYED/ ''4U7^%L:Q_#;2MHQN61C[GS&KJ1;P MBY:X$48G90C2A1N*@Y SUQR>*YJSA"I*,%9*Z.O#<]2C&I-W;L]O1DE%%%QSCI71!.5*27=?J=2C*>'M%7][]";PR +=_P#VG5^X^,,MQ=7'_"-^%-0UBRMV*R7<98+QWPJ-@8YY(K&^'-ZGB+XN M>(?$-O&R6!@8;Y!C +*%SZ9"$TVWL],T>ZOI/ 'Q(LM,B,A9K*\9#%N_V6;@ MC&!D*3QU-:.*]U26T5_3L;2C!U'S+73OV\CT70?&EEK/A677;BWN--MX%+3" MZC(P ,Y4_P 0]Q7('XU@[KV/PKJ3Z*K[#J / YQTV[<^V^L@^+-9\=?"?Q-! MF#7FGC#XDR^(?A_?VM_X1<9RH>,D?E2C_O?S?ZF-!7J->3-@?&2.VU M6"/6?#>HZ7IURV(+VX!&Y?[VPJ..1G#&M]?'07XCCPK=:>(5FA\VVO!/N$PV M[ON[>.C#J?N^]<9\8/%.@ZWX.LK32;^WO[J:Z22-(&#L@"G.0.5/(&#SS4GQ M%TNZT30?"OB6)3]MT7R8KC!Y*X'4^FX$?\#H4(.UU:[M_D_O*]G&26EG)/[U MM]YV&M^.#I?CC2_#-GIWVVYO@'D?S]@@7)YQM.>%8]NGO73W4KP68?#@?\ "6>/M>\9R*WD!OLMF&[# Y]CM"_]]&O5*QJ144H] M;:F%11C/E73?UZG@/@GQ;K$?Q-U6\.@WU[-?S>5-!NG:_-HWA_0[O7KRVS]H%L2!'CJ.%8G'?C ]:YGP'J-GIOQC\6+J-U M#:&>>5(A/($\QC-P!GJ3GI6)X6:]TSQOXDM)?%L/A>Z:X)=[JUCD$^'8_>D( M"]0??/M74XQFUITO_7H=M2$)5)R:VMW_ $/6O"'CC3_&&GW$UI%);W5J<7%K M-]Z,\]^XX//MTKD;'XV-J5C*UAX5O;N]C8EK:VD,BK& /G9PG')(Q@].M3?# M[1["/Q%K.L67BZWUV>YC9;J.*T$)W%L[\!L8R#T&#GK5/X!(HT76'VC<;I 3 MCD@+_P#7-9\D%S.VR7?J8N%.*D[7LT=3X;^)6E:_X6OM:ECDLETX9NHF.\KQ MD;2/O9Z#IS7._P#"Y;QH1>P^"M2?2RV!>;C@C./[A7.>,;NM87PUATN:'QU; MZY*D&G.Z),[/L"*6E'7L7ZGLFE:BFK:5;WT4,\"3H&$=Q&4=?8 M@UG>+/%NF^#M(^WZH7;)+CQ7X0M=5O+=;>:0LCJF= MK%3C*Y[&N&^-*-;:WX7U2ZC:33K>X(F&,@'FISTJ:E4Y M9=+_ (="]:_&/RKJW_X2/PSJ&CV5R<0W._!-8_QUUJYDL;'3(K* M7[ [)^+/BWP]JW@/['INHVM_=7,T;0QP.'9,') M) Y7C(YP>:ROB=9W&G_![PO:7H*W$+Q)(IZJ1"W'X=*VC&-XRY;:V_X)U48Q M52$K6O?_ (<[;X6V5K;>&9)K;P]/H,DTH$D,\DCM+M48D^<# .3P!BN)^-FM MWX\0Z5IZV5REK;OYR2!FV7;':=H&,$KC'?[W:O9-/_Y!MK_UQ3^0KRGXYD1W MWA>5_EC2>4LQZ#F,_P!#2IRYL2F^YSX:7-4NUNG^1G_%?6+O7/A[HU]J.E3Z M3.]\X:UGSN4!2 >54\]>E;LOQEBT^:T-SXSCM5'XX7]GJ7A#2;G3KJ&[@:]8"6"0.I(0YY'%7/C:BI\-M-55 "WD0 Z# MRGIQY7%)K=_Y&\8PFJ<9+?F^6IU_BWQSI7A'28;R\+SO<_\ 'M!#C=+QG//0 M*/#M]H,=T<0W%QDH?]M]2OIKM'B2U<2%1@CG' M0DL!CK^5$:4=%:]VUZ:D4Z49**:W5[_UV.Q\9^._^$1U+1[4:?\ ;!J0P2!U4,R8!( MXS\IXZT4Z49.&E[MW^6PH4HM1;6C3?SU_P" =WXN^(T7AO6(M'T[2;K6=4D3 MS/LUOD;5^H!.>,X Z4GA+XAR^(]8ETO4/#NH:3=QKN(E1F1>,X8E5*DCID8/ MKTK)\<:?X>F\86]Y%XO3P[XA2,)OW J5QD;QD!<@]R,CL:H^'/'>N6WC^T\- MZAJVG>)+:Z'%Y9 9CX)ZJ O&.1SUZU$(1E#1:_/_ (83IQ=.\5TOU_X8Z.\^ M(-U/X@O=(\*>'I=F 6!W'((_ U>\&>.;3QCI]U+#;2VEU9M MMN+:4Y*DYQ@]QP1T'0\5R&D>)->\<^)-;M_[>'A[3-+8AHX(D\UTW,,EV^Z1 MMY(X&1Q5#X'E#>>*O+E:9"T161SEG&9>3[FATTJ4G;5)/^NA4Z45"6FJM^/? M_@&E8_&QM2L96L/"M[=WL;$M;6TAD58P!\[.$XY)&,'IUKJO!WC_ $[Q;H5U MJ(C:Q-E_Q]1RMD1C&=V[N, ]AT-A_$:ULD+2O%M1$')YEX ]^E74IP7.DMDG^7^94J5-N22M9I?>['60_&:.[O M)I+'PSJ5UH\#8FU")2WEC^\5"X [\L#BL'X2:Y9:-H_BS6+UR+2&5)"0.2"6 MP /4D@?C6G\+?&'AS2OAO]GU+4;:UGM7E::&5@KR9)(*KU?C XSTQ6!\+X=% MO?"7BR'7I4M=+F>(.[N%\L98K@GN#C'O5."BIQ2VM\]1N,5&2Y6E=+UU.D_X M7)>^4EX?!6I?V9(P"7FYL,"<#'R;2?;=7I>GWJ:CIT%Y''-$LR!PD\91USV* MGH:\7.IW?A/P_P#:O"GQ&T_4;& ;H]-O$7S2N>$ .7_#Y?PKU/P7K\WB?PC9 M:M=6XMY;A6WHN=N0Q7(SV.,UE5A%1O%?G^IA6@HI2BM/G^HGB[QAIO@W21>Z MF7*M U?P3'8Z9J%MJ%W<7 M$;0QV[B1DQU) ^Z<'&#SS]:*<(N,6U>[^[^MS2%*+44UOU[&7\=M9NIVL=,% MC,MBI$Z7H8^7,Q4C:.,9 YZGK7?_ VLK6T\+&2T\/3Z 9IF:2TGDD=R0 -V M7 /('IBO/?BM:7%C\./"-I>Y^T0JJ2@GHPB (KVZ/_5K]!53:C2Y5W?X6(JR M_AJIX8^(]QKFO M#2-4\,:CI%R5W#S$9U4=MV54J#C@D8JG\0M.\.77B*PNKCQ0OA[7H4VP3*V< M)R1N&1@.M:4_BK7?$_P 2[OPSI&K1:+96D9?S MTA622< +T+<<[LC'89YJG%2C#3I?^OZN:5(IM/ET45W-WPW\0UUZZU/3KC29 M['6--C9WLFD$F_;QA6 Y.<#IW&,UX]8S?\))\2]0GUOPG>ZDUU+B2R$LJ-9Y M91N8JN<*.,$ 5U/PT6*/XU:ZD-])J"+;2J+J5PS2XDCR21P?PK1\!_\ )E)3Y5V_$X2XO9/$/Q/NKC6/"-[>M(JJ=)$LJ20 *H# M$JN[ '.,#K7M&LZ=9Z?KWA<65K%;[]0(L2VT$\D4DT,M15G[L+=D98B?OV6 MUK?>B2BBBN0Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=:\(:!XB MD636-,BN)5&!)DH^/3$M"\.,SZ-IL5M(PP M9,EWQZ;F)./;-)K7@_0/$4@EUC3(KB4#'F E'QZ;E()K:HJO:3YN:^I/LJ:C MR%-#\.;SHNG16S.,,X)9R/3E:;HLB%'4,K#!4C((I:*ERW;Y_FOTV[?NYV]..E:M%-U)MW M;=R%1IIAA:'X*\/ M^&[Q[O1;#[-.\9C9_.D?*Y!QAF(Z@5'J/@+PQJNI&_O](ADN2=S.&90Q]6"D M _B*Z&BCVM3FYN9W'["DH\G*K=K:&?J.A:;JVCG2KZT5['"CR$)C "D%0-I& M ,#I5:[\):)?Z#;Z-=V/F:?;8\J'S7&W ('S Y[GO6S14JES)$,(^]D8#TRI!(]J;+X/T*:^T^\DL 9 M]-1$M&$K@1*IRHP#@X]\UMT4U4FE9,3I4Y-MQ6OD95OX9TBT\03ZY;VFS4;A M2LLWFN=P./X2=HZ#H*(?#&D6_B*;78;3;J4R[9)_-N[/WOQK$_X5CX/^T^?_ &)'OSG'FR;?^^=V/PQ75T4U M4FFVF]12HTI)*44TO(9##%;PI#;QK%%&H5$1<*H'0 #H*S==\-:3XE@BAUNT M^TQPL70>8Z8.,?PD5JT5"DT[IZEN,91Y6M#)U3PQH^LWUG>:E:>=/8D-;OYK MKL.0>@(!Y ZYI=<\,:1XC^S_ -LVGVG[,Q:+]ZZ;2<9^Z1GH.M:M%4IR5K/; M8ETJ;O>*UW\_4*QM<\(Z%XDDBDUK3TN9(AA'WLC >F5()'M6S14QDXNZ>I4H MQFN62NC%;PAH3:C8WYL +G3XUCM7$K@1JO08S@XSW!J74_#.D:QJ=GJ&HVGG M75DP:WD\UUV$'<. 0#R.^:U:*KVD[WN3[*G9KE6OEV,G6_"VB^(U0:UI\5T4 M&%V:71/#&C>'(W71=/BM=_P!]AEF8>A9B21[9K5HHYY)L8.2IX./I7K= M%53JNG&276WX&=6C&K*,I=+_ #NK%#3]#TS2M+.G6%E##9D$-$%R'SP=V?O9 M]ZQX?AOX1@EEDCT2#=*I5MSNP /H"<*?<8Q73T5*J33;3>I;I4VDG%:;:;&- M#X1T*#0?[&73HWT\,7$$K-(%)[@L21^!JC9?#CPEI]XMU:Z-%YJG0 ^ MNUF(_2NGHIJK45[2>OF2Z%)VO%:;:;&=K6@:7XALQ:ZS9I=0JVY0Q(*GU!!! M'X&GZ1HUAH.GK8Z3;BWME)8(&+HJ>:7+RWT-.2/-SVU[G ?$G4M< MFMI?#VD^'+B_BOH0#>(&9(R6Y!&W (P#DMWKH/!/AX^&/"-GITF// ,DY!SF M1N3SWQT_"M^BM'5_=^S2\WYF*H+VWM6[]%Y&-K?A'0O$;J^LZ;%Q*Z?=/OE@\^0A MCQSDMD?='0]JW:*;JU'O)DJC23NHK[BII>F6>C:;#I^FP^3:P@B./<6VY))Y M))ZDU;HHJ&VW=FD8J*48JR04444AA1110 4444 %%%% !1110 4444 %%%% M!1110 5RVH_#3PAJEXUU>:)"9G.6,4CQ!CZD(P&:ZFBFI.+NBHRE'X78I:5H MVG:'9"TTBSAM( <[(EQD^I/4GW-8>H?#/P?JEXUU=Z)"9G.6,4CQ GU(1@*Z MFBGS23NGJ"G*+NF4],TC3]&L%LM*LXK6V7_EG&N 3ZGU/N:P)OACX-GOC=R: M#!YI.XA7=4S_ +@;;^E=710I23NF"G);,K2:=92Z:=/DM(6LRGEFW,8\O;Z; M>F*YZW^&?@^UCN$@T2)1H4ELK_ ,!Q7544*4ELP4I15DRKIFF6 MFC:9!I^FQ>3:P+MCCW%MHSGJ22>M4]7\+Z-KM]97FK60N9[%M]NQD8!#D'H" M >5'4&M:BES._-U$I-:HYNQ^'OA73=6&I66BV\5T&W*V6*H?55)VJ?H*YWXH M:GKUS;3>&='\,7&H17T"YOE5F2,[N01MP"-H.2W&:]&HJE-W3EK8TC4:ESO5 M^9S_ ('\._\ "+>#['3)-OGHN^OO M ?AG4=<75[S2HWOU8/YH=URPZ$J" 3[D4_7?!'ASQ+.L^M:5%<3*,>:&:-R/ M0LI!/XUO44YFZ/X>TG0+)K31K&*TA;EA&.7^K'D_B:CT#POH_ MA>WFAT*S^RQS.'D'FN^XXQGYB:UJ*.:6NNY/,]KF+I7@_0=%-]_9VGI&-0_X M^E=VD67KU#$C'S'@>M9;?"OP6]U]H.A1;]V[ ED"?]\AMN/;%==10IR3NF5[ M2=V[O4CM[>&TMX[>UB2&&-0J1QJ%50.P Z4R]L;74K.2UU"WBN;>08>*5 RM M^!J>BI(3ML38?4!B0#]*T-?\,Z3XHLX[77 M;3[5#%)YB+YCIAL$9RI!Z$UJT53E)N[97/*_-?4;'&L42QQC"H JCT K/USP M[I7B2R%IK=DEW"K;E#$J5/J&!!'X&M*BE=WN)-Q=TFQV&M6GVFVB<2)'YCIA@" A-:E%/ MFEW'SRO>Y1N=%TV]TE=,O+.*XLE146&5=P P.O.1Z]:R]'\ >%] OOMFE:/ M#%<#E9'9I"G^[N)V_A7144*4ELPYI)A0UG0],\0Z>;+6;..[MR=P5\C:? M4$<@^XK%7X:>$$M8;=-%B5(9?-0K+(&W=B6W9;Z$D5U-%"E*.S!3DE9,QM=\ M(:#XE*G6],ANG0860Y1P/3#/#WAF1I-$TN*VE88,N6=\>FYB2! M[9K#$WER/M89SPF=H_ "MFBCFE:U]!N%=&\.W%W-HUG]FDO6#3MYKOO()(^\3C[QZ>M M:]%#E)[L3E)WN]SFIOAWX3N-7.IS:';M=%MY/S!&;U*9VG\JN:=X1T+2DOTL MM.C5-1;==)(S2+*>>H8D8Y/ XK9HHYI6M<;G)[LY$?"OP6+K[0-"BW[MV#+) ML_[YW;<>V*ZN&&.WA2&"-8HHU"HB+A5 Z =!3Z*'*3W8I2E+XGSA';*NH] P(('XU6T/P-X;\-W)N-&TJ*WGQ@2LS2,! M[%B2/PK?HIJ4DK)Z#YY6Y;Z&#KO@GP[XFNH[G6],CN9XUVK)O=&QZ$J1D?6H MM5^'_A?6YXIM2TB*62%%C5U=T.T# !VD;L#CG-='10I26S&JDULS"T[P5X>T MG61JNF:9':78C\K="[*NW&,; =O8=NO/6I[#PMH^F:Y=ZQ8V?E7]YGSYO-<[ M\G)X)P.1V%:U%'-)]1.4GNS(@\+:-;>))]?@L]NISKMDG\USN& /ND[1PH[5 MKT44FV]Q-MZL****0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD= MU1"SG"@9)-4_M-S.,VZ+&AZ-)U/X4 7:*IXO/^>T?_?%+B\_Y[1_]\4 6Z*I MXO/^>T?_ 'Q3$FFDE>*.[@:2/&]% )7/3(SQ0!?HJGB\_P">T?\ WQ2XO/\ MGM'_ -\4 6Z*ID7O:6/\4I4NW218[I A8X5U^Z3Z>U %NBBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF2S101F2>1 M(T'5G8 #\361/XQ\-V^?-UW3\CJ%N%8C\C5*,I;(B4X1^)V-JBN:_P"%B>$M MV/[=M<_4_P"%6H/&?AJXQY6NV'/3=<*N?S(JG2J+>+^XA5Z3VDOO1MT5'!<0 MW,8DMI8YD/1HV##\Q4E9FVX444UW6.-G';&+42OVT6ZO*% M&!DC)P/J:!W-VBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !102 "2< =2:R;KQ5X?LF*W>MZ?$XZHURF[\LYII-[#2 M;V-:BN8?XC^$(VPVOVF?8D_R%30>/O"EQ_J]?L1_OS!/YXJN2?8KV<^S.AHJ MK9ZI8:BN[3[ZVNE]8)E?^1JU4;$;!1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 445@:IXY\,Z,6&H:U:HZG# M(C^8P/NJY--)O8:BY.R1OT5YU=_'#PG;.5A%_=?[44 _P#'F%4&^/>A@_)I M=\1[[!_6M50J/H;+#U7]D]4HKR^+X\^'&_UUAJ2?[J(W_LPK;T_XN>#K\JIU M-K5VZ+<0LOZ@$#\Z3HU%T$Z%5;Q.UHJM8ZE8ZG#YVFWD%W'_ 'X)0X'XBK-9 M;&.P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%87BGQ?I?A*Q\_4IYJHQE-\L5J1.<:<7*;LC2OR',$)/$C\CU YJ;ITKR[P-XTU/QEXVEDO0L5 MI#$3#;Q_=0YZD]SCO^6*W=0^+/A33-1GLKJ[F$T#E) L)(!'O6E2E*G+D>YE M1Q$*T/:1V.UK+\0ZE?:3H[W>EZ7)JMPKJJVT3A68%@"<^P.?PKEU^,GA%@"M MS2:+P=.DLN/,=;FW#/CID[^:QA\:/!I.!>3D_]<#3O^%R^ M$/\ GZN?_ =J.5]@YH]SM;2:6>TCDN;=K:5AEH796*'TRI(J>N _X73X-_Y_ M)_\ OP:4?&CP:>EY/_WX-'*^PYWU17$8EMW0_W>#Z5Q ^,?A%E!6XN2#P M"+9N:V-!\<:+XFNYK/3))C-''O9)82GR].]*S&I)]3HK23SK.*0\[E!J:O#K M+XGZCX7\47UE> WNF+Q:+KFG^(-.2]TJX6>%N#CJA M]&'8UM5P\Z24GLSFH8NE7;C%ZKH7Z***YSK"BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **R]?\1:;X9TUKW5I_+CZ(@Y>0^BCN?\FO"/&'Q,U; MQ.TEM;L;'3CD""-N9!_MGO\ 3I_.NK#X6I7>FB[G!B\=2PJM+5]CU7Q)\5?# M^@,\%O(=2NUX\JW8;5/HS]!^&37F&M_%WQ+JC,EG+'IL!R MNOS8]V/.?IBN M$HKVZ6"HT^EWYGS-?,L16ZV7D6;O4+S4)C+?7<]S(>"\TA8G\35:BBNU)+8\ MYMMW84444")[6]NK*82V=S+!(O1XG*D?B*[#1?BUXGTDJMQ'_ (8ZM>12 2S1?9X"#U>3Y1C\"3^%?.--\1:Q?S^'K#1)[MWM&N&N M5B=BVP(-HP.P)8_BM>-C,'"C#VD7\CZ/+LQJUZGLIJ[[F-8!8X54=ABMNVM& MD"[)XOFQQD_+]>*R8(42/YR.]K% M\VA"[FGC _X%_A5>XN%M62)2)6D./DY^7N<5=>VD>-S'OG9%^X&Y/M65_:EQ MI-C=V\^E".]NSQ=3!@T:?W5'3\:A5(S34=S94)0:E-:$OAJU76O%EAIJ*%2Z MNDWJ/[BG<1^0KZ6LYG?7HD@./WFT?[HZ_H*\,^"FG^=XIO=4DC!2PM3M8CH[ M' Q[X!KW3PM")=3>5AGRD)!]">/Y9K:.B,Y.[.OHHHI %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%175U!8VLES>3)!!$NYY)&PJCU) MKQ#QQ\:;B]:2P\(LUM;_ '6O2,2/_N#^$>_7Z5K3I2J.T3:E1G5=HGJ/B;QY MH'A-2-4O ;C&5M81OE/X=OJ2!7DOB#XZ:S>L\>@6L6G0]!*X$LA]^?E'TP?K M7E\LLDTK2S.TDCDLS,M%%=*26QUI):(****8QR2/&P:-V1@<@J<8-=3HWQ+\5Z(R M^1JTL\0/,5T?-4CT^;D?@17*45,HQEHT3*,9*TD>\>&_CKI]XR0>);0V$AX- MQ!EX_J5^\O\ X]7J%E?VFI6B76GW,5S _P!V2)PRG\17QO6SX<\5ZQX5OAA^O4=JY*F$B]8:'#5P47K#0^MZ*XGP+\3-,\8QK;2[;+5 M /FMF;B3U*'O].H]\9KMJ\Z490=I'ESA*#M(****DD**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHK&\3^*M,\):4;W59L9R(H5Y>5O11_7H*: M3;LAI.3LC6FFBMX7FN)$BB0;G=V"JH]23TKS#Q5\;M,TQGMO#D/]I7"\&=\K M"I_FWZ#T)KRSQE\0]8\97!6Y>(_$C.-2U*7R&_Y=XCLCQ_NCK]3DUSI.>M%%=JBHJR.^,5%62"B MBBF4%%%% $]G?7>GW"SV%S-;3+]V2%RC#\17HOAKXVZYI92'6T75;8<%V^25 M1_O#@_B,GU%>9T5$J<9KWD9SIPFK21]8^&/&VA^+;??I-V#,!E[:7Y94_#O] M1D5OU\:VMU<65U'/2_%CI#.<+%??=60 M^C]@??IZXZUY]7"N.L-4>96P;A[T-4>NT4=:*XC@"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK)\3^(K3 MPOH,^I7IR$&V*/.#(YZ*/\] :<8N3LB92C"+E+9&9XY\<6G@[3 V%GU"8'[/ M;Y_\>;T4?KT'XD.2S=O8#L/:G:UK-[K^K3:CJ4OF3 MS-D^BCL .P%4*^FPN%C0CYGQ>.QL\5/M%;(]-^"DZKKUW 0=S1A@?3%><^,= M0NK?QGK<,,S)&]VY91WYKT'X+1D^*+B3(P(<$?C7FWC?_D>M8_Z^G_G7F8K_ M 'F1[>!O]3CZLRQJ5VHB G8")]Z?[+>M5BQ8DDY)ZFDHK(Z!\4LD4JO$2KJ? ME(JU+/>AC*[G<5VM@C('N.U5H)!%.CLNX \@U9>6/RR#(S; =N6)W9_+%("G M2H[(X93@@Y!IM%,1XD6SVJS] MAFO&Z]6^ 7_(U:C_ ->G]:SJ+W6:TOC1SWBC_D:M2_Z^7_G4GA?Q3J'A35EO M-.?Y3@30L?EE7T(_D>U-\61F/Q9J2D@GSV/'N:QZ^AA%3I)/:Q\A5E*G7E*+ MLTV?5/AKQ)8^*='CO].?@\21$_-$W=3_ (]ZUZ^7_!GBRZ\(Z]'>0EGMW^2Y M@!XD3_$=0?\ Z]?3%A?6^IZ?!>V4@EMYT#QN.X/]?:O Q>&="6FS/K,!C5BH M:_$M_P#,L4445Q'I!1110 4444 %%%% !1110 4444 %%%% !6%XM\66/A'1 MFO;T[Y6RL%NIPTK>GL!W/;\A6CJVJVNB:5<:CJ$GEV\"[F/<^@'N3P*^9?%7 MB:]\5ZW+?WIPOW88@>(D[ ?U/RJ.PK*HHKZ.,5%61\;*4IR_BM;F]N[R&X%NB.(Y$ '5CPRGNQKE-)A%QJ]K&PRIE!(]A MR:ZGQ%\1+3PYJ'V6ZM;B4[0VZ/;CGZFO&S.=U&'S/I,DIZSJ_(L'X;:68BBZ MMJ.W&/\ 61__ !%0K\,[6/F#6KQ?=@C?TJWX;\9VWB:*=[.*>(0%0WF@#.<] M,$^E=%_:C&Q%KY<8 DWF3'S'C&,^E>+RKL?2]F=69XG(/S6RE@1Z'/%=1]KQU-.%U3L@4FMB/PCX6@\(:#=Q03M .@'^>M>B^$X#'ILDS#!E?@^H'_U\UR-2?M3^#DE=4TO6)%#$!Q%&-P]>7 MKT#XK_\ )(_$_P#V#9O_ $&ODKX0^!;#X@^+KK2=4ENHXXK"2Y3[+(J,SJR M#+*PQ\Q[4 >Y_P##5/A#_H$:S_W[B_\ BZ/^&J?"'_0(UG_OW%_\75>W_9=\ M*20QM/?:W$S*"ZBZA;:<=/\ 5<\\5RDW[/\ IB3.J-KA56('R*?!Y/MT'YD\7_PE]E_SQG_ M "'^->D#X!:>>HUP?\ 7_P"-TK? '3@./[<;_@"C_P!ITXYLHJR3^XVACY07 M+'\CS;_A+[+_ )XS_D/\:/\ A+[+_GC/^0_QKTD_ '3L#']N$GJ-BC'_ (Y0 M/@#IQQG^W!_P!>/_ "'5?VQZ_<5_:-3^D>;?\)?9?\\9_P A_C1_PE]E_P \ M9_R'^->D'X!:+=+\;^&[?6]#D9[:8E2L@P\;#JK#L1_A6W7C/[+O_ M "2>Z_["LO\ Z+BKV:NHT"BBB@ HHHH **** "BBB@ HHHH ***J74LB3 1D M@;>.)7S*^[M&@./UJ,W,X.!'='Z1#_&@5RGXN\66/@_0I-0OC MO<_+! #AIG]!Z#U/;\A7S#XB\1ZCXHUB34=6F,DC\*@^[&O95'8"OI76O"&D M>)/+O-:LVN9$3:BS,R[!] V!6/\ \*T\)_\ 0#C_ .^W_P#BJZZ%6G35VM3M MP]>E25VG<^;:*^DO^%:>$_\ H!Q_]]O_ /%4?\*T\)_] ./_ +[?_P"*KI^N M0[,ZOK]/LSYMHKZ2_P"%:>$_^@''_P!]O_\ %4?\*T\)_P#0#C_[[?\ ^*H^ MN0[,/K]/LSYMHKZ2_P"%:>$_^@''_P!]O_\ %4?\*T\)_P#0#C_[[?\ ^*H^ MN0[,/K]/LSYMHKZ2_P"%:>$_^@''_P!]O_\ %4?\*T\)_P#0#C_[[?\ ^*H^ MN0[,/K]/LSYMHKZ2_P"%:>$_^@''_P!]O_\ %4?\*T\)_P#0#C_[[?\ ^*H^ MN0[,/K]/LSYMHKZ2_P"%:>$_^@''_P!]O_\ %4?\*T\)_P#0#C_[[?\ ^*H^ MN0[,/K]/LSB_A3\3GLY8?#WB*?=;-A+2ZD/^J/9&/]WT/;Z=/P'K7K_P 1O$)\.^"[N>%]MS<#[/ 1U#-U/X#)^N*^:*]C+:-[U7\C MYW.<2TE0CZO] HHHKVCYH]-^"I']OW7KY8_G7F/C?_D>M8_Z^G_G7I/P7A#> M)IY23E(L 9XYKS;QO_R/6L?]?3_SKP<3_O,CZO _[G'U9@UHZRM*I.U)(\!AZYITV@^4Q"WMO)A"_RO^E$GA]H MX!*UY:[3Z2@D?@*0]>Q(]OH30,R7PQ6]TT<$AE4 ? M,1CDC./PZ?45K? +_D:M1_Z]/ZUY37JWP"_P"1KU'_ *]/ZTJGPLNE\:,7QI@^,=1Q MR/.-85:WBC_D:M2_Z^'_ )UDU]%1_AQ]$?'8C6M/U?YA7K'P8\6-!=OXI[*[FT^^@N[5RDT$BR1L.S Y%37I*M3<&5A: M\L/551?TCZYHJAH6K1:[H-GJ<& ES$'P#G:>Z_@5_%CXS)X O(],TRTBO-19!)(9F(CA4] M,@4?\ WRU9?AZW^T7LBCM'G]1771Z;&'RU'URO\ S,/J6%_Y]H\Y_P"$JN?^?=?^^&H_X2FY_P"?=?\ OAJ] M*$G/%/63UI_6Z_\ ,'U+"_\ /M'F7_"577_/NO\ WPU'_"577_/NO_?#5Z@6 MIA:CZW7_ )@^IX7_ )]H\R_X2JZ_Y]E_[X:C_A*KK_GV7_OAJ]-#U('H^MU_ MY@^IX7_GVCS6R\:WUA>I<16D3,FOO5/Q#XHFUZ[%Q?PI$^T#$:L! MQ]C3Z?+:P1). &>,G(P<]S[5ZMX?NEO="M)X'#QM$H7"XQ@8P> M37STO?ZU]'_"OP_=7_@*PFA\DJQ;@R $<^E-"9V,5OYFJV]OVS&GZ 5Z)6!! MH$HU9;MY$5%?<%')/^%;Q.!DD 4Y"0M%5EU"U>X$$RH_9FV2_V1+M; X_>Q>O%?2WQ7_P"21^)_^P;-_P"@U\W_ +,W_)3+_'_0 M(F_]&1?2@#Z6M[?7+B=@FIJ@0_?,:L#D#' /N:F_LK7(DRFKH2!P/(%7[ /] MJ?[VS:,%FW9]A\Q(QWX_&K\A(0E5+'L <9H%9'-8UT7"PG5$#%PI)A3C()_I M^OUJR]CKJ1ECK4>!_P!.PJ6,2?;8B?W8,BDQ,X)7Y3Q][^0K7<_NS]*.@6.; MNCK=HT*-J2OYIY<11J%],Y(]^GH?;-E+#774,-;B((R"+=>:O7' UF/_ ,!E MJQ9K(-4E+'*E3_'G^(]MQ_E^72M"7&X9Z$@=<>M 6.5DN->CD>-K[ 5RN_9% MS[XSGV_^MS5QK;7$M&N#K$>U4+D?9UZ8SBK\$Q6YD")O?>P$8F&<9ZXS5JYD MD&GS.8F#JC$)N'./?..:3;L%C*CL==EB5QK" ,H('V=3BD-EX@$@0:JI!_Y: M>0N!^%;<)WV\;$$94'![4UA']M4G[^WKN]_3/]*$W8+&7_9VN\_\3F/V_P!' M'%17%AKD4+22:PC*HR0(%!./>M]FQCZU%=Y^RR8QG;W.*>H6,33DU%;NWGO; MT3I(S1*@4#;@$YR#@]/UK7\S&=KI_P!]8JM&S/'IYD.6\ULG.?X&]S_.J\L\ MHGD$<+-R1GS)%_M48_X1+1,%3_I[=#_T MS->U0QWL"G9%&V?[]T[?S6O$/VH9VF\':'YB[&^WOQAO^>?N!ZTE*_0$=!^R M[_R2>Z_["LO_ *+BKV:O&?V7?^23W7_85E_]%Q5[-5#"BBB@ HHHH **** " MBBB@ HHHH *A_P"7W_MG_6IJA_Y??^V?]: *U[<:G$Q%E91W SP6E"X']>_I MCWJ%K[61&671XRVT$)]K'+]16-Q?V<4UZD,;QKG?\ :=4N& Z-PK0?3&/7%58F^IMM0/EY'R^[\>BCUQ4'V[7EA'IS5W[1KW_0-T[_ ,&$G_QFD Z*\U5GC$NE(BL^&(N@2BYQ MG&.>.<4JWFIFV=O[-7SE.%3[0 &X)SG' S@=^OM63>KJZ7#74MI&-OS%(M6F MV_\ ?(AYI;*+6!<1W,=K&Q\L8275YBI& .5,/7CTSG-&@]336\U8R8;2D5M&@KG7T5G6+W=I:A-1A MBC 8+&4NGG+9]2R*?YUHTBBC?W5_!(HLM/-TI')$BIM/OD_R'?M4+7^JD-Y> MCG*DXWW*#=]['3.,X7_OKV(K0;S0^0Z;,\J4.?SS_2I*8C/DNM26W65-.5W( M), F&1R,?,>,XZCU'4]TM+W4IKMH[K2C;0@-B7[0KY(( X'KR?R]2!HT4 98 MO]5,YC_L8[?,(\UKE I3>P#8&3DJ%.,?Q8XQ2O=ZLJ2%--1V5V"KYP&]1T(/ MOVSCGKQS6G10%C)CU#6&FQ+HFR/)+"PACEW_:$D8J# RL 1CKS[UG4J0IJ\G83:6[-:H[C_CW?Z4I9 MFAW18W%(?'#5S< M:]9:4C92UA\QP#_&Y[_@!^=>75T?C^^.H>/M8F/\-RT0/J$^0?\ H-& MAR48Q\CX/&5/:XB<>-_\ D>M8_P"OI_YUX.*_WF1]7@?]SCZLP:O)%9'22)%$@Q*4=CC!63BEV0*Q+K\J]0).3]*? MO7IFU.T?W3S32J^9R]N!P>^*0R.>.($F%P !G!?)^E5JMR* IQ) PY/ JN\A M<*"JC:,<#&:!#*]6^ 7_ "->H_\ 7I_6O*:]6^ /_(UZC_UZ?UJ:GPLTI?&C MG?%'_(U:E_U\/_.LJM;Q1_R-6I?]?+_SK)KZ*E_#CZ(^-K_Q9>K"BBBM#$]Q M^"&KFY\/WNER,2UG,)$S_=<=!]"I_P"^J]/KP+X+7WV;QR]L2<7=JZ =B1AO MY*?SKWVOFL=#DKOSU/M,KJ>TPL;]- HHHKB/3"BBB@ HHHH **** "BBB@ K MY#_:+_Y*K>?]LIJJ,U+'0!=BD-<'\3_\ CXT_ M_;+W^M>A^%S_Q)[;Z_UIH3/4O#=HMUXHM;.26X M$+R[65)F7C!]#7KEOX>T^W& LL@])9F?^9KR[P>F?&UIGM*W\C7LE4R4,CBC MA7;$BHOHHQ3Z**D84444 %%%% !1110 4444 %%%% !1110 4444 WG'MR*F_X2W2=H M_P!(Y)P1M;@>O2M>.UC3D+GC'))_G3_*3^XOY4]!:F&/$6A!@QO&ZY'#XS]/ MQJ4^*M%(_P"/P8_W&_PK3%I%YA8(VZHO3'2C0-3&;Q'HDO/ MVQ^!CY0X_D*>/%>BA0!>?FC?X5IM:1,02@R!@$4\0H% "KP,<$$'"-_A6HUI$SERHW4):1IG:HR3NY M.><8IZ!J98\4:(JA1><+T^1O\*#XHT8OO^V-QP?D;'\JUDMXXT"JB[5&!Q2/ M:Q/(K%>5Z8./T[]*6@:F2WB71)",WAS[*X_I2OXIT1T*M>9!&#A&S_*M?R(\ M8V+^5*8D(^XOY4] U,>'7--O;^WMK>1WD!W(2".<$=_;-3.J!V8VFYL]=JDM M[CFKT=M' O[M>K Y))_G7.:EHT=SXFM=4.I+$MOC,.1DE2>ASQUYJ)MI7BK@ M[HWX\^6N!LXX7'3]:\%_:H0)X9T' S>2$X&/X!7M-KIP1(XS-;R*&SA8P,X MZ]_:O&/VJ_\ D6= [7DG_H J^@S=_9=_P"23W7_ &%9?_1<5>S5XS^R[_R2 M>Z_["LO_ *+BKV:D 4444 %%%% !1110 4444 %%%% !4/\ R^_]L_ZU-4/_ M "^_]L_ZT 9U[%.9YO+DOMK8(\HQA4Z<#(SS^/?I4:)]\=?;%43U+<,4MQ,69KNWVA>&*8;DGW^AJY!"880C3-,02=\@&>3GMBL MNWG6WM9VLY]+23&6"RDJ& [G/H!6I#>6\Y"Q3Q2-C^!P:0T5[Y0R.OJN/E.T M_GVI;%<1Q@GD( =_+=.Y[FC4@A@E$NW85^;?TQ[TNG%#!$8MFQHP5V?=P?3V MK/J;?9)IQ^Z/*_@*R[*-XV3<\[\MDR.&QR< _P!/UK5NB1;L05! ."W3IWK$ MT^13?1C-KO97.$5PV-W&">W//UHEN8/ M&;C<2?\ 2X^I_P!EZX<7BG0LDKW3_ SG4Y#T#^UK<7J0?:;<[TWX+$-C&0>F M,8YZBF7&MVD%F+C[1;LGF!"RR;P._P#"#S@=*Y%_^1CM_P#KR7_T15%/^12E M_P"OU/\ T!JX99A45U;O^%B/;/L=V?$&G"8P^G2LG4?& M73$N]*BW@S>4PG0CMGL16.0/^$E8]_L7_M"J!_Y%[ICW]:Y&1!_PCT&>?]*DZ_P"ZE:\O M_(R7?_7B?_1(K*D_Y%Z#_KZD_P#04KEQ-2=3FW_A/9_, *>3\P(SD>6* MZH^5]DD\A0J^RXYKW,%)N,[_ ,S.B#;O<>-_^1ZUC_KZ?^=>C_!?_ )&V?_K@?YBJ&O?"+Q1KWB+4-3L(K8VUS<.\ M9>< XSZ5X.+:6(=SZS+XMX.-N[/*:*]'_P"%%^,?^>5G_P"! H_X47XQ_P"> M5G_X$"N?GCW.OV<^QYY:P_:KAXO.A@VINW3,%#>PR:D^Q9F*K?V7EAMN\R8_ M2N_/P)\8'K#9'_MX%)_PHCQ?_P \++_P(%+F7SEV/.*]6^ 7_ "->H_\ M7I_6J'_"B_&/_/*S_P# @5VOPM\ ZWX,\2W$NMI"JW-L5C\N4-R#S4SE%QT9 M=.$E)-H\X\4?\C5J7_7R_P#.LFM;Q1_R-6I?]?#_ ,ZR:^DI?PX^B/BZ_P#% MEZL****T,3K/AC+Y/Q'TIO5V7\T8?UKZ4KY>\$64VH>--.MK:ZDM)7D.V>( MLF 3D9KW/_A#M8_Z'35?^^(_\*\3,(Q=1-RMH?391.<:,E&-]?+LNYUU%S[6I_S[?WK_ M #.NHKD?^$.UC_H=-5_[XC_PH_X0[6/^ATU7_OB/_"CVSA_/^?\ MD'M:G_/M_>O\SKJ*Y'_A#M8_Z'35?^^(_P#"C_A#M8_Z'35?^^(_\*/9P_G_ M #_R#VM3_GV_O7^9UU%SA_/^?^0>UJ?\^W]Z_S.NKXI^,TQG^)VN,W)%XR?]\Y']*^J/\ A#M8_P"A MTU7_ +XC_P *^3?BI;R6GCW5[>:=[B2.[=6FD^](78H>!SC5I_^N/]17>!JX'P6<:K-_UR_J*[@/6!K/0@HV%^4<_+].1^5 C.S3D/-1BI$ZT 7$D$432-T49->, MZQJAU/49Y#_SV8@^Q_\ U5ZKK%[;VNDW"S3K&\D3!0>I.*\8\LQ3.I.3GK4/ MA1:'JFRW 6.:+> M$!SMKJ/!";M%L?\ >'\ZVIS4XJ2ZG/6INE-PET/8?"<.SQC;GTD;^1KUBO+O M#\\%GXFCN+N:."%';=)*P55X(Y)KO?\ A)]!_P"@WIW_ (%Q_P"-;G?^!P MWJ/,(W6TF21T!!^;:#R 0!^-:VCZ[IFOV@N=(O8KJ/OL/S+[,IY!^M-TYJ/, MUH*-:G*7(I*YH4445F:A1110 4444 HKFI(M>AF2,ZQ&V]2V3;C@#'^/ MZ5+#8^()(5=M9121G'V=30%SH**YY;37S*8SK$? X;R%_E4G]G:]WUN,_P#; MLM%@N;M%WOXW,8.6,(7)P#W&._O5I;'Q"8PSZRBMC)7[.IQ1 M8+G045SJVFO-;B7^V4&Y0=OV=>*>;+7ED"'68SN'7[.O'^-(#?HKG+FU\06Z M!QJ\X[>&)0L<2(HZ!5 _S_ /7KP3]J MA77PUH6]PV;V4C"XP-@X]Z .@_9=_P"23W7_ &%9?_1<5>S5\_\ [.?B_0-" M^&=Q:ZOJD%I.VI2N(Y"QKUG_ (63X/\ ^@_:?F?\*:A)ZI%JG-JZ M1T]%BN8_X63X/_P"@_:?F?\*/^%D^ M#_\ H/VGYG_"CV<^P>SGV9T]%H?^7W_ +9_UKGO^%D^#_\ H/VGYG_"M/2-;T[7F:ZT>[CNX%S& M9(^@88)'Y$4G&25VB7"25VAUXTOF2;)+A,?PQVP;/XD*6P+&-"V[++G#C!&>Q%,GN]-N(MLM[ $F7:!YH&X$9XY]#FI8;BR M6/?%=1,BD)N$@(!/09]:BSN:OX\_VJ-)1>$;&)::)%7.X MX!QWQTQQCKS6H+ZRG81I=0LS$@*'&20"2/R!JJ(]+L)\FY2)\%<--VR#T)_V MA^8]:&F9,T9/N_C3ZK)>6MV_E074;N.2J.">,9_F/SJS5%$ M';LZTTYEM\?9O+VAF)'[O8#]WUJH?"]W_8:VWVFUW&ZW!M[8/&W'W>N:Z^9; M:WMII9]L<2@R2N3C@_%#P%%WWUO^(>S MB8;^'KIM8N+CS;<*]J8P-QR"8]N3QTR*SV\*7KZ/!"L]N3Y[.&!?!#!0/X?: MNK2ZT]E*13QR#TN92]O+%,ZJ,E'#8!Y'3UHE@*,KWO MK^H>SBS%M]&NH/%$NHJ\#IL \L.0WW0/3'8UNW'_ ![O]*='&L2!4& /?--N M/^/=_I733I1I)J/5W+44MAZ?<7Z4M(GW%^E+6I04444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% 'RMXKM?L7C#5K?&T1WDH'TW M'!_*LBN\^,.F&Q\>R7 &$O84F7CC(&T_JN?QK@Z^MHRYZ49>1\!B8>SK2AV; M"BBBM3G/1O@O_P C;/\ ]<#_ #%>V:-_R#$_WF_]"->)_!?_ )&V?_K@?YBO M;-&_Y!B?[S?^A&OG,?\ QW\C[/*?]UC\_P R.=-9^TN;:6U\D_<#J&XS^'7]*;*FN% (I+0-CDE3UJY$"CM(] MUO0C(4X 'O4X8,,J01ZB@+%73S?F-_[2$(<-A?*S@C'6H;O_ )"]K_URD_I6 MC6==_P#(7M?^N4G]*0SYF\4?\C5J7_7P_P#.LFM;Q1_R-6I?]?+_ ,ZR:^NI M?PX^B/SZO_%EZL****T,3M_A%:--O7)W-_P"@K^=>R5\[F$N:O;L?8Y1#DPJ?=M_I^@4445YYZP44 M44 %%%% !1110 4444 %?&OQYMQ;?%C6$'1I(Y/^^HE;^M?95?(/[1( ^+%\ M1WC@S_W[%.^EA6NTSBO!I_XFDW_7+^HKMA7%^"UW:K-C_GC_ %%=P(C4D3W$ M!I0:<(Z7RCZ4[D #5ZS .SS?,$6\[S&N3T%54B-/"&F,U"+'S"%-[L .#L&2 M<#'Z[OTJ3&G#&&OR<\_NP,#'^-9(0GUIWEF@"S=A TOD><8<#:9EP;,X:MBWA#?ZD8^IK,U_5[/ M1-'N)77YRI5,9SNQQ1#$PG*R"6&E%79P&M7,^M:_+#!N9!)L4#O[5:\;>&!X M86G^L/TKN=*\?7-C8);7-N+@QKM1]V#CMFN&M/\ 6'Z5 M;K.I2A55IJYM0Q%6A+FINQ;UW5[C6;F2ZNB =N%4=%'I7HG@1#_8NGC_ &Q_ M.O*F5I'^; 13T'>O7/ 2YTK3_P#KJ/\ T*KC%15D8SG*O:'8V]_X@ M2VO8([B!W;?%*@96P">0?I7:?\(;X9_Z%_3/_ 1/\*Y7PP/^*JA_WI/_ $%J M]$K;FE'1,P=.$M9*YB_\(;X9_P"A?TS_ ,!$_P */^$-\,_]"_IG_@(G^%;5 M%+VD^[%[&G_*ON,7_A#?#/\ T+^F?^ B?X4?\(;X9_Z%_3/_ $3_"MJBCVD M^[#V-/\ E7W&+_PAOAG_ *%_3/\ P$3_ H_X0WPS_T+^F?^ B?X5M44>TGW M8>QI_P J^XQ?^$-\,_\ 0OZ9_P" B?X4?\(;X9_Z%_3/_ 1/\*VJ*/:3[L/8 MT_Y5]QR>N?#?P_K-G%;PV5OIRK,)))+.W1'=0#\F[' )(/?I6SHGAS2?#MKY M&CV4=N",,X&7?ZL>36G13=6@HT*49\\8JX4445F;!1110 4444 4?\ #06A9S_9%_\ FG^-+_PT'H?_ M $"+_P#-/\:%"0_:0[GI,Z%I()7C*,(V&5<<9()7MG..M7+8YMUQZ=Z\J_X: M"T,_\PB__-/\:/\ AH'1/^@1J'_?2?XT^278/:0[GJ"/G4'7:>%Z[AC\JLN2 MH) W'TKR;_AH'0\Y_L>__P"^D_QI?^&@M$_Z ^H?FG^-')+L+VD.YZ.R3?;] MT2>O(?KSZ>U7(1((?WQ;.3@'' R?3VKRO_AH'0_^@/?_ )I_C1_PT%HG_0'U M#\T_QHY)6V'[2'<]1MR%L8ST^4'ITIMQ/Y=Y;I@'?G^,#T'0]>O:O,/^&@=# M_P"@/J'_ 'TG^-!_:!T,G_D#W_YI_C24)6V%[2'<]6G<(JYD\O)P"?7%-FED MCB!AB,Q/HP&/?FO*_P#AH+1/^@/?_FG^-'_#06B=/['U#\T_QH]G+L/VD.YZ M1IESC_LQ65KXMH M96_M24;GC#''EQ^M>Q_V7I__ #XVW_?E?\*\C_9=_P"23W7_ &%9?_1<5>S5 M-V7=E7^R]/\ ^?&V_P"_*_X4?V7I_P#SXVW_ 'Y7_"K5%%V%V5?[+T__ )\; M;_ORO^%']EZ?_P ^-M_WY7_"K5%%V%V5?[+T_P#Y\;;_ +\K_A1_9>G_ //C M;?\ ?E?\*M4478795_LO3_\ GQMO^_*_X4?V7I__ #XVW_?E?\*M4478795_ MLO3_ /GQMO\ ORO^%']EZ?\ \^-M_P!^5_PJU11=A=E7^R]/_P"?&V_[\K_A M1#!#;W12WB2)=F=J*%&<^U6JA_Y??^V?]:+L5V,DM+>2X$LEO"TJXPY W#D' MKC/51^0IDNFV,[;YK&UD)&,O&IR" ,=/0 5/-Y* 23A?EZ$CI6%JGBC2]'F@ M%U;RE9R<.B XVXY(S[C\JSG45./-)V1K3I2JR4(*[9JRZ7I]T0T^GVDQQM!> M-6XYXZ>Y_,TXV%FL+1&SMA$QRR;!M/&.1CTXI--N[#48/MNG.DB2=748.?0] M\U;90PPP!'H151ES*Z(E%QE9K4H/I.EL5,FGV)*CY2T2\# '''H /P%/;3]/ M:"2![*T,3@!XRB[6 &!D8[#BH+N]M+.*1F+.J E@B*??O4>F:MINK.5MY/WN M,F*5 &Q[?_6K)UE&2@WJS.Z3L:*VL*NKK;0AE?P_*K&6[@?G7*2^,M M=8DT^]ADMW4@^ M>H.>_I741>48@T&TH_S!E.0V>]7*G**3:W,:.(IU92C"2;CH_(;<6\=Q'LEA MCE4D9#UR.NZEJ5AK#P:78Z28\ GSV1&+$<]6&1TYQ78RAF4J(T=2.0YQG]#6 M!>>']&O[^>ZU2T+2P[0I1GPJA01PN,\Y[5,;=362;6AC[_&'F%_^$=TO>6+% MMJY)/)/W^O%=+H5K*NDVQU&RAM;J/.8XNBXRH[G^'W[FK_VR#>B;_FD&4&T_ M,/:D%];$$B9E9]Y:QPVMY<16=J9 MC$_+XPW!/S9 X))S6B#D9'2J6J0B33KHK;QRN8'4!C@M\I^7/H<^HZTBF<9% MJ'BC4(9XH-'T>XCD7;,L;HP8$$8;#^F1S[U>TZ?Q?#=01OHMA!;%T61HR 0@ M./[_ &%:/A;3K32=.0BS^QW=RH,T2L[C(SC&2>Q[5L'4+81>87;9OV9\MNN< M>GZ^G/2J;\C.,7:[99J.X_X]W^E"7,,DK1)(#(O)3H1^'XC\Z+C_ (]W^E0: MCT^XOTI:1/N+]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** /./C1H1U#PM#J<*YDT^3+X_YYO@'\CM_6O!J^NKRTAO[& M>TNDWPSQM'(I[J1@U\M>)="G\-^(;K3+D',+_(Y'WT/*L/J*]W+:UX.F^A\M MG.'<:BK+9[^IE4445ZIX)Z-\%_\ D;9_^N!_F*]LT;_D&)_O-_Z$:\3^"_\ MR-L__7 _S%>V:-_R#$_WF_\ 0C7SF/\ X[^1]GE/^ZQ^?YEZJ(^S>=>!H&[> M:2F0_';UJ]5?%T&G(\L@X\H?AWK@/4**1Z3-"LR68VY&"+<@@_EFDA;2E+F* MS8%>I-LPSCZCGK5I7U$;LP6^T XPYR>?I2)+J31MNMX%; P#(<9[]J8ABQ:; M>%$:TSN^9=\! R/J*NPV\-LFR"-8U]%&.V/Y"G1ERG[P -_LGBG4AA6==_\ M(7M?^N4G]*T:SKO_ )"]K_URD_I0!\S>*/\ D:M2_P"OE_YUDUK>*/\ D:M2 M_P"OE_YUDU]=2_AQ]$?GU?\ BR]6%'7I177_ T\,'Q+XMA\^/=969$UQD<' M!^5?Q/Z9IU)JG%R?05*G*K-0CNSVKX=Z$?#_ ((LK:1-L\R_:)AC!W-S@^X& M!^%=/117RU'>3_OBO/O 7_(8N/^N'_LPKO\UQ5JLHSLCHA2C)78X26OK)_WQ3_- MM?63_OBHMU17$X@CWE689Q\HK'V\GL7["!9\V =-Y_X#6%=^)(;>\DA,9^4X MR3UK7!W#CTKF+_28+G4I9)+^*,D\JW45M3K2OJ1*C'H3/XQ"-@6VX?[_ /\ M6K0T376UC5$MEM]@ZEMV<"L)M!L>?$F?R[6.,')9\XJ ^-]7^\!'ZX%8.O\ B'^W)T;5(6#H,#8-M==+"SA+ MFD85*T91LCGK>W>(B3U5'(_E_ M6N[IR)04444AA1110 4444 %%%% !1110 4444 %%%% !1110!R/Q7_Y)'XG M_P"P;-_Z#7P]HNH)IE\9Y%9AL*C: >$-4M+R,2P36SI(A)& MX$W3^M>N_\*P\'_\ 0'7_ ,")?_BJ0>R@? M.O\ PE5K_P \)OT_QH_X2JU_YX3?I_C7T:/@OX _Z "_^!4W_P 72CX+> /^ MA?7_ ,"IO_BZ.>0>R@?.S5SO@CPUI/A707L- LUL[9IVE,:NS98A03EB3T KHJ M@T"BBB@ HHHH **** "BBB@ HHHH *A_Y??^V?\ 6IJA_P"7W_MG_6@#D=2U M"[O/B3:Z7%*8[>-/G3J'^4N3]<8%;TL^BWNZRF2&4!S$4>(X#9(QDCU'6L/Q M?H]]#JEOXAT5-]Q;@"6-1DL!WQWX.#[5"/B9;?9\'3;C[7G'E;AMS]>OZ5Y: MK*E.<*SM=W5U=->1[CP[Q%.G/#QO96=FDT^[]2'0(SH/Q$N]'M78VDR;@C'. M#M##\N172^*[N2ST"5H3M:1A'N'8'K^E8WA+2;^XU:X\0ZTACGG!$417!4=, MX[<# KI-9TX:KI4MKG:Y&4)[,.E.E3F\+-15KWMZ=#CS22G4LG>2BDWW?4I: M0EKIVCV27;[Y+A 067=G./E^GS 5D^)K.VM[>#6-*VPR++M)1< GGG'J"*;I MWB2;0XAI^LVLN8?E1UZX[#G@CW!IMQ=7GC"ZBM[:!X+&-MSN>?QSTSCH*YJE M:G5H*E'66B2L[I^IXSDG&RW.QMY/.MHI>F] WYBO.O"44>N>)=5\0:HS.;1O MW:#.%!SV] HQCWKTA$$<:HO"J !7G-W'J/@+Q)$M(J_P !ZX)[ M$$G&>"/T^GPMW&4%\37_ Z^9YV9^Y.C6FKPBW?K9VT=O)G4:CI6D^*;&>!K M?;*!A)FA*.A[$$@9''2L;X8W\]QHUU9S-N6TE C)[!L\?F#^=5=0^([ZG:M9 M^'=.NFNYEVAF4$H3U("YS]>*W_!?AY_#VA^711= 8I8]RL.W'3FL:[\0C3M0DM]1URTCP,A!:/N .-O.2#W[5TDP?=E#)_P !*X_7Z_I7 M#:QI=_JOC%HH?M$4#[0\_P!F61$.P'D^O3CWKAC9[GOR;6Q;@\5VR7DC3^)[ M:2W9W*H+)@Z N2HW=.%('3G&:Z'1IYKVV^UO>0W4$JKY1BB* 8X8\\\MGZ# M]S3T7PM%ILM M:U\8Z#>W<=M:WXDFE;:B^4XR?Q6LWPAH3?81?:D_V@7"?+!<6Z@Q\]<]\BNE M33[.-P\=I C*N^HK2E4E2FIQZ&-: MC&O3=.>S/C^BO6_BG\.FADE\0:%#F)LM=VZ#[A[R*/3U';KTZ>25]11K1K0Y MHGPV(P\\/4<)_P##GHWP7_Y&V?\ ZX'^8KVS1O\ D&)_O-_Z$:\3^"__ "-L M_P#UP/\ ,5[9HW_(,3_>;_T(UX6/_COY'U>4_P"ZQ^?YF9KGC&QT&^%KU_ZY2?TJ#PWX?7P[8/;+<&?>^_<5VXJ>[_ .0O:_\ 7*3^ ME>M1]I[->T^+J>'B/9*K+V/P]#YF\4?\C5J7_7R_\ZR:UO%'_(U:E_U\O_.L MM$:214C4LS' 4#))K[.E_#CZ(_-Z_P#%EZLDM;6:^O(K6TC:6>9PD:*.6)Z" MOI?P-X4B\)>&XK/Y6NI/WEU(/XGQT'L.@_/O7.?#+X=CP_"NKZQ'G4Y%_=QM M_P NZG_V8_H./6O1J\3'8I5'[.&R/ILKP+HKVM1>\_P04445YA[84444 %%% M% !1110 4444 %%%% !7R+^T-I-Y;?%"[N98B(KN..2%^S@(%/Y$&OKJLCQ% MX6T3Q98"S\0Z?%>PJVY0^0R'U##!'X&@#X@\+:DFB:D]Q=0R.K)M 0 Y.0?4 M>E=E-\1+"2>21=.9 [;M@B4@>PRU?07_ HKX>?] $_^!DW_ ,77)>/?@-H< M.F?;_"6G.DD )FM!/(YD7^\N6)R/3N.G/6%AXU9ZNUQSQ#HTW)*]NVYY./B! M8 ?\>#GG/,2_XT'X@:>6!_L]^!C'DK_C57_A']-!YMS_ -_&_P :/[ TW_GW M/_?QO\:[?[$EW7W_ / /*_U@H]G]R_S+'_"?6&XG^SWZY_U2_P#Q5557U7]?(/[E8.IWE[JEX9;EG90,("F&-D>QAN QS^^7/ M]:Z_^P--_P"?<_\ ?QO\:3_A']-_Y]S_ -_&_P :V^HXCNB/[9PW9_A_F#[<_YS3-1O9M16(O;K$R9R$^[^%=I%X=TMID#6W!8 _O& M_P :V#X/T//_ !YG_OZ_^-<>(P\Z+7/;7L>AA,9#$Q?)?3N>56\;(Q+#'%3Y MKT[_ (0_0_\ GS/_ ']?_&G+X.T+_GRS]97_ ,:Y3L/+5/7ZU[+\/898+325 ME0@M,K =\%JIP>%=$@D62+3XPRG(W,S?H373Z*/^)U9 =//3^8IB/3_"7_(? M?_KFW\Q7<5Q/@_\ Y#4O_7%O_0A7;4/<2"BBBD,**** "BBB@ HHHH **** M"BBB@ HHHH **** *>KV\EWH]W;PC,DD3*H)ZG%>8'0M5!(.G7/_ 'Z->MT4 MP/)/[#U7_H'77_?IJS=0N(=*N?L^IRK:3;0WESG8V#WP>U>VURGC_P #VWC3 M1#%\L6H0 M:SD=#_ '6_V3^G7V-0Y7*TMBH*+E:6QYG_ &WI?_00MO\ OZM/ M77-*_P"@C:_]_5KRW4M-N](U&:QU&![>Y@;:\;CD'^H]^]5:]#ZI%]3T_J,' MJI'L*Z]I/_02M?\ O\M2+K^D?]!.T_[_ "_XUXU11]4CW#ZA'N>V0:UIDS[( M=0MG;&<+*":MKJ%F/^7J'_OL5YQ\-M,_M'Q!/N7*16Y)^I90/ZUZ;_PCD?\ M<%DJ4^5#5U&R!_P"/J'_OL5(NIV/_ #]P_P#?8IO_ CD?]P4 M?\(Y'_<%8F ^37=*M\>?J-K'NZ;Y5&:1?$^A?]!BR_[_ *_XUQ?Q*T-+/1+6 MZ5<,MQY?X%2?_917FE=E+#QJ1YKGH4,+&K#F;/H-?%&@_P#08L?_ (7_&I% M\5:!_P!!FQ_\"%_QKYXHK7ZG'N;?4(=SZ+'BK0/^@U8_^!"_XTX>*_#_ /T& MK#_P(7_&OG*N]^&WPYG\77PO-05XM(A;YWZ&8_W%_J>U1+#0@KMD3P=.$>:4 MCVBS/V^U2YLO](@DY26/YE;Z'O5@6EQ_SQD_[Y-=!!!%;6\<%O&L442A$11@ M*H& *?7 >;IT*FFPO#:8D&TEB<'M5NBBD 4444 %%%% !1110 4444 %%%% M !46QOM6_'R[,9_&I:* #'O3/)C\S?L7?_>VC-/HH"YB:[XNT/PS+%'KE\;0 MS M&6A=@V.O*J1GV]Q63_P +6\%?]!U/^_$O_P 16UXG\-6'BO1)--U./*M\ MT<@'S1/V8?YYKYB\6>$]1\(:PUCJ294Y,,ZCY95]1_4=JZZ%*G45F]3MP]&E M55FW<^@7^*7@>08DUN)O]ZWD/_LE.7XJ^"%7"ZY&!Z"WE_\ B*^8**Z/J=/N MSJ^HT^[/I_\ X6MX*_Z#J?\ ?B7_ .(H_P"%K>"C_P QU/\ OQ+_ /$5\P44 M_J<.[#ZC3[L^G4^*/@:+/EZU$F>NVVD&?_'*=_PM;P5_T'4_[\2__$U\P44? M4X=V"P-);-GT^WQ5\$.N'UN-AZ&WE/\ [+5,_$GP!+B*5'UF']ZI5C]FE.01C^[Z&OF:BCZG#NP^HT^[/I2# MXD^#[?R8H/$R);Q1B,1"SD[# P=GTXQVKK8XKJXLE>.^8&0K(K-!MPO!P5." M#]R5PUHPC*T-3SJT*<)'I*G>YG?VCJ?_ $!V M_P# A/\ &C^T=3_Z [?^!"?XUHT5@=1G?VCJ?_0(;_P(3_&FIJU_)_J]+WO8/ 'PQ@\-;-1U?9M=5X?T2PTNW:X MM;:-+FZ/F3S ?-(3SR?3VZ5KUW5L;*<%3CHCR\/EL*=1U9ZN]_)!1117 >J% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YKX_\ A9#K9EU/P^B0 M:B?FD@SM2<^O^RWZ'VY->(7EG<:?=R6M["\$\1VO'(N"I^E?7-8?B7P?H_BJ MV\O5+;]ZHQ'<1_+(GT/<>QR*]/#8Z5/W:FJ/$QN5QK/GI:2_!GRW17?^)?A# MKNCL\VEK_:MJ.1Y0Q*H]T[_AFN#EBD@E:.:-HW4X96&"#7MTZL*BO!W/F:M" MK1?+45AE%%%:&(4444 %%%6+"T-_J$-J)%B\UPOF/]U<]S2;25V.*RV^9IV4AK@]3]/05S=UH]S$3A5D'MP:^>QE M=5I+EV1]CEN$EAH/G>K,O=2AJ?) \>/,1D^H_K4>P]JX3U"96K2T3_D.67_7 M9?YUE*"*T]#/_$ZM#_TU6D,]/\)OMUF4@_\ +$_^A"NU6;/6N!\+2?\ $TE( M_P">1_F*[ 2ME40;G;[J_P!3[5=D0:*NK-C/.,XIU0V\'DJ2QW2-]YO7V^E3 M5F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 JMW_F M.]?7%4]5TC3]J/CNBO M7_%?P,NH&DN?"EQ]ICZ_9)V"N/96Z'\09'U M /Z$5Z4:L9J\3U85H5%>#N=K\/&U'PO:7=[-I!E%X$$?F@J0HR?] .+\S7F\_Q0UJY0K-;V39[^6P_]FJI_P )]J/_ #[6G_?+?_%5QU*% M2I_P#">7?_ $ XO^^C1_PGEY_T XOS->6?\)]J/_/M:_\ M?+?_ !5'_"?:E_S[6O\ WRW_ ,54?5:AG]3K';>,=3U'Q;X=>P@T94D2195, M9Y)&>/R)KR*2-X9&CE1D="596&"#Z$5UUO\ $K5[7/E6UGSZHQ_]FK'\0>)+ MOQ+=1SWT-NDB#:##%M+?4]3750A.FN5K0[L-"K27+):&/1UZ5T_AOX>>(_%# M(UA8M%;-_P O5QE(\>H/5OP!KVKPA\(M%\-M'=7^-4OUY#RK^[C/^RGK[G]* MNI7A3]32KB*=/?5GG7P_^$=YK[1:EX@62STW(98B-LEP/;^ZI]>_;U'OUI:6 M]A9Q6MG"D$$2A8XT& HJ:BO+JU95'=GD5JTJKNPHHHK(Q"BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH *S/$'AW3/$^EO8:Q;B:)N5;HT;?WE/8_ MY-:=%--IW0TVG='S-XW^&.K>$I7N85:^TO/RW$:\QCT<=OKT_E7$5]GLH92K M $$8((ZUYYXJ^#>A:ZSW.E'^R;MN3Y2YB8^Z=OPP/8UZ%+%])GIT<:MJGWGS MG177Z_\ "_Q3H#,TNGM>0+_RWM/WB_4@AZIK4_DZ587%V^1D11EL?4]A7I7AKX%:C=E)O$U MTMC%U-O 0\I]B?NK^OTK.=2$/B9E.K"G\3/,-.TV\U:^CL]-MI+FXD.%CC7) M_P#K#WKW;X?_ AMM#:+4_$BQW6H+AHX =TI&177#J&'H1F M@"O]HB_YZ+^=+Y\7_/1?SIWV.V_Y]XO^^!1]CMO^?>+_ +X%,"-IH64@RJ/< M'I5-5E-SOEU4-"#D1*BKGV)[_ABK[65JZX:VA8>AC%,_LRP_Y\;;_ORO^% # MO/B_YZ+^='GQ?\]%_.G?8[;_ )]XO^^!1]DMO^?>+_O@4"&&XA R9%_.H'E- MY^YMLE&X>3L![>]6Q:6X.1;Q _[@J4# P.*!B*H50J] ,"EHHI %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;JOAW2-S#D?@:TJ*:DXNZ)E&,E:2NCSK4?@KX=NF9K&:[LF/15<.@_ C/ MZU@7'P(F&?LNNQOZ>9;E?Y,:]DHKJCC*\=I'#/+<+/5P^[0\/_X47K&[_D*V M./7#_P"%6[?X$7#?\?6NQI_USMRW\V%>RT5;Q^([_@9K*L(OL_BSSC3O@GX? MMBK7UU=WC#JNX1HWX 9_6NQTSPKH6C0F/3=*MH0RE&;9N9E/4%CDD?4UK45S MSKU:GQ2.NEA:%+6$4CG;KP/H\V3:)+I[GJ;23:#_ ,!.5_2L&]\":K%N-G=V M]Z@&0LRF)S[9&1^@KT"BLKLZ+'C=]I5W9?\ (3TRYMA_?V>8G_?2Y'YUF'2+ M.[!: HV>Z-S^E>[UDZAX7T74W,EUI\)E/)EC&Q\^NY<&GS!8\6D\.R@_NI/P M89J?2]'O8M4@9K*]&N? @M1-&T\VK*L2EYW].__ -:NPM+06R$L=\K? M>?\ H/:H]/T];*+G#3,/G<#]![5Z_9^3S45M&O4CLS>.(JQVD>#O\ =9#?N]8L6'^TKC^AJ:W^ &H$_Z5KEL@_Z9PLW M\\5[E15_6JOZNRT?X>>%M#97LM(@:4 M8/FSCS6SZC=G!^F*Z:BLY5JDMV92KU)[L****R,0HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-U+PYHVL9.J:7:7 M3$8WRPJ6'_ NHK2HIIM;#3:U1P]U\'O!ESG9ILEN3WAN'_J36:WP*\*L[$ZU1[R8R&"*VA6*WB2*->%1%"@?@*?1169D M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !116;KGB#2_#EDMWK5T+:%W$:L49LM@G&%!/8TTFW9"E)15WL:5 M%5KG4;2TTN34;B8+:1Q>QCT/^UWGQ8^1]H\W8W^KQNSC&>G;&::=7\<-C.BO%* MX(,@89&%QN)QSC&:AT/QEX?\1S/#HVI1W$J#)C*M&Q'J P!(^G2G[.=F[.R( M]M3NH\RN]M=S;HK'M?%FBWOB";1+:]#ZC#N\R QN,;>O)&#^!I!XNT,^)/[ M%\#J><>0(GZ[=WWL;>G/6CV<^W2_R[^@_:T]^9;VWZ]O7R-FBN2F^*/@^WGD MAFU?;)&Q1A]EF."#@_P5T6E:K9ZWIL6H:9-Y]K-G9)L*YP2#P0#U!IRISBN: M2:0HUJ4Y0,#\<4N63MIN'/'77;]2]1574M2M-( MTZ:_U&7R;:!=TC[2VT9QT )KF?\ A:W@O_H,_P#DK-_\151ISGK%-DSK4Z>D MY)>K.PHK.TS7M-UFXNH--N?.DLV59U\MEV$@D=0,]#TJM+XOT.&VU&XEOML6 MF2B&[;R7/EN3C'W>>?3-3R2O:Q7M(6O=6_RW_)FU17)P?$_P?F?$+PKK%\EG8:O&T\G"))&\6XYQ@%U )YZ=:Z2B4)0=I*P0J0J*\&G MZ!1114&@4444 %%%% !1110 4444 %%%1SSQVMM)/.VV*)"[MC. !DGB@"2B ML&3QOX>ATJRU*740EG?2&.WE:)P'8'!S\N5Y'4X%:%]K5AIU[96EY/Y<]\YC MMTV,=[#J,@8'7OBK<)IV:,U5IM74E_P^Q>HJKJ6I6FD:=-?ZC+Y-M NZ1]I; M:,XZ $US/_"UO!?_ $&?_)6;_P"(IQISGK%-BG6IT])R2]6=A16=IFO:;K-Q M=0:;<^=)9LJSKY;+L)!(Z@9Z'I4#>*]%2WU*=KS$6EOY=XWE/^Z;TZ<_AFIY M)7M8KVD&KW_K^DS8HKD%^*G@UW"KK&2QP!]EF_\ B*Z^G.G.'Q)HFG6IU+\D MD[=G<**YB?XC^$K;46L9M:A$RN$.U'9 3_M@;?JM/5O$ND:'ID6HZE>K M'9S$".9%:17R,C&T'@COTING-6NGKL"K4G>TEIOKMZFI17.:5\0/#.MZBECI M>I^?J.OHK+M_$FDW>J0:=;W>^ZN+87<4?EN-T1Z-DC ^AY]JH:I\0/"^BZ@ MUEJ.K1QW"??1(WDVGT)52 ?8\U*IS;LD[E.M24>9R5O4Z.BLC5?%6BZ)ID&H M:C?HEI<,%AFC5I560X1%+,<= * '45SI\>^&ETNQU%M3"V ME_*8;>5H9 '<'!'W7_U&7R;6W7?))M+;1] "37*_\ "W? _P#T M&_\ R4G_ /B*(QE+97'&G.2O%7.THK-TOQ!IFM7%U!IESY\EH5$Z^6R["PR. MH&>/2H&\6Z(D&J3->XCTE]EZ?*?]T?3I\WX9I"9)%1 M-:RS$ #[)-R?^^*[+K3E"4?B5@E&4?B5@HKEKSXE^#[#4WL+K6X5N(W",%C= MU4^A=5*\=^>.<]*U-5\3Z-HNCQZKJ-\B6$I41SQJTJON&1C8#D''6CEEH[;C M]G-.UC5HKF-(^(_A77=4AT[2M5\^[FSY5=V 2>64#H#WJI)\6O!,4K1R M:UAD8JP^R3<$?\ I^SG>UF/V52]N5_<=E161;>*M&N]2LK"WO-]S?VHO+>/R MG&^(@D-DC Z'@X/M5#5?B+X4T74FL-1UF*.Y3AT2-Y-ASC!*J0#[$Y%+DE>U MA*$GHD=-16/J_BO1-"TF#4]3U!([*X8+#/&K2JY()&-@/& >>E9VE_$KPGK6 MIPZ?INJ^==3G;'']FE7<<9ZE0.@IJ$GJD')+EYK:'4T445! 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%1W-Q%:6LMS<-LBA0R.V"<*!DG ]JQ)?'/ MAR#3+#49M2"6FHOY=K*T,@#MG']W*_4X%-)O8:BWLC?HK/OMB M[EJBN+_X6[X'_P"@W_Y*3_\ Q%=%I/B#3-2_P"Z<'&,;38B:%I,&IZGJ"1V5PP6&>-6E5R02,; >, \]*7+*R=MP]G.Z5MS8 MHKEM+^)7A/6M3AT_3=5\ZZG.V./[-*NXXSU*@=!74T2C*.Z%*+B[25@HHHJ2 M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQWXF>(])F\ M<6^F:RMQ-I]A;OYL=N 29I$^4\L/N@@YKV*L?1?#-GH=]J5Y;RW$]QJ4WFSR M3L">,X48 P!DUO1G&$N:78YL33G5@H0TN]?1:[==;?(YOX6ZQ!XB\!C3[T+< M-99M9HY5#!X_X,@\8V_+_P !-4(?#^C'XT3V)TBP-H-($@M_LR>6&\P#=MQC M/O79V/AFST[Q+?ZU:RW"S:@JB>'O?N:8OJ7CS_ (5G]G;1;$:']@"_:=X\SR=OWL>9 MUQ_L_A7L>J:=%J^DW6G7+.L-U$T3M&0& (P<9!YJFWANS;PC_P (Z9)_LGV; M[-OW#S-N,9SC&?PJ:590BTU?5;E5\/*I-.+:236GR/-H(+#4/$?@BS\0E#8? MV-&T$4QQ')-@84]CG X[\#G.#I^-M*T?1?$_A>;0K:WL=4?4(T\JU01[XB<, M2J\>V?!R",>U5?#7PTT#P MOJ'VZT6XN;H?ZN6Z<,8N,': .?4@GT[UM[>%^:[TOIWNW_GJ(ONI8ZU'%.WI%*KJW\JD\,HUS\0O#VMSH0*54?A@_G7HMQX"TJY@UN*:6Z*ZU(LMQ\R_(RG(V?+QU[YJ>#P9IMO>Z M)_&.::Q$.7SM;Y2% )'7W-<=<_!;P[=7ZH'E=G8++'@$G/'R5??P#; M6=GX?T_37N7ATN_^U"6:1.!G<0V ,Y/ P!CJ>G*K5*=6*2?;I_P?T'AZ-:C. M4G&^_5=_3]2?XH2W$7PYU,VN0S*JOC^X7 ;],UGGPSX)_P"%"#7"?\*8\*_VA M]H_T[RM^[[+YX\O']W.-^/\ @6?>L*4XJ')*36M]/Z^XZ:]*;JJI&*EI:S]; MWV?S^1QEU9RZ[X&\"6%_)(GVFZDMP_<)OVK^0Q5S3]9N[GQIX6T36 PU31KJ M:WF8_P#+1-@V/GW _'&>]>F:AX5T_4)M(=O,MUTB42VT4!54XQA2"#QP.F*B MOO!VF7WBRS\1/YT=]:# \ME"R<$#<",G&>Q%="Q,&]5_,_1N]OS.7ZE4BERO M5**]4M_\T;5S:P7EN]O>01W$,@P\X/!KSO2?#VBR?%K7K.32+![6*T MA:.!K9"B$@9(7& :])K*M?#UI:>)KW7(Y)C=7D212(S#8 N,8&,YX]:Y*53D MOKNO\CT*U)5.739GF>G7GBVP\:^*4\&Z39WL9O%$WGL%\O&[:!\Z^_KTK.\R M]E\">.9-6A2"]:_C,\49RJ/N&0.3Q^)KUS2?#MIHVIZI?6LDSRZG*)9A(P*J M1G[N ,#GOFLZX\!:7<6.LVKSW836)Q/<$.N58'.%^7@?7-=/UB%TK?RZ]=+7 M_(XOJE35W>\M.FO-;\U^)QN@:9XH-]IQNO 7AN*S\R,R7*6\7F*F1EQ^\)W8 MYZ=>U=]XTEN8?!.KR6)<3K:N5*?>'')'X9KE$^"/AN.17%[JF5((S+'_ /&Z M]%90ZE7 92,$$9!%1B*D)R3CK\K?JR\'1J4XRC-6^:?Y)'DT=CH-I\+],N-+ M\)Q^(I;I!'WEE??#CPM;_9Y;#16U007:27!D M(4,)36":K\./ VGRNR)=:@\+,O4!I&&1^= M6K75KM_%/A;P]K(;^TM%OWA=R.)8\#8X/T&/P![UZ%#X"TN'3=%LEGO#'HUQ M]HMR77+'!58P36Z45ZI;_P":-JYM8+RW>WO(([B&08>.5 RL/<'@UYWI M/A[19/BUKUG)I%@]K%:0M' ULA1"0,D+C ->DUE6OAZTM/$U[KDM<=*IR7UW7^1Z5:DJG+ILSS/3KSQ;8>-?%*>#=)L[V,WBB; MSV"^7C=M ^=??UZ55LY+V7P/X^DU:%(+UKD&>*,Y5'SR!R>/Q->JZ3X=M-&U M/5+ZUDF>74Y1+,)&!52,_=P!@<]\U1?P/ILEEK=L9[K9K4OFW!#KE#G/R?+P M/KFNCZQ':W2.O72U_P CC6$FGS7?Q2=NEGS6_-?B<#X>TOQ/+%I9D\!^''L6 M6+==-;Q&1HSCYS^\SNQSTZ]J]&\:RW$'@?5Y+,L)EM7VE>HXY/Y9KD_^%'^& M_P#G^U7_ +_1_P#QNO1C&C0F)U#H5VE6&01Z&EB:L)R3CK\K?JQX*A4I1<9J MVW5/\DOU.!\+^&O!MS\.;:>:ST^:)K7==77[CE2P!^O MTQ70W_@_2K[2=/TU%DM+73YDF@CMR!@KT!R#D'//<^M:?6*:ES7;NT]>EC'Z MK5<>7E2M%JZZW7IMU.;\'Z;KD6K32Z[X/T/1XTMV,5S8P1K)OX&,J['!!:N( M\*6'B.XTPQM(?FY!+.#Q]*]W9=RE3T(Q69X>T"U\-:0N MG6$DTD*NSAIF!;+')Z 5G'%6YI-*[MWZ7\S:6!348J3LKZZ7UMY'%WJFV^,@ M6RC6,Q: PA1%P%P6V@#\JB^'>@^&=2\ ->:I:6=UX56DC.3U8\I\N M#QCUKMF\-V;>+E\1&2?[6MM]F";AY>W.I&7/&*>KT?FE^*M^)S/B^ MVTJ#P!XU;/A/3O$D?B2V?5_!/A_3 M+50Q:ZLX(A+&=IQ@B0GD\=.]=!K'P_T35_#MIHFV>SLK.3S(DM7 .<$@Z)K%MJ5K=ZB\UM()$626,J3[X0']:T5>FZ;BWWW5WK\T92PM M558R4=$ELTEIZIZ?<=W1117G'L!1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !5;4_^03=_]<'_ /035FF3PK<6\D+DA9$*$CK@C%)ZJQ47 M9IG@$6F1ZS\.? ^FS.T<=UJ36\S' M)$J%5\MP>^0/QP#WKT6T^'>DV6GZ-9Q7%Z8]&N6N;1],5;U'P M3I6I>+K'Q'*9H[^R "^4RA9,9QO!!)QD]"*[O;1Y[]+MG4ZT6FO*5OG?]&;E MS:P7ML]O>01W$$@P\4J!E8>A!X->;:5X;T.3XQZY92:-I[6D5A"\<#6J&-&. MW)"XP#[UZ=63;>'+2U\57FOQR3F[O(5AD1F'EA5QC QG/'K7+"7*WZ'/&;C& M2OO_ )H\NLKSQAIWCSQ5'X(T>ROHOM:"83L%\O"G: /,3C&?7I5:PEU";P5\ M1I-9@CM[]IE-Q%&9]<3_ ,*%\,?\_P#J_P#W^B_^-UZ8L:K"(L;E"[<'N**\XSV( MJ5(\\9+6WR_5GG/@;PQX,O/AM:W%Q8Z=W4RJ7C?;\^7/*8]B,#GWKA MG:1O@JT-MFXM8O$'EV/FCB2/J,YQP23GIU-=]>_!/PG>:DUV@O;5&8,;:"91 M%[@94D ^@/TQ71:AX)T>^\.6FAQQR65C9S)+$ELP!!4D\E@M]?1_YG->"-+\01^(?-U_P3X?T>".%C'=6-O$L@?@8!5V M(!!;M7">%[#Q+<6%R^C>"]!UFV^V2C[5?PQM)G/*Y:13@?2OH&LGPWX,> MOO7=3^&+*?QC;>)'EG%Y;VQMDC#+Y94ECDC&<_,>]Z:E9C58Q )VWB5R')5P<8RQY''7M6QX0TSQ-'XFMI-:\">'=*M4#$W=G;Q" M6,[3C!61B,GCI72:U\/-#UGPQ::!MGLK"SD$D26K@$'##DL&SG<2>Y/>LC1O M@UX>T/6K74[2\U-YK602(LLL94D>N$!_6K52'*TWU8.I!TN6^NO];GH%%%%< MAR!1110 4444 %%%% !1110 4444 %%%% !1110!F^(_^16U7_KSF_\ 0#7C M-SID>L_#OP!ILSM''=7CQ,Z=5!8C(KW&]M$O["XM)BRQW$31,5/(##!Q[\US MT/@#2X-/T.S2>\,>B3F>V)=1],5K3DH[]U^%SHIU%!>>OY6/-K/6 M+R?QMX/\/ZV&&JZ%>36\S')$J%5\MP>^0/QP#WKVRYM8+VV>WO(([B"08>*5 M RL/0@\&L/4?!.E:EXNL?$AR?&/7+*31M/:TBL(7C@:U0QHQVY(7& ?>L73+WQEIW MC'Q5%X)T:QO;?^T,2^>P7RR,[0!YB<8^M>I6WARTM?%5YK\35)_/F$C A6YX7 &!SWS5*K;?72WXHOVR MUZ[;^FIY!8R7DOPX^(4FJQ)#>M?YN(HSE4DWC <]S]:O>'=*\6.^EF;X M>^&?L+&(M=?9X3+Y?&7SYF=V.>G7M7?MX TMM-UVR-Q>>5KEP;BY.]=R,6SA M/EX'US7,CX#>&!_R_P"K_P#?Z+_XW6L:L+N^FW3R]37VM-IIO=OIWMYG;>+I MKF#P9K$MB6%PEE*T97J#L/(]ZX_P-X8\&7GPVM;BXL=.N5:W)O;J95+QOM^? M+GE,>Q&!S[UZ/M&S81E<8(/<5Y[>_!/PG>:DUV@O;5&8,;:"91%[@94D ^@/ MTQ7/3DDG%NUS"G./+9MKKH<"[2-\%6AMLW%K%X@\NQ\T<21]1G.."2<].IKN M/!VE^((];>77_!/A_1X(X',=U8V\2R!^!@%78@$%NU=1J'@G1[[PY::''')9 M6-G,DL26S $%23R6!SDDDGJ?6N@9=RE3T(Q5U*MXM+K?\DBYUTU9+>_YGS[X M)T_Q+P1-*WSV^-D@L4"/%X=80H MBX ()V@#\J[;PSX0 ._I3#X8LSXR'B7S9_ MM@M?LOE[AY>S.LWQG;:3!\,?#=OX/=-2LQJL8@$[;Q*Y#D MJX.,98\CCKVKI]8^#7A;6-6DOS]LLVE.Z2*UE58V;.2<%3C/L0*U=:^'FAZS MX8M- VSV5A9R"2)+5P"#AAR6#9SN)/ZT[?UT*]K!33YF]6]3F M_"&F>)H_$UM)K7@3P[I5J@8F[L[>(2QG:<8*R,1D\=*]-KS_ $;X->'M#UJU MU.TO-3>:UD$B+++&5)'KA ?UKT"LZLHR::,*TE*=U_7YA1116)D%%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S'BGQ+>:) MKWAZRM(X'CU.[\F8RJ2RKE?NX(P>3US73UP/Q!_Y'#P7_P!A'^J5M0BI54GY M_DSGQ,G&C*4=QWAOXAR:GX[U/P[JD=O"8I72S>,$%]A.5;).3CD8QT-;'@SQ M%=^(K?5)+V.&,V>H2VL?DJ1E5 P3DGGFN$M?#TVN6OBF;36,>JZ?K3W-E(O4 M..=OXX_/%;GP:N)+OPYJEQ. LLVIR.X QABB$\5TU*=/V;E'=)?C;7YG%3JU M?;1A)Z-RMZ*^GRT+_C?7?%^AR/>X/S(1G/'F*2, = :P$\ M=>.8?#-QKNHZ/IL-C]F66VE7)WLSJ "HE)QM+'H.E=MXW_Y$/6_^O*7_ -!- M @/?UI?B5_8__ FFG?\ "1?; MOL?]F)_QX[/,W;CC[_&*WIT:3DN77673R6FYS5L1749.7NZ1Z]Y/6]M/N9Z- MX3OO&%Y<7(\7Z59V$2JI@:W<$L<\@XD;V]*9XS\73^'C9V&D6)U#5]08K;0? MPC'\38[?B._(Q7-?">\\+I?ZA9>&1J_F2Q+-*=0$6,*<#;L[_/WJ_P"/!?:' MXIT?Q;;6,E]:V,BO9:[$=CXX\3Z5K5G9^.M"@LH+^4107-J^51SV;YF!R2.XP,GFFZ MGXO\:S>,=5TCPOI.GWL6GE-QE.U@&4$9)D4'G/05F:EXJ_X6;>Z;I'AW3;Q; M:&\CN+RZN$ $*KG'W21R,]3R1@4Q_!6G>,OBCXG35)KJ(6I@*?9W5<[D&<[E M/I6T804KU(I.ST^:L[7]>ISRJ5)1Y:,W)SVE=7MY)[>1M:SXM\8:)X6T M^>]TNPBUB\O_ +*+&?#\$D[6G]J)#O=@9-K[\\@8S\Q[5O:)\.])\'K? MWFF7%[+)-:/$PN'1@!UXPHYXK*3I*DW97=[:?\'3\3>G&N\1&+;LN6^J^?37 M\#.@^)5V/ 5AJDUA'=:OJ,[P6UI;!@K,&(S@DGTX[D]NTFD^,/%UKXCLM-\8 M>'HH(]08I!+9?-M8#)+89QCUY&!D\XKD='M[^T\ >&/$>G6;WPTB[G>>W3.X MHSD$C'IC\.O0&NMTOXGOXF\16-CX9T:YFMRQ^VS70">2F.""I8#OUZXP.N1K M.DDYWEN5[SQ?XXN_%.K:;X8T?3KV#3 MI0C-*=K $<9S(H/0]!77^%KKQ!=Z6\GBNQM[&\$I"1V[ J4P,'AFYSGOVKQ; MQ+_PC7_"PO$'_"3_ -JY^T#R?[.\OT^;=O\ PQCWKU'X87FBW'A5X/#HOQ:V MT[*3?A/,+'#'[G&.:FM24:"DET73R[W_ $+P]:4L5*$I=9:7[-]+=O,[*BBB MO-/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO&.MZKI+:1;Z&+/[ M3J-\+;=>([(H*,V<*P/\-=+7$?$6S%_>>%K5IIX!+JZJ9+>4QR+^Z?E6'(-- M:R2\T*6D6RPNM>)M&UK3+;Q(FDW%KJ4YMDDL%DC>*3:6&5R3^3D8.T,< D=\9KD%C0? _P 181?FEOF/'4^>_/Z#\JK0FS_KYG<7 MGBO1K#5_[+N;MA?80^0D$CMAR0I^53QD'[74FL9]2194D$3 MMY;F*-S_ M(!L5O8D&LS0QN^)&L,>6_LNR^8]>LE<58QV%KX;N="\0^(-=@ MU#S)H9M'MHXBUR7=CF(-$2P<'.=W?J*.76PGZOXGTC0YDAU*[*32 M*76**)Y7VCJQ5 2%]R,4VZ\5Z)::=:WTE^CP7G_'N8%:9IO7:J L<=\#CO7# MWD<6A^-+Y];\0:IH=M=6EL+2Y3R]LHC0JR.S1L-X/. 1G<<4WR-&TW2=,NUU M37M'+SW,MKJ]Y#'M4R$%A(NW:$@=U4JA^I% M<2M]V$6H06OV<7PXS*5[G.1N'!QQ3-:\12W%GXAT];ZUT MB427$?\ 9-MIADNKD8(\PDG!WCG<%P!U/%#5E_7:/^8T[O\ KN_\CJMNZS;>)6T7Q2FG[Y+1KN&ZL2ZI MM5@K!U$H9+V]M1_PC0?S;&Y:%SS'QN7MSTKJW\.6/ MAK2=4U*TM+K6+\V;JQO9WN))U )$66)^4GL!S[TY)06OG^;1,6YO[OR3+5EX MW\/:CJ$-E::ANFN"1 6@D1)L==CLH5OP)J+7/&VD:5]NM5O8SJ%M"S>68W9$ M?:2JNX&U2<="03VKA+K7GU67PRR:Y:WB)J=J6L]/TXQ16G.,.[%BI&=H7Y2? M2M&76=-T'PSXGT76U9=2FGO)5MS$2UXLA8HZ&5M56\\/12F6]#%8E:4L!M4@L>W4= MS[%)7_KR;_0;=E_7=+]3T6BN O/$$FI0Z/'JFGV_V^T\1165P@=RB2!6(DC( M(/*D$!LCD@@XS5>+Q2GA?0]0?=;I/>>(+N")[N0I%&=[$NY'. !T'4X%/E_K M[O\ ,+_U]_\ D>CT5QOA3QL-8U^;1KB^TO4)5M_M,5SIC-L*A@K*RL258$@] M3D'MBNRI-- FF%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 45S7CN\E3P^NF6;[;S6)EL(2.J[_OM^"!C5'PE.VAVVM^'?KXM\4)X*L=?FM]*9]0>U2"U19!C MS'"DLY;OG(P/ESSNQS9N9M7A\76D=Q%IL^L?V1=O#/''*J AX]J;3)T)QGOQ MP15.-GKY_@KDJ2:T\OQ=CMZ*Y:+Q9-?V/AI].BB^TZPX,J2 D0QHI:;H1R"- MH]R*SO$'BGQ'H%C<:M>)HUK:0R';I\\I^T2QAL9#AMNXCD+M/IG-'*[V#FNK MH[JBN%O-7?1O$?BS5;>W-RUOIEG(L8)YYFY.,G ZG'85H^%]>U/5KPB:YT;4 M[%HMXO-*E(\E\C]VZ,S'D'(/'3D"CE8GWFH6=@([6YOM.BN"^H M65I+LDN(]AP!RNX!L$KD9K)\,V^@V_B,+X5EN-#N&MG\_1KVVEC$QXVR!7(& M5(Y*9R#VZTDKC;LST"BN!\(W7B9/!;R0K97]S+?SI&S[HUA'GR!WD)8E@".% M7!Q@>]2P^)=8GOM8T.>[TB:]AT\W4%U9!]B\[2KIO)##J,-WHEI?^O,$[O\ MKO8[FBO-]!N;F*W\ G5EM;F26VE>.=5D5HD%L"/XR&8C@D@@]@*O'Q;XB_X1 MX^*ELM/_ +$ \[[(2_VDV^?]9OSMW8^;;CIWS52C9V)C*ZN=U17&G7_$FJ>( M=8T_0$TM(=/$+QSW:R-YGF1A@N%8=\_-V&.#6]X9UG_A(?#-CJOE>2US'N:, M'(5@2" >XR#4V=K_ -:E73-2BBBD,**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHKGO'__ "3O7_\ KPF_]!-)NRN-;G0T5XO);>"9O#*KX7TN M\/B(VZ_9GLK.YCD6? PV\J% !Y))QC-=/#_PD'_"Q-4BTO["MT=+LS<3W89D M5AYG 52"M'&SL9*=U<]!HK@X_&FMZC;Z!%IUI8Q7NI37-O<>?O:. M)X<@LN""1E2<=\@9'6H]4\?7%IK$VD_VIH%A5E#%8T# JHS] MXD]>AQ4\K*YD>@45Y]/\3X)-#TF>VET^SN=2:56FO9B;>#RCM^1#9^5YF?ERC9QCZ# M\J+:A?2_]=CT2BN'TF)_"OC#4-!TA);BP?3!?VMD\V?*D#E"B,Q^56X/)P#F MG'Q/KNEZYI-KKTFBLNI3B!K6U=A/;L02#DL0X!&"0!R13M>UNHKVO?I_PYVU M%<)#XSU>]UNY@L3HY:VO&MSI$TICO716P9 S,%Y'S ;2,=\U#;MKY^('BY?# MZZ>A!M6:2]#L"?)X0*I&/][/'H:5M+^5_P O\QWUL>@T5YK.1UK7D\9ZAI=MJ=IJUG!-J]E)!'"MJS M+%=>>VV(C=DISD$(XM/G34@ZV\M@ M'39*JEO+8.3D$ X;(Z<@5GWOBKQ#HLMA<:T-%AAN[J.%].21OM,0=@H(?=M< MC()PH'7GO1RW=@&M,U#4;6QBL+V_LI8X82_G6ZF=&4NQX?(P#@#!/>B*NU MYV_$'*R?E?\ ])HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BL#QMJ%IQ9'_ $Z\9;.T'K+(=JG\,D_A65X)A'AO4]2\(ER8K0)= MV18\M#)]X?A(&_[Z%-;-_P!>8F[6.THKSNT\:>)F\)VGBB\MM+736E5)X$$G MG%3)Y9=6S@JOMC'MD9%7H/%]Y=>&-(FBA M@75K^\6RDA96*1R*Q$QQG.%5'(Y]*?*T[?UO87,K7.OHKRJ[N-3C\+^+Y=8^ MPW\":LB"$I*OS;X1U$F=H!& .XZD<5U=QK7B#4];U&S\,Q:VWV6XDC#2P"0/Y;8Y&X<'ZT M6TN.^MBS1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% '*WWA*74=2\2R7$D0M]7LX M8(=I.^-T#_,>.,%E(P3TJK#X0U,Z1HRW=S;2ZA!JZZEJ$H+!9#\V0G&3@%0, MXX%=I133:=_ZT$TGO_6ECC#X=\2:?;7VE:'=Z<--O)99$FN0_G6HE)+@*!M? MEB1DKUYS2?\ "+:SHVM6EWX9EL7M[72H]/%O>LZ^9M8G<653MZCG!SR,#K7: M44)M?U\@M?\ KSO^AQ8\&7_V:PDFNK>6^_MM-5OI,,J'"E2D8P3P-H&>N,TL MO@W4/L3RVEW;PZE;ZQ-J5F[!FC(ST^%[::UOH "@E M1AE& /S!@.O;-=E11TM_6HK:W.1?PI?-X$T/11+;_:=/DM'E?];5%5S.]_5_>K"Y4 ME;T7W.YRN@^$I]*\5ZCJ$\\4EFV\:?$N=T E;S)L\8Y?&,=JYJX^'&LR:'J& MF)'H!FN/,/\ :\L3M=3;F+ /\ORGG!8,V!T6O3Z*5VAV5[G,'P_JT>HZM>6- M]!9SW=E:PV\@7S-CQ;RVY2,%3N ]>O2JVD^&-1_X2V+7=5M])L)887C*Z6&) MNB^,M(S*O QP.>3UKL**?,[W%RJUC$\0Z;J]T]I>>'M16UN[5F_<7&YK>X5A M@K(JD'CJ".G/K6?9Z+K^H^(K'5/%$FFQ+IOF-;6^G[VW.Z[2SNX' !/ 'X\5 MU=%).PVKG 3^"M;ET$:8S:9/!:ZFUY!%,SF.[C9WS%IIL95827!!Z#?GG)PO88[UVU%%]+?UM8+:W_K>Y MQ6E^%-7C'AE-3:QVZ(DL#^1(Y\V,PB-2 5&&]1T'8FHCX2\1?\(\?"JWNG_V M(5,/VLA_M(M\_P"KV8V[L?+NSTYQFNZHIN3;NQ**2LC"T?0IM,\1ZY?,T7V> M_-OY"(3N41Q[#NX]>F":?X/T:X\/^$['2[QXGGMU8.T1)4YTTRUMY"I>&%(V*] M"0H'%9MGH]Q;^--3U=WB-O=VL$,:@G>&0N3D8QCYACFMJBFVV[B225CB])\' M:A87NBS336S+87E]/*%9LLLY8H%^7J-PSG'MFK5QHNO:9XAO]2\-2:?+%J01 MI[>_9T\N55VAU9 <@@#*D#IUKJJ*+A9'*7OAS7&_LG4[?4[>YUS3Q(LCW$7E MPW"28W)A.5 P,'D_+SFK"67BR;3KV2XU6SM;^1E-K#!#YD$(4\AF8!GW=">, M=A71T47"QPT7@W4KG4+_ %&\@TC3KB?3YK-8M.W;9FDQ\\K%03@C@8/4\U#/ MX(U(3Z5-]GT;51::9%9-;:F',<+KUDC^4YSWR >!R*[^BCF:_KU_S8N5?U\O M\DY1K9"BA65>-I^[@@C&3QCFJ%QHWBFP\9:MJ M^@KH\T&HQP*5O9I493&I'14(YW'O79447=QVTM_7O:^DUAJ#:-7'M.[C'7TS6Y1 M2OI;^OZT';6YP-EX-\0:78^&OL%UI_VK1H[E95E+F.;S""%!"Y QW[''!JV_ M@R_U.TU*ZU:]@BUB]E@EB>V4M%:^0VZ)1NP6&(+FQM!8QR_9ETXNY,KH4\UBX&, G"C/)ZU@)\.]8&D6EBE MKX=M7M9H9'NX(W\Z\\MU;+L5RI.,G[^3Z"O3:*%)IW0G%-69S^G>'9(;[Q&U M\T;V^L3AD6-CN">2L9!R.#P>F:PYO#'BR72].T9KW2VT_3[FW<3_ +P37$43 MJ0K+C"G"]03D@=,FN\HI)V:^7X; XIK[_P =PHHHI%!1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 (--;5$MY]&LDDD>V?),TS#: MI*XQM5=QZ]3TJI)X$M=,\0Z5JOA2TL].>WD>.\C52BSP.,$< Y8$ C/YUU]% M.^EA-)[G%?\ "&ZA_P *JB\,^=;?;4VYDW-Y?$XDZ[<]/;K3+[P?J4GBC4-0 MBM]#OEO61HKG4HFDFLL*%VHN"&7C(&Y>2/PVMU/;/_9$-U',R,WS^8P*E>/0T^&[^)6KWUE[\_Q M%RKE44<=J?A'6;NP\0Z=#)8_9M3O$O()7D<.K;HRRL-I&,(<$'TXJ]<:+K^F MZUJ5WX:FT]H=499)8[W>I@E"A=Z[0=P( RIQR.M=512OI;^NG^2';6YQMUX= M\0QV4=BLVF>(+/[.B.FMJVY91]Z0$*VX,3G:>F.#6]X9T8^'O#=EI33FX-M' MM,F, \DX [ 9P!Z 5J4478604444AA1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%9V@ZY9^(]#M]5TTN;6XW; M#(NT_*Q4\?4&@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAKM]+IGAW4;^W5&EM;62 M9 X)4LJDC..W%7ZQ_%W_ ").M_\ 8/G_ /1;5,MF5!7DD>;Z7XY^*NL:/%JV MG>&=)N+&12RR*V"P!(.%,V>Q[5WW@GQ9'XN\)Q:PT(M6W,D\9;(C9>O/IC!_ M&O$;?PUXGMOA7:>(=-\1:E+II#&XTR"=XA%%O(8KAB#T)/R\9)YKJ/%;Z?9_ M &Q'@YI%TVXGC6=I&R^"3O$A'?> #CCL.*Z9I:I=TO\ ASEIRD[-]F_^&/7- M/UC3-6\S^R]1M+WRSA_LTZR;#[[2<5'?:_H^F7*V^I:M8VDS#*Q7%RD;'Z G M->9:#X9U6P\?Z'J#W/A#3/W++]DTB:2-[R$J>=C#Y\=<^W)XK(\27%AKMGXO MN]$\,Z:J6SNMWJNI7)>9G&1^Z0Y*'CY<$#I]*S<4C12;1Z-X[\67OAC^Q#IT M=O*-0OTMI#,K-A&[K@CG\ZZXG R>!7AVL,S_ V^'!=BQ^WP#)/H2*[O6M3^ M(,7B[[-HVA:?G>(O%FJZ1!-:QK9LJ6K_:%+79^8NR 'E0%'3/J:N:#XB9M#>\\2:QH!_TD MPI/IUU^XZ#"%G/W^O'TKC?AOI6G1_$KQHR6%JK6=T@M2(5!@!\P$)Q\N1P<5 MP9_Y('<_]A__ -D%-13LEVC^+0VVF_)O\$_\CZ$BUS29KB>"'5+*2:V!:>-+ MA"T0'4L,Y'XU)8:G8:K 9M+O;>]B#;3);RK(H/IE2>:\F\1>$]#M_BUX1TZV MTRWAM)[=_/BC0*LVP$C>!][ISGKWS4F@Q-HGCWXAVN@0K;K#9"6W@A7"K)Y> M1A1P.6/%196OY/\ ?,^:WFOQ/45UO2FU(Z:^B;?S/LL7GE6EV# M>5.03CG'M3E'E%&?-T,/2-;G>;69-9U/0VM;*8A&LK@Y@3)XG+'"MP/0=:OQ M^(=%FN8+>+5[!YKA0\,2W*%I5/0J,Y(^E>0V'_(O?%;_ *^9/YO5#Q#H6F:; M\&?"VJV-E##J+W,#-=HN)6+*Q.6ZD9 P.V.*<8IM+_#^(G)I.W][\&>G:Y\0 M].T7QOIWA^::U03AGN[F:X55M@$)53SPQ('7'!'7-='?:UI>F/&FI:E9V;R_ MZM;B=8R_TR>:\V\5:5IUU\>?#<=W86LT=U:2-.LD*L)B$?!8$?,1@8SZ"N>; M3M6\0_$#QDAM_#MP\#[&_MT2;H(!N"M%M^Z,8);MD>M)).*]&_N=BI2:D_E^ M*N>Z/+''"TLDBI&J[F=FPH'KGTJA%XDT.?R/)UG3Y/M,AB@V72'S7&,JO/)Y M' ]17D7B:"_TKX$Z987&JVVH6_VY89KNPG,L;0;F(7=@< @#\ *M>,M(T#2? MB%X%70+>UMFDND+I; .FY-CD#J3\WS=3^%-03E;SM^I+FU&]NE_T/4[CQ'H MEG--%=ZQI\$EN0)DEND4QD]-P)XSVS3K[7]'TMHUU+5K&S:0;D%QS%)3L0YMJ_E?\ST?4-9TS2=G]JZ MC:67F<)]IG6/=]-Q&:EN-0LK2P-]=7<$%H%#&XDE58P#T.XG&#D5Y?X=T_3? M$'Q2\8_\);;6]WNV1:]I%Q>I9P:K92W,B!T@2 MX0NRD9#!027=J9+B-<22%E5CN;J>?7I M7N%.45'[VB826D-_8SVE MVGF07$;12)DCZT32HK:=Q@REF=@/0%B<#Z8J&Y^'7A*\UB74[K1+>2[FR9'8MM8 MGJ=N=N??&<\UTU%%V%EL8!\#^'FTO3M.:P)M-,F\^TC-Q(?*?).<[LGDG@DB MM^BBAMO<$DMC#'@S0!XH'B)=.1=5Y_TA9'&25VDE0=I.#C.*K_\ "O?#']@- MHO\ 9G_$O>X^TM#]HEYDQC=NW9_#.*Z2BB[6P61F77AW2[W7++5[FUWW]BI6 MWE\QAL!!!X!P>IZ@TMIX>TNQUR]UBUM?+O[X*MQ-YC'> !\I.!T'0"M*BE< M+(YA?AQX136O[570K878?>#EM@;U\O.S/X5T]%%.[M8+*]S#C\&Z#%;ZK EA MB/6&+WR^=)^^)SG^+Y>I^[BEO/!N@W^@6FB7=CYFG6;*T$/G2#85! ^8-D\$ M]36W11=_UY;!9?UY[_>8GB#P=H'BEH&U[3DNVM\^4V]D*^V5()'L:@UOP%X8 M\1WB76LZ3%<7" 2AW1F Z!BI&[\X;P7+I?AO3=,F 4( MEC>1D0LG=1M(P>X.>OYUP.A^ -2N/$FAS/X4M/#-CI,QN)BM\+E[J3C&#DD# M*CACP">:]@HIQDXNXI14E8S;3P]I=CKE[K%K:^7?WP5;B;S&.\ #@G Z#H! M6=??#_PMJ6MG5[[1;>:])RSL6VL?5DSM)]R*Z.BI'9&"G@GP\GAEO#XTY6TM MF+_9WE=L$G.0Q;<.?0TV+P+XD2-+9#SY/W+%@Q/WOFY&>XA*D$CV-6KCPQHUSX<;09+"-=+ M90IMHB8UP#NZJ0>HSUYK5HI=+#MK9!ICH]HGFN/**#" MG(.3@#OFMBBBG=L226P4444AA1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 < M5X8_Y*OXY^FG_P#HEJ[6N*\,?\E7\<_33_\ T2U=K52W)CL%<5\(/^24Z-]) MO_1SUVCJ'1E/1A@XKA[;X1^'K2W6&WNM6CC7.%2_=0.<]!@4*UK [WNCN:*X MK_A5>A_\_NL?^#&3_&C_ (57H?\ S^ZQ_P"#&3_&C0+R[':T5Q7_ JO0_\ MG]UC_P &,G^-'_"J]#_Y_=8_\&,G^-&@7EV.UHKBO^%5Z'_S^ZQ_X,9/\:/^ M%5Z'_P _NL?^#&3_ !HT"\NQVM%>30>!M/D^)MWHC7^K?8HM,2Y4?;Y-V\R% M3SGI@5TG_"J]#_Y_=8_\&,G^-%D)2;Z':T5Q7_"K-#_Y_=8_\&,G^-'_ JO M0_\ G]UC_P &,G^-&@[R[':T5Q7_ JO0_\ G]UC_P &,G^-'_"J]#_Y_=8_ M\&,G^-&@7EV.UHKBO^%5Z'_S^ZQ_X,9/\:/^%5Z'_P _NL?^#&3_ !HT"\NQ MVM%<5_PJO0_^?W6/_!C)_C1_PJO0_P#G]UC_ ,&,G^-&@7EV.UHKBO\ A5>A M_P#/[K'_ (,9/\:/^%5Z'_S^ZQ_X,9/\:- O+L=K17%?\*KT/_G]UC_P8R?X MT?\ "J]#_P"?W6/_ 8R?XT:!>78[6BN*_X57H?_ #^ZQ_X,9/\ &C_A5>A_ M\_NL?^#&3_&C0+R[':T5Q7_"J]#_ .?W6/\ P8R?XT?\*KT/_G]UC_P8R?XT M:!>78[6BN*_X57H?_/[K'_@QD_QH_P"%5Z'_ ,_NL?\ @QD_QHT"\NQVM%>3 M> O VG^(?"<=_J5_JS3M/,A*7\BC"R,HXSZ 5TG_ JO0_\ G]UC_P &,G^- M#23$I-J]CM:*XE?A=H+C*WVL,,D9&I2=1P>]+_PJO0_^?W6/_!C)_C1H.\NQ MVM%<5_PJO0_^?W6/_!C)_C1_PJO0_P#G]UC_ ,&,G^-&@7EV.UHKBO\ A5>A M_P#/[K'_ (,9/\:/^%5Z'_S^ZQ_X,9/\:- O+L=K17%?\*KT/_G]UC_P8R?X MT?\ "J]#_P"?W6/_ 8R?XT:!>78[6BN*_X57H?_ #^ZQ_X,9/\ &C_A5>A_ M\_NL?^#&3_&C0+R[':T5Q7_"J]#_ .?W6/\ P8R?XT?\*KT/_G]UC_P8R?XT M:!>78[6BN*_X57H?_/[K'_@QD_QH_P"%5Z'_ ,_NL?\ @QD_QHT"\NQVM%<5 M_P *KT/_ )_=8_\ !C)_C1_PJO0_^?W6/_!C)_C1H%Y=CM:*XK_A5>A_\_NL M?^#&3_&C_A5>A_\ /[K'_@QD_P :- O+L=K17%?\*KT/_G]UC_P8R?XT?\*K MT/\ Y_=8_P#!C)_C1H%Y=CM:*\F^'W@?3_$7@:PU34[_ %9KF=I0Y2_D4?+* MZCC/HHKI/^%5Z'_S^ZQ_X,9/\:&DF)2;5[':T5Q*_"W074,E]K#*PR"-2D(( M_.E_X57H?_/[K'_@QD_QHT'>78[6BN*_X57H?_/[K'_@QD_QH_X57H?_ #^Z MQ_X,9/\ &C0+R[':T5Q7_"J]#_Y_=8_\&,G^-'_"J]#_ .?W6/\ P8R?XT:! M>78[6BN*_P"%5Z'_ ,_NL?\ @QD_QH_X57H?_/[K'_@QD_QHT"\NQVM%<5_P MJO0_^?W6/_!C)_C1_P *KT/_ )_=8_\ !C)_C1H%Y=CM:*XK_A5>A_\ /[K' M_@QD_P :/^%5Z'_S^ZQ_X,9/\:- O+L=K17%?\*KT/\ Y_=8_P#!C)_C1_PJ MO0_^?W6/_!C)_C1H%Y=CM:*XK_A5>A_\_NL?^#&3_&C_ (57H?\ S^ZQ_P"# M&3_&C0+R[':T5Q7_ JO0_\ G]UC_P &,G^-'_"J]#_Y_=8_\&,G^-&@7EV. MUHKBO^%5Z'_S^ZQ_X,9/\:S?$?PYTG3/"NJW]K?:N)[6RFFC+:A(0&5"1D9] M119!>78]'HKSCPY\.=)U/PMI5_=7VKF>ZLH9I"NH2 %F0$X&?4UHM\+="12S M7VL*H&23J4F /SHLA7EV.VHKBO\ A5>A_P#/[K'_ (,9/\:/^%5Z'_S^ZQ_X M,9/\:-!WEV.UHKBO^%5Z'_S^ZQ_X,9/\:/\ A5>A_P#/[K'_ (,9/\:- O+L M=K17%?\ "J]#_P"?W6/_ 8R?XT?\*KT/_G]UC_P8R?XT:!>78[6BN*_X57H M?_/[K'_@QD_QH_X57H?_ #^ZQ_X,9/\ &C0+R[':T5Q7_"J]#_Y_=8_\&,G^ M-'_"J]#_ .?W6/\ P8R?XT:!>78[6BN*_P"%5Z'_ ,_NL?\ @QD_QH_X57H? M_/[K'_@QD_QHT"\NQVM%<5_PJO0_^?W6/_!C)_C1_P *KT/_ )_=8_\ !C)_ MC1H%Y=CM:*XK_A5>A_\ /[K'_@QD_P :/^%5Z'_S^ZQ_X,9/\:- O+L=K17% M?\*KT/\ Y_=8_P#!C)_C1_PJO0_^?W6/_!C)_C1H%Y=CM:*XK_A5>A_\_NL? M^#&3_&N;^(/@;3_#O@:_U33+_5EN8#$$+W\C#YI44\9]&-"2;L)R:5['K-%< M5_PJO0_^?W6/_!C)_C2'X6Z$HRU]K &0.=2D_P :-!WEV.VHKBO^%5Z'_P _ MNL?^#&3_ !H_X57H?_/[K'_@QD_QHT"\NQVM%<5_PJO0_P#G]UC_ ,&,G^-' M_"J]#_Y_=8_\&,G^-&@7EV.UHKBO^%5Z'_S^ZQ_X,9/\:/\ A5>A_P#/[K'_ M (,9/\:- O+L=K17%?\ "J]#_P"?W6/_ 8R?XT?\*KT/_G]UC_P8R?XT:!> M78[6BN*_X57H?_/[K'_@QD_QH_X57H?_ #^ZQ_X,9/\ &C0+R[':T5Q7_"J] M#_Y_=8_\&,G^-'_"J]#_ .?W6/\ P8R?XT:!>78[6BN*_P"%5Z'_ ,_NL?\ M@QD_QH_X57H?_/[K'_@QD_QHT"\NQVM%<5_PJO0_^?W6/_!C)_C1_P *KT/_ M )_=8_\ !C)_C1H%Y=CM:*XK_A5>A_\ /[K'_@QD_P :/^%5Z'_S^ZQ_X,9/ M\:- O+L=K17%?\*KT/\ Y_=8_P#!C)_C7-^,/ VGZ-+X?6QO]6 O]8@M)MU_ M(A_\_NL?^#&3_&@_"W0AC-]K SP/^)E M)S^M&@[R[':T5Q7_ JO0_\ G]UC_P &,G^-'_"J]#_Y_=8_\&,G^-&@7EV. MUHKBO^%5Z'_S^ZQ_X,9/\:/^%5Z'_P _NL?^#&3_ !HT"\NQVM%<5_PJO0_^ M?W6/_!C)_C1_PJO0_P#G]UC_ ,&,G^-&@7EV.UHKBO\ A5>A_P#/[K'_ (,9 M/\:/^%5Z'_S^ZQ_X,9/\:- O+L=K17%?\*KT/_G]UC_P8R?XT?\ "J]#_P"? MW6/_ 8R?XT:!>78[6BN*_X57H?_ #^ZQ_X,9/\ &C_A5>A_\_NL?^#&3_&C M0+R[':T5Q7_"J]#_ .?W6/\ P8R?XT?\*KT/_G]UC_P8R?XT:!>78[6BN*_X M57H?_/[K'_@QD_QH_P"%5Z'_ ,_NL?\ @QD_QHT"\NQVM%>3>/\ P-I_AWP; MA_P#/[K'_ (,9/\:+*PN9WM8[ M6BN*/PLT(=;W6!_W$I/\:/\ A5>A_P#/[K'_ (,9/\:-!WEV.UHKBO\ A5>A M_P#/[K'_ (,9/\:/^%5Z'_S^ZQ_X,9/\:- O+L=K17%?\*KT/_G]UC_P8R?X MT?\ "J]#_P"?W6/_ 8R?XT:!>78[6BN*_X57H?_ #^ZQ_X,9/\ &C_A5>A_ M\_NL?^#&3_&C0+R[!X8_Y*OXY^FG_P#HEJ[6N?\ #7@O3/"MW>W.FO=22WH0 M3-.] E^,UQ-'=2L+BQCL(U^S2;C.)3E,;K54B(M.]CQGP-XVUF^^+&J#4K&]BL-28(B20L!:E0?*W MS5Q?AG_DJ_CC_=T__P!$M7:42W"%TM0HHHJ2PHHHH **** "BBB@ HHHH ** M** "BBB@ HHJAK6M67A_29=2U1WCM8<>8Z1L^W)P"0H)QDB@#FOA-_R($/\ MU]7/_HYJW_$VL-H/AR\U"*![F>*,^3!&A9I)#PHP.>O7T&37&_!OQ#IM]X;; M2;29I+NWDFFE7RF"JKRL5^8C&2#TSZ^E>CU4OB(AK%6/*O@GXEU/4+"^TS6X M[DR+,UQ#<2QD!][9=1\TAQT"C)STSCUK%^"^OZ=>^"K?1[69I+RQ$CW"^4P5 \SLO MS$8)(/0>]=MX@_Y%K4_^O27_ - -6]):F<=8:'(_!_7KO5?!,-IJ<,T=S88B M5Y4*^;%_ P)ZX'R_@/6N^KF_AW_R3C0?^O*/^5=)4RW*C\*"BBBD4%%%% !1 M110 4444 %%%% !1110 4444 %%%% !6+XS_ .1#U_\ [!MS_P"BFK:KE/B1 MKVGZ+X)U&/4I6B-_:S6L!$;,&D:-MJD@'&??T--;BEL:/@S_ )$/0/\ L&V_ M_HI:Y+XT>(+S3/"/]GZ7%.T]\=LLL2$B&('G)'3<<*/7FMSX;Z]I^M>"=.CT MV5I386L-K.3&RA9%C7L-"UX#U MVY\0>#[.ZU&"6"^1?+N$E0H2X_BP>S#!_'VKHZ@L?^0=;?\ 7)?Y"IZE[EK8 M****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXO?\DLU;_>M_\ MT?'7:5YS\:-?TZR\$W.CW4S1WE\(WMU,3%7"3(S?,!@$ =_:JC\2(G\+/1J\ ME^-'BC5K";2]-T&*YWQSINV'B/2H]2TF1Y M;20D)(T;)NP<' 8 XSD?A7-?$[_D$Z)_V'+3_P!#-$=):A/6.ATNA:I_;.A6 MFH&"2W:>(,\,BE6C;NI!]#FM"BBI+"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH *XOXB_\ 'QX1_P"QBMOY/7:5YC\4?%FCV&L^'[&\N7BN+'5K M>^F4PN0(0&!8$#!Z]!SUJH[D3=HGIU>-?$;QKK-C\2M(CTBSNY;73'W.L<3$ M73,,2*./FPAQ[$FO7-.OX-4TVWOK,LUO<1B2)G0H64\@X/(R.:Y/Q=_R43P/ M_P!?%U_Z)HCHPGJM#L;>=+FVBGBSLE0.NX8.",\CM4E%%26%%%% !1110 44 M44 %%%% !1110 4444 %%%% '%?%O_DFU]_UVM__ $>E=K7G'QF\0:=8^$9- M(NIFCO+MHI8%\IBKJDJEOF QD =,^E=OHFMV/B+28]2TJ1Y;24D1R/&R;L'! M(# '&0:IKW2$US,\T^,WBG5["]TK3M!AN=T,Z74LT<3%6D!_=QY YZ$D?2O3 M=%U(:QHEIJ'DR6YN(@[0RJ5:-NZD'T.17,?$S_CR\._]C!9_^A&NUH?PH%?F M84445)84444 %%%% !1110 4444 %%%% !1110 4444 <5:_#NSMOBG<^*P% MV20AHXL?=G;(=_\ OD9^K&NUHHIMMB22V.+\,_\ )5_''^[I_P#Z):NTK%TS MP]_9WBO7-:^T^9_:PMQY/EX\KRD*_>SSG.>@Q[UM4,459!1112*"BBB@ HHH MH **** "BBB@ HHHH **** "J]_8V^IZ=<6-Y&)+>XC:*13W4C!JQ10!R7P[ M\$Q^"-!FM2XEN9YV>68#[R@D(/\ OGGZDUUM%%-N[N)))61Q?PJ_Y$V3_L(7 M7_HTUVE8OA7P]_PC&C-8?:?M6ZXEGW^7L^^Q;&,GIFMJA[BBK)(****10444 M4 %%%% !1110 4444 %%%% !1110 4444 %5=3TZWU?2[G3[Y-]O=1-%(OL1 MCCWJU10!RGP\\%IX(\-FQ9UFNIIFDGF44? M\JZ2LWP[I']@>'+#2A/]H^QPK%YNS;OQWQDX_.M*A[@M$%%%%(84444 %%%% M !1110 4444 %%%% !1110 4444 %8OB_P .0^*_"M[I,V TR9B<_P $@Y5O MSZ^V:VJ*-A-75C%\(>'8?"OA6RTF'!:%,RN/XY#RS?GT]L5F?%+_ ))?K?\ MUP'_ *&M=;63XIT+_A)?#%[HYN/LWVM GF[-^WD'ID9Z>M-/6[$U[MD7['_D M'6W_ %R7^0J>HX(O(MXXL[O+0+G&,X&*DI%!1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %-_#8L5=8;J&59()F'"63ZY QZ9-=G133:V$TFK,1$6-%2-0JJ,*JC ]*XOQ=_R43P/_ -?%U_Z) MKM:Q=7\/?VKXBT35?M/E?V3)*_E>7N\W>FW&<\8Z]#0MQ25T;5%%%(H**** M"BBB@ HHHH **** "BBB@ HHHH **** .3^(G@J/QOX>CLU=8;J&99(9F'W1 MG#CZ%<_B!71Z=86^E:;;6%DGEV]M&L4:^@ Q5FBG=VL*RO7AW_L8 M+/\ ]"-=K6+XF\/?\)%#IT?VK[/]AU"&]SY>_?Y9)V]1C.>O/TK:HZ"2U844 M44B@HHHH **** "BBB@ KF]?^(/AGPQJ0L-Z7XAGN+)&N))#;PLIVCDEU.XG)_*LK1 M=.M-3^+YLM:\%Z=HRQ:0S&P AGC8[QB3Y5"YP<>O%9M13^_\#52E9/O;\3L? M^%Q^!/\ H.?^2D__ ,11_P +C\"?]!S_ ,E)_P#XBO&-)^'%M=Z/;:MXAU^+ M0X-1NC!8H;5IFE.2,G!&P9'4\>N.,LLOA9J#:_K%EK%_!IUEHR"2\ORC2*%* M[EV+P6R.W&/K@&N2/4GGJ7T1[5_PN/P)_P!!S_R4G_\ B*/^%Q^!/^@Y_P"2 MD_\ \17E^A_#?0[?QKH*W>OVNJZ7J4)GMT$+(\[#HC1[MRJ>3N/&4*D#O8U+ MX8:+K&O>)+RP\20V5GILI>YC73F5+;EBR#YAG:%XVC!Z"DXP0U*HUTZ?CK_7 M_ /2/^%Q^!/^@Y_Y*3__ !%'_"X_ G_0<_\ )2?_ .(KQ:Q^'FFWEKJ&KMXH MC@\.6;K$NIR6+[IY"%R%ASNP"V,Y[=.N)6^%4O\ PEFC:;#J\4^F:U&TEGJ4 M4).X*FX@QEA@].,]#ZY KV<;V_KN3[2I:]CV3_A\UFV\$6&G1:9'-J5DTADM[+R&50D9+3/N;S" >N!SGCFDH1>W M]:-_H#J5$KM'JO\ PN/P)_T'/_)2?_XBC_A3(FT'./O*,]#TKY!KV;] MG?\ Y"&N_P#7*'^;T2II*X0JRE*S/=:SYO$&C6TSPW&K6,4J'#(]RBLI]""> M*T*^3OB=_P E-US_ *^?_9141CS,UJ3Y%<^G?^$FT'_H-Z=_X%Q_XT?\)-H/ M_0;T[_P+C_QKXXHK3V2[F/MWV/L?_A)M!_Z#>G?^!-9(I+V%71URK N 00>HKZ/G\.VA\3?VOZN/$B:9I&FZE):@M;&8!1MQ@ALL/="BOMG?^!,7'AC3$NO'YT:;2[J&SMVE=9]*.ZU?][F*$[QL*[1\X!!XXXK'TOX317% MKI2:SXCATS4]7C,MG8FU:0LH7<-S!@%./4?F>*.16OZ?B.4Y*7+;O^![_P#\ M)-H/_0;T[_P+C_QH_P"$FT'_ *#>G?\ @7'_ (U\WZ7\.8GTF]U?Q'X@M=)T MNWN3:QW441N1<2 XR@4C*]>?8\<5C>,?"EUX.UYM.NIDN$9!+!<1C"RQG.&Q MV/!R/Y]:.2/<7M)I-V/JG_A)M!_Z#>G?^!G?^!:T*^5/A1_R5+1/^NK_P#H MMJ^JZSE'E9M3GSJYB>(_&&A>$EMSX@OOL@N2PB_'6L/_ (7' MX$_Z#G_DI/\ _$5Q?[17^I\/?[UQ_P"TZ\/JXP35S.=64961]2?\+C\"?]!S M_P E)_\ XBC_ (7'X$_Z#G_DI/\ _$5\MT57LD1[>1]2?\+C\"?]!S_R4G_^ M(H_X7'X$_P"@Y_Y*3_\ Q%?+=%'LD'MY'U)_PN/P)_T'/_)2?_XBC_AR0>WD?4G_"X_ G_0<_\E)__B*/^%Q^!/\ H.?^2D__ M ,17RW11[)![>1]2?\+C\"?]!S_R4G_^(H_X7'X$_P"@Y_Y*3_\ Q%?+=%'L MD'MY'U)_PN/P)_T'/_)2?_XBC_AR0>WD?4G_" MX_ G_0<_\E)__B*/^%Q^!/\ H.?^2D__ ,17RW11[)![>1]2?\+C\"?]!S_R M4G_^(H_X7'X$_P"@Y_Y*3_\ Q%?+=%'LD'MY'U)_PN/P)_T'/_)2?_XBC_A< M?@3_ *#G_DI/_P#$5\MT4>R0>WD?4G_"X_ G_0<_\E)__B*/^%Q^!/\ H.?^ M2D__ ,17RW11[)![>1]E:%K^F^)=,&H:+&0E6'V2;@C_@%-_P"%Q^!/ M^@Y_Y*3_ /Q%?,>H?\A*Y_Z[/_,U7K?V:.;V\CZD_P"%Q^!/^@Y_Y*3_ /Q% M'_"X_ G_ $'/_)2?_P"(KY;HH]D@]O(^I/\ A1(F$! )RR@=6%?(U>I?L_?\C]?? M]@Q__1L53*FDKE1K2_9%N2PB/DN^[;C/W0<=1UK M:KQ?]HG_ (\] _ZZ3_R2LXJ[L;3DXQNCL?\ A/?#?BJ^DL]!U'[5<1Q&5D\B1,*"! MG+*!U(KHJ^>/V?O^1ZO_ /L&O_Z-CKZ'K&2Y78Z*&=2_L_ M6]3^S76P/Y?V>5_E/0Y52.U9O_"X_ G_ $'/_)2?_P"(KR/XZ_\ )2#_ ->< M7_LU>;UK&FFKF$JTE)H^I/\ A,]!\6-<+X?OOM9M@IE_ MAZ5N5X=^SK_Q\>(/]VW_ )R5[C6,E9V.B$G*-V%?-_QY_P"2BQ_]>,?_ *$] M?2%?-_QY_P"2BQ_]>,?_ *$]53^(BM\)YI11172<9[A9>+_!M[X*T"PO_&6L M:-IJIH_B;P;H'Q%CU2'Q3J6IVTFG20S76HB M65U?T^&_B9I[^#]/TR?Q--X#SX!"S%E7"G#9 P?F'3/>APB[M]=/Z^XKGGH_F=9: MZGX%\+^*_#%QH-S6Z)(&!&1&WS C.<#C'J>FU?>*?"5KI/C:.P M\0?;9=>!F@3[%+'MOM[C'/06_Q \.:?XG\)Z;8W MDK:)H*2>;J$L+ S.T1&0@&X#)].I]!D\ ?!&J'POI>N1/;RP:I=_9+>%7(D\ MS+ 9R H&5/.>XJ_;?#+6KGQC=^&EN+%+ZTMQ<2,\C^7MPIP"%)S\X[8Z\U3L MI._]67Z((\UM%_3?^9N>'_%VAV-U\0'NKW8NL+,+$^4Y\[<92.B_+]Y?O8ZU MI1_$G1-+NO US;RM=C3+![74(TB96BW)&O&X ,05/3/3W%>044**7]>J_44I MMJW]='^AW_B6/X>PZ-JDVE:G0,GCIR:X"B MBE&*BK(4IS?L[_\A#7?^N4/\WKQFO9OV=_^0AKO_7*'^;T3^$JE\:/= M:^3OB=_R4W7/^OG_ -E%?6-?)WQ._P"2FZY_U\_^RBLJ6YO7^%'*T445T'(% M%=?X5^&FM>,-#N=4TJ>R2*WD:-HYY'5V8*&XPI'<=2*/!OPUUKQO8W%WI4UG M##;R"-CQ'YTFTKWZ#Y7IYF!H%U#9>)=,NKI]D,%W%)(V"=JJX M).!ST%=;\0O'U[J?C"^D\.>(=0_LF546-(IY8HR-@##8<=\]N:X21#%*\;8R MK%3CVIM)I2LRDY0O'^M#N=.\1:5!\$]5T"6ZVZG<:@LT4'EL=R#R^=V-H^Z> MI[5UWAKQYX;M?!WA^T;7[K0WTV4/>V5M:,QO2#GEU' )Y//(R".E>,44VKZ^ MGX:"4FFON^\]DG\>>&+_ ,0^+].O-0:/2=>CC,&HQV\C>4ZQ!3N0@,>1V';W MR,6RU7P+X6\9>&;G0KBYNUL\_P!HZAY;JDA92NX1M\P(SDXXQC&XUYK14J"3 M3]/P&YMW^?X[GKI\3>%=/_X3LVFOB\_MZU9[;_0Y8\2MYN8^1VW+\QP#GVI) MO$'@7QE:>'KOQ7JN>W'6O(Z*.5?E^&@Y5 M'*5WY_C_ ,,>Q>%OB+HMGX7NM"L=8NO"X@NWEL;N6T%YNA9L['4 _-R?IQR> M<\3\1?$11QL^"22 B+A>>,C/KZ5R=%'(KW%[27 M+RA116S:^%M1NO"-[XD3RET^SF6%BS_,[L0,*!Z;ESG'7C/-7TN1:YC4444 M=A\*/^2I:)_UU?\ ]%M7U77RI\*/^2I:)_UU?_T6U?5=<]789Z4_Q!X%\2>%K:*XUW2WMH96V+()$D7/H2A.#] M>N#Z5Z'\&I+6+P/XJDU"^N-/M5V&6ZM6(DA7:WS*0"<_0&I]6\7^&9-#L_#& MCZQJ?B5M0U.!Y9]4+/Y2"1"5RZKD';PH!'+9/8Q)OGY5Y?B7!1=/FEY_@>*T M5[1XO73Y_B9#X,T?PAH[0R/"\K)$+>5SC>0)5!V)M SA@:GX M"\2NUCX?CU#2B6']BVQ3[,PR0C2X'F''7"@ Y&,BI=1*'.7[)\W+<\%J_%H6 MIS:'/K*6 >,8Y;!X@BB^ -Y=6^AZ:D4=Z;=+6:'S%"D@!F MZ;I #][CD XHE.R;7]:V)5/5*7]:7/)]:\-ZMX>%H=8M?L_VR(30?O$?>GK\ MI..O>LNO?QX*T#4?&7AN*72[9((]%-Y)!#$L:W$@* ;\#YOO9YZ]^,BN,-]H MWCFUTRSE\)1:+3&>"!V(ZD546V[?UO8GE]U2?; M]+GF=6M-TV[U?4H-/TZ+SKJX<)%'N"[CZ9) 'XU[QK?A[PDC:KHE^/"&F6D5 ML%LI([A4U"*4*,&3."S6 MIU$1M9M,S1"+ W_(3@87)SVQ6E+H]A8^)/%^KRZ7H?V**_57U#66,T<655Y% MCMPN7?+'^),Z/HNHZ_J26&CVDEW*I.AC=D<893@CWKZ:T[3M*T/XIVL>C:98P)J>E--(\4&S:48 M >6/X P;D=\#OG/#^'3:7>FZIXEU70?"VGVTMX(?M5[$7B15 !6*U ^9C@DG M>"2>^*:G=Z?UK8/9))Z_U:YXY17H?QHT/3=$\96XT>TBM(KFS29XX5VINW,, MA>B\ <"O/*J,N97,YQ<'9A1115$GTO\ [_DFB5R2^)G?#X4?%FH?\A*Y_Z[/_,U7JQJ'_(2N?\ KL_\S5>NHX H MHHI@=O\ #OQ)I&DW0TW5O"]EK+W]U&B3W(0F $[> R-GKGJ*[;QS_9=]XGG\ M >'O!NEP:A<>6(M2C6.(QY D8X$>0 H.<'I^5>/Z)<16FOZ?U>@ZGX_TNT^.'_"4:=(][INU47R]0MUM6B:'G!(R3N .>>F >>, M5U'C/X>Q:[X^T_3M%AL](M$TI;F[GC@")&H9@6(7&6Z?EUXIOC+XA6-SX>U6 M&Q\9WVK/?,T<%C'IT<$<,3=5D=X]S8'&5(/3ZUI-\5_#]KX]AN(+Z233KC2D MM)KF*W;=!*KL0VU@"0 QZ ]1UK)<[_KR?Z_\.:?NTFOZ^)?I_P ,<2? =II] MUX>UG2]6@U[1+S4HK9Y#;-$0^_E6C;/! /7KZ=,]5XJ^&&D:YXZU*ST76K+3 M]1%N)X=(ALB$"A%'+KA5)/. "<'.#5'Q#X^LYAHMJWB^\U[R]0AN+N8Z?';0 M1HCYX01B3=]&(X/TJ:R\=>'(?CG?^(9-1QI7<%R)/Y?GZ]CF=$^&\%UH-GJGB37XM#CU"X^SV2-;-,TK9(R<$;1D=3 MQZD<9@M_AZEOXFU/2?$FO6>D#3@I,A4RO<%AE1%'D,_'IR.!BNW\/?$W3I/" M-AILWB>;PY=6$I621-.%R+J')P%^5MIQCDCKV/:'1_B/HTNJ^)6NM=O-/GO$ MCCL=9N+-)9@BC!!2- !SR!@<=P0*IN5W9?UI_7Z:$N,%I?KO]_X?ULRV\5>%]3T7QEHVH:RVG)JNIM=6UT;224.A8$?*!D? M<[X^\/>HES-/Y_FOZ_IFL/9JWR_)EO6?!'A_5/#/@HSZE9>'YKRT2,-'8[Y+ MR9UCQNVX]_F8]6]Z\O\ %'A^?POXEO-'NI%E>V< 2*,!U(!4X[9!'':NTU_Q M7HEXGP^6UOO,_L98Q?8B<>5@Q9ZK\WW&Z9Z5@?$O6K#Q!X^O]2TB?[1:3"/9 M)L9,X10>& /4'M6KOS^5W^>ABU%Q?=)'*44459B%>I?L_?\ (_7W_8,?_P!& MQ5Y;7J7[/W_(_7W_ &#'_P#1L51/X673^-'T37B_[1/_ !YZ!_UTG_DE>T5X MO^T3_P >>@?]=)_Y)6$/B.NK\#/#****ZCA"BBB@ HHJUINFW>KZE!I^G1>= M=7#A(H]P7WT M:#SVA/VB%=H(Z?.9%'/I5#QK\.Y/"MI8W^GZK!K6FWS>7%'_ (#?;M3T>WUF :BRFUN-NTDD8/*L./I6?IGC2X\>^.O# M>CZ7;0>&M/LY6EBBMTCEVN$8DC2[WU_- MI'G-UX8U^Q6-KW1-2MA+((HS-:2)O<]%&1R3Z5 =%U1=5&F-IMX-0/2T,#>: M>,_ZPQN)(VVF0&:5B#[$]1WKKQJM]+\ M=+K2GNI3IZZ/N%MN/E[BRG=MZ9Y//7'%5.3@VGYK[E<480;MZ?B['SGIVA:M MJZNVDZ7>WRQD!S;6[R!2>F=H.*99Z1J6HB] %K!\,_#1T>/Q RK=DR+H6S,8SVI+#4?)\4_$/4+" MUFTZZCTZ*1XYC&S1RB-SGY&9>P/7KG-*52S:]?P'&C>R>^GXGB4?A+7CJUGI MT^D7MK#;WP7K7V&Z\R:(HI2Z\ADCE;:" MP4GKM)Q_05Z5::SJ-S\)/"^HWFH7$EVFOHGVJ24F0*6<$%R3G8N_9GCKUQ^--R?,E_73_,%3CRN7E?\ &WZ' MFU%%%:& 4444 >J?L_?\CU?_ /8-?_T;'7T/7SQ^S]_R/5__ -@U_P#T;'7T M/7-4^([*/P'S9\=?^2D'_KSB_P#9J\WKTCXZ_P#)2#_UYQ?^S5YO6\?A1S5/ MB844451 4444 %%%% !1110 4444 %%%% !1110![5^SK_Q\>(/]VW_G)7N- M>'?LZ_\ 'QX@_P!VW_G)7N-7:Q^6B^6N ,9 !/0=+]>N1I M?F:C(ITA/+L6B58VA7 & 5 )X4#G-0HV=_/]'^.IK*:<>6W1?G^1Z]XNNM/\ M1^$=:M+W5WUF]M[W;:3C1)8%L7WJ# 9-I7'09)!YYSQ75Z.VW6I_"NJW4=T( M]-!?3K331#901\#!9RS.3GC!VX!R :^?]>\?^)_$UBMGK6K27%NK;_+6-(P3 MVSL49_&KR_%GQNJ0J->DQ",+F"(YXQ\V5^;\<^O6L_9OEM_6UBO:KFO_ %N= MYI=[<:5\-? LUA)Y4@\0&+.T-\KO,C#G/56(KIK35[VZ^/6IV%S*)+6PTMOL M\111LW^2S<@9.2.^:\$G\5ZU<:/;:7)>D6=I<&Y@CCC1/+D))W!E /5CQG K M6D^*?C*:^BO)-8W7$43PH_V6'A'*EA]SOM7\JTDFY-^OXH:JQ3?;3\[G8RZW M=^,O@9KU[K@AEEL+Y!:;(500+F/"K@#@!B/7!ZUY!6G;>(]5L_#UUH=M=;-. MO'$D\'EH=[#&#N(W#[HZ'M691&-F_P"NAE*2E%+J%%%%60%>S?L[_P#(0UW_ M *Y0_P WKQFO9OV=_P#D(:[_ -(]5MO# MMQH4%UMTVYE$TL'EJ=SC!!W8W#[HZ'M6JWQ(\6/K<6KMJQ-]# ;>.4P185"< MD;=NWKWQFHJ1&_#^A&XOUM8=6U!A';Z=I M^^:Z)? \V9R5 Z@*#M'!X-7;3R=%\:_$>>RMH5$5C%/Y10;&?RF8Y7OD\GU MR:\;TSXB>*]&THZ;IFL206A9F""-"5+')PQ7*\\\$=:;)X_\2S76HW$FH@RZ MI"(+QA;1#S4 ( X7C@D9*@VW;S-8UH\UVNM_Q/4$:]\??#OPM>ZHEE>ZJ MVL^4LUU -A0%R0RIMRN%&5&,[1]:W=8NTU?P;XTL-0O)-4DTVW?<6L%M[:"0 M(Q58@*SM+@7,"(B@I)DG<&QN[GC.* MU;WXI>,M1MI[>]UDRPW$+0RQFVB"LAX(P$Z\]>M$H-II?UM_D3&HM+_UJ_T: M/3KO4[[PQ)X"T3PU:PMI>HQQM#T'(KDM<^)&I'X@:EX@\+7<^GI=;4"LJG>JJ%& MY#E2>I]LT2BW)_/\_P"D.$E&";\M/Z^_U/5+";3+_P"(_A74;666ZOY[*=;F M^;3I+1;P"-=L@#* >I^Z3P1VQ5)/%^H7'@+Q=J5Q':R3Z-J3IIN;=,6O(52H MQ@E=Q()YKR5_B!XHD\11Z[)JTCZC$ACCE:-"J*1@@)MVC/L/>JB^*]:32M1T MU;S%IJH: OMVCC^\Z:IXHU"S^,FA^'[?R5L+VR#7*F)2TO$F,MC/&W@9QR:QM0U_4M'^%_BHZ M9.ML-.UF2RM%2%-L4)=/D QC'SMUYY]A7D4_CCQ#=>)+77I]0W:G:1^7#/Y$ M8V+SQM"[3]X]1WJ:P^(GBG3/M_V+53&-0E::Y!@C82.WWC@J0,^V*CV?NM?U MNG^5U\QJHE_7E_G9G-4445L8'8?"C_DJ6B?]=7_]%M7U77RI\*/^2I:)_P!= M7_\ 1;5]5USU=SKH?">*?M%?ZGP]_O7'_M.O#Z]P_:*_U/A[_>N/_:=>'UI3 M^$PJ_&PHHHK0S-[1O%]_HGAW5=&M(;9[;55"SM*K%U !'RD, .O<&LBRNWL- M0M[R$*TEO*LJ!AP2IR,^W%:W@FWTR\\;:7::[#Y]C<3B&2/>RY+?*O*D$?,1 MWKT[P[\,="_X3KQ-'KUH3I-C/'#:1M,Z+NE(*C<&R2 5')_BJ=%*_7_+_ARH MQ.3G[HXZYV$\":/I&D^.KS6;3S1I]1> M#C9[6_/4U?M$]]?\M"/3OB[K^GV-G ]II=[<6,;16M]=VQ>XA4C&%;<.W'3G MOFJ6G_$C5[+1;_3+NUT_5;>_N'N9O[0@,A$C=6&& '(STX-3:7\,-4U/PQ;Z M_)JNCZ?83EE#W]RT6PABN#\N,D@XY-36?PDUZ\LH)A=Z7!/=H\EG9SW12>Z5 M1G**5Z$<\D8[XJI*-VG_ %U_X)"YU:Q5G^)_B"76-)U.'[-;7&EP?9XO)1ML ML?&5<%CG..V/;!P:=K7Q/UO5].6Q@M]/TFW%P+ETTVW\KS90P8,V2>0P!XQD M]L M:9IT0MM1DU5-]G+8S;XYAU.&('0$'/3!SFBT>:W7_/45I1CY?TB]>_%O7[W3 M[F'[+IEO=W< @N=2M[79H!!_6NEUGX6ZUI&EWE]%>Z7J:6#8O(M/N3));=/O#IFG'EO[N[%-2:M+^NATUQ\?/%DUM M)'';:7;NZD"6.!RR'U&YR,_4$5SFA?$35M#T^^L9+:PU6UOY_M$T6IP&93)U M+]1DD@'G/(%6H?A7K>/3&#CBKU_\(=?L;&\F6\TJ[N;&(37-A:W)>XB4C/*;1VYZ\XXS2O"U M_P"N_P#P1>^VU_7;_@&'XM\8ZAXSO;:[U>*V2>WA$.^!&7> 2K"BBBF(^E_@=_R3.'_KYE_G7HE>=_ [_DF';K7+2S\W3K-]D\PD3*'C^'.[^(<@5DUZ;\&+V.[O=9\*WC[8-:LG5,GH MZ@C@>NUF/_ 12=^5M;CC9R2>QP^G>&-7U71KW5K&T\RQL!FXF,J($XST8@DX M[#/;UK*KV:YTEM ^&_ASP=??Z->>(=47[9L/S"/S ,Y]<>76_J_AWPA%/J.A M:BOA'3;".U"6TBW*IJ,J* M]A>YT?PQ\)_"^K'PQI&HWEU*8Y7N[56W+EBK MP03+91^7"29(EWJI)Q\I /N">]3/#X=M_B=%\/QX2TQ].:#RS=-%FZWF,R;_ M #>N.WKWSVHG_!L>%T5[3+H6E:M>V^KS M6<4]]:K+N D<9&4445U'"%%%% !73_#;_DI6A?\ 7VM+?"7AGQA?WUYXLUR>]@+ MA]'+R-;AMOW578%^GS8SWK#\*6NGR:;8ZGK>C>';1-)&D]U)YCK$"%!]@23^M=)H_P 4=;T; M0;72H[73;I+)R]I/=VQDEMR>Z'.!C)P<=\5A&%HJ^^G_ 3>52\G;;7_ (!W M>H>%]#N]4\;^%=.TRUBO8HDO]/98E\U3L5G16QD+NQ\H.!N-26W@W0GU_P * M>#[RPMA<6]DVH:G(L8$D[D<1EQ\Q&XL2/0"L/P3KQ\0?$IO&>O:OH^C"W7;/ M 9S&UP/+*C8K$Y[9Y[#BN3UOQM>S_$FZ\4:3.8IA<$VSE9-1?;\M%_7D5*46G)?UM?\ 7[SOO&>E^&[KPGJC32>$;35+.X+6*:+<*KO' MN ,?]4]=\=Z MQKWBFU\02>19W]JB+$UJA"KM)(.&+9Z_3VIQB[*_1_HA2FK.V_\ P3TOQ79: M3JWAO59O"VA>&M6L%@6:*;2F6VO+$;22\J8)8V=J4GE&,'+ECVXSCC/&*X6B$6F[DSDI6L%%%%:&84444 M %?8?A#_ )$C0_\ L'6__HM:^/*^P_"'_(D:'_V#K?\ ]%K6-78Z*&[-BOBJ M\_X_I_\ KHW\Z^U:^*KS_C^G_P"NC?SI4NHZ_0AHHHK]_$#X?:6^M:1JN@Z=:QQVE]!;ZC:00*J& M-G4AB@&#][!]01Z5S'B?P!#K/Q.UZ.T>UT31=+MXY[J=(!LA!B!^6-<9)()[ M=#WP#C&HG_78Z'1DOZ[GGDWB?7KD3+=:YJ4RSQB*8/=R-YB#/RMD\CYCP?4^ MM=3X@\::(/A];^$O"-OJ,=JTYFNIM0*;W.=(I'[EE!RA//.>-IR!5OQG\.]*O-4\3WOA[5HEFT MI%GFTJ*P,:Q#'*AL@'@$\#OBB4H[/^K6_K_AT*,9M_UU/,CJVHM8P6;7]T;6 MW?S(8#,VR)N3N5'%&HAVUF18Y0;*HM/TJ* M[:TMKHV;2/!C-MJ^O]?U^)*C*UT<3I^O:OI(D&E:K> MV0E.9!;7#Q[SZG:1FH[?5M2M!X*.-PVGYLGDX]\YK8\*>#M!N/#WBVTT.Z@ M\3W:V:""8V'EF&4^8 (RY)[ [A@=.:3:LY>7ZV*4)7/*#J=^VFKIS7UR;)'W MK;&9O+5O[P7.,\GGWJ34-;U75UC75=3O+Y8L^6+FX>0)GKC<3CH*[&7X7!?% MVG>&+?789]5G7?>HD!\NS 7<1NW9=L=!@=LXS5/Q3X'TO0=.N)].\4VVH7-I M<>1<6,UN;6=3QRJ,Q+#D<@8QSDX-'-'^ON_ID\LON_XK__ +!K_P#HV.OH>OGC]G[_ )'J_P#^P:__ *-CKZ'KFJ?$=E'X#YL^ M.O\ R4@_]><7_LU>;UZ1\=?^2D'_ *\XO_9J\WK>/PHYJGQ,****H@***5-A MD7S"P3(W%1D@>PH$>^_"33CX>\$VM[/IUS(+T1/Y4#-Y4&&"L^!PN@MX9^/TFDG=LMQ-Y1;JT93 YI]+TRTMEA\ MNXMH6=F''?=@8 Z'UJZ?BKH,_C70O$MS9WXN[6R>WOPD28=BO!3Y^0&+=<<$ M5GKSN7>Z_#3^O,V?+R*/:S_'7^O(]+U%M76PU<_$$^'AX;\APOD^;YN=PV;M M_&=V,5Q.I:%%XE\#?#K2)[G[+'=':TO&0!$3@9[G&![FO&=5NDOM9O;N M(,([BX>50PY 9B1GWYKN=0\>:!J'A;PMI-YI5U?)I(Q>0R/Y22C9M^5T;=P> M>@Z5FH/E7R+=1-M>3_0=XZ\$^&?#>G7 M)];LM1AGV11:G &BO%&,M%)&NWH MP/)SQ@@&O.:]2UGXD:!_PA^JZ/HRZ]?G4B%5=:F62.T7_IF0Q;CC /H#GCGR MVM(7ZF<^6RL%%%%:&84444 >U?LZ_P#'QX@_W;?^XUX=^SK_Q\>(/]VW_ M )R5[C7+4^([:7P(*^;_ (\_\E%C_P"O&/\ ]">OI"OF_P"//_)18_\ KQC_ M /0GIT_B%6^$\THHHKI.,*Z_X7:'IWB+QY;:=K-O]IM)(Y&:/>R9(4D!O ^LZI M<:/%X)\0Z6^)%74)TE2)2O\ $K-(P.>V00:\RTGX:ZIK$-W=Q7VG66GP7)MH M[V_G\J.X<,1\F <__7P,\UW>D?$=?$]QK7AGQ-K0L8YI)?[/U:&80!,$[59E M(!7'3/7H.'&N8DMI4+L?,B;(#'YN"/0YQD& MN:'-9-]E_P /\O\ @]#IDHO[W_7G?_@'GUK\-?$=UXPN/#@MXXKJV7S)II'Q M"D?9]V.AR,8&?;@X76/AMKNDG3F@:SU6#4Y!%:W&G3^;&\AS\N2!SP3GI[\& MO18/&VDZEXT\0:7JFMV/EZAI@L(M2AMS!;AU\S^\[.H)P;#^PO M 6I>%KV[\4)K%S:SRBXMK*?[3;6\3[AO0@#:1D$C&6/TYN,F[7_KEWUQ8H)+JQL[K?<0 C/S)@=O?GMFFK\+-37PY::W M>:SHEC9WD(FB-W=-&3E=P3&SEL9X&>E=KI\V@^#_ !1XB\7R>*--U*WOXI/L MMG:S"2X#U]*2DVTO3IMN5R0O]_SM:WWDGAGX2W\NI:-/K\NG1PWK+(=+ENS'=2Q= M6(4 =%Y.&R![\5RWCW2[/1?'>JZ=ID/D6MO*%CCW%MHV@]223UKU:\N?#_B; MQIX:\8Q>*M,LK:UA1;BSNK@)/&RL< )[EL$G &1D5Y?\2+NWOOB+K%S97$5 MS!),"DL+AU8;1T(X-.\O:)>OYJQ#BE%V\OR=SF****U,@KV;]G?_ )"&N_\ M7*'^;UXS7LW[._\ R$-=_P"N4/\ -ZB?PFE+XT>ZU\G?$[_DINN?]?/_ +** M^L:^3OB=_P E-US_ *^?_9165+(9[B8QFUT\LS0 ,1]U64G/!.2>HX')KR.O6/AVNDIH$/IO#&K M*Y^V6]ZT;V\F<@,L;[5)P!SEB/R-*7PNQ4/B1EZIX*T/Q+XP33_A]?+;.\#O M-8:BLT;6TB8#1@LI)/)XYP5;GI7.:7X)U75="U35HS#!;Z8PCE6%>A^//&^EV'B;PO>Z=J,.LZKI/%]?VR!4F0@97Y?E.06. 2%R:L M?%^YL?#VEV.B:3(]LNJ7[ZI=O%]X9(P<9&>3D#(^X*SC)Z+OI^/^7?L:R@KO MRU_#_.WWG(7/P>\0V]G,PNM+FO;>W%Q+ID-T6N44_P"QMQQ]<''!/%:$WPYT MY/@];:Y#?6+:I,_G&5KL[67:Q\B-0,&3@#:>=P(S76RWF@:Q9%_&WB+PQKVF MK9[H[U$^SZGNSN"[%.0!D_*,$]QUS@:1J6F7'P?TN&'5=/BN]&U0WTEG=W"Q M2S(C,^U%/WF8, .VI M7_C'2AJ4_B/3-9\(PVKVH(FEM&EU)FX'EE ZL1Q^''&!FN.O]^*\_KWFS\1Z./CQK5_)K-B+%]+$<5RUTGEL MV(_E5LX)SG@>]>#4XN3W[?JQ5(1CM_6B?ZA1116AD%%%% '8?"C_ )*EHG_7 M5_\ T6U?5=?*GPH_Y*EHG_75_P#T6U?5=<]7_WKC_ -IUX?6E/X3"K\;"BBBM#,DMYY+6ZBN(&*2Q.'1AV(.0 M:]P^*/CC2G\'VA\.W]I)?ZA97>,QJI!;'0@J@Y]/:O"Z*F2O;R=RH MRY;^:L>X?$_QCH.H>#+&/3;R"=M6NX;F_@@E5I%147(8 _*>$&#@\?6NFT?6 M_#>D:[G2]>\,V&@3VH6*UMF2.9Y< [IF[8 (&2/O8(S7S314\BLTOZTM^'0K MVCNG_6]_QZGI'B?4K&3X)Z#IT-_:RWD&HS-+;QSJSH-TN"5!SCD<].1ZUWX\ M8Z3JZ:1K5AJ?A.S^S6NVX;58"][;.JYVQ*&4L.2, COC.<5\\44W&[;[NX_: MOFO_ %W/5+CQ)97_ ,)_%X?4;7[;?:SY\<*L(GE0O&=RQ%BP& 3C)QSSQ6Y: M>-=#T2'X?7%Q?6\T=K920W8AD$CVQ:- "RKDCD=,9ZUX?13Y5_7I83J-N[_K M6Y[';2Z+X$MO%FIR>(],U=]71X;.TLIQ,S[RQ!D ^[C//;KSD@5>EET+Q,_@ M;6AXHTFQ32(XOM5M_XV_P D>X'7X9/B-XI?2?%VD6\5SY9%KJ4:R6-\ODJIS,&^7!)! Z^X! GL M->\$^%_'FFSP3:9#=7UB\&I2Z6Q>RBD)C*D=E4E6''3.6QUKPBBGR[>EOPL/ MVCUT\SV3Q3X@@TWPLFF1ZUX6M_M5]')Y?ANR+&)4=6\XL)-H8;1\I&3T!ZD: M>H7?A_5]-N9?&VN^&-:LULQ]FO[1?)U-GZJ#&"<8+'Y1^(ZX\(HIB5YW\#O^29P_\ 7S+_ #KT2N27 MQ,[X?"CXLU#_ )"5S_UV?^9JO5C4/^0E<_\ 79_YFJ]=1P!1113 *O:)K%UH M&MVFJZ>5%Q:R"1-XRI]0<=B,@_6J-% '1>*_'&K>+]9M]3U Q6\UL@2$6H9% M3!SN&6)SGOGL*V+OXN^(;NQFB-OID-[<0"WFU.&UVW4B=P6SCGV'&>,5PM%3 MRQM:VA7/*][F_J/C#4-3\*:9X?GAMEM--O8"MAOBSXB/B MX>(8TLX[@VPM9(%B;R98P20&!8G.3G((_GGB**=E_7F)-I61VFK_ !/U;5O# M4FA#3M*L+%Y%=$L;=HO**L&^7#8&6&>GO'6N(HHLMA:SJEQJ.I3&>ZN'WR2$8R?H.@[8JK1132LK(&VW=A1113$%>I?L_?\C]?? M]@Q__1L5>6UZE^S]_P C]??]@Q__ $;%43^%ET_C1]$UXO\ M$_\>>@?]=)_ MY)7M%>+_ +1/_'GH'_72?^25A#XCKJ_ SPRBBBNHX0HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "OL/PA_R)&A_]@ZW_P#1:U\>5]A^$/\ D2-# M_P"P=;_^BUK&KL=%#=FQ7Q5>?\?T_P#UT;^=?:M?%5Y_Q_3_ /71OYTJ74=? MH0T445NPU:*+[-J4 M=J7^SRI%MW&-ADC/;!Z>AS7B-%9JFDK&_M97;/6=<^(5DWB#PT&\27NOP6-X MES=W,EG';Q*0UB+Q?X8T[XM76KQ:TM]H^M0217ZM:2H( M!M&T$$9?)7&0.YKQZBFHI._K^)/._P OP/>;3XOZ"+SQ%/=SF003^?HRO"YW MD0^7A?E^3)!^]C[Y]ZX^T\1^'O%?P]M/#_BO5YM'O-.N6EBN_LS3K.K%B057 MD'YCUQT!RA%7?&?C#PYJ/@J\LKK7/\ A*M3DF_T"X;3/LTEFF5) M!?:,CY><<7_LU>;UO'X4U?LZ_P#'QX@_W;?^XUX=^SK_Q\>(/]VW_ )R5[C7+4^([:7P( M*^;_ (\_\E%C_P"O&/\ ]">OI"J%YH6D:C/Y^H:7974N-OF3VZ.V/3)%*,N5 MW*G'F5CXSHK[%_X1/P[_ - #2_\ P#C_ ,*/^$3\._\ 0 TO_P X_\ "M?: MKL8>P?<^.J*^Q?\ A$_#O_0 TO\ \ X_\*/^$3\._P#0 TO_ , X_P#"CVJ[ M![!]SXZHK[%_X1/P[_T -+_\ X_\*/\ A$_#O_0 TO\ \ X_\*/:KL'L'W/C MJBOL7_A$_#O_ $ -+_\ ./_ H_X1/P[_T -+_\ X_\*/:KL'L'W/CJBOL7 M_A$_#O\ T -+_P# ./\ PH_X1/P[_P! #2__ #C_P */:KL'L'W/CJBOL7_ M (1/P[_T -+_ / ./_"C_A$_#O\ T -+_P# ./\ PH]JNP>P?<^.J*^Q?^$3 M\._] #2__ ./_"C_ (1/P[_T -+_ / ./_"CVJ[![!]SXZKV;]G?_D(:[_UR MA_F]>O\ _")^'?\ H :7_P" HKZA_X4SX&_P"@0_\ X%R__%4?\*9\#?\ 0(?_ M ,"Y?_BJ/:1#V$CY>HKZA_X4SX&_Z!#_ /@7+_\ %4?\*9\#?] A_P#P+E_^ M*H]I$/82/F_0M8;0M6COTL;*^:,'$-]#YD9)'7;D)]1\7:X^J:L8 M_.90BI$NU(U'15!)..2>2>M?1/\ PIGP-_T"'_\ N7_ .*H_P"%,^!O^@0_ M_@7+_P#%4G4BW<:HS2LCY>HKZA_X4SX&_P"@0_\ X%R__%4?\*9\#?\ 0(?_ M ,"Y?_BJ?M(B]A(^7J*^H?\ A3/@;_H$/_X%R_\ Q5'_ IGP-_T"'_\"Y?_ M (JCVD0]A(^7J*^H?^%,^!O^@0__ (%R_P#Q5'_"F? W_0(?_P "Y?\ XJCV MD0]A(^7J*^H?^%,^!O\ H$/_ .!Y\=45]B_P#")^'?^@!I M?_@''_A1_P (GX=_Z &E_P#@''_A5>U78CV#[GQU17V+_P (GX=_Z &E_P#@ M''_A1_PB?AW_ * &E_\ @''_ (4>U78/8/N?'5%?8O\ PB?AW_H :7_X!Q_X M4?\ ")^'?^@!I?\ X!Q_X4>U78/8/N?'5%?8O_")^'?^@!I?_@''_A1_PB?A MW_H :7_X!Q_X4>U78/8/N?'5%?8O_")^'?\ H :7_P" U78/8/N?'5%?8O_ B?AW_H :7_ . P?<^.J*^Q?^$3\._] M #2__ ./_"C_ (1/P[_T -+_ / ./_"CVJ[![!]SXZHK[%_X1/P[_P! #2__ M #C_P */^$3\._] #2__ ./_"CVJ[![!]SXZHK[%_X1/P[_ - #2_\ P#C_ M ,*/^$3\._\ 0 TO_P X_\ "CVJ[![!]SXZHK[%_P"$3\._] #2_P#P#C_P MH_X1/P[_ - #2_\ P#C_ ,*/:KL'L'W/CJO4OV?O^1^OO^P8_P#Z-BKW/_A$ M_#O_ $ -+_\ ./_ J>RT/2=-N#/IVEV5I,5*&2"W1&*D@D9 SC(''L*4JB M:L5&BXN]R_7B_P"T3_QYZ!_UTG_DE>T54OM)T[5/+_M.PM;SR\[/M$*R;:-CXOHK[%_X1/P[_ - #2_\ P#C_ ,*/^$3\._\ 0 TO M_P X_\ "M?:KL<_L'W/CJBOL7_A$_#O_0 TO_P#C_PH_P"$3\._] #2_P#P M#C_PH]JNP>P?<^.J*^Q?^$3\._\ 0 TO_P X_\ "C_A$_#O_0 TO_P#C_PH M]JNP>P?<^.J*^Q?^$3\._P#0 TO_ , X_P#"C_A$_#O_ $ -+_\ ./_ H] MJNP>P?<^.J*^Q?\ A$_#O_0 TO\ \ X_\*/^$3\._P#0 TO_ , X_P#"CVJ[ M![!]SXZHK[%_X1/P[_T -+_\ X_\*/\ A$_#O_0 TO\ \ X_\*/:KL'L'W/C MJBOL7_A$_#O_ $ -+_\ ./_ H_X1/P[_T -+_\ X_\*/:KL'L'W/CJBOL7 M_A$_#O\ T -+_P# ./\ PH_X1/P[_P! #2__ #C_P */:KL'L'W/CJBOL7_ M (1/P[_T -+_ / ./_"C_A$_#O\ T -+_P# ./\ PH]JNP>P?<^.J^P_"'_( MD:'_ -@ZW_\ 1:T[_A$_#O\ T -+_P# ./\ PK3AACMX(X;>-(HHU")&BA55 M0, #H .U1.?,:4Z;@Q]?%5Y_P ?T_\ UT;^=?:M9/\ PBGAW_H :7_X!Q_X M4H2Y1U(U78/8/N?'5% M?8O_ B?AW_H :7_ . K*4N9W-X1Y58^;/CK_R4@_\ 7G%_[-7F]?9EYH.D M:A<>??Z58W4V /,GMD=L>F2,U!_PB?AW_H :7_X!Q_X5HJB2L92HMN]SXZHK M[%_X1/P[_P! #2__ #C_P */^$3\._] #2__ ./_"G[5=B?8/N?'5%?8O\ MPB?AW_H :7_X!Q_X4?\ ")^'?^@!I?\ X!Q_X4>U78/8/N?'5%?8O_")^'?^ M@!I?_@''_A1_PB?AW_H :7_X!Q_X4>U78/8/N?'5%?8O_")^'?\ H :7_P" MU78/8/N?'5%?8O_ B?AW_H :7_ . (/]VW_G)7N-4['1],TMI&TS3K2S:0 .;>!8 MRX&<9P!G&3^=7*RD[NYO"/+&P4445)84444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !115?4$9]/G5)9HCL/SVX!D'^[D'G\*3=E<"Q16;X>M)+'PY86\X83+ M IEW,2=Y&6R3R3N)Y//K7+:EJE[>>([35;2]FBTFQU./3_+CY2;^[S'=T5S6L>*YM/\11Z/:65O-BD'/6K?@^SOK7PY;OK#2- M?SJ)9R]W)."Q';=@)_NJ-H[9ZT[?U_7H%_Z_KU-VBN?O[RX;QO86L!E,-O8S MW4\<;X\PDJB*1D _QD9XR*HZ7X[BO=4-G.FGY^S27'^@ZDMTT(3&5E 4!#\W M8L,@\]Z72_\ 6G_#!UL==17+Z1XMO=0ET@WNC?88-6@:6(M<[Y$*J&.Y-H 4 MCH=V>1E1GBS;>*/M&GZ-.!:^(H]-GAL%$EVMJ(AJ2-> MPKF *<+D@_?R%.2.U/N_%M[$FL7%K MI"2V6DR,DMQ)=;/-VH&.Q0AS@D@YP!C@DY $F]OZ_JX[I.W]?UH=316;#JQN M?$,VFVT'F16L*O<7&_ 1VY6,#')V_,>1@%>N>,WQ9#''!)?ZEJ.HPV$,!58- M/,D;"3D^8TD9!P!Q\V$');MA;#W.DHKB]>O?$MM\/+>>WN[2"^:UC$]T!YC& M5MJ@1@87DM][) [*5I9A$8D>2,2LVX$EC\Q)*@\=L+H0NM1LM7BT;4[J/37D5-/OI MRUP_3]XR-(273/W6)(SG&0 *+!?6S.NHKE?"\@_X2#5;:PNKV73[=(D,>H32 M/,D_S;B!*?,"E=AYPI/*]ZZJA@G<****0PHHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K M:C!0^6T>H& MU1I]Z,&WEN"22.3GG)KJJ*:;6PFD]SFM5\+7>J2W,$NJJ^F74R326\]N9)(B MN.(9-X$8^4$?*2"20>>-76]*_MC3#;+.UO*LD1OV?-N[$!,8QWK-TOPC=VE MSI#W^K+<1:1;O!;P06WDKR@0.V78EPH89Z<\ QTF)9ZWY%E?8\Z&:W,SQ_*%80L7 0$#H5 M8 DGOBMZBAN[NQ17*K(RM0T**\L=/LH7\BWLKB&8)MW;EB(*KUXY"\\]*MPR MW,FJ7*,H%K&B!"8R&+G);DG!&-O0=<\]A:HHNPLCGO$/AZ_UK4K&>WU&UBMK M3+_8[JS:>.23/RNP$B9VXX!R >>N,37FC:C^*VZ*72P6UNJS:;"C:K#!>V\PDBEM;5HX2H&-CQ&0EEP3QN'8C&*V:* M=V%D9>D:3-8W%W>W]TEW?7A42R1P^4@500JJN6( R3RQ))/., :E%%&X)6"B MBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$! end GRAPHIC 15 phr-20230131_g2.jpg GRAPHIC begin 644 phr-20230131_g2.jpg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htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
12 Months Ended
Jan. 31, 2023
Mar. 17, 2023
Jul. 31, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jan. 31, 2023    
Current Fiscal Year End Date --01-31    
Document Transition Report false    
Entity File Number 001-38977    
Entity Registrant Name PHREESIA, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-2275479    
Entity Address, Address Line One 1521 Concord Pike    
Entity Address, Address Line Two Suite 301 PMB 221    
Entity Address, City or Town Wilmington    
Entity Address, State or Province DE    
Entity Address, Postal Zip Code 19803    
City Area Code 888    
Local Phone Number 654-7473    
Title of 12(b) Security Common stock, $0.01 par value per share    
Trading Symbol PHR    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 1,157,351,642
Entity Common Stock, Shares Outstanding (in shares)   53,355,050  
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement relating to its 2023 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
   
Amendment Flag false    
Entity Central Index Key 0001412408    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Audit Information
12 Months Ended
Jan. 31, 2023
Audit Information [Abstract]  
Auditor Name KPMG LLP
Auditor Location Pittsburgh, PA
Auditor Firm ID 185
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Current:    
Cash and cash equivalents $ 176,683 $ 313,812
Settlement assets 22,599 19,590
Accounts receivable, net of allowance for doubtful accounts of $1,053 and $863 as of January 31, 2023 and 2022, respectively 51,394 40,262
Deferred contract acquisition costs 1,056 1,642
Prepaid expenses and other current assets 10,709 11,043
Total current assets 262,441 386,349
Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively 21,670 34,645
Capitalized internal-use software, net of accumulated amortization of $37,236 and $31,139 as of January 31, 2023 and 2022, respectively 35,150 17,643
Operating lease right-of-use assets 569 2,337
Deferred contract acquisition costs 1,754 2,437
Intangible assets, net of accumulated amortization of $2,549 and $1,178 as of January 31, 2023 and 2022, respectively 11,401 12,772
Deferred tax asset 81 515
Goodwill 33,736 33,621
Other assets 3,255 4,157
Total Assets 370,057 494,476
Current:    
Settlement obligations 22,599 19,590
Current portion of finance lease liabilities and other debt 5,172 5,821
Current portion of operating lease liabilities 934 1,281
Accounts payable 10,836 5,119
Accrued expenses 21,810 20,128
Deferred revenue 17,688 16,493
Total current liabilities 79,039 68,432
Long-term finance lease liabilities and other debt 2,725 7,423
Operating lease liabilities, non-current 349 1,276
Long-term deferred revenue 125 65
Total Liabilities 82,238 77,196
Commitments and contingencies (Note 11)
Stockholders’ Equity:    
Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2023 and 2022; 54,187,172 and 52,095,964 shares issued as of January 31, 2023 and 2022, respectively 542 521
Additional paid-in capital 926,957 860,657
Accumulated deficit (606,084) (429,938)
Treasury stock, at cost, 971,236 and 301,003 shares as of January 31, 2023 and 2022, respectively (33,596) (13,960)
Total Stockholders’ Equity 287,819 417,280
Total Liabilities and Stockholders’ Equity $ 370,057 $ 494,476
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for doubtful accounts $ 1,053 $ 863
Accumulated depreciation and amortization, property and equipment 59,847 53,321
Accumulated amortization of capitalized internal-use software 37,236 31,139
Accumulated amortization of intangible assets $ 2,549 $ 1,178
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 54,187,172 52,095,964
Treasury stock (in shares) 971,236 301,003
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Revenue:      
Total revenue $ 280,910 $ 213,233 $ 148,677
Expenses:      
Cost of revenue (excluding depreciation and amortization) 58,944 42,669 23,461
Payment processing expense 50,323 38,719 28,925
Sales and marketing 151,263 106,421 42,972
Research and development 91,244 52,265 22,622
General and administrative 80,384 68,674 40,460
Depreciation 17,988 14,985 9,770
Amortization 7,316 6,317 6,138
Total expenses 457,462 330,050 174,348
Operating loss (176,552) (116,817) (25,671)
Other (expense) income, net (175) (78) 1
Interest income (expense), net 1,064 (1,084) (1,573)
Total other income (expense), net 889 (1,162) (1,572)
Loss before provision for income taxes (175,663) (117,979) (27,243)
Provision for income taxes (483) (182) (49)
Net loss $ (176,146) $ (118,161) $ (27,292)
Net loss per share attributable to common stockholders - basic (in dollars per share) $ (3.36) $ (2.37) $ (0.69)
Net loss per share attributable to common stockholders - diluted (in dollars per share) $ (3.36) $ (2.37) $ (0.69)
Weighted-average common shares outstanding - basic (in shares) 52,440,067 49,888,436 39,519,640
Weighted-average common shares outstanding - diluted (in shares) 52,440,067 49,888,436 39,519,640
Subscription and related services      
Revenue:      
Total revenue $ 128,975 $ 95,514 $ 69,042
Payment processing fees      
Revenue:      
Total revenue 78,368 65,201 49,900
Network solutions      
Revenue:      
Total revenue $ 73,567 $ 52,518 $ 29,735
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated deficit
Treasury stock
Beginning balance, stockholders' equity (in shares) at Jan. 31, 2020   36,610,763      
Beginning balance, stockholders' equity at Jan. 31, 2020 $ 101,865 $ 366 $ 386,383 $ (284,485) $ (399)
Stockholders’ equity          
Net loss (27,292)     (27,292)  
Stock-based compensation expense $ 13,489   13,489    
Exercise of stock options and vesting of restricted stock units (in shares) 2,216,368 2,459,782      
Exercise of stock options and vesting of restricted stock units $ 5,300 $ 25 5,275    
Issuance of common stock, net of issuance costs (in shares)   5,750,000      
Issuance of common stock, net of issuance costs 174,510 $ 57 174,453    
Cashless exercise of common stock warrants (in shares)   60,338      
Cashless exercise of common stock warrants 0 $ 1 (1)    
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings (4,566)       (4,566)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2021   44,880,883      
Ending balance, stockholders' equity at Jan. 31, 2021 263,306 $ 449 579,599 (311,777) (4,965)
Stockholders’ equity          
Net loss (118,161)     (118,161)  
Stock-based compensation expense $ 29,668   29,668    
Exercise of stock options and vesting of restricted stock units (in shares) 1,439,186 1,997,551      
Exercise of stock options and vesting of restricted stock units $ 4,143 $ 20 4,123    
Issuance of common stock for employee stock purchase plan (in shares)   42,530      
Issuance of common stock for employee stock purchase plan 1,506   1,506    
Issuance of common stock, net of issuance costs (in shares)   5,175,000      
Issuance of common stock, net of issuance costs 245,813 $ 52 245,761    
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings (8,995)       (8,995)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2022   52,095,964      
Ending balance, stockholders' equity at Jan. 31, 2022 417,280 $ 521 860,657 (429,938) (13,960)
Stockholders’ equity          
Net loss (176,146)     (176,146)  
Stock-based compensation expense $ 52,506   52,506    
Exercise of stock options and vesting of restricted stock units (in shares) 311,743 1,626,123      
Exercise of stock options and vesting of restricted stock units $ 1,531 $ 16 1,515    
Issuance of common stock for employee stock purchase plan (in shares)   162,154      
Issuance of common stock for employee stock purchase plan 3,472 $ 2 3,470    
Issuance of stock for share-settled bonus awards (in shares)   302,931      
Issuance of stock for share-settled bonus awards 8,812 $ 3 8,809    
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings (19,636)       (19,636)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2023   54,187,172      
Ending balance, stockholders' equity at Jan. 31, 2023 $ 287,819 $ 542 $ 926,957 $ (606,084) $ (33,596)
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)
$ in Thousands
12 Months Ended
Jan. 31, 2021
USD ($)
Statement of Stockholders' Equity [Abstract]  
Issuance costs $ 290
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Operating activities:      
Net loss $ (176,146) $ (118,161) $ (27,292)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and amortization 25,304 21,302 15,908
Non-cash stock-based compensation expense 58,775 36,144 13,489
Amortization of deferred financing costs and debt discount 310 288 389
Cost of Phreesia hardware purchased by customers 1,598 672 762
Deferred contract acquisition costs amortization 1,696 2,211 2,025
Non-cash operating lease expense 1,768 1,004 1,766
Change in fair value of contingent consideration liabilities 0 258 0
Deferred tax asset 434 143 (65)
Changes in operating assets and liabilities, net of acquisitions:      
Accounts receivable (11,132) (10,216) (6,619)
Prepaid expenses and other assets 250 (7,192) (1,600)
Deferred contract acquisition costs (427) (3,349) (1,652)
Accounts payable 4,774 2,881 (3,821)
Accrued expenses and other liabilities 2,720 (2,983) 6,004
Lease liability (1,302) (1,060) (1,786)
Deferred revenue 1,255 3,348 5,382
Net cash (used in) provided by operating activities (90,123) (74,710) 2,890
Investing activities:      
Acquisitions, net of cash acquired 0 (34,423) (6,510)
Capitalized internal-use software (21,471) (12,385) (7,334)
Purchases of property and equipment (4,732) (18,420) (11,241)
Net cash used in investing activities (26,203) (65,228) (25,085)
Financing activities:      
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions 0 245,813 174,800
Proceeds from issuance of common stock upon exercise of stock options 1,603 4,889 4,385
Treasury stock to satisfy tax withholdings on stock compensation awards (19,383) (8,995) (4,965)
Payment of offering costs 0 0 (290)
Proceeds from employee stock purchase plan 3,321 1,979 0
Insurance financing agreement 0 0 2,009
Finance lease payments (5,731) (4,267) (2,630)
Principal payments on financing agreements (216) (1,039) (1,691)
Debt issuance costs and facility fees (397) (125) (294)
Financing payments of acquisition-related liabilities 0 (3,286) 0
Payments of revolving line of credit 0 0 (20,663)
Net cash (used in) provided by financing activities (20,803) 234,969 150,661
Net (decrease) increase in cash and cash equivalents (137,129) 95,031 128,466
Cash and cash equivalents—beginning of year 313,812 218,781 90,315
Cash and cash equivalents—end of year 176,683 313,812 218,781
Supplemental information of non-cash investing and financing activities:      
Right-of-use assets recorded in exchange for operating lease liabilities 0 81 4,359
Property and equipment acquisitions through finance leases 526 7,394 8,885
Capitalized software acquired through vendor financing 0 0 174
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities 2,345 1,124 3,359
Cashless transfer of term loan and related accrued fees into increase in debt balance 0 0 20,257
Cashless transfer of lender fees through increase in debt balance 0 0 406
Receivables for cash in-transit on stock option exercises 97 169 915
Cashless exercise of common stock warrants 0 0 3,060
Capitalized stock based compensation 1,372 489 0
Issuance of stock to settle liabilities for stock-based compensation 12,284 0 0
Cash paid for:      
Interest 763 802 1,465
Income taxes $ 39 $ 49 $ 64
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Background and liquidity
12 Months Ended
Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background and liquidity Background and liquidity
(a) Background
Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through the SaaS-based technology platform (the "Phreesia Platform" or "Platform"), the Company offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration and payments. The Company’s Platform also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. In connection with the patient intake and registration process, Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005.
During the fiscal year ended January 31, 2023, the Company ceased using its Raleigh, North Carolina office as its principal executive offices.
b) Liquidity
Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year.
On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023.
On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company.
The Company is also party to the Second Amended and Restated Loan and Security Agreement with SVB, as amended by the First Loan Modification Agreement (the “Third SVB Facility”), which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations. See Note 6 - Finance Leases and Other Debt and Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.
Management believes that the Company’s cash and cash equivalents at January 31, 2023, along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months.
The Company will seek to obtain additional financing, if needed, to successfully implement its long-term strategy.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of presentation
12 Months Ended
Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of presentation Basis of presentation(a) Consolidated Financial Statements
The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company").
(b) Fiscal year
The Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
(c) Network solutions revenue
During the year ended January 31, 2023, the Company relabeled its Life sciences category of revenue presented on its Consolidated Statements of Operations to Network solutions revenue. The Company's Network solutions revenue includes fees from life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health using the Phreesia Platform. Prior to the year ended January 31, 2023, the Company's Network solutions revenue was generated by its life sciences clients. There have been no changes to previously reported revenues.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies
12 Months Ended
Jan. 31, 2023
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies(a) Use of estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.
(b) Revenue recognition

The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers, as well as for additional details about the Company's products and service lines.
(c) Concentrations of credit risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor.
The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2023 and January 31, 2022. As of both January 31, 2023 and January 31, 2022, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable.
See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.
(d) Risks and uncertainties
The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. Certain of the Company's
service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and Contingencies, for a summary of our contractual commitments as of January 31, 2023. See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.
(e) Cost of revenue (excluding depreciation and amortization)
Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
(f) Payment processing expense
Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways.
(g) Sales and marketing
Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $2,634, $4,007 and $558 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
(h) Research and development
Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
(i) General and administrative
General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
(j) Depreciation
Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.
(k) Amortization
Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
(l) Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents.
(m) Settlement assets
Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one to two business days of the transaction date.
(n) Settlement obligations
Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
(o) Accounts receivable
Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2023 and 2022, the Company has reserved $1,053 and $863, respectively, for the allowance for doubtful accounts.
Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5).
(p) Property and equipment
Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three and seven years. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.
Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
(q) Capitalized internal-use software
The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software. These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period.
(r) Business combinations
The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date,
the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations.
When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.
(s) Goodwill and intangible assets
Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.
The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.
All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
(t) Long-lived assets
Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
(u) Income taxes
An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure.
The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
(v) Segment information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements.
(w) Stock-based compensation
The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718, Compensation — Stock Compensation, which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.
The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield.

During fiscal 2022, the Company activated the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date.

For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares.
See Note 8 - Equity-Based Compensation, for additional information on stock-based compensation.
(x) Fair value of financial instruments
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.
Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
(y) Equity offering costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations.
(z) Foreign currency
The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net.
(aa) New accounting pronouncements
Impact of recently adopted accounting pronouncements
During the year ended January 31, 2023, the Company did not adopt any accounting pronouncements.
Recent accounting pronouncements not yet adopted
There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions
12 Months Ended
Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]  
Composition of certain financial statement captions Composition of certain financial statement captions
(a) Accrued expenses
Accrued expenses at January 31, 2023 and 2022 are as follows:
January 31,
20232022
Payroll-related expenses and taxes$10,345 $10,780 
Payment processing fees liability4,796 3,502 
Acquisition-related liabilities96 96 
Tax liabilities1,491 2,093 
Information technology services2,249 1,266 
Other2,833 2,391 
Total$21,810 $20,128 
(b) Property and equipment
Property and equipment at January 31, 2023 and 2022 are as follows:
Useful life
(years)
January 31,
20232022
PhreesiaPads and Arrivals Kiosks3$17,932 $26,387 
Computer equipment
354,485 53,957 
Computer software
3 to 5
8,571 5,311 
Hardware development
3529 1,024 
Furniture and fixtures
7— 539 
Leasehold improvements
2— 748 
Total property and equipment
$81,517 $87,966 
Less accumulated depreciation(59,847)(53,321)
Property and equipment — net$21,670 $34,645 
Depreciation expense related to property and equipment amounted to $17,988, $14,985 and $9,770 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
Assets acquired under finance leases included in computer equipment were $27,813 and $27,310 at January 31, 2023 and 2022, respectively. Accumulated amortization of assets under finance leases was $20,657 and $15,025 at January 31, 2023 and 2022, respectively.
(c) Capitalized internal-use software
For the fiscal years ended January 31, 2023, 2022 and 2021, the Company capitalized $23,604, $12,830 and $7,663 of costs related to the Phreesia Platform, respectively.
During the fiscal years ended January 31, 2023, 2022 and 2021 amortization expense related to capitalized internal-use software was $5,945, $5,664 and $5,884, respectively.
(d) Intangible assets and goodwill
The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022.
Useful LifeJanuary 31,
(years)20232022
Acquired technology5$1,410 $1,410 
Customer relationship
7 to 10
6,340 6,340 
License156,200 6,200 
Total intangible assets, gross carrying value$13,950 $13,950 
Less accumulated amortization(2,549)(1,178)
Net carrying value$11,401 $12,772 
The remaining useful life for acquired technology in years is 2.7 and 3.5 as of January 31, 2023 and 2022, respectively. The remaining useful life for customer relationships in years is 8.3 and 9.2 as of January 31, 2023 and 2022, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years is 13.8 and 14.8 as of January 31, 2023 and 2022, respectively. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes.
Amortization expense associated with intangible assets for the fiscal years ended January 31, 2023, 2022 and 2021 was $1,371, $653 and $254, respectively.
The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023:
January 31, 2023
2024$1,358 
20251,273 
20261,242 
2027949 
Thereafter6,579 
Total$11,401 
The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023:
Balance at January 31, 2021$8,307 
Goodwill acquired during the year ended January 31, 202225,314 
Balance at January 31, 202233,621 
Measurement period adjustments to goodwill during the year ended January 31, 2023115 
Balance at January 31, 2023$33,736 
The Company did not record any impairments of goodwill during the years ended January 31, 2023, 2022 or 2021. Additions to goodwill during the year ended January 31, 2022 are net of a $96 measurement period adjustment for the QueueDr acquisition. Additions to goodwill during the year ended January 31, 2023 represent measurement period adjustments for the Insignia acquisition. Substantially all of the Company's goodwill is amortizable for tax purposes.
(e) Accounts receivable
Accounts Receivable as of January 31, 2023 and 2022 are as follows:
January 31,
20232022
Billed$51,458 $40,733 
Unbilled989 392 
Total accounts receivable, gross52,447 41,125 
Less accounts receivable allowances(1,053)(863)
Total accounts receivable$51,394 $40,262 

Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022:
Balance, January 31, 2021$699 
Bad debt expense212 
Write-offs and adjustments(48)
Balance, January 31, 2022863 
Bad debt expense587 
Write-offs and adjustments(397)
Balance, January 31, 2023
$1,053 

The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible.

(f) Prepaid and other current assets
Prepaid and other current assets as of January 31, 2023 and 2022 are as follows:
January 31,
20232022
Prepaid software and business systems$3,426 $3,738 
Prepaid data center expenses2,389 3,230 
Prepaid insurance1,552 1,924 
Other prepaid expenses and other current assets3,342 2,151 
Total prepaid and other current assets$10,709 $11,043 

(g) Cloud computing implementation costs

The Company enters into cloud computing service contracts to support its sales and marketing, product development and administrative activities. The Company capitalizes certain implementation costs for cloud computing arrangements that meet the definition of a service contract. The Company includes these capitalized implementation costs within Prepaid expenses and other current assets and within other assets on its consolidated balance sheets. Once placed in service, the Company amortizes these costs over the remaining subscription term to the same caption in the consolidated statements of operations as the related cloud subscription. Capitalized implementation costs for cloud computing arrangements accounted for as service contracts were $1,532 as of January 31, 2023. Accumulated amortization of capitalized implementation costs for these arrangements was $610 as of January 31, 2023.

(h) Other (expense) income, net

Other (expense) income, net for the year ended January 31, 2023 and 2022 was expense of $175 and $78, respectively, driven by foreign exchange losses, partially offset by other miscellaneous income.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue and Contract Costs
12 Months Ended
Jan. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue and Contract Costs Revenue and Contract Costs
The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Phreesia Platform, payment processing fees based on patient payment volume, and fees from life sciences and payer clients for delivering direct communications to patients using the Phreesia Platform.
The Company accounts for revenue from contracts with customers by applying the requirements of ASC 606. Accordingly, the Company determines revenue recognition through the following steps:
identification of the contract, or contracts, with a customer;
identification of the performance obligations in the contract;
determination of the transaction price;
allocation of the transaction price to the performance obligations in the contract; and
recognition of revenue when, or as, the Company satisfies a performance obligation.
Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services.
The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. We typically establish a range of SSPs for each of our performance obligations. We use the residual method to the estimate the SSP for certain performance obligations with highly variable pricing.
(a) Subscription and related services
In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other applications. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. The Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 842, Leases.
The amount of subscription and related services revenues recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $10,197, $6,489 and $6,312 for the years ended January 31, 2023, 2022 and 2021, respectively.
In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from Phreesia’s Platform and are therefore recognized over the term of the contract. Revenue from sales of Phreesia hardware and training are recognized in the period they are delivered to clients.
(b) Payment processing fees
The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions.
The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees.
The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers.
The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company.
As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations.
(c) Network solutions
The Company's Network solutions revenue includes fees from life sciences companies and payers for direct communications to activate, engage and educate patients about topics critical to their health using the Phreesia platform.
The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered.
The Company generates revenue from sales of qualified leads to health plans and other payer organizations which is based largely on the delivery of qualified leads to health plans and other payer organizations at a contracted price per lead. The Company identifies the qualified leads based on direct communications delivered to patients. Revenue for leads is recognized based on our estimate of leads accepted by health plans and other payer organizations.
(d) Disaggregation of revenue
Revenue from the Company’s contracts with its customers are disaggregated by service offering on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees, digital marketing solutions sold to life sciences companies and qualified leads sold to health plans and other payer organizations. In addition, substantially all of the Company’s revenue is derived from customers in the United States.
(e) Remaining performance obligations
The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue).
(f) Contract balances
Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred
revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying balance sheets.
The following table represents a roll-forward of contract assets:
January 31,
20232022
Beginning Balance$392 $1,287 
Amount transferred to receivables from beginning balance of contract assets(392)(1,287)
Increases in contract assets due to acquisitions— 243 
Contract asset additions, net of reclassification to receivables989 149 
Ending Balance$989 $392 
The following table represents a roll-forward of deferred revenue:
 January 31,
20232022
Beginning Balance$16,558 $10,838 
Revenue recognized that was included in deferred revenue at the beginning of the period(16,005)(10,838)
Increases in deferred revenue due to acquisitions— 2,372 
Other current year activity in deferred revenue17,260 14,186 
Ending Balance$17,813 $16,558 
(g) Cost to obtain a contract
The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three to five years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $1,696 and $2,211 for the years ended January 31, 2023 and 2022, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.
The following table represents a roll-forward of deferred contract acquisition costs:
January 31,
20232022
Beginning balance$4,079 $2,941 
Additions to deferred contract acquisition costs427 3,349 
Amortization of deferred contract acquisition costs(1,696)(2,211)
Ending balance$2,810 $4,079 
Deferred contract acquisition costs, current (to be amortized in next 12 months)$1,056 $1,642 
Deferred contract acquisition costs, non-current1,754 2,437 
Total deferred contract acquisition costs$2,810 $4,079 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Finance leases and other debt
12 Months Ended
Jan. 31, 2023
Debt Disclosure [Abstract]  
Finance leases and other debt Finance leases and other debt
As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt:
January 31,
20232022
Finance leases$7,651 $12,884 
Financing arrangements46 266 
Accrued interest and payments200 94 
Total finance lease liabilities and other debt$7,897 $13,244 
Less - current portion of finance lease liabilities and other debt(5,172)(5,821)
Long-term finance leases and other debt$2,725 $7,423 
(a) Finance leases

See Note 10 - Leases for more information regarding finance leases.

(b) Amended and Restated Loan and Security Agreement

On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. In connection with the transaction, the Company recorded a $1,073 loss on extinguishment of debt within other (expense) income, net for the settlement of previously outstanding loans payable.

On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility. The Second SVB Facility modified the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. The borrowing capacity could be increased to $65,000 at the sole discretion of Silicon Valley Bank. Upon entering into the Second SVB Facility, the Company borrowed $20,663 against the revolving credit facility and used the proceeds to repay all amounts due under the First SVB Facility term loan. The Company repaid the balance on the Second SVB Facility during the fiscal year ended January 31, 2021.

On March 28, 2022 (the "Third SVB Effective Date"), the Company entered into a First Loan Modification Agreement
to the Second SVB Facility (as amended, the "Third SVB Facility") to increase the borrowing capacity from $50,000
to $100,000 and to reduce the interest rate on the facility. Borrowings under the Third SVB Facility are payable on May 5, 2025. Borrowings under the Third SVB Facility bear interest, which is payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%. As of January 31, 2023, the interest rate on the Third SVB Facility was 7%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual commitment fee of approximately $250 per year and a quarterly fee of 0.15% per annum of the average unused revolving line under the facility. The Company had $100,000 of availability under the facility as of January 31, 2023.

In the event that the Company terminates the Third SVB Facility prior to May 5, 2024, the Company will be required to pay a termination fee of up to 1.5% of borrowing capacity based on the length of time between termination and maturity. Any Company obligations under the Third SVB Facility are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The Third SVB Facility includes a financial covenant that requires the Company to maintain a minimum Adjusted Quick Ratio as defined in the Third SVB Facility. The Third SVB Facility also includes a financial covenant that requires the Company to achieve certain profitability and liquidity thresholds. The financial covenant will not be effective if the Company maintains certain levels of liquidity as defined. Additionally, the Third SVB facility contains a covenant limiting the amount of cash and cash equivalents the Company can hold outside SVB. The Third SVB Facility also contains customary events of default. The Company was in compliance with all covenants related to the Third SVB Facility as of January 31, 2023.

As of January 31, 2023 and 2022, there was no debt outstanding related to the Third SVB Facility and the Second SVB Facility, respectively. As a result, the Company presented all unamortized deferred costs within other assets as of January 31, 2023 and 2022, respectively. The Company is amortizing the remaining unamortized costs over the remaining term of the Third SVB Facility.
Maturities of finance leases and other debt in each of the next five years and thereafter are as follows:
 TotalFinance LeasesOther Debt
Fiscal year ending January 31:
2024$5,172 $4,926 $246 
20252,518 2,518 — 
2026207 207 — 
Total maturities of finance leases and other debt$7,897 $7,651 $246 
The following table presents the components of interest income (expense), net:
Fiscal years ended January 31,
 202320222021
Interest expense (1)
$(1,411)$(1,163)$(1,695)
Interest income2,475 79 122 
Interest income (expense), net$1,064 $(1,084)$(1,573)
(1) Includes amortization of deferred financing costs and original issue discount
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
12 Months Ended
Jan. 31, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
(a) Common stock
The Company closed an IPO on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share.
On April 12, 2021, the Company completed a follow-on offering of its common stock. In connection with this offering, the Company issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share.
(b) Treasury stock
The Company's equity-based compensation plan allows for the grant of non-vested stock options, RSUs and TSR PSUs to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Under the provision of the plans, for RSU and PSU awards, unless otherwise elected, participants fulfill their related income tax withholding obligation by having shares withheld at the time of vesting. On the date of vesting of the RSU or PSU, the Company divides the participant's estimated income tax obligation in dollars by the closing price of its common stock and withholds the resulting number of vested shares. The shares withheld are then transferred to the Company's treasury stock at cost.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation
12 Months Ended
Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Equity-based compensation Equity-based compensation
(a) Equity award plans
In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock.
In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2023, 2022 and 2021 were made pursuant to the 2019 plan, respectively.
In June 2019, the Board of Directors also adopted the ESPP, which became effective immediately prior to the
effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares.
In August 2021, the Company amended its fiscal 2022 incentive bonus to allow eligible employees to elect to receive all or a portion of their fiscal 2022 year end incentive compensation in the form of immediately vested restricted stock units instead of cash. The Company's fiscal 2023 incentive bonus allows eligible employees to elect to receive all or a portion of their fiscal 2023 incentive compensation in the form of immediately vested restricted stock units instead of cash.
As of January 31, 2023, there are 3,408,720 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase which occurs on February 1 of each fiscal year, as well as an additional 576,304 shares available for future grant pursuant to the ESPP. During fiscal 2022, the Company activated its ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions.
(b) Summary of stock-based compensation

The following table sets forth stock-based compensation by type of award:

For the fiscal years ended
January 31,
 202320222021
RSUs$42,214 $24,222 $10,693 
Liability awards7,641 7,055 — 
PSUs7,282 2,389 93 
Stock options1,489 2,294 2,703 
ESPP1,521 763 — 
Total stock-based compensation$60,147 $36,723 $13,489 

The following table sets forth the presentation of stock-based compensation in the Company's financial statements:


For the fiscal years ended
January 31,
 202320222021
Stock-based compensation expense recorded to additional paid-in capital(1)
$52,506 $29,668 $13,489 
Stock-based compensation expense recorded to accrued expenses7,641 7,055 — 
Total stock-based compensation60,147 36,723 13,489 
Less stock-based compensation expense capitalized as internal-use software(1,372)(489)— 
Stock-based compensation expense per consolidated statements of operations(2)
$58,775 $36,234 $13,489 
(1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts.
(2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.

The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense.
(c) Restricted stock units

The Company has issued restricted stock units to employees and independent directors that vest based on a time-based condition. For RSUs granted to employees prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The restricted stock units expire seven years from the grant date.

During the year ended January 31, 2022, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its 2022 proxy statement ("2022 NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than 2022 NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For 2022 NEOs and other members of the Company's executive management team, RSUs granted from January 1, 2022 through December 31, 2022 vest 6.25% each quarter over four years based on continued service. Beginning January 2023, all RSUs granted vest 25% each year over four years based on continued service.

Additionally, the Company provides certain employees the option to settle their incentive bonus in immediately vested RSUs. RSUs granted to settle bonus awards are included in RSUs granted and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards.
  Restricted stock units
Unvested, January 31, 20201,447,418 
Granted during year
972,271 
Vested(242,049)
Forfeited and expired(124,602)
Unvested, January 31, 20212,053,038 
Granted during year
1,836,534 
Vested(559,767)
Forfeited and expired(195,966)
Unvested, January 31, 20223,133,839 
Granted during year
2,907,838 
Vested(1,626,679)
Forfeited and expired (497,245)
Unvested, January 31, 2023
3,917,753 

As of January 31, 2023, there is $112,482 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.8 years.
For the years ended January 31, 2023, 2022 and 2021, the weighted average grant date fair value of restricted stock units granted was $26.79, $46.60 and $32.78 respectively.
(d) Stock options
Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis.
Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows:
Number of
options
Weighted-
average
exercise price
Weighted-
average
remaining
contractual life
(in years)
Aggregate Intrinsic
value
Outstanding—January 31, 20205,516,452 $3.80 
Granted during the year— $— 
Exercised(2,216,368)$2.39 
Forfeited(88,730)$7.45 
Outstanding and expected to vest — January 31, 2021
3,211,354 $4.67 5.99$194,676 
Outstanding—January 31, 20213,211,354 $4.67 
Granted during the year— $— 
Exercised(1,439,186)$2.88 
Forfeited and expired(67,018)$9.02 
Outstanding and expected to vest — January 31, 2022
1,705,150 $6.01 5.94$42,938 
Outstanding—January 31, 20221,705,150 $6.01 
Granted during the year— $— 
Exercised(311,743)$4.92 
Forfeited and expired(8,214)$4.68 
Outstanding and expected to vest — January 31, 2023
1,385,193 $6.26 5.06$43,341 
Exercisable — January 31, 2023
1,362,903 $6.12 5.03$42,750 
Amount vested during year ended January 31, 2023
258,735 $8.27 

The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2023, 2022 and 2021 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $6,970, $73,624 and $33,575, respectively.
As of January 31, 2023, there is $45 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 0.33 years.
For the year ended January 31, 2023, stock-based compensation expense for stock options includes $322 related to the modification of stock options.
(e) TSR performance-based restricted stock units (PSUs)

The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Peer Group. Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. PSUs granted during the years ended January 31, 2023, 2022 and 2021 vest in a maximum of 220%, 200% and 200% of the number of PSUs originally granted, respectively. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%.

The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period.
The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions:

Fiscal years ended
January 31,
 202320222021
Correlation coefficient0.4957 0.3878 0.4230 
Valuation date stock price$35.41 $36.03 $62.96 
Simulation term3.00 Years2.99 Years3.00 Years
Volatility64.98 %44.32 %43.71 %
Risk-free rate3.84 %1.23 %0.20 %
Dividend yield— %— %— %
Weighted average fair value of grants
$56.52 $48.47 $84.38 


Market based PSU activity for the years ended January 31, 2023, 2022 and 2021 are as follows:
Performance
stock units
Outstanding February 1, 2020— 
Granted during the year ended January 31, 202170,806 
Outstanding, February 1, 202170,806 
Granted during the year ended January 31, 2022325,410 
Vested— 
Forfeited and expired— 
Outstanding, February 1, 2022396,216 
Granted during the year ended January 31, 2023
255,572 
Vested— 
Forfeited and expired(3,555)
Outstanding, January 31, 2023
648,233 
As of January 31, 2023, unrecognized compensation cost for the PSUs was $26,128, to be recognized over a weighted average remaining vesting period of 2.4 years, subject to the participants' continued employment with the Company.

(f) Employee stock purchase plan
The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986.

The fair value of shares granted under the ESPP during the year ended January 31, 2023 was estimated using a Black-Scholes pricing model with the following assumptions:
Year ended
January 31, 2023
Year ended
January 31, 2022
Risk-free interest rate
3.68 %0.17 %
Expected dividends
nonenone
Expected term (in years)
0.47 years0.49 years
Volatility
74.8 %55.7 %

During the fiscal years ended January 31, 2023 and 2022, the Company issued 162,154 and 42,530 shares of common stock, respectively, for the ESPP. In connection with these issuances, during the years ended January 31, 2023 and 2022, the Company recorded increases of $3,470 and $1,506, respectively, to additional paid-in capital
within stockholders' equity. As of January 31, 2023, unrecognized compensation cost related to the ESPP was $605, to be recognized over the next five months.

(g) Liability awards
The Company's amended fiscal 2022 incentive bonus and the Company's fiscal 2023 incentive bonus allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the bonuses converted. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities, within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. During the year-ended January 31, 2023, the Company settled $8,812 of share-settled bonus awards by issuing 302,931 immediately vested RSUs. See (c) Restricted Stock Units above for additional discussion regarding RSUs.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Fair value measurements
12 Months Ended
Jan. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands):
 Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2023
 
Money market mutual funds$163,563 $— $— $163,563 
Total assets$163,563 $— $— $163,563 

The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands):
 Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2022
 
Money market mutual funds$197,601 $— $— $197,601 
Total assets$197,601 $— $— $197,601 

The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of January 31, 2023, the carrying value of the Company's debt approximated fair value because the interest rates approximated market rates and the debt maturities were relatively short-term.

The Company did not have any transfers of assets and liabilities between levels of the fair value measurements hierarchy during both the years ended January 31, 2023 and 2022.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
12 Months Ended
Jan. 31, 2023
Leases [Abstract]  
Leases Leases
(a) Phreesia as Lessee
The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option
date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two to three years and are secured by the underlying equipment.
During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada
and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to
cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company
shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The
financial impact of the change in useful lives of the related right of use assets was not significant.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:
January 31,
20232022
Operating leases:
Lease right-of-use assets$569 $2,337 
Lease liabilities, current934 1,281 
Lease liabilities, non-current349 1,276 
Total operating lease liabilities$1,283 $2,557 
Finance leases:
Property and equipment, at cost$27,813 $27,310 
Accumulated depreciation(20,657)(15,025)
Property and equipment, net$7,156 $12,285 
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)4,926 5,600 
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)2,725 7,284 
Total finance lease liabilities$7,651 $12,884 

For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.
As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.
The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:
Fiscal years ended
January 31,
202320222021
Operating leases:
Operating lease cost$1,835 $1,096 $1,766 
Variable lease cost62 223 257 
Total operating lease cost$1,897 $1,319 $2,023 
Finance leases:
Amortization of right-of-use assets$5,632 $4,636 $2,876 
Interest on lease liabilities368 378 326 
Total finance lease cost$6,000 $5,014 $3,202 

The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:
January 31, 2023
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2024$958 $5,102 
2025225 2,566 
202686 209 
202742 — 
Thereafter— 
Total future minimum lease payments$1,318 $7,877 
Less: interest(35)(226)
Present value of lease liabilities$1,283 $7,651 

As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.

Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:
Fiscal years ended
January 31,
202320222021
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,347 $1,206 $1,629 
Operating cash used for finance leases396 377 326 
Financing cash used for finance leases5,731 4,267 2,630 
Total$7,474 $5,850 $4,585 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and
do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.
During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less.
Leases Leases
(a) Phreesia as Lessee
The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option
date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two to three years and are secured by the underlying equipment.
During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada
and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to
cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company
shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The
financial impact of the change in useful lives of the related right of use assets was not significant.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:
January 31,
20232022
Operating leases:
Lease right-of-use assets$569 $2,337 
Lease liabilities, current934 1,281 
Lease liabilities, non-current349 1,276 
Total operating lease liabilities$1,283 $2,557 
Finance leases:
Property and equipment, at cost$27,813 $27,310 
Accumulated depreciation(20,657)(15,025)
Property and equipment, net$7,156 $12,285 
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)4,926 5,600 
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)2,725 7,284 
Total finance lease liabilities$7,651 $12,884 

For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.
As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.
The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:
Fiscal years ended
January 31,
202320222021
Operating leases:
Operating lease cost$1,835 $1,096 $1,766 
Variable lease cost62 223 257 
Total operating lease cost$1,897 $1,319 $2,023 
Finance leases:
Amortization of right-of-use assets$5,632 $4,636 $2,876 
Interest on lease liabilities368 378 326 
Total finance lease cost$6,000 $5,014 $3,202 

The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:
January 31, 2023
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2024$958 $5,102 
2025225 2,566 
202686 209 
202742 — 
Thereafter— 
Total future minimum lease payments$1,318 $7,877 
Less: interest(35)(226)
Present value of lease liabilities$1,283 $7,651 

As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.

Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:
Fiscal years ended
January 31,
202320222021
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,347 $1,206 $1,629 
Operating cash used for finance leases396 377 326 
Financing cash used for finance leases5,731 4,267 2,630 
Total$7,474 $5,850 $4,585 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and
do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.
During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less.
Leases Leases
(a) Phreesia as Lessee
The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option
date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two to three years and are secured by the underlying equipment.
During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada
and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to
cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company
shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The
financial impact of the change in useful lives of the related right of use assets was not significant.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:
January 31,
20232022
Operating leases:
Lease right-of-use assets$569 $2,337 
Lease liabilities, current934 1,281 
Lease liabilities, non-current349 1,276 
Total operating lease liabilities$1,283 $2,557 
Finance leases:
Property and equipment, at cost$27,813 $27,310 
Accumulated depreciation(20,657)(15,025)
Property and equipment, net$7,156 $12,285 
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)4,926 5,600 
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)2,725 7,284 
Total finance lease liabilities$7,651 $12,884 

For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.
As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.
The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:
Fiscal years ended
January 31,
202320222021
Operating leases:
Operating lease cost$1,835 $1,096 $1,766 
Variable lease cost62 223 257 
Total operating lease cost$1,897 $1,319 $2,023 
Finance leases:
Amortization of right-of-use assets$5,632 $4,636 $2,876 
Interest on lease liabilities368 378 326 
Total finance lease cost$6,000 $5,014 $3,202 

The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:
January 31, 2023
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2024$958 $5,102 
2025225 2,566 
202686 209 
202742 — 
Thereafter— 
Total future minimum lease payments$1,318 $7,877 
Less: interest(35)(226)
Present value of lease liabilities$1,283 $7,651 

As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.

Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:
Fiscal years ended
January 31,
202320222021
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,347 $1,206 $1,629 
Operating cash used for finance leases396 377 326 
Financing cash used for finance leases5,731 4,267 2,630 
Total$7,474 $5,850 $4,585 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and
do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.
During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and contingencies
12 Months Ended
Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
(a) Indemnifications
The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third-party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued any liabilities related to such obligations in its consolidated financial statements.
In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions.
(b) Legal proceedings
In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.
(c) Other contractual commitments

Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below.
Purchase obligations
Year ending January 31,
2024$11,646 
20258,115 
20263,530 
2027598 
Total$23,889 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes
12 Months Ended
Jan. 31, 2023
Income Tax Disclosure [Abstract]  
Income taxes Income taxesThe Company recorded a tax provision of $483, $182 and $49, for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's provision for income taxes was 0.3%, 0.2% and 0.2% of loss before income taxes for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against the
majority of its deferred tax assets, and due to foreign income tax expense recorded for the Company's Canada branch related to the use of net operating loss carry forwards to offset current income.
Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2023 and 2022.
The Company’s loss before income taxes was primarily generated in the United States for fiscal 2023, fiscal 2022 and fiscal 2021.
The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021:
Fiscal years ended January 31,
202320222021
Current tax
Federal$— $— $— 
State49 39 114 
Foreign— — — 
Deferred tax
Federal109 — (116)
State— — (65)
Foreign325 143 116 
Total provision for income taxes$483 $182 $49 
A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows:
Fiscal years ended January 31,
202320222021
Federal income tax benefit at statutory rate21 %21 %21 %
State and local tax, net of federal benefit%%10 %
Permanent differences— %— %— %
Equity compensation— %%44 %
Foreign taxes— %— %— %
Other— %— %(4)%
Change in valuation allowance(26)%(36)%(71)%
Effective income tax rate— %— %— %

The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2023 and 2022 are as follows:
January 31,
Deferred tax assets (liabilities)20232022
Net operating loss carryforwards$131,574 $88,979 
Stock based compensation7,765 5,374 
Accruals, reserves, and other expenses2,7633,697
Reserve for bad debts530 521 
Disallowed interest expense1,9341,934
Total deferred tax assets144,566 100,505 
Less valuation allowance(143,135)(97,279)
Net deferred tax assets1,431 3,226 
Depreciation and amortization(295)(1,250)
Intangible assets(305)(373)
Deferred contract acquisition costs(750)(1,088)
Total deferred tax liabilities(1,350)(2,711)
Deferred taxes, net$81 $515 

The Company has accumulated a Federal net operating loss carryforward of approximately $493,333 and $332,544 as of January 31, 2023 and 2022, respectively. This carryforward may be available to offset future income tax liabilities and will expire beginning in 2025. As of January 31, 2023, the Company's foreign branch had net operating loss carryforwards of approximately $716, which may be available to offset future income in Canada and will expire beginning in 2034.
Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized.
On the basis of this evaluation, as of January 31, 2023 and 2022, the Company recorded a valuation allowance of $143,135 and $97,279, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $45,856 increase in the valuation allowance recorded during the fiscal year ended January 31, 2023 relates primarily to deferred tax assets established and recorded during the fiscal year ended January 31, 2023. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced.
Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2023, the Company has U.S. net operating loss carryforwards of approximately $493.3 million. The Company has completed a Section 382 study and as a result of the analysis, it is more likely than not that the Company has experienced an “ownership change”. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership. Accordingly, if the Company earns net taxable income, it is more likely than not that the Company's ability to use its pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability.
The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2018 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2023 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets in accordance with ASC 740 and adjusts these balances when its judgement changes as a result of the evaluation of new information previously not available. The Company recognized interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2023 and for the years ended January
31, 2023, 2022 and 2021, the Company did not have a balance of unrecognized tax benefits. As of January 31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Net loss per share attributable to common stockholders
12 Months Ended
Jan. 31, 2023
Earnings Per Share [Abstract]  
Net loss per share attributable to common stockholders Net loss per share attributable to common stockholders
(a) Net loss per share attributable to common stockholders
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
Fiscal years ended January 31,
202320222021
Numerator:
Net loss$(176,146)$(118,161)$(27,292)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted52,440,067 49,888,436 39,519,640 
Net loss per share attributable to common stockholders$(3.36)$(2.37)$(0.69)
(b) Potential dilutive securities
The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock awards, and grants under the Company's ESPP, our employee stock purchase plan, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Fiscal years ended January 31,
202320222021
Stock options to purchase common stock, restricted stock units and performance stock awards6,745,591 5,632,823 5,406,004 
Employee stock purchase plan74,685 75,370 — 
Total6,820,276 5,708,193 5,406,004 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Retirement savings plan
12 Months Ended
Jan. 31, 2023
Retirement Benefits [Abstract]  
Retirement savings plan Retirement savings planOn February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in the years ended January 31, 2023, 2022 or 2021
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions
12 Months Ended
Jan. 31, 2023
Related Party Transactions [Abstract]  
Related party transactions Related party transactions
For the years ended January 31, 2023 and 2022, the Company recognized revenue totaling $775 and $482 for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of January 31, 2023 and 2022, accounts receivable from the pharmaceutical company totaled $339 and $173, respectively.
For the years ended January 31, 2023 and 2022, the Company recognized general and administrative expenses totaling $374 and $182 for software agreements with a software company, respectively. One of the Company's independent members of its board of directors serves as the chief executive officer and on the board of directors for this software company. As of January 31, 2023 and 2022, prepaid expenses and other current assets include approximately $51 and $374 of payments to this software company, respectively. As of January 31, 2022, other assets included $51 of payments to this software company. This software company has been a related party since October 2021 when this software company's chief executive officer and board member became an independent member of the Company's board of directors, and the disclosures above represent transactions occurring while the software company was a related party.


The Company recognized revenue totaling approximately $2,425 from an affiliate of a stockholder of the Company for the year ended January 31, 2021. The revenue presented above includes revenue earned while the entity was a related party. The entity was a related party for a portion of the year ended January 31, 2021 and was no longer a related party during the years ended January 31, 2022 and 2023.
One of the Company's independent members of its board of directors has served as the chief financial officer of a
software company since April 2022. The Company recognized de minimis expenses during the year ended January 31, 2023 for software agreements with this software company.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions
12 Months Ended
Jan. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions
Acquisition of Insignia Health, LLC

On December 3, 2021, the Company entered into an agreement to acquire 100% of the outstanding equity of Insignia, a founder-led and mission-oriented company for cash consideration of $37,208. Insignia provides coaching and education solutions in conjunction with Insignia's exclusive worldwide license to the PAM. The PAM is a survey measuring a patient's knowledge, skills and ability to manage their care. The Company acquired Insignia to enable the Company to understand and engage patients in more personalized ways based on their level of activation. The acquisition of Insignia was accounted for as a business combination.
The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:
Cash consideration paid to sellers$37,112 
Liabilities incurred to sellers96 
Total fair value of acquisition consideration$37,208 

The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022.
Cash consideration paid to sellers$37,112 
Less: Cash acquired(2,689)
Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows$34,423 
The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations.

The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition:
Cash$2,689 
Accounts receivable994 
Prepaid expenses and other assets358 
Operating lease right-of-use assets606 
Intangibles10,700 
Goodwill25,410 
Total assets acquired40,757 
Accounts payable(84)
Accrued liabilities(487)
Deferred revenue(2,372)
Operating lease liabilities(606)
Total purchase price$37,208 
The components of intangible assets acquired were as follows:
Estimated Useful Life
(in Years)
Fair Value
PAM license15$6,200 
Customer relationships104,500 
Total identifiable intangible assets acquired$10,700 
The weighted average amortization period for acquired intangible assets as of the date of acquisition is 13 years.
The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Insignia. The fair value of the acquired PAM license was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset.
The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes.
The goodwill recognized in the acquisition of Insignia is primarily attributable to expected synergies of the combined businesses driven by integrating the PAM into the Phreesia Platform and engaging with patients in more personalized ways based on their level of activation, as well as the acquisition of an assembled workforce. The goodwill is expected to be deductible for tax purposes.

During the fiscal year ended January 31, 2022, the Company incurred $720 of acquisition related costs for the acquisition of Insignia. These costs are primarily included within general and administrative expenses in our consolidated statement of operations.


Acquisition of QueueDr
On January 8, 2021, the Company entered into a stock purchase agreement with QueueDr to acquire 100% of the outstanding equity of QueueDr, an early-stage software company that automates the process of rescheduling cancellations and no-shows. We acquired QueueDr to enhance our appointments solution. The acquisition of QueueDr was accounted for as a business combination.
The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:
Cash consideration paid on acquisition date$5,773 
Liabilities incurred2,111 
Contingent consideration2,240 
Total fair value of acquisition consideration$10,124 
The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021:
Cash consideration paid on acquisition date$5,773 
Payments of acquisition date fair value of contingent consideration954 
Less cash acquired(217)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows$6,510 
During the fiscal year ended January 31, 2021, the Company incurred $282 of acquisition related costs for the acquisition of QueueDr. During the fiscal year ended January 31, 2022, the Company incurred $258 of expenses to remeasure the acquisition-date fair value of contingent consideration to its ultimate settlement amount of $1,544. Each of these costs were included within general and administrative expenses in our consolidated statements of operations.
During the years ended January 31, 2023 and, 2022, the Company recorded certain measurement period adjustments related to the acquisitions of Insignia and QueueDr. The financial impact of measurement period adjustments was not material.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent event
12 Months Ended
Jan. 31, 2023
Subsequent Events [Abstract]  
Subsequent event Subsequent event
On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023.

On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company.

The Company is also party to the Third SVB Facility which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations.
Management believes that the Company’s cash and cash equivalents along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months.
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies (Policies)
12 Months Ended
Jan. 31, 2023
Accounting Policies [Abstract]  
Consolidated Financial Statements Consolidated Financial StatementsThe accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company").
Fiscal year Fiscal yearThe Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
Use of estimates Use of estimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.
Revenue recognition Revenue recognitionThe Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers, as well as for additional details about the Company's products and service lines.
Concentrations of credit risk and risks and uncertainties Concentrations of credit riskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor.The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies.Risks and uncertaintiesThe Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and Contingencies, for a summary of our contractual commitments as of January 31, 2023.
Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization)Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
Payment processing expense Payment processing expensePayment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways.
Sales and marketing Sales and marketingSales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred.
Research and development Research and developmentResearch and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
General and administrative General and administrativeGeneral and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation and amortization DepreciationDepreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.AmortizationAmortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
Cash and cash equivalents Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents.
Settlement assets Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one to two business days of the transaction date.
Settlement obligations Settlement obligationsSettlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
Accounts receivable Accounts receivableAccounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted.
Property and equipment Property and equipment
Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three and seven years. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.
Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
Capitalized internal-use software Capitalized internal-use softwareThe Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software. These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period.
Business combinations Business combinationsThe Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date,
the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations.
When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.
Goodwill and intangible assets Goodwill and intangible assets
Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.
The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.
All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long-lived assets Long-lived assetsLong-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Income taxes Income taxes
An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure.
The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
Segment information Segment informationOperating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements.
Stock-based compensation Stock-based compensationThe Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718, Compensation — Stock Compensation, which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield.

During fiscal 2022, the Company activated the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date.

For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares.
Fair value of financial instruments Fair value of financial instruments
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.
Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Equity offering costs Equity offering costsThe Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations.
Foreign currency Foreign currencyThe Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net.
New accounting pronouncements New accounting pronouncements
Impact of recently adopted accounting pronouncements
During the year ended January 31, 2023, the Company did not adopt any accounting pronouncements.
Recent accounting pronouncements not yet adopted
There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions (Tables)
12 Months Ended
Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]  
Schedule of accrued expenses Accrued expenses at January 31, 2023 and 2022 are as follows:
January 31,
20232022
Payroll-related expenses and taxes$10,345 $10,780 
Payment processing fees liability4,796 3,502 
Acquisition-related liabilities96 96 
Tax liabilities1,491 2,093 
Information technology services2,249 1,266 
Other2,833 2,391 
Total$21,810 $20,128 
Schedule of property and equipment Property and equipment at January 31, 2023 and 2022 are as follows:
Useful life
(years)
January 31,
20232022
PhreesiaPads and Arrivals Kiosks3$17,932 $26,387 
Computer equipment
354,485 53,957 
Computer software
3 to 5
8,571 5,311 
Hardware development
3529 1,024 
Furniture and fixtures
7— 539 
Leasehold improvements
2— 748 
Total property and equipment
$81,517 $87,966 
Less accumulated depreciation(59,847)(53,321)
Property and equipment — net$21,670 $34,645 
Schedule of intangible assets
The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022.
Useful LifeJanuary 31,
(years)20232022
Acquired technology5$1,410 $1,410 
Customer relationship
7 to 10
6,340 6,340 
License156,200 6,200 
Total intangible assets, gross carrying value$13,950 $13,950 
Less accumulated amortization(2,549)(1,178)
Net carrying value$11,401 $12,772 
Schedule of estimated amortization expense for intangible assets The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023:
January 31, 2023
2024$1,358 
20251,273 
20261,242 
2027949 
Thereafter6,579 
Total$11,401 
Schedule of goodwill The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023:
Balance at January 31, 2021$8,307 
Goodwill acquired during the year ended January 31, 202225,314 
Balance at January 31, 202233,621 
Measurement period adjustments to goodwill during the year ended January 31, 2023115 
Balance at January 31, 2023$33,736 
Schedule of accounts receivable Accounts Receivable as of January 31, 2023 and 2022 are as follows:
January 31,
20232022
Billed$51,458 $40,733 
Unbilled989 392 
Total accounts receivable, gross52,447 41,125 
Less accounts receivable allowances(1,053)(863)
Total accounts receivable$51,394 $40,262 
Schedule of allowance for doubtful accounts

Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022:
Balance, January 31, 2021$699 
Bad debt expense212 
Write-offs and adjustments(48)
Balance, January 31, 2022863 
Bad debt expense587 
Write-offs and adjustments(397)
Balance, January 31, 2023
$1,053 
Schedule of prepaid and other current assets Prepaid and other current assets as of January 31, 2023 and 2022 are as follows:
January 31,
20232022
Prepaid software and business systems$3,426 $3,738 
Prepaid data center expenses2,389 3,230 
Prepaid insurance1,552 1,924 
Other prepaid expenses and other current assets3,342 2,151 
Total prepaid and other current assets$10,709 $11,043 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue and Contract Costs (Tables)
12 Months Ended
Jan. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of rollforward of contract assets and contract liabilities
The following table represents a roll-forward of contract assets:
January 31,
20232022
Beginning Balance$392 $1,287 
Amount transferred to receivables from beginning balance of contract assets(392)(1,287)
Increases in contract assets due to acquisitions— 243 
Contract asset additions, net of reclassification to receivables989 149 
Ending Balance$989 $392 
The following table represents a roll-forward of deferred revenue:
 January 31,
20232022
Beginning Balance$16,558 $10,838 
Revenue recognized that was included in deferred revenue at the beginning of the period(16,005)(10,838)
Increases in deferred revenue due to acquisitions— 2,372 
Other current year activity in deferred revenue17,260 14,186 
Ending Balance$17,813 $16,558 
Schedule of deferred contract acquisition costs The following table represents a roll-forward of deferred contract acquisition costs:
January 31,
20232022
Beginning balance$4,079 $2,941 
Additions to deferred contract acquisition costs427 3,349 
Amortization of deferred contract acquisition costs(1,696)(2,211)
Ending balance$2,810 $4,079 
Deferred contract acquisition costs, current (to be amortized in next 12 months)$1,056 $1,642 
Deferred contract acquisition costs, non-current1,754 2,437 
Total deferred contract acquisition costs$2,810 $4,079 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Finance leases and other debt (Tables)
12 Months Ended
Jan. 31, 2023
Debt Disclosure [Abstract]  
Schedule of long-term debt instruments As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt:
January 31,
20232022
Finance leases$7,651 $12,884 
Financing arrangements46 266 
Accrued interest and payments200 94 
Total finance lease liabilities and other debt$7,897 $13,244 
Less - current portion of finance lease liabilities and other debt(5,172)(5,821)
Long-term finance leases and other debt$2,725 $7,423 
Schedule of long-term debt and finance lease maturities Maturities of finance leases and other debt in each of the next five years and thereafter are as follows:
 TotalFinance LeasesOther Debt
Fiscal year ending January 31:
2024$5,172 $4,926 $246 
20252,518 2,518 — 
2026207 207 — 
Total maturities of finance leases and other debt$7,897 $7,651 $246 
Schedule of components of interest income (expense) The following table presents the components of interest income (expense), net:
Fiscal years ended January 31,
 202320222021
Interest expense (1)
$(1,411)$(1,163)$(1,695)
Interest income2,475 79 122 
Interest income (expense), net$1,064 $(1,084)$(1,573)
(1) Includes amortization of deferred financing costs and original issue discount
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation (Tables)
12 Months Ended
Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of stock based compensation by type of award The following table sets forth stock-based compensation by type of award:
For the fiscal years ended
January 31,
 202320222021
RSUs$42,214 $24,222 $10,693 
Liability awards7,641 7,055 — 
PSUs7,282 2,389 93 
Stock options1,489 2,294 2,703 
ESPP1,521 763 — 
Total stock-based compensation$60,147 $36,723 $13,489 
Schedule of stock based compensation in financial statements
The following table sets forth the presentation of stock-based compensation in the Company's financial statements:


For the fiscal years ended
January 31,
 202320222021
Stock-based compensation expense recorded to additional paid-in capital(1)
$52,506 $29,668 $13,489 
Stock-based compensation expense recorded to accrued expenses7,641 7,055 — 
Total stock-based compensation60,147 36,723 13,489 
Less stock-based compensation expense capitalized as internal-use software(1,372)(489)— 
Stock-based compensation expense per consolidated statements of operations(2)
$58,775 $36,234 $13,489 
(1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts.
(2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.
Schedule of restricted stock unit activity
  Restricted stock units
Unvested, January 31, 20201,447,418 
Granted during year
972,271 
Vested(242,049)
Forfeited and expired(124,602)
Unvested, January 31, 20212,053,038 
Granted during year
1,836,534 
Vested(559,767)
Forfeited and expired(195,966)
Unvested, January 31, 20223,133,839 
Granted during year
2,907,838 
Vested(1,626,679)
Forfeited and expired (497,245)
Unvested, January 31, 2023
3,917,753 
Schedule of stock option activity Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows:
Number of
options
Weighted-
average
exercise price
Weighted-
average
remaining
contractual life
(in years)
Aggregate Intrinsic
value
Outstanding—January 31, 20205,516,452 $3.80 
Granted during the year— $— 
Exercised(2,216,368)$2.39 
Forfeited(88,730)$7.45 
Outstanding and expected to vest — January 31, 2021
3,211,354 $4.67 5.99$194,676 
Outstanding—January 31, 20213,211,354 $4.67 
Granted during the year— $— 
Exercised(1,439,186)$2.88 
Forfeited and expired(67,018)$9.02 
Outstanding and expected to vest — January 31, 2022
1,705,150 $6.01 5.94$42,938 
Outstanding—January 31, 20221,705,150 $6.01 
Granted during the year— $— 
Exercised(311,743)$4.92 
Forfeited and expired(8,214)$4.68 
Outstanding and expected to vest — January 31, 2023
1,385,193 $6.26 5.06$43,341 
Exercisable — January 31, 2023
1,362,903 $6.12 5.03$42,750 
Amount vested during year ended January 31, 2023
258,735 $8.27 
Schedule of measurement inputs and valuation techniques The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions:
Fiscal years ended
January 31,
 202320222021
Correlation coefficient0.4957 0.3878 0.4230 
Valuation date stock price$35.41 $36.03 $62.96 
Simulation term3.00 Years2.99 Years3.00 Years
Volatility64.98 %44.32 %43.71 %
Risk-free rate3.84 %1.23 %0.20 %
Dividend yield— %— %— %
Weighted average fair value of grants
$56.52 $48.47 $84.38 
Schedule of market-based performance stock unit activity Market based PSU activity for the years ended January 31, 2023, 2022 and 2021 are as follows:
Performance
stock units
Outstanding February 1, 2020— 
Granted during the year ended January 31, 202170,806 
Outstanding, February 1, 202170,806 
Granted during the year ended January 31, 2022325,410 
Vested— 
Forfeited and expired— 
Outstanding, February 1, 2022396,216 
Granted during the year ended January 31, 2023
255,572 
Vested— 
Forfeited and expired(3,555)
Outstanding, January 31, 2023
648,233 
Schedule of ESPP valuation assumptions The fair value of shares granted under the ESPP during the year ended January 31, 2023 was estimated using a Black-Scholes pricing model with the following assumptions:
Year ended
January 31, 2023
Year ended
January 31, 2022
Risk-free interest rate
3.68 %0.17 %
Expected dividends
nonenone
Expected term (in years)
0.47 years0.49 years
Volatility
74.8 %55.7 %
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Fair value measurements (Tables)
12 Months Ended
Jan. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of fair value, assets and liabilities measured on recurring basis
The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands):
 Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2023
 
Money market mutual funds$163,563 $— $— $163,563 
Total assets$163,563 $— $— $163,563 

The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands):
 Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2022
 
Money market mutual funds$197,601 $— $— $197,601 
Total assets$197,601 $— $— $197,601 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
12 Months Ended
Jan. 31, 2023
Leases [Abstract]  
Schedule of operating and finance leases
Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:
January 31,
20232022
Operating leases:
Lease right-of-use assets$569 $2,337 
Lease liabilities, current934 1,281 
Lease liabilities, non-current349 1,276 
Total operating lease liabilities$1,283 $2,557 
Finance leases:
Property and equipment, at cost$27,813 $27,310 
Accumulated depreciation(20,657)(15,025)
Property and equipment, net$7,156 $12,285 
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)4,926 5,600 
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)2,725 7,284 
Total finance lease liabilities$7,651 $12,884 
Schedule of lease expense and cash flow information The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:
Fiscal years ended
January 31,
202320222021
Operating leases:
Operating lease cost$1,835 $1,096 $1,766 
Variable lease cost62 223 257 
Total operating lease cost$1,897 $1,319 $2,023 
Finance leases:
Amortization of right-of-use assets$5,632 $4,636 $2,876 
Interest on lease liabilities368 378 326 
Total finance lease cost$6,000 $5,014 $3,202 
Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:
Fiscal years ended
January 31,
202320222021
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,347 $1,206 $1,629 
Operating cash used for finance leases396 377 326 
Financing cash used for finance leases5,731 4,267 2,630 
Total$7,474 $5,850 $4,585 
Schedule of maturing lease commitments of operating leases The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:
January 31, 2023
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2024$958 $5,102 
2025225 2,566 
202686 209 
202742 — 
Thereafter— 
Total future minimum lease payments$1,318 $7,877 
Less: interest(35)(226)
Present value of lease liabilities$1,283 $7,651 
Schedule of maturing lease commitments of finance leases The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:
January 31, 2023
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2024$958 $5,102 
2025225 2,566 
202686 209 
202742 — 
Thereafter— 
Total future minimum lease payments$1,318 $7,877 
Less: interest(35)(226)
Present value of lease liabilities$1,283 $7,651 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Commitment and contingencies (Tables)
12 Months Ended
Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Minimum Payments Under Purchase Commitments Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below.
Purchase obligations
Year ending January 31,
2024$11,646 
20258,115 
20263,530 
2027598 
Total$23,889 
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Tables)
12 Months Ended
Jan. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of income tax (benefit) The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021:
Fiscal years ended January 31,
202320222021
Current tax
Federal$— $— $— 
State49 39 114 
Foreign— — — 
Deferred tax
Federal109 — (116)
State— — (65)
Foreign325 143 116 
Total provision for income taxes$483 $182 $49 
Schedule of effective tax rate A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows:
Fiscal years ended January 31,
202320222021
Federal income tax benefit at statutory rate21 %21 %21 %
State and local tax, net of federal benefit%%10 %
Permanent differences— %— %— %
Equity compensation— %%44 %
Foreign taxes— %— %— %
Other— %— %(4)%
Change in valuation allowance(26)%(36)%(71)%
Effective income tax rate— %— %— %
Schedule of deferred tax assets and liabilities
The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2023 and 2022 are as follows:
January 31,
Deferred tax assets (liabilities)20232022
Net operating loss carryforwards$131,574 $88,979 
Stock based compensation7,765 5,374 
Accruals, reserves, and other expenses2,7633,697
Reserve for bad debts530 521 
Disallowed interest expense1,9341,934
Total deferred tax assets144,566 100,505 
Less valuation allowance(143,135)(97,279)
Net deferred tax assets1,431 3,226 
Depreciation and amortization(295)(1,250)
Intangible assets(305)(373)
Deferred contract acquisition costs(750)(1,088)
Total deferred tax liabilities(1,350)(2,711)
Deferred taxes, net$81 $515 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Net loss per share attributable to common stockholders (Tables)
12 Months Ended
Jan. 31, 2023
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
Fiscal years ended January 31,
202320222021
Numerator:
Net loss$(176,146)$(118,161)$(27,292)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted52,440,067 49,888,436 39,519,640 
Net loss per share attributable to common stockholders$(3.36)$(2.37)$(0.69)
Schedule of shares excluded from computation of diluted net loss per share The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Fiscal years ended January 31,
202320222021
Stock options to purchase common stock, restricted stock units and performance stock awards6,745,591 5,632,823 5,406,004 
Employee stock purchase plan74,685 75,370 — 
Total6,820,276 5,708,193 5,406,004 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions (Tables)
12 Months Ended
Jan. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of purchase price considerations at acquisition date
The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:
Cash consideration paid to sellers$37,112 
Liabilities incurred to sellers96 
Total fair value of acquisition consideration$37,208 

The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022.
Cash consideration paid to sellers$37,112 
Less: Cash acquired(2,689)
Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows$34,423 
The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:
Cash consideration paid on acquisition date$5,773 
Liabilities incurred2,111 
Contingent consideration2,240 
Total fair value of acquisition consideration$10,124 
The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021:
Cash consideration paid on acquisition date$5,773 
Payments of acquisition date fair value of contingent consideration954 
Less cash acquired(217)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows$6,510 
Schedule of allocation of purchase price of assets acquired and liabilities assumed The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition:
Cash$2,689 
Accounts receivable994 
Prepaid expenses and other assets358 
Operating lease right-of-use assets606 
Intangibles10,700 
Goodwill25,410 
Total assets acquired40,757 
Accounts payable(84)
Accrued liabilities(487)
Deferred revenue(2,372)
Operating lease liabilities(606)
Total purchase price$37,208 
Schedule of intangible assets acquired The components of intangible assets acquired were as follows:
Estimated Useful Life
(in Years)
Fair Value
PAM license15$6,200 
Customer relationships104,500 
Total identifiable intangible assets acquired$10,700 
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Background and liquidity (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Mar. 10, 2023
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Debt Instrument [Line Items]          
Cash and cash equivalents $ 176,683   $ 313,812 $ 218,781 $ 90,315
Third SVB Facility          
Debt Instrument [Line Items]          
Number of months with sufficient funds to operate (in months) 12 months        
Third SVB Facility | Subsequent event          
Debt Instrument [Line Items]          
Cash and cash equivalents   $ 170,000      
Third SVB Facility | Revolving credit facility | Subsequent event          
Debt Instrument [Line Items]          
Allowable cash hold outside of facility   $ 165,000      
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies (Details)
12 Months Ended
Jan. 31, 2023
USD ($)
segment
processor
Jan. 31, 2022
USD ($)
Jan. 31, 2021
USD ($)
Accounting Policies [Line Items]      
Settlement period (in days) 2 days    
Number of third party payment processors | processor 1    
Advertising expense $ 2,634,000 $ 4,007,000 $ 558,000
Allowance for doubtful accounts 1,053,000 863,000 699,000
Asset impairment charges $ 0 $ 0 $ 0
Number of operating segment | segment 1    
ESPP      
Accounting Policies [Line Items]      
Employee purchase price of common stock (as a percent) 85.00%    
Customer One | Revenue Benchmark | Customer Concentration Risk      
Accounting Policies [Line Items]      
Concentration risk (as a percent) 10.00% 10.00%  
Minimum      
Accounting Policies [Line Items]      
Customer payment period 30 days    
Settlement period (in days) 1 day    
Useful life (in years) 3 years    
Minimum | Computer software      
Accounting Policies [Line Items]      
Estimated useful life (in years) 3 years    
Maximum      
Accounting Policies [Line Items]      
Customer payment period 60 days    
Settlement period (in days) 2 days    
Useful life (in years) 7 years    
Maximum | Computer software      
Accounting Policies [Line Items]      
Estimated useful life (in years) 5 years    
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of accrued expenses (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]    
Payroll-related expenses and taxes $ 10,345 $ 10,780
Payment processing fees liability 4,796 3,502
Acquisition-related liabilities 96 96
Tax liabilities 1,491 2,093
Information technology services 2,249 1,266
Other 2,833 2,391
Total $ 21,810 $ 20,128
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of property and equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 81,517 $ 87,966
Less accumulated depreciation (59,847) (53,321)
Property and equipment — net $ 21,670 34,645
Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 7 years  
PhreesiaPads and Arrivals Kiosks    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Total property and equipment $ 17,932 26,387
Computer equipment    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Total property and equipment $ 54,485 53,957
Computer software    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 8,571 5,311
Computer software | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Computer software | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 5 years  
Hardware development    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Total property and equipment $ 529 1,024
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 7 years  
Total property and equipment $ 0 539
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 2 years  
Total property and equipment $ 0 $ 748
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Narrative (Details) - USD ($)
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]      
Depreciation $ 17,988,000 $ 14,985,000 $ 9,770,000
Property and equipment, at cost 27,813,000 27,310,000  
Assets under finance lease, accumulated amortization 20,657,000 15,025,000  
Capitalized cost of computer software 23,604,000 12,830,000 7,663,000
Capitalized computed software amortization 5,945,000 5,664,000 5,884,000
Amortization of intangible assets 1,371,000 653,000 254,000
Impairment of goodwill 0 0 0
Goodwill adjustments during the year 115,000    
Capitalized implementation costs 1,532,000,000    
Capitalized implementation costs, accumulated amortization 610,000,000    
Other (expense) income, net $ (175,000) (78,000) $ 1,000
QueueDr      
Finite-Lived Intangible Assets [Line Items]      
Goodwill adjustments during the year   $ 96,000  
Acquired technology      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 2 years 8 months 12 days 3 years 6 months  
Customer relationship      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 8 years 3 months 18 days 9 years 2 months 12 days  
License      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 13 years 9 months 18 days 14 years 9 months 18 days  
Computer equipment      
Finite-Lived Intangible Assets [Line Items]      
Property and equipment, at cost $ 27,813,000 $ 27,310,000  
Assets under finance lease, accumulated amortization $ 20,657,000 $ 15,025,000  
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of intangible assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross carrying value $ 13,950 $ 13,950
Less accumulated amortization (2,549) (1,178)
Net carrying value $ 11,401 12,772
Acquired technology    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 5 years  
Total intangible assets, gross carrying value $ 1,410 1,410
Customer relationship    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross carrying value $ 6,340 6,340
Customer relationship | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 7 years  
Customer relationship | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 10 years  
License    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 15 years  
Total intangible assets, gross carrying value $ 6,200 $ 6,200
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of future amortization expense (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]    
2024 $ 1,358  
2025 1,273  
2026 1,242  
2027 949  
Thereafter 6,579  
Net carrying value $ 11,401 $ 12,772
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Goodwill [Roll Forward]    
Goodwill balance at beginning of period $ 33,621 $ 8,307
Goodwill additions during the year   25,314
Measurement period adjustments to goodwill during the year 115  
Goodwill balance at end of period $ 33,736 $ 33,621
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of accounts receivable (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Composition Of Certain Financial Statement [Abstract]      
Billed $ 51,458 $ 40,733  
Unbilled 989 392  
Total accounts receivable, gross 52,447 41,125  
Less accounts receivable allowances (1,053) (863) $ (699)
Total accounts receivable $ 51,394 $ 40,262  
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Allowance for doubtful accounts at beginning of period $ 863 $ 699
Bad debt expense 587 212
Write-offs and adjustments (397) (48)
Allowance for doubtful accounts at end of period $ 1,053 $ 863
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]    
Prepaid software and business systems $ 3,426 $ 3,738
Prepaid data center expenses 2,389 3,230
Prepaid insurance 1,552 1,924
Other prepaid expenses and other current assets 3,342 2,151
Total prepaid and other current assets $ 10,709 $ 11,043
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue and Contract Costs - Narrative (Details) - USD ($)
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Revenue from External Customer [Line Items]      
Settlement period (in days) 2 days    
Capitalized contract cost, amortization $ 1,696,000 $ 2,211,000 $ 2,025,000
Capitalized contract cost, impairment loss $ 0 0  
Minimum      
Revenue from External Customer [Line Items]      
Settlement period (in days) 1 day    
Capitalized contract cost, amortization period (in years) 3 years    
Maximum      
Revenue from External Customer [Line Items]      
Settlement period (in days) 2 days    
Capitalized contract cost, amortization period (in years) 5 years    
Subscription and related services      
Revenue from External Customer [Line Items]      
Lease income $ 10,197,000 $ 6,489,000 $ 6,312,000
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Contract With Customer Asset [Roll Forward]    
Beginning balance - Contract assets (unbilled accounts receivable) $ 392 $ 1,287
Amount transferred to receivables from beginning balance of contract assets (392) (1,287)
Increases in contract assets due to acquisitions 0 243
Contract asset additions, net of reclassification to receivables 989 149
Ending balance - Contract assets (unbilled accounts receivable) 989 392
Contract With Customer Liability [Roll Forward]    
Beginning balance - Contract liabilities (deferred revenue) 16,558 10,838
Revenue recognized that was included in deferred revenue at the beginning of the period (16,005) (10,838)
Increases in deferred revenue due to acquisitions 0 2,372
Other current year activity in deferred revenue 17,260 14,186
Ending balance - Contract liabilities (deferred revenue) $ 17,813 $ 16,558
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Capitalized Contract Cost [Roll Forward]      
Capitalized contract costs at beginning of period $ 4,079 $ 2,941  
Additions to deferred contract acquisition costs 427 3,349  
Amortization of deferred contract acquisition costs (1,696) (2,211) $ (2,025)
Capitalized contract costs at end of period 2,810 4,079 2,941
Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,056 1,642  
Deferred contract acquisition costs, non-current 1,754 2,437  
Total deferred contract acquisition costs $ 2,810 $ 4,079 $ 2,941
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Finance leases and other debt - Schedule of outstanding loan balances (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Debt Instrument [Line Items]    
Finance leases $ 7,651 $ 12,884
Long-term debt 246  
Total finance lease liabilities and other debt 7,897 13,244
Less - current portion of finance lease liabilities and other debt (5,172) (5,821)
Long-term finance leases and other debt 2,725 7,423
Financing arrangements    
Debt Instrument [Line Items]    
Long-term debt 46 266
Accrued interest and payments    
Debt Instrument [Line Items]    
Long-term debt $ 200 $ 94
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Finance leases and other debt - Amended and restated loan and security agreement (Details) - USD ($)
12 Months Ended
Jan. 31, 2023
Jan. 31, 2021
Mar. 28, 2022
Mar. 27, 2022
Jan. 31, 2022
May 05, 2020
Feb. 28, 2019
Term loan              
Debt Instrument [Line Items]              
Debt instrument, face amount             $ 20,000,000
Loss on extinguishment of debt   $ 1,073,000          
Second SVB Facility | Revolving credit facility              
Debt Instrument [Line Items]              
Line of credit borrowing capacity           $ 50,000,000  
Accordion feature, potential new maximum borrowing capacity           65,000,000  
Long term debt $ 0       $ 0 $ 20,663,000  
Third SVB Facility | Revolving credit facility              
Debt Instrument [Line Items]              
Line of credit borrowing capacity     $ 100,000 $ 50,000      
Stated interest rate (as a percent) 3.25%            
Interest rate (as a percent) 7.00%            
Annual commitment fee $ 250,000            
Unused capacity, commitment fee (as a percent) 0.15%            
Remaining borrowing capacity $ 100,000,000            
Termination fee percentage (up to) (as a percent)           1.50%  
Third SVB Facility | Revolving credit facility | Prime Rate              
Debt Instrument [Line Items]              
Scheduled reduction in interest rate (as a percent) 0.50%            
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Finance leases and other debt - Schedule of long-term debt maturities (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Total    
2024 $ 5,172  
2025 2,518  
2026 207  
Total maturities of finance leases and other debt 7,897  
Finance Leases    
2024 4,926  
2025 2,518  
2026 207  
Total finance lease liabilities 7,651 $ 12,884
Other Debt    
2024 246  
2025 0  
2026 0  
Total long-term debt maturities $ 246  
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Finance leases and other debt - Schedule of interest income (expense), net (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Debt Disclosure [Abstract]      
Interest expense $ (1,411) $ (1,163) $ (1,695)
Interest income 2,475 79 122
Interest income (expense), net $ 1,064 $ (1,084) $ (1,573)
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity (Details) - $ / shares
Apr. 12, 2021
Jan. 31, 2023
Jan. 31, 2022
Jul. 22, 2019
Class of Stock [Line Items]        
Common stock authorized (up to) (in shares)   500,000,000 500,000,000 500,000,000
Common stock par value   $ 0.01 $ 0.01 $ 0.01
Follow-on Offering        
Class of Stock [Line Items]        
Issuance of common stock, net of issuance costs (in shares) 5,175,000      
Issue price per share (in dollars per share) $ 50.00      
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jan. 02, 2023
Jan. 01, 2021
Dec. 31, 2020
Jun. 30, 2019
shares
Jan. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
Jan. 31, 2022
USD ($)
offering_period
$ / shares
shares
Jan. 31, 2021
USD ($)
$ / shares
shares
Jan. 31, 2018
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Weighted average fair market value of grants (in USD per share) | $ / shares         $ 26.79   $ 46.60 $ 32.78  
Intrinsic value         $ 6,970   $ 73,624 $ 33,575  
Unrecognized compensation cost to stock option         45        
Issuance of common stock for employee stock purchase plan         3,472   $ 1,506    
Share settled bonuses         8,812        
ESPP                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
ESPP, employee common stock purchase discount (as a percent)             15.00%    
Unrecognized compensation costs         $ 605        
Weighted average term for recognition (in years)         5 months        
Employee purchase price of common stock (as a percent)         85.00%        
RSUs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)     7 years            
Unrecognized compensation costs         $ 112,482        
Weighted average term for recognition (in years)         2 years 9 months 18 days        
Bonus settlement in shares (as a percent)         115.00%        
Awards vested during period (in shares) | shares         1,626,679   559,767 242,049  
RSUs | Employees Other than NEOs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)   4 years              
Quarterly vesting rate (as a percent)   6.25%              
RSUs | NEOs and Other Members of Executive Management                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years) 4 years         4 years      
Quarterly vesting rate (as a percent) 25.00%         6.25%      
RSUs | Share-based Payment Arrangement, Year 1                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)     10.00%            
Vesting term (in years)     1 year            
RSUs | Share-based Payment Arrangement, Year 2                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)     20.00%            
Vesting term (in years)     2 years            
RSUs | Share-based Payment Arrangement, Year 3                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)     30.00%            
Vesting term (in years)     3 years            
RSUs | Share-based Payment Arrangement, Year 4                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)     40.00%            
Vesting term (in years)     4 years            
Stock options                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)         4 years        
Weighted average term for recognition (in years)         3 months 29 days        
Expiration period / maximum term (in years)         10 years        
Incremental expense associated with the modification of stock options         $ 322        
PSUs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         100.00%        
Vesting term (in years)         3 years        
Unrecognized compensation costs         $ 26,128        
Weighted average term for recognition (in years)         2 years 4 months 24 days        
Weighted average fair market value of grants (in USD per share) | $ / shares         $ 56.52   $ 48.47 $ 84.38  
Awards vested during period (in shares) | shares         0   0    
PSUs | Minimum                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         0.00%        
PSUs | Maximum                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         220.00%   200.00% 200.00%  
2018 Stock Option Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares available for issuance (in shares) | shares                 3,048,490
2019 Stock Option And Incentive Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock reserve for future issuance (in shares) | shares       2,139,683          
Percentage increase in number of shares reserved (as a percent)       5.00%          
2019 Stock Option And Incentive Plan | ESPP                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares available for grant (in shares) | shares       855,873 3,408,720        
Additional shares authorized (in shares) | shares             576,304    
ESPP, number of offering periods per year | offering_period             2    
ESPP offering period (in months)             6 months    
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 1                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         25.00%        
Vesting term (in years)         1 year        
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 2                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         25.00%        
Vesting term (in years)         1 year        
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 3                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         25.00%        
Vesting term (in years)         1 year        
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 4                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)         25.00%        
Vesting term (in years)         1 year        
2022 Share Settled Bonus Award Program | RSUs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Awards vested during period (in shares) | shares         302,931        
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Stock-based compensation (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation $ 60,147 $ 36,723 $ 13,489
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 42,214 24,222 10,693
Liability awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 7,641 7,055 0
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 7,282 2,389 93
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 1,489 2,294 2,703
ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation $ 1,521 $ 763 $ 0
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Stock-based compensation in our financial statements (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation $ 60,147 $ 36,723 $ 13,489
Less stock-based compensation expense capitalized as internal-use software (1,372) (489) 0
Stock-based compensation expense 58,775 36,234 13,489
Non-cash stock-based compensation expense 58,775 36,144 13,489
Cash settled stock based compensation expense   90  
Additional paid-in capital      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation 52,506 29,668 13,489
Accrued expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation $ 7,641 $ 7,055 $ 0
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Performance-based restricted stock units (Details) - shares
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
RSUs      
Restricted Stock Unit Activity:      
Beginning balance (in shares) 3,133,839 2,053,038 1,447,418
Granted (in shares) 2,907,838 1,836,534 972,271
Vested (in shares) (1,626,679) (559,767) (242,049)
Forfeited and expired (in shares) (497,245) (195,966) (124,602)
Ending balance (in shares) 3,917,753 3,133,839 2,053,038
PSUs      
Restricted Stock Unit Activity:      
Beginning balance (in shares) 396,216 70,806 0
Granted (in shares) 255,572 325,410 70,806
Vested (in shares) 0 0  
Forfeited and expired (in shares) (3,555) 0  
Ending balance (in shares) 648,233 396,216 70,806
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details)
12 Months Ended
Jan. 31, 2023
$ / shares
Jan. 31, 2022
$ / shares
Jan. 31, 2021
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average fair market value of grants (in USD per share) $ 26.79 $ 46.60 $ 32.78
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Correlation coefficient 0.4957 0.3878 0.4230
Valuation date stock price (in USD per share) $ 35.41 $ 36.03 $ 62.96
Simulation term (in years) 3 years 2 years 11 months 26 days 3 years
Volatility (as a percent) 64.98% 44.32% 43.71%
Risk-free rate (as a percent) 3.84% 1.23% 0.20%
Dividend yield (as a percent) 0.00% 0.00% 0.00%
Weighted average fair market value of grants (in USD per share) $ 56.52 $ 48.47 $ 84.38
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Weighted average assumptions (Details) - ESPP
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate (as a percent) 3.68% 0.17%
Expected dividends (as a percent) 0.00% 0.00%
Expected term (in years) 5 months 19 days 5 months 26 days
Volatility (as a percent) 74.80% 55.70%
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Equity-based compensation - Stock option activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Number of options      
Number of options outstanding at beginning of period (in shares) 1,705,150 3,211,354 5,516,452
Granted (in shares) 0 0 0
Exercised (in shares) (311,743) (1,439,186) (2,216,368)
Forfeited and expired (in shares) (8,214) (67,018) (88,730)
Number of options outstanding at end of period (in shares) 1,385,193 1,705,150 3,211,354
Exercisable (in shares) 1,362,903    
Amount vested at the end of the period (in shares) 258,735    
Weighted- average exercise price      
Weighted- average exercise price outstanding at beginning of period (in dollars per share) $ 6.01 $ 4.67 $ 3.80
Granted (in dollars per share) 0 0 0
Exercised (in dollars per share) 4.92 2.88 2.39
Forfeited and expired (in dollars per share) 4.68 9.02 7.45
Weighted- average exercise price outstanding at end of period (in dollars per share) 6.26 $ 6.01 $ 4.67
Exercisable (in dollars per share) 6.12    
Amount vested at the end of the period (in dollars per share) $ 8.27    
Weighted-average remaining contractual life of options outstanding and expected to vest (in years) 5 years 21 days 5 years 11 months 8 days 5 years 11 months 26 days
Weighted-average remaining contractual life of options exercisable (in years) 5 years 10 days    
Aggregate intrinsic value outstanding and expected to vest $ 43,341 $ 42,938 $ 194,676
Aggregate intrinsic value exercisable $ 42,750    
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) - Fair value, recurring - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds $ 163,563 $ 197,601
Total assets 163,563 197,601
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 163,563 197,601
Total assets 163,563 197,601
Significant Other Observable Inputs (Level 2)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 0 0
Total assets 0 0
Significant Unobservable Inputs (Level 3)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 0 0
Total assets $ 0 $ 0
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Lessee, Lease, Description [Line Items]      
Operating lease, weighted average remaining lease term (in years) 1 year 7 months 6 days    
Operating lease, weighted average discount rate (as a percent) 3.50%    
Finance lease, weighted average remaining lease term (in years) 1 year 7 months 6 days    
Finance lease, weighted average discount rate (as a percent) 3.60%    
Purchase obligation $ 8,115    
Subscription and related services      
Lessee, Lease, Description [Line Items]      
Lease income 10,197 $ 6,489 $ 6,312
Computer equipment      
Lessee, Lease, Description [Line Items]      
Purchase obligation $ 8,058    
Computer equipment | Minimum      
Lessee, Lease, Description [Line Items]      
Finance lease, term of contract (in years) 2 years    
Computer equipment | Maximum      
Lessee, Lease, Description [Line Items]      
Finance lease, term of contract (in years) 3 years    
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule of operating and finance leases (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Leases [Abstract]    
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Long-Term Debt and Lease Obligation, Current Long-Term Debt and Lease Obligation, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Long-term finance leases and other debt Long-term finance leases and other debt
Operating leases:    
Lease right-of-use assets $ 569 $ 2,337
Lease liabilities, current 934 1,281
Lease liabilities, non-current 349 1,276
Total operating lease liabilities 1,283 2,557
Finance leases:    
Property and equipment, at cost 27,813 27,310
Accumulated depreciation (20,657) (15,025)
Property and equipment, net 7,156 12,285
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,926 5,600
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 2,725 7,284
Total finance lease liabilities $ 7,651 $ 12,884
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule of lease expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Operating leases:      
Operating lease cost $ 1,835 $ 1,096 $ 1,766
Variable lease cost 62 223 257
Total operating lease cost 1,897 1,319 2,023
Finance leases:      
Amortization of right-of-use assets 5,632 4,636 2,876
Interest on lease liabilities 368 378 326
Total finance lease cost $ 6,000 $ 5,014 $ 3,202
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule of maturing lease payments (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Operating    
2024 $ 958  
2025 225  
2026 86  
2027 42  
Thereafter 7  
Total future minimum lease payments 1,318  
Less: interest (35)  
Total operating lease liabilities 1,283 $ 2,557
Finance    
2024 5,102  
2025 2,566  
2026 209  
2027 0  
Finance Lease, Liability, to be Paid, After Year Four 0  
Total future minimum lease payments 7,877  
Less: interest (226)  
Finance leases $ 7,651 $ 12,884
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule of supplemental cash flow information (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash used for operating leases $ 1,347 $ 1,206 $ 1,629
Operating cash used for finance leases 396 377 326
Financing cash used for finance leases 5,731 4,267 2,630
Total cash paid in measurement of lease liabilities $ 7,474 $ 5,850 $ 4,585
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details)
$ in Thousands
Jan. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2024 $ 11,646
2025 8,115
2026 3,530
2027 598
Total $ 23,889
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes - Narratives (Details) - USD ($)
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Operating Loss Carryforwards [Line Items]      
Provision for income taxes $ 483,000 $ 182,000 $ 49,000
Effective tax rate (as a percent) 0.30% 0.20% (0.20%)
Valuation allowance $ (143,135,000) $ (97,279,000)  
Increase in valuation allowance 45,856,000    
Tax examination, penalties and interest accrued 0    
Domestic Tax Authority      
Operating Loss Carryforwards [Line Items]      
Accumulated federal net operating loss carryforward 493,333,000 $ 332,544,000  
Foreign Tax Authority      
Operating Loss Carryforwards [Line Items]      
Accumulated federal net operating loss carryforward $ 716,000    
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes - Components of tax (benefit) (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Current tax      
Federal $ 0 $ 0 $ 0
State 49 39 114
Foreign 0 0 0
Deferred tax      
Federal 109 0 (116)
State 0 0 (65)
Foreign 325 143 116
Total provision for income taxes $ 483 $ 182 $ 49
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes - Effective tax rate reconciliation (Details)
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Income Tax Disclosure [Abstract]      
Federal income tax benefit at statutory rate (as a percent) 21.00% 21.00% 21.00%
State and local tax, net of federal benefit (as a percent) 5.00% 9.00% 10.00%
Permanent differences (as a percent) 0.00% 0.00% 0.00%
Equity compensation (as a percent) 0.00% 6.00% 44.00%
Foreign taxes (as a percent) 0.00% 0.00% 0.00%
Other (as a percent) 0.00% 0.00% (4.00%)
Change in valuation allowance (as a percent) (26.00%) (36.00%) (71.00%)
Effective income tax rate (as a percent) 0.30% 0.20% (0.20%)
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes - Company's deferred tax assets and deferred tax liabilities (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Deferred tax assets    
Net operating loss carryforwards $ 131,574 $ 88,979
Stock based compensation 7,765 5,374
Accruals, reserves, and other expenses 2,763 3,697
Reserve for bad debts 530 521
Disallowed interest expense 1,934 1,934
Total deferred tax assets 144,566 100,505
Valuation allowance 143,135 97,279
Net deferred tax assets 1,431 3,226
Depreciation and amortization (295) (1,250)
Intangible assets (305) (373)
Deferred contract acquisition costs (750) (1,088)
Total deferred tax liabilities (1,350) (2,711)
Deferred taxes, net $ 81 $ 515
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.23.1
Net loss per share attributable to common stockholders - Schedule of computation (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Numerator:      
Net loss $ (176,146) $ (118,161) $ (27,292)
Denominator:      
Weighted-average common shares outstanding - basic (in shares) 52,440,067 49,888,436 39,519,640
Weighted-average common shares outstanding - diluted (in shares) 52,440,067 49,888,436 39,519,640
Net loss per share attributable to common stockholders - basic (in dollars per share) $ (3.36) $ (2.37) $ (0.69)
Net loss per share attributable to common stockholders - diluted (in dollars per share) $ (3.36) $ (2.37) $ (0.69)
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.23.1
Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) - shares
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 6,820,276 5,708,193 5,406,004
Stock options to purchase common stock, restricted stock units and performance stock awards      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 6,745,591 5,632,823 5,406,004
Employee stock purchase plan      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 74,685 75,370 0
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.23.1
Retirement savings plan (Details) - USD ($)
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Retirement Benefits [Abstract]      
Company contributions $ 0 $ 0 $ 0
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Advertisements with Pharmaceutical Company | Affiliate of Director      
Related Party Transaction [Line Items]      
Recognized revenue from related parties $ 775 $ 482  
Accounts receivable from related parties 339 173  
Software Agreement | Affiliate of Director      
Related Party Transaction [Line Items]      
General and administrative expenses from transactions with related party 374 182  
Software Agreement | Affiliate of Director | Prepaid and other current assets      
Related Party Transaction [Line Items]      
Due from related parties, current $ 51 374  
Software Agreement | Affiliate of Director | Other assets      
Related Party Transaction [Line Items]      
Due from related parties, noncurrent   $ 51  
Revenue from Affiliate of Stockholder | Affiliated Entity      
Related Party Transaction [Line Items]      
Recognized revenue from related parties     $ 2,425
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 03, 2021
Jan. 08, 2021
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Business Acquisition [Line Items]          
Change in fair value of contingent consideration liabilities     $ 0 $ 258 $ 0
Insignia          
Business Acquisition [Line Items]          
Percentage of equity acquired (as a percent) 100.00%        
Consideration transferred $ 37,208        
Weighted average amortization period (in years)   13 years      
Acquisition related costs       720  
QueueDr          
Business Acquisition [Line Items]          
Percentage of equity acquired (as a percent)   100.00%      
Consideration transferred   $ 10,124      
Acquisition related costs         $ 282
Acquisition related costs incurred       258  
Change in fair value of contingent consideration liabilities       $ 1,544  
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details) - USD ($)
$ in Thousands
Dec. 03, 2021
Jan. 08, 2021
Insignia    
Business Acquisition [Line Items]    
Cash consideration paid on acquisition date $ 37,112  
Liabilities incurred 96  
Total fair value of acquisition consideration $ 37,208  
QueueDr    
Business Acquisition [Line Items]    
Cash consideration paid on acquisition date   $ 5,773
Liabilities incurred   2,111
Contingent consideration   2,240
Total fair value of acquisition consideration   $ 10,124
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Schedule of consideration paid (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 03, 2021
Jan. 08, 2021
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2021
Business Acquisition [Line Items]          
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows     $ 0 $ 34,423 $ 6,510
Insignia          
Business Acquisition [Line Items]          
Cash consideration paid on acquisition date $ 37,112        
Less cash acquired (2,689)        
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows $ 34,423        
QueueDr          
Business Acquisition [Line Items]          
Cash consideration paid on acquisition date   $ 5,773      
Payments of acquisition date fair value of contingent consideration   954      
Less cash acquired   (217)      
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows   $ 6,510      
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details) - USD ($)
$ in Thousands
Jan. 31, 2023
Jan. 31, 2022
Dec. 03, 2021
Jan. 31, 2021
Business Acquisition [Line Items]        
Goodwill $ 33,736 $ 33,621   $ 8,307
Insignia        
Business Acquisition [Line Items]        
Cash     $ 2,689  
Accounts receivable     994  
Prepaid expenses and other assets     358  
Operating lease right-of-use assets     606  
Intangibles     10,700  
Goodwill     25,410  
Total assets acquired     40,757  
Accounts payable     (84)  
Accrued liabilities     (487)  
Deferred revenue     (2,372)  
Operating lease liabilities     (606)  
Total purchase price     $ 37,208  
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 03, 2021
Jan. 31, 2023
License    
Acquired Finite-Lived Intangible Assets [Line Items]    
Estimated Useful Life (in Years)   15 years
Insignia    
Acquired Finite-Lived Intangible Assets [Line Items]    
Fair Value $ 10,700  
Insignia | License    
Acquired Finite-Lived Intangible Assets [Line Items]    
Estimated Useful Life (in Years) 15 years  
Fair Value $ 6,200  
Insignia | Customer relationship    
Acquired Finite-Lived Intangible Assets [Line Items]    
Estimated Useful Life (in Years) 10 years  
Fair Value $ 4,500  
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent event (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2023
Mar. 10, 2023
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Subsequent Event [Line Items]          
Cash and cash equivalents $ 176,683   $ 313,812 $ 218,781 $ 90,315
Third SVB Facility          
Subsequent Event [Line Items]          
Number of months with sufficient funds to operate (in months) 12 months        
Subsequent event | Third SVB Facility          
Subsequent Event [Line Items]          
Cash and cash equivalents   $ 170,000      
Subsequent event | Third SVB Facility | Revolving credit facility          
Subsequent Event [Line Items]          
Allowable cash hold outside of facility   $ 165,000      
XML 99 phr-20230131_htm.xml IDEA: XBRL DOCUMENT 0001412408 2022-02-01 2023-01-31 0001412408 2022-07-31 0001412408 2023-03-17 0001412408 2023-01-31 0001412408 2022-01-31 0001412408 phr:SubscriptionAndServicesMember 2022-02-01 2023-01-31 0001412408 phr:SubscriptionAndServicesMember 2021-02-01 2022-01-31 0001412408 phr:SubscriptionAndServicesMember 2020-02-01 2021-01-31 0001412408 phr:PaymentProcessingFeesMember 2022-02-01 2023-01-31 0001412408 phr:PaymentProcessingFeesMember 2021-02-01 2022-01-31 0001412408 phr:PaymentProcessingFeesMember 2020-02-01 2021-01-31 0001412408 phr:NetworkSolutionsMember 2022-02-01 2023-01-31 0001412408 phr:NetworkSolutionsMember 2021-02-01 2022-01-31 0001412408 phr:NetworkSolutionsMember 2020-02-01 2021-01-31 0001412408 2021-02-01 2022-01-31 0001412408 2020-02-01 2021-01-31 0001412408 us-gaap:CommonStockMember 2020-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001412408 us-gaap:RetainedEarningsMember 2020-01-31 0001412408 us-gaap:TreasuryStockMember 2020-01-31 0001412408 2020-01-31 0001412408 us-gaap:RetainedEarningsMember 2020-02-01 2021-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2021-01-31 0001412408 us-gaap:CommonStockMember 2020-02-01 2021-01-31 0001412408 us-gaap:TreasuryStockMember 2020-02-01 2021-01-31 0001412408 us-gaap:CommonStockMember 2021-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001412408 us-gaap:RetainedEarningsMember 2021-01-31 0001412408 us-gaap:TreasuryStockMember 2021-01-31 0001412408 2021-01-31 0001412408 us-gaap:RetainedEarningsMember 2021-02-01 2022-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2022-01-31 0001412408 us-gaap:CommonStockMember 2021-02-01 2022-01-31 0001412408 us-gaap:TreasuryStockMember 2021-02-01 2022-01-31 0001412408 us-gaap:CommonStockMember 2022-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001412408 us-gaap:RetainedEarningsMember 2022-01-31 0001412408 us-gaap:TreasuryStockMember 2022-01-31 0001412408 us-gaap:RetainedEarningsMember 2022-02-01 2023-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2023-01-31 0001412408 us-gaap:CommonStockMember 2022-02-01 2023-01-31 0001412408 us-gaap:TreasuryStockMember 2022-02-01 2023-01-31 0001412408 us-gaap:CommonStockMember 2023-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001412408 us-gaap:RetainedEarningsMember 2023-01-31 0001412408 us-gaap:TreasuryStockMember 2023-01-31 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:SubsequentEventMember 2023-03-10 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2023-03-10 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember 2022-02-01 2023-01-31 0001412408 srt:MinimumMember 2023-01-31 0001412408 srt:MaximumMember 2023-01-31 0001412408 srt:MinimumMember 2022-02-01 2023-01-31 0001412408 srt:MaximumMember 2022-02-01 2023-01-31 0001412408 phr:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2023-01-31 0001412408 phr:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-02-01 2022-01-31 0001412408 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2022-02-01 2023-01-31 0001412408 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2022-02-01 2023-01-31 0001412408 us-gaap:EmployeeStockMember 2022-02-01 2023-01-31 0001412408 phr:PhreesiaPadsAndArrivalsStationsMember 2022-02-01 2023-01-31 0001412408 phr:PhreesiaPadsAndArrivalsStationsMember 2023-01-31 0001412408 phr:PhreesiaPadsAndArrivalsStationsMember 2022-01-31 0001412408 us-gaap:ComputerEquipmentMember 2022-02-01 2023-01-31 0001412408 us-gaap:ComputerEquipmentMember 2023-01-31 0001412408 us-gaap:ComputerEquipmentMember 2022-01-31 0001412408 srt:MinimumMember phr:ComputerSoftwareMember 2022-02-01 2023-01-31 0001412408 srt:MaximumMember phr:ComputerSoftwareMember 2022-02-01 2023-01-31 0001412408 phr:ComputerSoftwareMember 2023-01-31 0001412408 phr:ComputerSoftwareMember 2022-01-31 0001412408 phr:HardwareDevelopmentMember 2022-02-01 2023-01-31 0001412408 phr:HardwareDevelopmentMember 2023-01-31 0001412408 phr:HardwareDevelopmentMember 2022-01-31 0001412408 us-gaap:FurnitureAndFixturesMember 2022-02-01 2023-01-31 0001412408 us-gaap:FurnitureAndFixturesMember 2023-01-31 0001412408 us-gaap:FurnitureAndFixturesMember 2022-01-31 0001412408 us-gaap:LeaseholdImprovementsMember 2022-02-01 2023-01-31 0001412408 us-gaap:LeaseholdImprovementsMember 2023-01-31 0001412408 us-gaap:LeaseholdImprovementsMember 2022-01-31 0001412408 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-02-01 2023-01-31 0001412408 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-31 0001412408 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-31 0001412408 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-02-01 2023-01-31 0001412408 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-02-01 2023-01-31 0001412408 us-gaap:CustomerRelationshipsMember 2023-01-31 0001412408 us-gaap:CustomerRelationshipsMember 2022-01-31 0001412408 us-gaap:LicenseMember 2022-02-01 2023-01-31 0001412408 us-gaap:LicenseMember 2023-01-31 0001412408 us-gaap:LicenseMember 2022-01-31 0001412408 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-02-01 2022-01-31 0001412408 us-gaap:CustomerRelationshipsMember 2022-02-01 2023-01-31 0001412408 us-gaap:CustomerRelationshipsMember 2021-02-01 2022-01-31 0001412408 us-gaap:LicenseMember 2021-02-01 2022-01-31 0001412408 phr:QueueDrMember 2021-02-01 2022-01-31 0001412408 phr:SubscriptionAndRelatedServicesMember 2022-02-01 2023-01-31 0001412408 phr:SubscriptionAndRelatedServicesMember 2021-02-01 2022-01-31 0001412408 phr:SubscriptionAndRelatedServicesMember 2020-02-01 2021-01-31 0001412408 phr:FinancingArrangementsMember 2023-01-31 0001412408 phr:FinancingArrangementsMember 2022-01-31 0001412408 phr:AccruedInterestAndPaymentsMember 2023-01-31 0001412408 phr:AccruedInterestAndPaymentsMember 2022-01-31 0001412408 phr:TermLoanMember 2019-02-28 0001412408 phr:TermLoanMember 2020-02-01 2021-01-31 0001412408 phr:SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2020-05-05 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-03-27 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-03-28 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2023-01-31 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2022-02-01 2023-01-31 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-02-01 2023-01-31 0001412408 phr:ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2020-05-05 0001412408 phr:SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2023-01-31 0001412408 phr:SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-01-31 0001412408 2019-07-22 0001412408 phr:FollowOnOfferingMember 2021-04-12 2021-04-12 0001412408 phr:FollowOnOfferingMember 2021-04-12 0001412408 phr:TwoThousandEighteenStockOptionPlanMember 2018-01-31 0001412408 phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember 2019-06-30 0001412408 phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember 2019-06-01 2019-06-30 0001412408 us-gaap:EmployeeStockMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember 2019-06-30 0001412408 us-gaap:EmployeeStockMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember 2023-01-31 0001412408 us-gaap:EmployeeStockMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember 2021-02-01 2022-01-31 0001412408 us-gaap:EmployeeStockMember 2021-02-01 2022-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2022-02-01 2023-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2021-02-01 2022-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2021-01-31 0001412408 phr:LiabilityAwardsMember 2022-02-01 2023-01-31 0001412408 phr:LiabilityAwardsMember 2021-02-01 2022-01-31 0001412408 phr:LiabilityAwardsMember 2020-02-01 2021-01-31 0001412408 us-gaap:PerformanceSharesMember 2022-02-01 2023-01-31 0001412408 us-gaap:PerformanceSharesMember 2021-02-01 2022-01-31 0001412408 us-gaap:PerformanceSharesMember 2020-02-01 2021-01-31 0001412408 us-gaap:EmployeeStockOptionMember 2022-02-01 2023-01-31 0001412408 us-gaap:EmployeeStockOptionMember 2021-02-01 2022-01-31 0001412408 us-gaap:EmployeeStockOptionMember 2020-02-01 2021-01-31 0001412408 us-gaap:EmployeeStockMember 2020-02-01 2021-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2023-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2022-01-31 0001412408 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2021-01-31 0001412408 us-gaap:AccruedLiabilitiesMember 2022-02-01 2023-01-31 0001412408 us-gaap:AccruedLiabilitiesMember 2021-02-01 2022-01-31 0001412408 us-gaap:AccruedLiabilitiesMember 2020-02-01 2021-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-12-31 2020-12-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-12-31 2020-12-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-12-31 2020-12-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember phr:ShareBasedPaymentArrangementTrancheFourMember 2020-12-31 2020-12-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 2020-12-31 0001412408 phr:EmployeesOtherThanNamedExecutiveOfficersMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-01-01 0001412408 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001412408 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-02 2023-01-02 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2020-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2022-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember 2023-01-31 0001412408 us-gaap:EmployeeStockOptionMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2022-02-01 2023-01-31 0001412408 us-gaap:EmployeeStockOptionMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-02-01 2023-01-31 0001412408 us-gaap:EmployeeStockOptionMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember phr:ShareBasedPaymentArrangementTrancheFourMember 2022-02-01 2023-01-31 0001412408 us-gaap:EmployeeStockOptionMember phr:TwoThousandAndNineteenStockOptionAndIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-02-01 2023-01-31 0001412408 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-02-01 2023-01-31 0001412408 srt:MaximumMember us-gaap:PerformanceSharesMember 2022-02-01 2023-01-31 0001412408 srt:MaximumMember us-gaap:PerformanceSharesMember 2021-02-01 2022-01-31 0001412408 srt:MaximumMember us-gaap:PerformanceSharesMember 2020-02-01 2021-01-31 0001412408 us-gaap:PerformanceSharesMember 2023-01-31 0001412408 us-gaap:PerformanceSharesMember 2022-01-31 0001412408 us-gaap:PerformanceSharesMember 2021-01-31 0001412408 us-gaap:PerformanceSharesMember 2020-01-31 0001412408 us-gaap:EmployeeStockMember 2023-01-31 0001412408 us-gaap:RestrictedStockUnitsRSUMember phr:A2022ShareSettledBonusAwardProgramMember 2022-02-01 2023-01-31 0001412408 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-31 0001412408 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-31 0001412408 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-31 0001412408 us-gaap:FairValueMeasurementsRecurringMember 2023-01-31 0001412408 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-01-31 0001412408 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-01-31 0001412408 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-01-31 0001412408 us-gaap:FairValueMeasurementsRecurringMember 2022-01-31 0001412408 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-01-31 0001412408 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-01-31 0001412408 us-gaap:DomesticCountryMember 2023-01-31 0001412408 us-gaap:DomesticCountryMember 2022-01-31 0001412408 us-gaap:ForeignCountryMember 2023-01-31 0001412408 us-gaap:StockCompensationPlanMember 2022-02-01 2023-01-31 0001412408 us-gaap:StockCompensationPlanMember 2021-02-01 2022-01-31 0001412408 us-gaap:StockCompensationPlanMember 2020-02-01 2021-01-31 0001412408 us-gaap:EmployeeStockMember 2022-02-01 2023-01-31 0001412408 us-gaap:EmployeeStockMember 2021-02-01 2022-01-31 0001412408 us-gaap:EmployeeStockMember 2020-02-01 2021-01-31 0001412408 phr:AdvertisementsWithPharmaceuticalCompanyMember phr:AffiliateOfDirectorMember 2022-02-01 2023-01-31 0001412408 phr:AdvertisementsWithPharmaceuticalCompanyMember phr:AffiliateOfDirectorMember 2021-02-01 2022-01-31 0001412408 phr:AdvertisementsWithPharmaceuticalCompanyMember phr:AffiliateOfDirectorMember 2023-01-31 0001412408 phr:AdvertisementsWithPharmaceuticalCompanyMember phr:AffiliateOfDirectorMember 2022-01-31 0001412408 phr:SoftwareAgreementMember phr:AffiliateOfDirectorMember 2022-02-01 2023-01-31 0001412408 phr:SoftwareAgreementMember phr:AffiliateOfDirectorMember 2021-02-01 2022-01-31 0001412408 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember phr:SoftwareAgreementMember phr:AffiliateOfDirectorMember 2023-01-31 0001412408 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember phr:SoftwareAgreementMember phr:AffiliateOfDirectorMember 2022-01-31 0001412408 us-gaap:OtherAssetsMember phr:SoftwareAgreementMember phr:AffiliateOfDirectorMember 2022-01-31 0001412408 phr:RevenueFromAffiliateOfStockholderMember srt:AffiliatedEntityMember 2020-02-01 2021-01-31 0001412408 phr:InsigniaHealthLLCMember 2021-12-03 0001412408 phr:InsigniaHealthLLCMember 2021-12-03 2021-12-03 0001412408 phr:InsigniaHealthLLCMember us-gaap:LicenseMember 2021-12-03 2021-12-03 0001412408 phr:InsigniaHealthLLCMember us-gaap:LicenseMember 2021-12-03 0001412408 phr:InsigniaHealthLLCMember us-gaap:CustomerRelationshipsMember 2021-12-03 2021-12-03 0001412408 phr:InsigniaHealthLLCMember us-gaap:CustomerRelationshipsMember 2021-12-03 0001412408 phr:InsigniaHealthLLCMember 2021-01-08 2021-01-08 0001412408 phr:InsigniaHealthLLCMember 2021-02-01 2022-01-31 0001412408 phr:QueueDrMember 2021-01-08 0001412408 phr:QueueDrMember 2021-01-08 2021-01-08 0001412408 phr:QueueDrMember 2020-02-01 2021-01-31 0001412408 phr:QueueDrMember 2022-01-31 iso4217:USD shares iso4217:USD shares phr:processor pure phr:segment phr:offering_period false 0001412408 2023 FY P1D P2D P1D P2D P3Y P3Y P2D P3Y P2Y http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations 10-K true 2023-01-31 --01-31 false 001-38977 PHREESIA, INC. DE 20-2275479 1521 Concord Pike Suite 301 PMB 221 Wilmington DE 19803 888 654-7473 Common stock, $0.01 par value per share PHR NYSE Yes No Yes Yes Large Accelerated Filer false false true false 1157351642 53355050 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:174%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Portions of the registrant’s Definitive Proxy Statement relating to its 2023 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span></div> KPMG LLP Pittsburgh, PA 185 176683000 313812000 22599000 19590000 1053000 863000 51394000 40262000 1056000 1642000 10709000 11043000 262441000 386349000 59847000 53321000 21670000 34645000 37236000 31139000 35150000 17643000 569000 2337000 1754000 2437000 2549000 1178000 11401000 12772000 81000 515000 33736000 33621000 3255000 4157000 370057000 494476000 22599000 19590000 5172000 5821000 934000 1281000 10836000 5119000 21810000 20128000 17688000 16493000 79039000 68432000 2725000 7423000 349000 1276000 125000 65000 82238000 77196000 0.01 0.01 500000000 500000000 54187172 52095964 542000 521000 926957000 860657000 -606084000 -429938000 971236 301003 33596000 13960000 287819000 417280000 370057000 494476000 128975000 95514000 69042000 78368000 65201000 49900000 73567000 52518000 29735000 280910000 213233000 148677000 58944000 42669000 23461000 50323000 38719000 28925000 151263000 106421000 42972000 91244000 52265000 22622000 80384000 68674000 40460000 17988000 14985000 9770000 7316000 6317000 6138000 457462000 330050000 174348000 -176552000 -116817000 -25671000 -175000 -78000 1000 1064000 -1084000 -1573000 889000 -1162000 -1572000 -175663000 -117979000 -27243000 483000 182000 49000 -176146000 -118161000 -27292000 -3.36 -3.36 -2.37 -2.37 -0.69 -0.69 52440067 52440067 49888436 49888436 39519640 39519640 36610763 366000 386383000 -284485000 -399000 101865000 -27292000 -27292000 13489000 13489000 2459782 25000 5275000 5300000 4566000 4566000 290000 5750000 57000 174453000 174510000 60338 1000 -1000 0 44880883 449000 579599000 -311777000 -4965000 263306000 -118161000 -118161000 29668000 29668000 1997551 20000 4123000 4143000 42530 1506000 1506000 8995000 8995000 5175000 52000 245761000 245813000 52095964 521000 860657000 -429938000 -13960000 417280000 -176146000 -176146000 52506000 52506000 1626123 16000 1515000 1531000 162154 2000 3470000 3472000 302931 3000 8809000 8812000 19636000 19636000 54187172 542000 926957000 -606084000 -33596000 287819000 -176146000 -118161000 -27292000 25304000 21302000 15908000 58775000 36144000 13489000 310000 288000 389000 1598000 672000 762000 1696000 2211000 2025000 1768000 1004000 1766000 0 258000 0 434000 143000 -65000 11132000 10216000 6619000 -250000 7192000 1600000 427000 3349000 1652000 4774000 2881000 -3821000 2720000 -2983000 6004000 -1302000 -1060000 -1786000 1255000 3348000 5382000 -90123000 -74710000 2890000 0 34423000 6510000 21471000 12385000 7334000 4732000 18420000 11241000 -26203000 -65228000 -25085000 0 245813000 174800000 1603000 4889000 4385000 19383000 8995000 4965000 0 0 290000 3321000 1979000 0 0 0 2009000 5731000 4267000 2630000 216000 1039000 1691000 397000 125000 294000 0 3286000 0 0 0 20663000 -20803000 234969000 150661000 -137129000 95031000 128466000 313812000 218781000 90315000 176683000 313812000 218781000 0 81000 4359000 526000 7394000 8885000 0 0 174000 2345000 1124000 3359000 0 0 20257000 0 0 406000 97000 169000 915000 0 0 3060000 1372000 489000 0 12284000 0 0 763000 802000 1465000 39000 49000 64000 Background and liquidity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Background</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through the SaaS-based technology platform (the "Phreesia Platform" or "Platform"), the Company offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration and payments. The Company’s Platform also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. In connection with the patient intake and registration process, Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended January 31, 2023, the Company ceased using its Raleigh, North Carolina office as its principal executive offices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b) Liquidity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also party to the Second Amended and Restated Loan and Security Agreement with SVB, as amended by the First Loan Modification Agreement (the “Third SVB Facility”), which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations. See Note 6 - Finance Leases and Other Debt and Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Company’s cash and cash equivalents at January 31, 2023, along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months. </span></div>The Company will seek to obtain additional financing, if needed, to successfully implement its long-term strategy. 170000000 165000000 P12M Basis of presentation(a) Consolidated Financial Statements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company").</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Network solutions revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January 31, 2023, the Company relabeled its Life sciences category of revenue presented on its Consolidated Statements of Operations to Network solutions revenue. The Company's Network solutions revenue includes fees from life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health using the Phreesia Platform. Prior to the year ended January 31, 2023, the Company's Network solutions revenue was generated by its life sciences clients. There have been no changes to previously reported revenues.</span></div> Consolidated Financial StatementsThe accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company"). Fiscal yearThe Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively. Summary of significant accounting policies(a) Use of estimates<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Revenue recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as for additional details about the Company's products and service lines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Concentrations of credit risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take <span style="-sec-ix-hidden:f-425">one</span> or <span style="-sec-ix-hidden:f-426">two</span> business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2023 and January 31, 2022. As of both January 31, 2023 and January 31, 2022, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Risks and uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. Certain of the Company's </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and Contingencies, for a summary of our contractual commitments as of January 31, 2023. See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Cost of revenue (excluding depreciation and amortization)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f) Payment processing expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g) Sales and marketing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $2,634, $4,007 and $558 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h) Research and development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i) General and administrative</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k) Amortization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l) Cash and cash equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m) Settlement assets </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within <span style="-sec-ix-hidden:f-441">one</span> to <span style="-sec-ix-hidden:f-442">two</span> business days of the transaction date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n) Settlement obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o) Accounts receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2023 and 2022, the Company has reserved $1,053 and $863, respectively, for the allowance for doubtful accounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p) Property and equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between <span style="-sec-ix-hidden:f-448">three</span> and seven years. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q) Capitalized internal-use software</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other—Internal use software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally <span style="-sec-ix-hidden:f-451">three</span> to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r) Business combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(s) Goodwill and intangible assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(t) Long-lived assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(u) Income taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Uncertainty in Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(v) Segment information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(w) Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Compensation — Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield. <br/><br/>During fiscal 2022, the Company activated the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date. <br/><br/>For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 - Equity-Based Compensation, for additional information on stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(x) Fair value of financial instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(y) Equity offering costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(z) Foreign currency</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(aa) New accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of recently adopted accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 31, 2023, the Company did not adopt any accounting pronouncements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.</span></div> Use of estimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets. Revenue recognition<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as for additional details about the Company's products and service lines.</span> Concentrations of credit riskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take <span style="-sec-ix-hidden:f-425">one</span> or <span style="-sec-ix-hidden:f-426">two</span> business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor.The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies.Risks and uncertaintiesThe Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and Contingencies, for a summary of our contractual commitments as of January 31, 2023. P30D P60D 1 0.10 0.10 Cost of revenue (excluding depreciation and amortization)Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation. Payment processing expensePayment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways. Sales and marketingSales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. 2634000 4007000 558000 Research and developmentResearch and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period. General and administrativeGeneral and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead. DepreciationDepreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.AmortizationAmortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets. Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents. Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within <span style="-sec-ix-hidden:f-441">one</span> to <span style="-sec-ix-hidden:f-442">two</span> business days of the transaction date. Settlement obligationsSettlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor. Accounts receivableAccounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. 1053000 863000 Property and equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between <span style="-sec-ix-hidden:f-448">three</span> and seven years. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.</span></div> P7Y Capitalized internal-use software<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other—Internal use software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally <span style="-sec-ix-hidden:f-451">three</span> to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period.</span> P5Y Business combinationsThe Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.</span></div> Goodwill and intangible assets<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.</span></div> Long-lived assetsLong-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented. 0 0 0 Income taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Uncertainty in Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.</span></div> Segment informationOperating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements. 1 Stock-based compensation<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Compensation — Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.</span>The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield. <br/><br/>During fiscal 2022, the Company activated the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date. <br/><br/>For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares. 0.85 Fair value of financial instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></div> Equity offering costsThe Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations. Foreign currencyThe Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net. New accounting pronouncements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of recently adopted accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 31, 2023, the Company did not adopt any accounting pronouncements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.</span></div> Composition of certain financial statement captions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Accrued expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses and taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment processing fees liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Property and equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment at January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PhreesiaPads and Arrivals Kiosks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,957 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hardware development</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,847)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,321)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment — net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,645 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment amounted to $17,988, $14,985 and $9,770 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases included in computer equipment were $27,813 and $27,310 at January 31, 2023 and 2022, respectively. Accumulated amortization of assets under finance leases was $20,657 and $15,025 at January 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Capitalized internal-use software </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January 31, 2023, 2022 and 2021, the Company capitalized $23,604, $12,830 and $7,663 of costs related to the Phreesia Platform, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended January 31, 2023, 2022 and 2021 amortization expense related to capitalized internal-use software was $5,945, $5,664 and $5,884, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Intangible assets and goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationship</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, gross carrying value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,772 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining useful life for acquired technology in years is 2.7 and 3.5 as of January 31, 2023 and 2022, respectively. The remaining useful life for customer relationships in years is 8.3 and 9.2 as of January 31, 2023 and 2022, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years is 13.8 and 14.8 as of January 31, 2023 and 2022, respectively. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with intangible assets for the fiscal years ended January 31, 2023, 2022 and 2021 was $1,371, $653 and $254, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,401 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year ended January 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,314 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments to goodwill during the year ended January 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,736 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any impairments of goodwill during the years ended January 31, 2023, 2022 or 2021. Additions to goodwill during the year ended January 31, 2022 are net of a $96 measurement period adjustment for the QueueDr acquisition. Additions to goodwill during the year ended January 31, 2023 represent measurement period adjustments for the Insignia acquisition. Substantially all of the Company's goodwill is amortizable for tax purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Accounts receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Receivable as of January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,447 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accounts receivable allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,053)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(863)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,394 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs and adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs and adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f) Prepaid and other current assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets as of January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software and business systems</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid data center expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,709 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g) Cloud computing implementation costs</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The Company enters into cloud computing service contracts to support its sales and marketing, product development and administrative activities. The Company capitalizes certain implementation costs for cloud computing arrangements that meet the definition of a service contract. The Company includes these capitalized implementation costs within Prepaid expenses and other current assets and within other assets on its consolidated balance sheets. Once placed in service, the Company amortizes these costs over the remaining subscription term to the same caption in the consolidated statements of operations as the related cloud subscription. Capitalized implementation costs for cloud computing arrangements accounted for as service contracts were $1,532 as of January 31, 2023. Accumulated amortization of capitalized implementation costs for these arrangements was $610 as of January 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h) Other (expense) income, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net for the year ended January 31, 2023 and 2022 was expense of $175 and $78, respectively, driven by foreign exchange losses, partially offset by other miscellaneous income.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses and taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment processing fees liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 10345000 10780000 4796000 3502000 96000 96000 1491000 2093000 2249000 1266000 2833000 2391000 21810000 20128000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment at January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PhreesiaPads and Arrivals Kiosks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,957 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hardware development</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,847)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,321)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment — net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,645 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P3Y 17932000 26387000 P3Y 54485000 53957000 P3Y P5Y 8571000 5311000 P3Y 529000 1024000 P7Y 0 539000 P2Y 0 748000 81517000 87966000 59847000 53321000 21670000 34645000 17988000 14985000 9770000 27813000 27310000 20657000 15025000 23604000 12830000 7663000 5945000 5664000 5884000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationship</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, gross carrying value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,772 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P5Y 1410000 1410000 P7Y P10Y 6340000 6340000 P15Y 6200000 6200000 13950000 13950000 2549000 1178000 11401000 12772000 P2Y8M12D P3Y6M P8Y3M18D P9Y2M12D P13Y9M18D P14Y9M18D 1371000 653000 254000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,401 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1358000 1273000 1242000 949000 6579000 11401000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year ended January 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,314 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments to goodwill during the year ended January 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,736 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 8307000 25314000 33621000 115000 33736000 0 0 0 96000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Receivable as of January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,447 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accounts receivable allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,053)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(863)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,394 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 51458000 40733000 989000 392000 52447000 41125000 1053000 863000 51394000 40262000 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs and adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs and adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 699000 212000 48000 863000 587000 397000 1053000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets as of January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software and business systems</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid data center expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,709 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3426000 3738000 2389000 3230000 1552000 1924000 3342000 2151000 10709000 11043000 1532000000 610000000 -175000 -78000 Revenue and Contract Costs<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Phreesia Platform, payment processing fees based on patient payment volume, and fees from life sciences and payer clients for delivering direct communications to patients using the Phreesia Platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue from contracts with customers by applying the requirements of ASC 606. Accordingly, the Company determines revenue recognition through the following steps:</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of the contract, or contracts, with a customer;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of the performance obligations in the contract;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determination of the transaction price;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of revenue when, or as, the Company satisfies a performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. We typically establish a range of SSPs for each of our performance obligations. We use the residual method to the estimate the SSP for certain performance obligations with highly variable pricing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Subscription and related services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other applications. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. The Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of subscription and related services revenues recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $10,197, $6,489 and $6,312 for the years ended January 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from Phreesia’s Platform and are therefore recognized over the term of the contract. Revenue from sales of Phreesia hardware and training are recognized in the period they are delivered to clients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Payment processing fees</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately <span style="-sec-ix-hidden:f-604">two</span> business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Network solutions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's Network solutions revenue includes fees from life sciences companies and payers for direct communications to activate, engage and educate patients about topics critical to their health using the Phreesia platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company generates revenue from sales of qualified leads to health plans and other payer organizations which is based largely on the delivery of qualified leads to health plans and other payer organizations at a contracted price per lead. The Company identifies the qualified leads based on direct communications delivered to patients. Revenue for leads is recognized based on our estimate of leads accepted by health plans and other payer organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(d) Disaggregation of revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Company’s contracts with its customers are disaggregated by service offering on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees, digital marketing solutions sold to life sciences companies and qualified leads sold to health plans and other payer organizations. In addition, substantially all of the Company’s revenue is derived from customers in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Remaining performance obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f) Contract balances</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a roll-forward of contract assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount transferred to receivables from beginning balance of contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in contract assets due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset additions, net of reclassification to receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a roll-forward of deferred revenue:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:70.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized that was included in deferred revenue at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,838)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in deferred revenue due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current year activity in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,186 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g) Cost to obtain a contract</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be <span style="-sec-ix-hidden:f-626">three</span> to five years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $1,696 and $2,211 for the years ended January 31, 2023 and 2022, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a roll-forward of deferred contract acquisition costs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to deferred contract acquisition costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred contract acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred contract acquisition costs, current (to be amortized in next 12 months)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred contract acquisition costs, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred contract acquisition costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10197000 6489000 6312000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a roll-forward of contract assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount transferred to receivables from beginning balance of contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in contract assets due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset additions, net of reclassification to receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a roll-forward of deferred revenue:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:70.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized that was included in deferred revenue at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,838)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in deferred revenue due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current year activity in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,186 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 392000 1287000 392000 1287000 0 243000 989000 149000 989000 392000 16558000 10838000 16005000 10838000 0 2372000 17260000 14186000 17813000 16558000 P5Y 1696000 2211000 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a roll-forward of deferred contract acquisition costs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to deferred contract acquisition costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred contract acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred contract acquisition costs, current (to be amortized in next 12 months)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred contract acquisition costs, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred contract acquisition costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4079000 2941000 427000 3349000 1696000 2211000 2810000 4079000 1056000 1642000 1754000 2437000 2810000 4079000 Finance leases and other debt<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest and payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities and other debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - current portion of finance lease liabilities and other debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance leases and other debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,423 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Finance leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 - Leases for more information regarding finance leases. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/><br/>(b) Amended and Restated Loan and Security Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. In connection with the transaction, the Company recorded a $1,073 loss on extinguishment of debt within other (expense) income, net for the settlement of previously outstanding loans payable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility. The Second SVB Facility modified the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. The borrowing capacity could be increased to $65,000 at the sole discretion of Silicon Valley Bank. Upon entering into the Second SVB Facility, the Company borrowed $20,663 against the revolving credit facility and used the proceeds to repay all amounts due under the First SVB Facility term loan. The Company repaid the balance on the Second SVB Facility during the fiscal year ended January 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022 (the "Third SVB Effective Date"), the Company entered into a First Loan Modification Agreement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Second SVB Facility (as amended, the "Third SVB Facility") to increase the borrowing capacity from $50,000</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to $100,000 and to reduce the interest rate on the facility. Borrowings under the Third SVB Facility are payable on May 5, 2025. Borrowings under the Third SVB Facility bear interest, which is payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%. As of January 31, 2023, the interest rate on the Third SVB Facility was 7%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual commitment fee of approximately $250 per year and a quarterly fee of 0.15% per annum of the average unused revolving line under the facility. The Company had $100,000 of availability under the facility as of January 31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Company terminates the Third SVB Facility prior to May 5, 2024, the Company will be required to pay a termination fee of up to 1.5% of borrowing capacity based on the length of time between termination and maturity. Any Company obligations under the Third SVB Facility are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The Third SVB Facility includes a financial covenant that requires the Company to maintain a minimum Adjusted Quick Ratio as defined in the Third SVB Facility. The Third SVB Facility also includes a financial covenant that requires the Company to achieve certain profitability and liquidity thresholds. The financial covenant will not be effective if the Company maintains certain levels of liquidity as defined. Additionally, the Third SVB facility contains a covenant limiting the amount of cash and cash equivalents the Company can hold outside SVB. The Third SVB Facility also contains customary events of default. The Company was in compliance with all covenants related to the Third SVB Facility as of January 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023 and 2022, there was no debt outstanding related to the Third SVB Facility and the Second SVB Facility, respectively. As a result, the Company presented all unamortized deferred costs within other assets as of January 31, 2023 and 2022, respectively. The Company is amortizing the remaining unamortized costs over the remaining term of the Third SVB Facility.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of finance leases and other debt in each of the next five years and thereafter are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:55.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities of finance leases and other debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of interest income (expense), net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:55.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,163)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,084)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Includes amortization of deferred financing costs and original issue discount</span></div></td></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest and payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities and other debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - current portion of finance lease liabilities and other debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance leases and other debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,423 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7651000 12884000 46000 266000 200000 94000 7897000 13244000 5172000 5821000 2725000 7423000 20000000 -1073000 50000000 65000000 20663000 50000 100000 0.0325 -0.005 0.07 250000 0.0015 100000000 0.015 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of finance leases and other debt in each of the next five years and thereafter are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:55.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities of finance leases and other debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5172000 4926000 246000 2518000 2518000 0 207000 207000 0 7897000 7651000 246000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of interest income (expense), net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:55.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,163)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,084)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Includes amortization of deferred financing costs and original issue discount</span></div></td></tr></table> 1411000 1163000 1695000 2475000 79000 122000 1064000 -1084000 -1573000 Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Common stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company closed an IPO on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2021, the Company completed a follow-on offering of its common stock. In connection with this offering, the Company issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Treasury stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's equity-based compensation plan allows for the grant of non-vested stock options, RSUs and TSR PSUs to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Under the provision of the plans, for RSU and PSU awards, unless otherwise elected, participants fulfill their related income tax withholding obligation by having shares withheld at the time of vesting. On the date of vesting of the RSU or PSU, the Company divides the participant's estimated income tax obligation in dollars by the closing price of its common stock and withholds the resulting number of vested shares. The shares withheld are then transferred to the Company's treasury stock at cost.</span></div> 500000000 0.01 5175000 50.00 Equity-based compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Equity award plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2023, 2022 and 2021 were made pursuant to the 2019 plan, respectively.<br/>In June 2019, the Board of Directors also adopted the ESPP, which became effective immediately prior to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company amended its fiscal 2022 incentive bonus to allow eligible employees to elect to receive all or a portion of their fiscal 2022 year end incentive compensation in the form of immediately vested restricted stock units instead of cash. The Company's fiscal 2023 incentive bonus allows eligible employees to elect to receive all or a portion of their fiscal 2023 incentive compensation in the form of immediately vested restricted stock units instead of cash. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, there are 3,408,720 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase which occurs on February 1 of each fiscal year, as well as an additional 576,304 shares available for future grant pursuant to the ESPP. During fiscal 2022, the Company activated its ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">(b) Summary of stock-based compensation<br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table sets forth stock-based compensation by type of award:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,147 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,723 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table sets forth the presentation of stock-based compensation in the Company's financial statements:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the fiscal years ended<br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense recorded to additional paid-in capital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,506 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense recorded to accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,723 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less stock-based compensation expense capitalized as internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense per consolidated statements of operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,234 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="21" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts.</span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.</span></div></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">(c) Restricted stock units<br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has issued restricted stock units to employees and independent directors that vest based on a time-based condition. For RSUs granted to employees prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The restricted stock units expire seven years from the grant date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January 31, 2022, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its 2022 proxy statement ("2022 NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than 2022 NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For 2022 NEOs and other members of the Company's executive management team, RSUs granted from January 1, 2022 through December 31, 2022 vest 6.25% each quarter over four years based on continued service. Beginning January 2023, all RSUs granted vest 25% each year over four years based on continued service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company provides certain employees the option to settle their incentive bonus in immediately vested RSUs. RSUs granted to settle bonus awards are included in RSUs granted and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted stock units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,626,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,917,753 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, there is $112,482 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.8 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended January 31, 2023, 2022 and 2021, the weighted average grant date fair value of restricted stock units granted was $26.79, $46.60 and $32.78 respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Stock options </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding—January 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,216,368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and expected to vest — January 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding—January 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,439,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and expected to vest — January 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding—January 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and expected to vest — January 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable — January 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362,903 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount vested during year ended January 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2023, 2022 and 2021 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $6,970, $73,624 and $33,575, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, there is $45 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 0.33 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended January 31, 2023, stock-based compensation expense for stock options includes $322 related to the modification of stock options.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) TSR performance-based restricted stock units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Peer Group. Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. PSUs granted during the years ended January 31, 2023, 2022 and 2021 vest in a maximum of 220%, 200% and 200% of the number of PSUs originally granted, respectively. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Correlation coefficient</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4957 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation date stock price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simulation term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 Years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of grants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/>Market based PSU activity for the years ended January 31, 2023, 2022 and 2021 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance<br/>stock units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding February 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted during the year ended January 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, February 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted during the year ended January 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, February 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted during the year ended January 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, January 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, unrecognized compensation cost for the PSUs was $26,128, to be recognized over a weighted average remaining vesting period of 2.4 years, subject to the participants' continued employment with the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f) Employee stock purchase plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986. <br/><br/>The fair value of shares granted under the ESPP during the year ended January 31, 2023 was estimated using a Black-Scholes pricing model with the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>January 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>January 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>During the fiscal years ended January 31, 2023 and 2022, the Company issued 162,154 and 42,530 shares of common stock, respectively, for the ESPP. In connection with these issuances, during the years ended January 31, 2023 and 2022, the Company recorded increases of $3,470 and $1,506, respectively, to additional paid-in capital </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within stockholders' equity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, unrecognized compensation cost related to the ESPP was $605, to be recognized over the next five months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g) Liability awards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended fiscal 2022 incentive bonus and the Company's fiscal 2023 incentive bonus allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the bonuses converted. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities, within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. During the year-ended January 31, 2023, the Company settled $8,812 of share-settled bonus awards by issuing 302,931 immediately vested RSUs. See (c) Restricted Stock Units above for additional discussion regarding RSUs.</span></div> 3048490 2139683 0.05 855873 3408720 576304 2 P6M 0.15 The following table sets forth stock-based compensation by type of award:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,147 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,723 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 42214000 24222000 10693000 7641000 7055000 0 7282000 2389000 93000 1489000 2294000 2703000 1521000 763000 0 60147000 36723000 13489000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table sets forth the presentation of stock-based compensation in the Company's financial statements:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the fiscal years ended<br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense recorded to additional paid-in capital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,506 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense recorded to accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,723 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less stock-based compensation expense capitalized as internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense per consolidated statements of operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,234 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="21" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts.</span></div></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.</span></div></td></tr></table></div> 52506000 29668000 13489000 7641000 7055000 0 60147000 36723000 13489000 1372000 489000 0 58775000 36234000 13489000 36144000 90000 0.10 P1Y 0.20 P2Y 0.30 P3Y 0.40 P4Y P7Y 0.0625 P4Y 0.0625 P4Y 0.25 P4Y <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted stock units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,626,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,917,753 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1447418 972271 242049 124602 2053038 1836534 559767 195966 3133839 2907838 1626679 497245 3917753 112482000 P2Y9M18D 26.79 46.60 32.78 P10Y P4Y 0.25 0.25 0.25 0.25 P1Y P1Y P1Y P1Y <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding—January 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,216,368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and expected to vest — January 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding—January 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,439,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and expected to vest — January 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding—January 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and expected to vest — January 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable — January 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362,903 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount vested during year ended January 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table> 5516452 3.80 0 0 2216368 2.39 88730 7.45 3211354 4.67 P5Y11M26D 194676000 3211354 4.67 0 0 1439186 2.88 67018 9.02 1705150 6.01 P5Y11M8D 42938000 1705150 6.01 0 0 311743 4.92 8214 4.68 1385193 6.26 P5Y21D 43341000 1362903 6.12 P5Y10D 42750000 258735 8.27 6970000 73624000 33575000 45000 P0Y3M29D 322000 P3Y 0 2.20 2.20 2 2 1 1 The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Correlation coefficient</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4957 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation date stock price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simulation term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 Years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value of grants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0.4957 0.3878 0.4230 35.41 36.03 62.96 P3Y P2Y11M26D P3Y 0.6498 0.4432 0.4371 0.0384 0.0123 0.0020 0 0 0 56.52 48.47 84.38 Market based PSU activity for the years ended January 31, 2023, 2022 and 2021 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance<br/>stock units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding February 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted during the year ended January 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, February 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted during the year ended January 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, February 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted during the year ended January 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, January 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 70806 70806 325410 0 0 396216 255572 0 3555 648233 26128000 P2Y4M24D 0.85 0.85 The fair value of shares granted under the ESPP during the year ended January 31, 2023 was estimated using a Black-Scholes pricing model with the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>January 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>January 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.0368 0.0017 0 0 P0Y5M19D P0Y5M26D 0.748 0.557 162154 42530 3470000 1506000 605000 P5M 1.15 8812000 302931 Fair Value Measurements<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs <br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs <br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of January 31, 2023, the carrying value of the Company's debt approximated fair value because the interest rates approximated market rates and the debt maturities were relatively short-term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any transfers of assets and liabilities between levels of the fair value measurements hierarchy during both the years ended January 31, 2023 and 2022.</span></div> <div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs <br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,563 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs <br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 163563000 0 0 163563000 163563000 0 0 163563000 197601000 0 0 197601000 197601000 0 0 197601000 Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Phreesia as Lessee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for <span style="-sec-ix-hidden:f-930">two</span> to three years and are secured by the underlying equipment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial impact of the change in useful lives of the related right of use assets was not significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, non-current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,813 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-945"><span style="-sec-ix-hidden:f-946">Property and equipment, net</span></span></span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-949"><span style="-sec-ix-hidden:f-950">Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-953"><span style="-sec-ix-hidden:f-954">Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash used for finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Phreesia as Lessor</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.</span></div>Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less. Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Phreesia as Lessee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for <span style="-sec-ix-hidden:f-930">two</span> to three years and are secured by the underlying equipment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial impact of the change in useful lives of the related right of use assets was not significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, non-current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,813 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-945"><span style="-sec-ix-hidden:f-946">Property and equipment, net</span></span></span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-949"><span style="-sec-ix-hidden:f-950">Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-953"><span style="-sec-ix-hidden:f-954">Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash used for finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Phreesia as Lessor</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.</span></div>Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less. Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Phreesia as Lessee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for <span style="-sec-ix-hidden:f-930">two</span> to three years and are secured by the underlying equipment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial impact of the change in useful lives of the related right of use assets was not significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, non-current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,813 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-945"><span style="-sec-ix-hidden:f-946">Property and equipment, net</span></span></span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-949"><span style="-sec-ix-hidden:f-950">Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-953"><span style="-sec-ix-hidden:f-954">Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash used for finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Phreesia as Lessor</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.</span></div>Future lease payments receivable under operating leases were immaterial as of January 31, 2023 and 2022, except for those with terms of one year or less. P3Y <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, non-current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,813 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-945"><span style="-sec-ix-hidden:f-946">Property and equipment, net</span></span></span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-949"><span style="-sec-ix-hidden:f-950">Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-953"><span style="-sec-ix-hidden:f-954">Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 569000 2337000 934000 1281000 349000 1276000 1283000 2557000 27813000 27310000 20657000 15025000 7156000 12285000 4926000 5600000 2725000 7284000 7651000 12884000 P1Y7M6D 0.035 P1Y7M6D 0.036 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended <br/>January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash used for finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash used for finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1835000 1096000 1766000 62000 223000 257000 1897000 1319000 2023000 5632000 4636000 2876000 368000 378000 326000 6000000 5014000 3202000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ending January 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 958000 5102000 225000 2566000 86000 209000 42000 0 7000 0 1318000 7877000 35000 226000 1283000 7651000 8058000 1347000 1206000 1629000 396000 377000 326000 5731000 4267000 2630000 7474000 5850000 4585000 10197000 6489000 6312000 Commitments and contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third-party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ny liabilities related to such obligations in its consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceedi</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Legal proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Other contractual commitments<br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.561%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase obligations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending January 31,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,646 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.561%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase obligations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending January 31,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,646 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 11646000 8115000 3530000 598000 23889000 Income taxesThe Company recorded a tax provision of $483, $182 and $49, for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's provision for income taxes was 0.3%, 0.2% and 0.2% of loss before income taxes for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against the <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">majority of its deferred tax assets, and due to foreign income tax expense recorded for the Company's Canada branch related to the use of net operating loss carry forwards to offset current income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s loss before income taxes was primarily generated in the United States for fiscal 2023, fiscal 2022 and fiscal 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:55.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax benefit at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local tax, net of federal benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:71.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets (liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,574 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,765 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserves, and other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for bad debts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,934</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,566 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,505 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,250)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred contract acquisition costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,350)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,711)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accumulated a Federal net operating loss carryforward of approximately $493,333 and $332,544 as of January 31, 2023 and 2022, respectively. This carryforward may be available to offset future income tax liabilities and will expire beginning in 2025. As of January 31, 2023, the Company's foreign branch had net operating loss carryforwards of approximately $716, which may be available to offset future income in Canada and will expire beginning in 2034.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of this evaluation, as of January 31, 2023 and 2022, the Company recorded a valuation allowance of $143,135 and $97,279, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $45,856 increase in the valuation allowance recorded during the fiscal year ended January 31, 2023 relates primarily to deferred tax assets established and recorded during the fiscal year ended January 31, 2023. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2023, the Company has U.S. net operating loss carryforwards of approximately $493.3 million. The Company has completed a Section 382 study and as a result of the analysis, it is more likely than not that the Company has experienced an “ownership change”. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership. Accordingly, if the Company earns net taxable income, it is more likely than not that the Company's ability to use its pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2018 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2023 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets in accordance with ASC 740 and adjusts these balances when its judgement changes as a result of the evaluation of new information previously not available. The Company recognized interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2023 and for the years ended January </span></div>31, 2023, 2022 and 2021, the Company did not have a balance of unrecognized tax benefits. As of January 31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions. 483000 182000 49000 0.003 0.002 -0.002 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:55.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table> 0 0 0 49000 39000 114000 0 0 0 109000 0 -116000 0 0 -65000 325000 143000 116000 483000 182000 49000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax benefit at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local tax, net of federal benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table> 0.21 0.21 0.21 0.05 0.09 0.10 0 0 0 0 0.06 0.44 0 0 0 0 0 -0.04 -0.26 -0.36 -0.71 0 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2023 and 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:71.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets (liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,574 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,765 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserves, and other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for bad debts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disallowed interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,934</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,566 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,505 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,250)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred contract acquisition costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,350)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,711)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table> 131574000 88979000 7765000 5374000 2763000 3697000 530000 521000 1934000 1934000 144566000 100505000 143135000 97279000 1431000 3226000 295000 1250000 305000 373000 750000 1088000 1350000 2711000 81000 515000 493333000 332544000 716000 143135000 97279000 45856000 493300000 0 Net loss per share attributable to common stockholders<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Net loss per share attributable to common stockholders</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:61.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,440,067 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,888,436 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,519,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Potential dilutive securities</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock awards, and grants under the Company's ESPP, our employee stock purchase plan, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:62.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock, restricted stock units and performance stock awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,820,276 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,708,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:61.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,440,067 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,888,436 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,519,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -176146000 -118161000 -27292000 52440067 52440067 49888436 49888436 39519640 39519640 -3.36 -3.36 -2.37 -2.37 -0.69 -0.69 The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:62.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal years ended January 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock, restricted stock units and performance stock awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,820,276 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,708,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6745591 5632823 5406004 74685 75370 0 6820276 5708193 5406004 Retirement savings planOn February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in the years ended January 31, 2023, 2022 or 2021 0 0 0 Related party transactions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended January 31, 2023 and 2022, the Company recognized revenue totaling $775 and $482 for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of January 31, 2023 and 2022, accounts receivable from the pharmaceutical company totaled $339 and $173, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended January 31, 2023 and 2022, the Company recognized general and administrative expenses totaling $374 and $182 for software agreements with a software company, respectively. One of the Company's independent members of its board of directors serves as the chief executive officer and on the board of directors for this software company. As of January 31, 2023 and 2022, prepaid expenses and other current assets include approximately $51 and $374 of payments to this software company, respectively. As of January 31, 2022, other assets included $51 of payments to this software company. This software company has been a related party since October 2021 when this software company's chief executive officer and board member became an independent member of the Company's board of directors, and the disclosures above represent transactions occurring while the software company was a related party. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/>The Company recognized revenue totaling approximately $2,425 from an affiliate of a stockholder of the Company for the year ended January 31, 2021. The revenue presented above includes revenue earned while the entity was a related party. The entity was a related party for a portion of the year ended January 31, 2021 and was no longer a related party during the years ended January 31, 2022 and 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the Company's independent members of its board of directors has served as the chief financial officer of a</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">software company since April 2022. The Company recognized de minimis expenses during the year ended January 31, 2023 for software agreements with this software company.<br/></span></div> 775000 482000 339000 173000 374000 182000 51000 374000 51000 2425000 Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Acquisition of Insignia Health, LLC<br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company entered into an agreement to acquire 100% of the outstanding equity of Insignia, a founder-led and mission-oriented company for cash consideration of $37,208. Insignia provides coaching and education solutions in conjunction with Insignia's exclusive worldwide license to the PAM. The PAM is a survey measuring a patient's knowledge, skills and ability to manage their care. The Company acquired Insignia to enable the Company to understand and engage patients in more personalized ways based on their level of activation. The acquisition of Insignia was accounted for as a business combination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration paid to sellers</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities incurred to sellers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of acquisition consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022.<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash consideration paid to sellers</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,423 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations.<br/><br/>The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total purchase price</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,208 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets acquired were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAM license</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for acquired intangible assets as of the date of acquisition is 13 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Insignia. The fair value of the acquired PAM license was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized in the acquisition of Insignia is primarily attributable to expected synergies of the combined businesses driven by integrating the PAM into the Phreesia Platform and engaging with patients in more personalized ways based on their level of activation, as well as the acquisition of an assembled workforce. The goodwill is expected to be deductible for tax purposes.<br/><br/>During the fiscal year ended January 31, 2022, the Company incurred $720 of acquisition related costs for the acquisition of Insignia. These costs are primarily included within general and administrative expenses in our consolidated statement of operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><br/><br/>Acquisition of QueueDr</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into a stock purchase agreement with QueueDr to acquire 100% of the outstanding equity of QueueDr, an early-stage software company that automates the process of rescheduling cancellations and no-shows. We acquired QueueDr to enhance our appointments solution. The acquisition of QueueDr was accounted for as a business combination.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash consideration paid on acquisition date</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of acquisition consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash consideration paid on acquisition date</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of acquisition date fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended January 31, 2021, the Company incurred $282 of acquisition related costs for the acquisition of QueueDr. During the fiscal year ended January 31, 2022, the Company incurred $258 of expenses to remeasure the acquisition-date fair value of contingent consideration to its ultimate settlement amount of $1,544. Each of these costs were included within general and administrative expenses in our consolidated statements of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended January 31, 2023 and, 2022, the Company recorded certain measurement period adjustments related to the acquisitions of Insignia and QueueDr. The financial impact of measurement period adjustments was not material.</span></div> 1 37208000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration paid to sellers</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities incurred to sellers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of acquisition consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022.<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash consideration paid to sellers</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,423 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash consideration paid on acquisition date</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of acquisition consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash consideration paid on acquisition date</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of acquisition date fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 37112000 96000 37208000 37112000 2689000 34423000 The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total purchase price</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,208 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2689000 994000 358000 606000 10700000 25410000 40757000 84000 487000 2372000 606000 37208000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets acquired were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAM license</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P15Y 6200000 P10Y 4500000 10700000 P13Y 720000 1 5773000 2111000 2240000 10124000 5773000 954000 217000 6510000 282000 258000 1544000 Subsequent event <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also party to the Third SVB Facility which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations.</span></div>Management believes that the Company’s cash and cash equivalents along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months. 170000000 165000000 P12M EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 206 474 1 false 65 0 false 7 false false R1.htm 0000001 - Document - Cover Sheet http://www.phreesia.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.phreesia.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://www.phreesia.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://www.phreesia.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Background and liquidity Sheet http://www.phreesia.com/role/Backgroundandliquidity Background and liquidity Notes 9 false false R10.htm 0000010 - Disclosure - Basis of presentation Sheet http://www.phreesia.com/role/Basisofpresentation Basis of presentation Notes 10 false false R11.htm 0000011 - Disclosure - Summary of significant accounting policies Sheet http://www.phreesia.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 11 false false R12.htm 0000012 - Disclosure - Composition of certain financial statement captions Sheet http://www.phreesia.com/role/Compositionofcertainfinancialstatementcaptions Composition of certain financial statement captions Notes 12 false false R13.htm 0000013 - Disclosure - Revenue and Contract Costs Sheet http://www.phreesia.com/role/RevenueandContractCosts Revenue and Contract Costs Notes 13 false false R14.htm 0000014 - Disclosure - Finance leases and other debt Sheet http://www.phreesia.com/role/Financeleasesandotherdebt Finance leases and other debt Notes 14 false false R15.htm 0000015 - Disclosure - Stockholders' Equity Sheet http://www.phreesia.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 0000016 - Disclosure - Equity-based compensation Sheet http://www.phreesia.com/role/Equitybasedcompensation Equity-based compensation Notes 16 false false R17.htm 0000017 - Disclosure - Fair value measurements Sheet http://www.phreesia.com/role/Fairvaluemeasurements Fair value measurements Notes 17 false false R18.htm 0000018 - Disclosure - Leases Sheet http://www.phreesia.com/role/Leases Leases Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and contingencies Sheet http://www.phreesia.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Income taxes Sheet http://www.phreesia.com/role/Incometaxes Income taxes Notes 20 false false R21.htm 0000021 - Disclosure - Net loss per share attributable to common stockholders Sheet http://www.phreesia.com/role/Netlosspershareattributabletocommonstockholders Net loss per share attributable to common stockholders Notes 21 false false R22.htm 0000022 - Disclosure - Retirement savings plan Sheet http://www.phreesia.com/role/Retirementsavingsplan Retirement savings plan Notes 22 false false R23.htm 0000023 - Disclosure - Related party transactions Sheet http://www.phreesia.com/role/Relatedpartytransactions Related party transactions Notes 23 false false R24.htm 0000024 - Disclosure - Acquisitions Sheet http://www.phreesia.com/role/Acquisitions Acquisitions Notes 24 false false R25.htm 0000025 - Disclosure - Subsequent event Sheet http://www.phreesia.com/role/Subsequentevent Subsequent event Notes 25 false false R26.htm 0000026 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 26 false false R27.htm 0000027 - Disclosure - Composition of certain financial statement captions (Tables) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables Composition of certain financial statement captions (Tables) Tables http://www.phreesia.com/role/Compositionofcertainfinancialstatementcaptions 27 false false R28.htm 0000028 - Disclosure - Revenue and Contract Costs (Tables) Sheet http://www.phreesia.com/role/RevenueandContractCostsTables Revenue and Contract Costs (Tables) Tables http://www.phreesia.com/role/RevenueandContractCosts 28 false false R29.htm 0000029 - Disclosure - Finance leases and other debt (Tables) Sheet http://www.phreesia.com/role/FinanceleasesandotherdebtTables Finance leases and other debt (Tables) Tables http://www.phreesia.com/role/Financeleasesandotherdebt 29 false false R30.htm 0000030 - Disclosure - Equity-based compensation (Tables) Sheet http://www.phreesia.com/role/EquitybasedcompensationTables Equity-based compensation (Tables) Tables http://www.phreesia.com/role/Equitybasedcompensation 30 false false R31.htm 0000031 - Disclosure - Fair value measurements (Tables) Sheet http://www.phreesia.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables http://www.phreesia.com/role/Fairvaluemeasurements 31 false false R32.htm 0000032 - Disclosure - Leases (Tables) Sheet http://www.phreesia.com/role/LeasesTables Leases (Tables) Tables http://www.phreesia.com/role/Leases 32 false false R33.htm 0000033 - Disclosure - Commitment and contingencies (Tables) Sheet http://www.phreesia.com/role/CommitmentandcontingenciesTables Commitment and contingencies (Tables) Tables 33 false false R34.htm 0000034 - Disclosure - Income taxes (Tables) Sheet http://www.phreesia.com/role/IncometaxesTables Income taxes (Tables) Tables http://www.phreesia.com/role/Incometaxes 34 false false R35.htm 0000035 - Disclosure - Net loss per share attributable to common stockholders (Tables) Sheet http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersTables Net loss per share attributable to common stockholders (Tables) Tables http://www.phreesia.com/role/Netlosspershareattributabletocommonstockholders 35 false false R36.htm 0000036 - Disclosure - Acquisitions (Tables) Sheet http://www.phreesia.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.phreesia.com/role/Acquisitions 36 false false R37.htm 0000037 - Disclosure - Background and liquidity (Details) Sheet http://www.phreesia.com/role/BackgroundandliquidityDetails Background and liquidity (Details) Details http://www.phreesia.com/role/Backgroundandliquidity 37 false false R38.htm 0000038 - Disclosure - Summary of significant accounting policies (Details) Sheet http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails Summary of significant accounting policies (Details) Details http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies 38 false false R39.htm 0000039 - Disclosure - Composition of certain financial statement captions - Schedule of accrued expenses (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails Composition of certain financial statement captions - Schedule of accrued expenses (Details) Details 39 false false R40.htm 0000040 - Disclosure - Composition of certain financial statement captions - Schedule of property and equipment (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails Composition of certain financial statement captions - Schedule of property and equipment (Details) Details 40 false false R41.htm 0000041 - Disclosure - Composition of certain financial statement captions - Narrative (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails Composition of certain financial statement captions - Narrative (Details) Details http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables 41 false false R42.htm 0000042 - Disclosure - Composition of certain financial statement captions - Schedule of intangible assets (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails Composition of certain financial statement captions - Schedule of intangible assets (Details) Details 42 false false R43.htm 0000043 - Disclosure - Composition of certain financial statement captions - Schedule of future amortization expense (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails Composition of certain financial statement captions - Schedule of future amortization expense (Details) Details 43 false false R44.htm 0000044 - Disclosure - Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofgoodwillrollforwardDetails Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) Details 44 false false R45.htm 0000045 - Disclosure - Composition of certain financial statement captions - Schedule of accounts receivable (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails Composition of certain financial statement captions - Schedule of accounts receivable (Details) Details 45 false false R46.htm 0000046 - Disclosure - Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofallowancefordoubtfulaccountsDetails Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) Details 46 false false R47.htm 0000047 - Disclosure - Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) Sheet http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) Details 47 false false R48.htm 0000048 - Disclosure - Revenue and Contract Costs - Narrative (Details) Sheet http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails Revenue and Contract Costs - Narrative (Details) Details 48 false false R49.htm 0000049 - Disclosure - Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details) Sheet http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details) Details 49 false false R50.htm 0000050 - Disclosure - Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details) Sheet http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details) Details 50 false false R51.htm 0000051 - Disclosure - Finance leases and other debt - Schedule of outstanding loan balances (Details) Sheet http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails Finance leases and other debt - Schedule of outstanding loan balances (Details) Details 51 false false R52.htm 0000052 - Disclosure - Finance leases and other debt - Amended and restated loan and security agreement (Details) Sheet http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails Finance leases and other debt - Amended and restated loan and security agreement (Details) Details 52 false false R53.htm 0000053 - Disclosure - Finance leases and other debt - Schedule of long-term debt maturities (Details) Sheet http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails Finance leases and other debt - Schedule of long-term debt maturities (Details) Details 53 false false R54.htm 0000054 - Disclosure - Finance leases and other debt - Schedule of interest income (expense), net (Details) Sheet http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails Finance leases and other debt - Schedule of interest income (expense), net (Details) Details 54 false false R55.htm 0000055 - Disclosure - Stockholders' Equity (Details) Sheet http://www.phreesia.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.phreesia.com/role/StockholdersEquity 55 false false R56.htm 0000056 - Disclosure - Equity-based compensation - Narrative (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails Equity-based compensation - Narrative (Details) Details 56 false false R57.htm 0000057 - Disclosure - Equity-based compensation - Stock-based compensation (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails Equity-based compensation - Stock-based compensation (Details) Details 57 false false R58.htm 0000058 - Disclosure - Equity-based compensation - Stock-based compensation in our financial statements (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails Equity-based compensation - Stock-based compensation in our financial statements (Details) Details 58 false false R59.htm 0000059 - Disclosure - Equity-based compensation - Performance-based restricted stock units (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails Equity-based compensation - Performance-based restricted stock units (Details) Details 59 false false R60.htm 0000060 - Disclosure - Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details) Details 60 false false R61.htm 0000061 - Disclosure - Equity-based compensation - Weighted average assumptions (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails Equity-based compensation - Weighted average assumptions (Details) Details 61 false false R62.htm 0000062 - Disclosure - Equity-based compensation - Stock option activity (Details) Sheet http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails Equity-based compensation - Stock option activity (Details) Details 62 false false R63.htm 0000063 - Disclosure - Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) Sheet http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) Details 63 false false R64.htm 0000064 - Disclosure - Leases - Narrative (Details) Sheet http://www.phreesia.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 64 false false R65.htm 0000065 - Disclosure - Leases - Schedule of operating and finance leases (Details) Sheet http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails Leases - Schedule of operating and finance leases (Details) Details 65 false false R66.htm 0000066 - Disclosure - Leases - Schedule of lease expenses (Details) Sheet http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails Leases - Schedule of lease expenses (Details) Details 66 false false R67.htm 0000067 - Disclosure - Leases - Schedule of maturing lease payments (Details) Sheet http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails Leases - Schedule of maturing lease payments (Details) Details 67 false false R68.htm 0000068 - Disclosure - Leases - Schedule of supplemental cash flow information (Details) Sheet http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails Leases - Schedule of supplemental cash flow information (Details) Details 68 false false R69.htm 0000069 - Disclosure - Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details) Sheet http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details) Details 69 false false R70.htm 0000070 - Disclosure - Income taxes - Narratives (Details) Sheet http://www.phreesia.com/role/IncometaxesNarrativesDetails Income taxes - Narratives (Details) Details 70 false false R71.htm 0000071 - Disclosure - Income taxes - Components of tax (benefit) (Details) Sheet http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails Income taxes - Components of tax (benefit) (Details) Details 71 false false R72.htm 0000072 - Disclosure - Income taxes - Effective tax rate reconciliation (Details) Sheet http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails Income taxes - Effective tax rate reconciliation (Details) Details 72 false false R73.htm 0000073 - Disclosure - Income taxes - Company's deferred tax assets and deferred tax liabilities (Details) Sheet http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails Income taxes - Company's deferred tax assets and deferred tax liabilities (Details) Details 73 false false R74.htm 0000074 - Disclosure - Net loss per share attributable to common stockholders - Schedule of computation (Details) Sheet http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails Net loss per share attributable to common stockholders - Schedule of computation (Details) Details 74 false false R75.htm 0000075 - Disclosure - Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) Sheet http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) Details 75 false false R76.htm 0000076 - Disclosure - Retirement savings plan (Details) Sheet http://www.phreesia.com/role/RetirementsavingsplanDetails Retirement savings plan (Details) Details http://www.phreesia.com/role/Retirementsavingsplan 76 false false R77.htm 0000077 - Disclosure - Related party transactions (Details) Sheet http://www.phreesia.com/role/RelatedpartytransactionsDetails Related party transactions (Details) Details http://www.phreesia.com/role/Relatedpartytransactions 77 false false R78.htm 0000078 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.phreesia.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 78 false false R79.htm 0000079 - Disclosure - Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details) Sheet http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details) Details 79 false false R80.htm 0000080 - Disclosure - Acquisitions - Schedule of consideration paid (Details) Sheet http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails Acquisitions - Schedule of consideration paid (Details) Details 80 false false R81.htm 0000081 - Disclosure - Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details) Sheet http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details) Details 81 false false R82.htm 0000082 - Disclosure - Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details) Sheet http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details) Details 82 false false R83.htm 0000083 - Disclosure - Subsequent event (Details) Sheet http://www.phreesia.com/role/SubsequenteventDetails Subsequent event (Details) Details http://www.phreesia.com/role/Subsequentevent 83 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 7 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. phr-20230131.htm 4 [dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. phr-20230131.htm 4 [dq-0542-Deprecated-Concept] Concept AccountsReceivableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. phr-20230131.htm 4 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. phr-20230131.htm 4 [dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. phr-20230131.htm 4 [dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. phr-20230131.htm 4 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: phr:SettlementAssetsSettlementPeriod, us-gaap:CapitalizedContractCostAmortizationPeriod, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:LesseeFinanceLeaseTermOfContract1, us-gaap:PropertyPlantAndEquipmentUsefulLife - phr-20230131.htm 4 phr-20230131.htm ex32-phrthirdamendedandres.htm phr-20230131.xsd phr-20230131_cal.xml phr-20230131_def.xml phr-20230131_lab.xml phr-20230131_pre.xml phr-fy2023xex231x10xkconse.htm phr-fy2023xex311x10xkxceo3.htm phr-fy2023xex312x10xkxcfo3.htm phr-fy2023xex321x10xkxceo1.htm phr-fy2023xex322x10xkcfo13.htm phrfy2023-exhibit211.htm phr-20230131_g1.jpg phr-20230131_g2.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 106 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "phr-20230131.htm": { "axisCustom": 0, "axisStandard": 25, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 1050, "http://xbrl.sec.gov/dei/2022": 38 }, "contextCount": 206, "dts": { "calculationLink": { "local": [ "phr-20230131_cal.xml" ] }, "definitionLink": { "local": [ "phr-20230131_def.xml" ] }, "inline": { "local": [ "phr-20230131.htm" ] }, "labelLink": { "local": [ "phr-20230131_lab.xml" ] }, "presentationLink": { "local": [ "phr-20230131_pre.xml" ] }, "schema": { "local": [ "phr-20230131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 678, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 10, "http://www.phreesia.com/20230131": 5, "http://xbrl.sec.gov/dei/2022": 4, "total": 19 }, "keyCustom": 56, "keyStandard": 418, "memberCustom": 26, "memberStandard": 37, "nsprefix": "phr", "nsuri": "http://www.phreesia.com/20230131", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.phreesia.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Basis of presentation", "menuCat": "Notes", "order": "10", "role": "http://www.phreesia.com/role/Basisofpresentation", "shortName": "Basis of presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Summary of significant accounting policies", "menuCat": "Notes", "order": "11", "role": "http://www.phreesia.com/role/Summaryofsignificantaccountingpolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Composition of certain financial statement captions", "menuCat": "Notes", "order": "12", "role": "http://www.phreesia.com/role/Compositionofcertainfinancialstatementcaptions", "shortName": "Composition of certain financial statement captions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Revenue and Contract Costs", "menuCat": "Notes", "order": "13", "role": "http://www.phreesia.com/role/RevenueandContractCosts", "shortName": "Revenue and Contract Costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Finance leases and other debt", "menuCat": "Notes", "order": "14", "role": "http://www.phreesia.com/role/Financeleasesandotherdebt", "shortName": "Finance leases and other debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "15", "role": "http://www.phreesia.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Equity-based compensation", "menuCat": "Notes", "order": "16", "role": "http://www.phreesia.com/role/Equitybasedcompensation", "shortName": "Equity-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Fair value measurements", "menuCat": "Notes", "order": "17", "role": "http://www.phreesia.com/role/Fairvaluemeasurements", "shortName": "Fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Leases", "menuCat": "Notes", "order": "18", "role": "http://www.phreesia.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Commitments and contingencies", "menuCat": "Notes", "order": "19", "role": "http://www.phreesia.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.phreesia.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income taxes", "menuCat": "Notes", "order": "20", "role": "http://www.phreesia.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Net loss per share attributable to common stockholders", "menuCat": "Notes", "order": "21", "role": "http://www.phreesia.com/role/Netlosspershareattributabletocommonstockholders", "shortName": "Net loss per share attributable to common stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Retirement savings plan", "menuCat": "Notes", "order": "22", "role": "http://www.phreesia.com/role/Retirementsavingsplan", "shortName": "Retirement savings plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Related party transactions", "menuCat": "Notes", "order": "23", "role": "http://www.phreesia.com/role/Relatedpartytransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "24", "role": "http://www.phreesia.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Subsequent event", "menuCat": "Notes", "order": "25", "role": "http://www.phreesia.com/role/Subsequentevent", "shortName": "Subsequent event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Summary of significant accounting policies (Policies)", "menuCat": "Policies", "order": "26", "role": "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Composition of certain financial statement captions (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables", "shortName": "Composition of certain financial statement captions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Revenue and Contract Costs (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.phreesia.com/role/RevenueandContractCostsTables", "shortName": "Revenue and Contract Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Finance leases and other debt (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.phreesia.com/role/FinanceleasesandotherdebtTables", "shortName": "Finance leases and other debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "3", "role": "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Equity-based compensation (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.phreesia.com/role/EquitybasedcompensationTables", "shortName": "Equity-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Fair value measurements (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.phreesia.com/role/FairvaluemeasurementsTables", "shortName": "Fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "phr:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.phreesia.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "phr:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Commitment and contingencies (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.phreesia.com/role/CommitmentandcontingenciesTables", "shortName": "Commitment and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Income taxes (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.phreesia.com/role/IncometaxesTables", "shortName": "Income taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Net loss per share attributable to common stockholders (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersTables", "shortName": "Net loss per share attributable to common stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Acquisitions (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.phreesia.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Background and liquidity (Details)", "menuCat": "Details", "order": "37", "role": "http://www.phreesia.com/role/BackgroundandliquidityDetails", "shortName": "Background and liquidity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "phr:NumberOfThirdPartyPaymentProcessors", "reportCount": 1, "unique": true, "unitRef": "processor", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Summary of significant accounting policies (Details)", "menuCat": "Details", "order": "38", "role": "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails", "shortName": "Summary of significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "phr:NumberOfThirdPartyPaymentProcessors", "reportCount": 1, "unique": true, "unitRef": "processor", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Composition of certain financial statement captions - Schedule of accrued expenses (Details)", "menuCat": "Details", "order": "39", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails", "shortName": "Composition of certain financial statement captions - Schedule of accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Composition of certain financial statement captions - Schedule of property and equipment (Details)", "menuCat": "Details", "order": "40", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "shortName": "Composition of certain financial statement captions - Schedule of property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Composition of certain financial statement captions - Narrative (Details)", "menuCat": "Details", "order": "41", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "shortName": "Composition of certain financial statement captions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Composition of certain financial statement captions - Schedule of intangible assets (Details)", "menuCat": "Details", "order": "42", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "shortName": "Composition of certain financial statement captions - Schedule of intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Composition of certain financial statement captions - Schedule of future amortization expense (Details)", "menuCat": "Details", "order": "43", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails", "shortName": "Composition of certain financial statement captions - Schedule of future amortization expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i76589ace19a84a0388dffdffe2669edf_I20220131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details)", "menuCat": "Details", "order": "44", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofgoodwillrollforwardDetails", "shortName": "Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "id215308536654bd4989a29049d2e9a4e_D20210201-20220131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BilledContractReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Composition of certain financial statement captions - Schedule of accounts receivable (Details)", "menuCat": "Details", "order": "45", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails", "shortName": "Composition of certain financial statement captions - Schedule of accounts receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BilledContractReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i76589ace19a84a0388dffdffe2669edf_I20220131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details)", "menuCat": "Details", "order": "46", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofallowancefordoubtfulaccountsDetails", "shortName": "Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:PrepaidSoftwareAndBusinessSystemsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details)", "menuCat": "Details", "order": "47", "role": "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails", "shortName": "Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:PrepaidSoftwareAndBusinessSystemsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:CapitalizedContractCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Revenue and Contract Costs - Narrative (Details)", "menuCat": "Details", "order": "48", "role": "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "shortName": "Revenue and Contract Costs - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CapitalizedContractCostImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i76589ace19a84a0388dffdffe2669edf_I20220131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details)", "menuCat": "Details", "order": "49", "role": "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails", "shortName": "Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i95af0a751d164db0b3fe5175a6614c3e_I20210131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "5", "role": "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:CapitalizedContractCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i76589ace19a84a0388dffdffe2669edf_I20220131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CapitalizedContractCostNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details)", "menuCat": "Details", "order": "50", "role": "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails", "shortName": "Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:CapitalizedContractCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "phr:DeferredContractAcquisitionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Finance leases and other debt - Schedule of outstanding loan balances (Details)", "menuCat": "Details", "order": "51", "role": "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails", "shortName": "Finance leases and other debt - Schedule of outstanding loan balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i1d5580f969884b6581132f4f484e7632_I20190228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Finance leases and other debt - Amended and restated loan and security agreement (Details)", "menuCat": "Details", "order": "52", "role": "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "shortName": "Finance leases and other debt - Amended and restated loan and security agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i1d5580f969884b6581132f4f484e7632_I20190228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Finance leases and other debt - Schedule of long-term debt maturities (Details)", "menuCat": "Details", "order": "53", "role": "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails", "shortName": "Finance leases and other debt - Schedule of long-term debt maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Finance leases and other debt - Schedule of interest income (expense), net (Details)", "menuCat": "Details", "order": "54", "role": "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails", "shortName": "Finance leases and other debt - Schedule of interest income (expense), net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "55", "role": "http://www.phreesia.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i6595d3086ae542af80f91a4529ff0472_I20190722", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Equity-based compensation - Narrative (Details)", "menuCat": "Details", "order": "56", "role": "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "shortName": "Equity-based compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Equity-based compensation - Stock-based compensation (Details)", "menuCat": "Details", "order": "57", "role": "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "shortName": "Equity-based compensation - Stock-based compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i7a69924c40404494baa73a2d7aafb740_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Equity-based compensation - Stock-based compensation in our financial statements (Details)", "menuCat": "Details", "order": "58", "role": "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails", "shortName": "Equity-based compensation - Stock-based compensation in our financial statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i896ccc1489b742a797cab1c7a742f1c1_I20220131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Equity-based compensation - Performance-based restricted stock units (Details)", "menuCat": "Details", "order": "59", "role": "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "shortName": "Equity-based compensation - Performance-based restricted stock units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i9e822a07dd4043388174639394c35aa1_I20200131", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i2025fa3230774045aff9c099fb4a5f14_I20200131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i2025fa3230774045aff9c099fb4a5f14_I20200131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details)", "menuCat": "Details", "order": "60", "role": "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "shortName": "Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i97c1215d78ab40ff80f77975e97bc246_I20230131", "decimals": "4", "lang": "en-US", "name": "phr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCorrelationCoefficient", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i4b9940f28cac4259abc2a65db17e71a5_D20220201-20230131", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Equity-based compensation - Weighted average assumptions (Details)", "menuCat": "Details", "order": "61", "role": "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails", "shortName": "Equity-based compensation - Weighted average assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i4b9940f28cac4259abc2a65db17e71a5_D20220201-20230131", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i76589ace19a84a0388dffdffe2669edf_I20220131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Equity-based compensation - Stock option activity (Details)", "menuCat": "Details", "order": "62", "role": "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails", "shortName": "Equity-based compensation - Stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i72cfc1739faf4f04bf69fecf4b37b678_I20200131", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i06ec12cb5e514758abcfbf0eb19ed78f_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Fair value measurements - Schedule of assets and liabilities measured at fair value (Details)", "menuCat": "Details", "order": "63", "role": "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails", "shortName": "Fair value measurements - Schedule of assets and liabilities measured at fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i06ec12cb5e514758abcfbf0eb19ed78f_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "64", "role": "http://www.phreesia.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "phr:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Leases - Schedule of operating and finance leases (Details)", "menuCat": "Details", "order": "65", "role": "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails", "shortName": "Leases - Schedule of operating and finance leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "phr:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:OperatingLeaseCostExcludingVariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Leases - Schedule of lease expenses (Details)", "menuCat": "Details", "order": "66", "role": "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails", "shortName": "Leases - Schedule of lease expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:OperatingLeaseCostExcludingVariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Leases - Schedule of maturing lease payments (Details)", "menuCat": "Details", "order": "67", "role": "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails", "shortName": "Leases - Schedule of maturing lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Leases - Schedule of supplemental cash flow information (Details)", "menuCat": "Details", "order": "68", "role": "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails", "shortName": "Leases - Schedule of supplemental cash flow information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details)", "menuCat": "Details", "order": "69", "role": "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails", "shortName": "Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i0b21da9d888d4aaa80d4c16368aefcab_D20200201-20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i0b21da9d888d4aaa80d4c16368aefcab_D20200201-20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Income taxes - Narratives (Details)", "menuCat": "Details", "order": "70", "role": "http://www.phreesia.com/role/IncometaxesNarrativesDetails", "shortName": "Income taxes - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Income taxes - Components of tax (benefit) (Details)", "menuCat": "Details", "order": "71", "role": "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails", "shortName": "Income taxes - Components of tax (benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Income taxes - Effective tax rate reconciliation (Details)", "menuCat": "Details", "order": "72", "role": "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails", "shortName": "Income taxes - Effective tax rate reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Income taxes - Company's deferred tax assets and deferred tax liabilities (Details)", "menuCat": "Details", "order": "73", "role": "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails", "shortName": "Income taxes - Company's deferred tax assets and deferred tax liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Net loss per share attributable to common stockholders - Schedule of computation (Details)", "menuCat": "Details", "order": "74", "role": "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails", "shortName": "Net loss per share attributable to common stockholders - Schedule of computation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details)", "menuCat": "Details", "order": "75", "role": "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails", "shortName": "Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "us-gaap:DefinedContributionPlanCostRecognized", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Retirement savings plan (Details)", "menuCat": "Details", "order": "76", "role": "http://www.phreesia.com/role/RetirementsavingsplanDetails", "shortName": "Retirement savings plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DefinedContributionPlanCostRecognized", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i6e4dbe3fe5f14facaf42be2fc4da821b_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Related party transactions (Details)", "menuCat": "Details", "order": "77", "role": "http://www.phreesia.com/role/RelatedpartytransactionsDetails", "shortName": "Related party transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i6e4dbe3fe5f14facaf42be2fc4da821b_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Acquisitions - Narrative (Details)", "menuCat": "Details", "order": "78", "role": "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "iae3cf8c19a414085a8c80e6645f9570c_I20211203", "decimals": "INF", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i7f80214c3c4e4a5bbeb2892c8c9f3cb6_D20211203-20211203", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details)", "menuCat": "Details", "order": "79", "role": "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "shortName": "Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i7f80214c3c4e4a5bbeb2892c8c9f3cb6_D20211203-20211203", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "phr:PaymentsToAcquireBusinessesIncludingContingentConsiderationNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Acquisitions - Schedule of consideration paid (Details)", "menuCat": "Details", "order": "80", "role": "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "shortName": "Acquisitions - Schedule of consideration paid (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i7f80214c3c4e4a5bbeb2892c8c9f3cb6_D20211203-20211203", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details)", "menuCat": "Details", "order": "81", "role": "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails", "shortName": "Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "iae3cf8c19a414085a8c80e6645f9570c_I20211203", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i4103a9fd55c44545b93376bda5264e7d_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details)", "menuCat": "Details", "order": "82", "role": "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "shortName": "Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "iae3cf8c19a414085a8c80e6645f9570c_I20211203", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i936ff8ff758241fa9410c930b2d2e462_I20230131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Subsequent event (Details)", "menuCat": "Details", "order": "83", "role": "http://www.phreesia.com/role/SubsequenteventDetails", "shortName": "Subsequent event (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Background and liquidity", "menuCat": "Notes", "order": "9", "role": "http://www.phreesia.com/role/Backgroundandliquidity", "shortName": "Background and liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "phr-20230131.htm", "contextRef": "i768539f45db644c3b3d6da011369b09c_D20220201-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phreesia.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "phr_A2022ShareSettledBonusAwardProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Share Settled Bonus Award Program", "label": "2022 Share Settled Bonus Award Program [Member]", "terseLabel": "2022 Share Settled Bonus Award Program" } } }, "localname": "A2022ShareSettledBonusAwardProgramMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "phr_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "phr_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "phr_AccruedInformationTechnologyServicesExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Information Technology Services Expenses, Current", "label": "Accrued Information Technology Services Expenses, Current", "terseLabel": "Information technology services" } } }, "localname": "AccruedInformationTechnologyServicesExpensesCurrent", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "phr_AccruedInterestAndPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Interest And Payments", "label": "Accrued Interest And Payments [Member]", "terseLabel": "Accrued interest and payments" } } }, "localname": "AccruedInterestAndPaymentsMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "domainItemType" }, "phr_AccruedProcessingFeeCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued processing fee.", "label": "Accrued Processing Fee, Current", "terseLabel": "Payment processing fees liability" } } }, "localname": "AccruedProcessingFeeCurrent", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "phr_AcquisitionRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Acquisition Related Liabilities, Current", "label": "Acquisition Related Liabilities, Current", "terseLabel": "Acquisition-related liabilities" } } }, "localname": "AcquisitionRelatedLiabilitiesCurrent", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "phr_AdvertisementsWithPharmaceuticalCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advertisements With Pharmaceutical Company", "label": "Advertisements With Pharmaceutical Company [Member]", "terseLabel": "Advertisements with Pharmaceutical Company" } } }, "localname": "AdvertisementsWithPharmaceuticalCompanyMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "phr_AffiliateOfDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affiliate of Director", "label": "Affiliate of Director [Member]", "terseLabel": "Affiliate of Director" } } }, "localname": "AffiliateOfDirectorMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "phr_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of operating and finance leases" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "phr_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.phreesia.com/20230131", "xbrltype": "stringItemType" }, "phr_BusinessCombinationConsiderationTransferredContingentConsideration": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Contingent Consideration", "label": "Business Combination, Consideration Transferred, Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredContingentConsideration", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails" ], "xbrltype": "monetaryItemType" }, "phr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Liabilities", "negatedTerseLabel": "Accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "phr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Right-Of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "phr_CapitalizedContractCostRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalized Contract Cost", "label": "Capitalized Contract Cost [Roll Forward]", "terseLabel": "Capitalized Contract Cost [Roll Forward]" } } }, "localname": "CapitalizedContractCostRollForward", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails" ], "xbrltype": "stringItemType" }, "phr_CapitalizedSoftwareObtainedThroughFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized Software Obtained Through Financing", "label": "Capitalized Software Obtained Through Financing", "terseLabel": "Capitalized software acquired through vendor financing" } } }, "localname": "CapitalizedSoftwareObtainedThroughFinancing", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_CashPaidForMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Paid For Measurement Of Lease Liabilities", "label": "Cash Paid For Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails" ], "xbrltype": "stringItemType" }, "phr_CashlessExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of common stock warrants.", "label": "Cashless Exercise of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "CashlessExerciseOfCommonStockWarrants", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "phr_CashlessExerciseOfCommonStockWarrantsSupplementalCashFlowInformation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cashless Exercise of Common Stock Warrants, Supplemental Cash Flow Information", "label": "Cashless Exercise of Common Stock Warrants, Supplemental Cash Flow Information", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "CashlessExerciseOfCommonStockWarrantsSupplementalCashFlowInformation", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_CompositionOfCertainFinancialStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Composition of Certain Financial Statement [Abstract]", "label": "Composition Of Certain Financial Statement [Abstract]", "terseLabel": "Composition of Certain Financial Statement Captions [Abstract]" } } }, "localname": "CompositionOfCertainFinancialStatementAbstract", "nsuri": "http://www.phreesia.com/20230131", "xbrltype": "stringItemType" }, "phr_CompositionOfCertainFinancialStatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Composition Of Certain Financial Statement", "label": "Composition Of Certain Financial Statement [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "CompositionOfCertainFinancialStatementLineItems", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "phr_CompositionOfCertainFinancialStatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Composition Of Certain Financial Statement", "label": "Composition Of Certain Financial Statement [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "CompositionOfCertainFinancialStatementTable", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "phr_ComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Software [Member]", "label": "Computer Software [Member]", "terseLabel": "Computer software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "phr_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer Asset", "label": "Contract With Customer Asset [Roll Forward]", "terseLabel": "Contract With Customer Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "stringItemType" }, "phr_ContractWithCustomerLiabilityOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Other", "label": "Contract With Customer, Liability, Other", "terseLabel": "Other current year activity in deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityOther", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_ContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer Liability", "label": "Contract With Customer Liability [Roll Forward]", "terseLabel": "Contract With Customer Liability [Roll Forward]" } } }, "localname": "ContractWithCustomerLiabilityRollForward", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "stringItemType" }, "phr_ContractWithCustomerPaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Payment Period", "label": "Contract With Customer, Payment Period", "terseLabel": "Customer payment period" } } }, "localname": "ContractWithCustomerPaymentPeriod", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "durationItemType" }, "phr_CostOfPhreesiaHardwarePurchasedByOthers": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost Of Phreesia Hardware Purchased By Others", "label": "Cost Of Phreesia Hardware Purchased By Others", "verboseLabel": "Cost of Phreesia hardware purchased by customers" } } }, "localname": "CostOfPhreesiaHardwarePurchasedByOthers", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One", "label": "Customer One [Member]", "terseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "phr_DebtConversionCashlessTransferOfLenderFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Cashless Transfer Of Lender Fees", "label": "Debt Conversion, Cashless Transfer Of Lender Fees", "terseLabel": "Cashless transfer of lender fees through increase in debt balance" } } }, "localname": "DebtConversionCashlessTransferOfLenderFees", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_DebtInstrumentCovenantCashHoldOutsideOfFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Cash Hold Outside Of Facility", "label": "Debt Instrument, Covenant, Cash Hold Outside Of Facility", "terseLabel": "Allowable cash hold outside of facility" } } }, "localname": "DebtInstrumentCovenantCashHoldOutsideOfFacility", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "monetaryItemType" }, "phr_DebtInstrumentTerminationFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Fee, Percentage", "label": "Debt Instrument, Termination Fee, Percentage", "terseLabel": "Termination fee percentage (up to) (as a percent)" } } }, "localname": "DebtInstrumentTerminationFeePercentage", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "percentItemType" }, "phr_DeferredContractAcquisitionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Contract Acquisition Costs", "label": "Deferred Contract Acquisition Costs", "terseLabel": "Additions to deferred contract acquisition costs" } } }, "localname": "DeferredContractAcquisitionCosts", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails" ], "xbrltype": "monetaryItemType" }, "phr_DeferredTaxAssetsDisallowedInterestExpense": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Disallowed Interest Expense", "label": "Deferred Tax Assets Disallowed Interest Expense", "terseLabel": "Disallowed interest expense" } } }, "localname": "DeferredTaxAssetsDisallowedInterestExpense", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_ESPPEmployeeCommonStockPurchaseDiscountPercentOfDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ESPP, Employee Common Stock Purchase Discount, Percent of Discount", "label": "ESPP, Employee Common Stock Purchase Discount, Percent of Discount", "terseLabel": "ESPP, employee common stock purchase discount (as a percent)" } } }, "localname": "ESPPEmployeeCommonStockPurchaseDiscountPercentOfDiscount", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "phr_EmployeeStockPurchasePlanNumberOfOfferingPeriodsPerYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan, Number Of Offering Periods Per Year", "label": "Employee Stock Purchase Plan, Number Of Offering Periods Per Year", "terseLabel": "ESPP, number of offering periods per year" } } }, "localname": "EmployeeStockPurchasePlanNumberOfOfferingPeriodsPerYear", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "phr_EmployeesOtherThanNamedExecutiveOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees Other Than Named Executive Officers", "label": "Employees Other Than Named Executive Officers [Member]", "terseLabel": "Employees Other than NEOs" } } }, "localname": "EmployeesOtherThanNamedExecutiveOfficersMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "phr_EstimatedNumberOfMonthsTheCompanyHaveSufficientToFundItsOperations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated Number Of Months The Company Have Sufficient To Fund Its Operations", "label": "Estimated Number Of Months The Company Have Sufficient To Fund Its Operations", "terseLabel": "Number of months with sufficient funds to operate (in months)" } } }, "localname": "EstimatedNumberOfMonthsTheCompanyHaveSufficientToFundItsOperations", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "durationItemType" }, "phr_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails" ], "xbrltype": "monetaryItemType" }, "phr_FinanceLeaseLiabilityPaymentsDueYearOneDiscountedObligation": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, Payments, Due Year One, Discounted Obligation", "label": "Finance Lease, Liability, Payments, Due Year One, Discounted Obligation", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearOneDiscountedObligation", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_FinanceLeaseLiabilityPaymentsDueYearThreeDiscountedObligation": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 2.0, "parentTag": "phr_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, Payments, Due Year Three, Discounted Obligation", "label": "Finance Lease, Liability, Payments, Due Year Three, Discounted Obligation", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThreeDiscountedObligation", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_FinanceLeaseLiabilityPaymentsDueYearTwoDiscountedObligation": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, Payments, Due Year Two, Discounted Obligation", "label": "Finance Lease, Liability, Payments, Due Year Two, Discounted Obligation", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwoDiscountedObligation", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, to be Paid, After Year Four", "label": "Finance Lease, Liability, to be Paid, After Year Four", "terseLabel": "Finance Lease, Liability, to be Paid, After Year Four" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "phr_FinancingArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing Arrangements", "label": "Financing Arrangements [Member]", "terseLabel": "Financing arrangements" } } }, "localname": "FinancingArrangementsMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "domainItemType" }, "phr_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets, Amortization Expense, after Year Four", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "phr_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-On Offering", "label": "Follow-On Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "phr_HardwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hardware development [Member]", "label": "Hardware Development [Member]", "terseLabel": "Hardware development" } } }, "localname": "HardwareDevelopmentMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "phr_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_InsigniaHealthLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insignia Health, LLC", "label": "Insignia Health, LLC [Member]", "terseLabel": "Insignia" } } }, "localname": "InsigniaHealthLLCMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails" ], "xbrltype": "domainItemType" }, "phr_LeasePayments": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Payments", "label": "Lease, Payments", "totalLabel": "Total cash paid in measurement of lease liabilities" } } }, "localname": "LeasePayments", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails" ], "xbrltype": "monetaryItemType" }, "phr_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "phr_LiabilityAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability Awards", "label": "Liability Awards [Member]", "terseLabel": "Liability awards" } } }, "localname": "LiabilityAwardsMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails" ], "xbrltype": "domainItemType" }, "phr_LineOfCreditFacilityAccordionFeaturePotentialMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Accordion Feature, Potential Maximum Borrowing Capacity", "label": "Line Of Credit Facility, Accordion Feature, Potential Maximum Borrowing Capacity", "terseLabel": "Accordion feature, potential new maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityAccordionFeaturePotentialMaximumBorrowingCapacity", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "phr_LongTermDebtAndFinanceLeaseObligationsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term Debt And Finance Lease Obligations, Fiscal Year Maturity", "label": "Long-term Debt And Finance Lease Obligations, Fiscal Year Maturity [Abstract]", "terseLabel": "Total" } } }, "localname": "LongTermDebtAndFinanceLeaseObligationsFiscalYearMaturityAbstract", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "stringItemType" }, "phr_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 3.0, "parentTag": "phr_LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year One", "label": "Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year One", "totalLabel": "2024" } } }, "localname": "LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 2.0, "parentTag": "phr_LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Three", "label": "Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Three", "totalLabel": "2026" } } }, "localname": "LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 1.0, "parentTag": "phr_LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Two", "label": "Long-term Debt And Finance Lease Obligations, Maturities, Repayments Of Principal In Year Two", "totalLabel": "2025" } } }, "localname": "LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt And Lease Obligations, Gross, Including Original Issue Discount", "label": "Long-term Debt And Lease Obligations, Gross, Including Original Issue Discount", "totalLabel": "Total maturities of finance leases and other debt" } } }, "localname": "LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "phr_NetworkSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Network Solutions", "label": "Network Solutions [Member]", "terseLabel": "Network solutions" } } }, "localname": "NetworkSolutionsMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "phr_NoncashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Operating Lease Expense", "label": "Noncash Operating Lease Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "NoncashOperatingLeaseExpense", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_NumberOfThirdPartyPaymentProcessors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Third-Party Payment Processors", "label": "Number of Third-Party Payment Processors", "terseLabel": "Number of third party payment processors" } } }, "localname": "NumberOfThirdPartyPaymentProcessors", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "integerItemType" }, "phr_OperatingLeaseCostExcludingVariableLeaseCost": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Cost, Excluding Variable Lease Cost", "label": "Operating Lease Cost, Excluding Variable Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCostExcludingVariableLeaseCost", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails" ], "xbrltype": "monetaryItemType" }, "phr_OtherPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Prepaid Expenses And Other Current Assets", "label": "Other Prepaid Expenses And Other Current Assets", "terseLabel": "Other prepaid expenses and other current assets" } } }, "localname": "OtherPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "phr_PaymentProcessingExpense": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment processing expense.", "label": "Payment Processing Expense", "terseLabel": "Payment processing expense" } } }, "localname": "PaymentProcessingExpense", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "phr_PaymentProcessingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment processing fees.", "label": "Payment Processing Fees [Member]", "terseLabel": "Payment processing fees" } } }, "localname": "PaymentProcessingFeesMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "phr_PaymentServiceObligationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment Service Obligations [Policy Text Block]", "label": "Payment Service Obligations [Policy Text Block]", "terseLabel": "Payment processing expense" } } }, "localname": "PaymentServiceObligationsPolicyTextBlock", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "phr_PaymentsToAcquireBusinessesIncludingContingentConsiderationNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Businesses Including Contingent Consideration, Net Of Cash Acquired", "label": "Payments To Acquire Businesses Including Contingent Consideration, Net Of Cash Acquired", "negatedLabel": "Acquisitions, net of cash acquired", "totalLabel": "Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows" } } }, "localname": "PaymentsToAcquireBusinessesIncludingContingentConsiderationNetOfCashAcquired", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_PercentageIncreaseInNumberOfSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Increase In Number of Shares Reserved For Future Issuance", "label": "Percentage Increase In Number of Shares Reserved For Future Issuance", "terseLabel": "Percentage increase in number of shares reserved (as a percent)" } } }, "localname": "PercentageIncreaseInNumberOfSharesReservedForFutureIssuance", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "phr_PhreesiaPadsAndArrivalsStationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phreesia pads and arrivals stations [Member]", "label": "Phreesia Pads and Arrivals Stations [Member]", "terseLabel": "PhreesiaPads and Arrivals Kiosks" } } }, "localname": "PhreesiaPadsAndArrivalsStationsMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "phr_PrepaidDataCenterExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Data Center Expenses, Current", "label": "Prepaid Data Center Expenses, Current", "terseLabel": "Prepaid data center expenses" } } }, "localname": "PrepaidDataCenterExpensesCurrent", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "phr_PrepaidSoftwareAndBusinessSystemsCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Software And Business Systems, Current", "label": "Prepaid Software And Business Systems, Current", "terseLabel": "Prepaid software and business systems" } } }, "localname": "PrepaidSoftwareAndBusinessSystemsCurrent", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "phr_ProceedsFromInsuranceFinancingArrangement": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Insurance Financing Arrangement", "label": "Proceeds From Insurance Financing Arrangement", "terseLabel": "Insurance financing agreement" } } }, "localname": "ProceedsFromInsuranceFinancingArrangement", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_QueueDrMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "QueueDr", "label": "QueueDr [Member]", "terseLabel": "QueueDr" } } }, "localname": "QueueDrMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "phr_ReceivablesForCashInTransitOnStockOptionExercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables For Cash In-Transit On Stock Option Exercise", "label": "Receivables For Cash In-Transit On Stock Option Exercise", "terseLabel": "Receivables for cash in-transit on stock option exercises" } } }, "localname": "ReceivablesForCashInTransitOnStockOptionExercise", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "phr_RevenueFromAffiliateOfStockholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Affiliate Of Stockholder", "label": "Revenue From Affiliate Of Stockholder [Member]", "terseLabel": "Revenue from Affiliate of Stockholder" } } }, "localname": "RevenueFromAffiliateOfStockholderMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "phr_SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amended And Restated Loan And Security Agreement (Second SVB Facility)", "label": "Second Amended And Restated Loan And Security Agreement (Second SVB Facility) [Member]", "terseLabel": "Second SVB Facility" } } }, "localname": "SecondAmendedAndRestatedLoanAndSecurityAgreementSecondSVBFacilityMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "domainItemType" }, "phr_SettlementAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Assets Policy [Text Block]", "label": "Settlement Assets Policy [Policy Text Block]", "terseLabel": "Settlement assets" } } }, "localname": "SettlementAssetsPolicyPolicyTextBlock", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "phr_SettlementAssetsSettlementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Assets, Settlement Period", "label": "Settlement Assets, Settlement Period", "terseLabel": "Settlement period (in days)" } } }, "localname": "SettlementAssetsSettlementPeriod", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "durationItemType" }, "phr_SettlementObligationsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Obligations Policy [Text Block]", "label": "Settlement Obligations Policy [Policy Text Block]", "terseLabel": "Settlement obligations" } } }, "localname": "SettlementObligationsPolicyPolicyTextBlock", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "phr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentageQuarterly": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage, Quarterly", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage, Quarterly", "terseLabel": "Quarterly vesting rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentageQuarterly", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "phr_ShareBasedCompensationArrangementByShareBasedPaymentAwardBonusSettlementInSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Bonus Settlement In Shares, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Bonus Settlement In Shares, Percentage", "terseLabel": "Bonus settlement in shares (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardBonusSettlementInSharesPercentage", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "phr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCorrelationCoefficient": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Correlation Coefficient", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Correlation Coefficient", "terseLabel": "Correlation coefficient" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCorrelationCoefficient", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails" ], "xbrltype": "pureItemType" }, "phr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price", "terseLabel": "Amount vested at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "phr_ShareBasedPaymentArrangementTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Tranche Four", "label": "Share-Based Payment Arrangement, Tranche Four [Member]", "terseLabel": "Share-based Payment Arrangement, Year 4" } } }, "localname": "ShareBasedPaymentArrangementTrancheFourMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "phr_SoftwareAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software Agreement", "label": "Software Agreement [Member]", "terseLabel": "Software Agreement" } } }, "localname": "SoftwareAgreementMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "phr_StockIssuedUponCashlessExerciseOfCommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued upon cashless exercise of common stock warrants.", "label": "Stock Issued Upon Cashless Exercise of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants (in shares)" } } }, "localname": "StockIssuedUponCashlessExerciseOfCommonStockWarrants", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "phr_SubscriptionAndRelatedServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription And Related Services", "label": "Subscription And Related Services [Member]", "terseLabel": "Subscription and related services" } } }, "localname": "SubscriptionAndRelatedServicesMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "domainItemType" }, "phr_SubscriptionAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription and related services.", "label": "Subscription And Services [Member]", "terseLabel": "Subscription and related services" } } }, "localname": "SubscriptionAndServicesMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "phr_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan", "label": "Term Loan [Member]", "terseLabel": "Term loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "domainItemType" }, "phr_ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Amended And Restated Loan And Security Agreement (Third SVB Facility)", "label": "Third Amended And Restated Loan And Security Agreement (Third SVB Facility) [Member]", "terseLabel": "Third SVB Facility" } } }, "localname": "ThirdAmendedAndRestatedLoanAndSecurityAgreementThirdSVBFacilityMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "domainItemType" }, "phr_TreasuryStockFromVestingOfShareBasedAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock From Vesting Of Share-Based Awards", "label": "Treasury Stock From Vesting Of Share-Based Awards", "negatedTerseLabel": "Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings" } } }, "localname": "TreasuryStockFromVestingOfShareBasedAwards", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "phr_TwoThousandAndNineteenStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Nineteen Stock Option And Incentive Plan [Member]", "label": "Two Thousand And Nineteen Stock Option And Incentive Plan [Member]", "terseLabel": "2019 Stock Option And Incentive Plan" } } }, "localname": "TwoThousandAndNineteenStockOptionAndIncentivePlanMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "phr_TwoThousandEighteenStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen stock option plan.", "label": "Two Thousand Eighteen Stock Option Plan [Member]", "terseLabel": "2018 Stock Option Plan" } } }, "localname": "TwoThousandEighteenStockOptionPlanMember", "nsuri": "http://www.phreesia.com/20230131", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r581", "r585", "r686", "r730", "r731", "r733" ], "lang": { "en-us": { "role": { "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.", "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Minimum Payments Under Purchase Commitments" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/CommitmentandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of executive officer.", "label": "Executive Officer [Member]", "terseLabel": "NEOs and Other Members of Executive Management" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r283", "r607", "r683", "r744" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r311", "r312", "r313", "r314", "r405", "r547", "r570", "r582", "r583", "r603", "r613", "r621", "r681", "r736", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r311", "r312", "r313", "r314", "r405", "r547", "r570", "r582", "r583", "r603", "r613", "r621", "r681", "r736", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r283", "r607", "r683", "r744" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r281", "r550", "r606", "r620", "r676", "r677", "r683", "r743" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r281", "r550", "r606", "r620", "r676", "r677", "r683", "r743" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r311", "r312", "r313", "r314", "r387", "r405", "r436", "r437", "r438", "r546", "r547", "r570", "r582", "r583", "r603", "r613", "r621", "r675", "r681", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r311", "r312", "r313", "r314", "r387", "r405", "r436", "r437", "r438", "r546", "r547", "r570", "r582", "r583", "r603", "r613", "r621", "r675", "r681", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r652", "r732" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r619" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of allowance for doubtful accounts" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r202", "r284", "r285", "r587" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "totalLabel": "Total accounts receivable, gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r284", "r285" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $1,053 and $863 as of January\u00a031, 2023 and 2022, respectively", "totalLabel": "Total accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r154", "r156", "r204", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable from related parties" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r2", "r160", "r174" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Tax liabilities" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average amortization period (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Composition of certain financial statement captions" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Compositionofcertainfinancialstatementcaptions" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r8", "r619" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r449", "r450", "r451", "r645", "r646", "r647", "r722" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r45", "r71" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r110", "r111", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r90", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Sales and marketing" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r441" ], "calculation": { "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails": { "order": 2.0, "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r205", "r288", "r292" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedTerseLabel": "Less accounts receivable allowances", "periodEndLabel": "Allowance for doubtful accounts at end of period", "periodStartLabel": "Allowance for doubtful accounts at beginning of period", "terseLabel": "Allowance for doubtful accounts", "verboseLabel": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofallowancefordoubtfulaccountsDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofallowancefordoubtfulaccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs and adjustments" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofallowancefordoubtfulaccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r348", "r512", "r601", "r602", "r638" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r45", "r65", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r45", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r158", "r173", "r198", "r225", "r266", "r275", "r279", "r290", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r487", "r489", "r502", "r619", "r679", "r680", "r734" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r191", "r206", "r225", "r290", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r487", "r489", "r502", "r619", "r679", "r680", "r734" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r143" ], "calculation": { "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r436", "r437", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails", "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails", "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Basisofpresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Consolidated Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BilledContractReceivables": { "auth_ref": [ "r549" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.", "label": "Billed Contracts Receivable", "terseLabel": "Billed" } } }, "localname": "BilledContractReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r482", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r126", "r127", "r482", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Acquisition related costs incurred" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of equity acquired (as a percent)" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r124" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r134", "r135", "r136" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "totalLabel": "Total fair value of acquisition consideration", "verboseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r133", "r134", "r135", "r485" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Liabilities incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r486", "r637" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r137", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedTerseLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r128", "r129" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r129" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r50", "r51", "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r50", "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Lease Obligation Incurred", "terseLabel": "Property and equipment acquisitions through finance leases" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "auth_ref": [ "r746" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.", "label": "Capitalized Computer Software, Accumulated Amortization", "terseLabel": "Accumulated amortization of capitalized internal-use software" } } }, "localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized cost of computer software" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "auth_ref": [ "r182", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for amortization of capitalized computer software costs.", "label": "Capitalized Computer Software, Amortization", "terseLabel": "Capitalized computed software amortization" } } }, "localname": "CapitalizedComputerSoftwareAmortization1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r584" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "verboseLabel": "Capitalized internal-use software, net of accumulated amortization of $37,236 and $31,139 as of January\u00a031, 2023 and 2022, respectively" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r297" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "negatedLabel": "Amortization of deferred contract acquisition costs", "terseLabel": "Deferred contract acquisition costs amortization", "verboseLabel": "Capitalized contract cost, amortization" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Capitalized Contract Cost, Amortization Period", "terseLabel": "Capitalized contract cost, amortization period (in years)" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Impairment Loss", "terseLabel": "Capitalized contract cost, impairment loss" } } }, "localname": "CapitalizedContractCostImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r296" ], "calculation": { "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Net", "periodEndLabel": "Capitalized contract costs at end of period", "periodStartLabel": "Capitalized contract costs at beginning of period", "totalLabel": "Total deferred contract acquisition costs" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetCurrent": { "auth_ref": [ "r296" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails": { "order": 1.0, "parentTag": "us-gaap_CapitalizedContractCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Capitalized Contract Cost, Net, Current", "terseLabel": "Deferred contract acquisition costs", "verboseLabel": "Deferred contract acquisition costs, current (to be amortized in next 12 months)" } } }, "localname": "CapitalizedContractCostNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r296" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalizedContractCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Capitalized Contract Cost, Net, Noncurrent", "terseLabel": "Deferred contract acquisition costs, non-current", "verboseLabel": "Deferred contract acquisition costs" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/RevenueandContractCostsScheduleofdeferredcontractacquisitioncostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostTableTextBlock": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Table Text Block]", "terseLabel": "Schedule of deferred contract acquisition costs" } } }, "localname": "CapitalizedContractCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r33" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails": { "order": 3.0, "parentTag": "phr_PaymentsToAcquireBusinessesIncludingContingentConsiderationNetOfCashAcquired", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "negatedTerseLabel": "Less cash acquired" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r47", "r193", "r586" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market mutual funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r41", "r47", "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents\u2014end of year", "periodStartLabel": "Cash and cash equivalents\u2014beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r41", "r149" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r21", "r164", "r178" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r81", "r309", "r310", "r578", "r678" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserve for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r645", "r646", "r722" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (up to) (in shares)", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r619" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value\u2014500,000,000 shares authorized as of both January\u00a031, 2023 and 2022; 54,187,172 and 52,095,964 shares issued as of January\u00a031, 2023 and 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r617", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r57", "r58", "r147", "r148", "r283", "r577" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r57", "r58", "r147", "r148", "r283", "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r57", "r58", "r147", "r148", "r283", "r577", "r745" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r170", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk and risks and uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r57", "r58", "r147", "r148", "r283" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r57", "r58", "r147", "r148", "r283", "r577" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r682" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of rollforward of contract assets and contract liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r372", "r374", "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Ending balance - Contract assets (unbilled accounts receivable)", "periodStartLabel": "Beginning balance - Contract assets (unbilled accounts receivable)" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetPurchase": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.", "label": "Contract with Customer, Asset, Purchase", "terseLabel": "Contract asset additions, net of reclassification to receivables" } } }, "localname": "ContractWithCustomerAssetPurchase", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r605" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "Contract with Customer, Asset, Reclassified to Receivable", "negatedLabel": "Amount transferred to receivables from beginning balance of contract assets" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r372", "r373", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance - Contract liabilities (deferred revenue)", "periodStartLabel": "Beginning balance - Contract liabilities (deferred revenue)" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r372", "r373", "r383" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r604" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Increases in deferred revenue due to acquisitions" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r372", "r373", "r383" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Revenue recognized that was included in deferred revenue at the beginning of the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r635", "r636" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of revenue (excluding depreciation and amortization)" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of revenue (excluding depreciation and amortization)" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r28" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r642", "r718", "r720" ], "calculation": { "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r642", "r718" ], "calculation": { "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current tax" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r642", "r718", "r720" ], "calculation": { "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r56", "r283" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationship" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r50", "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Cashless transfer of term loan and related accrued fees into increase in debt balance" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r86", "r223", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r342", "r349", "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Finance leases and other debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Financeleasesandotherdebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r159", "r162", "r172", "r228", "r326", "r327", "r328", "r329", "r330", "r332", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r513", "r598", "r599", "r600", "r601", "r602", "r640" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r162", "r172", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Long term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r151", "r153", "r326", "r513", "r599", "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Annual commitment fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "negatedLabel": "Scheduled reduction in interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r18", "r327" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r228", "r326", "r327", "r328", "r329", "r330", "r332", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r513", "r598", "r599", "r600", "r601", "r602", "r640" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r20", "r91", "r94", "r95", "r96", "r150", "r151", "r153", "r169", "r228", "r326", "r327", "r328", "r329", "r330", "r332", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r513", "r598", "r599", "r600", "r601", "r602", "r640" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Equity offering costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r642", "r719", "r720" ], "calculation": { "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r642", "r719" ], "calculation": { "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred tax" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r161", "r171", "r465" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r46" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r642", "r719", "r720" ], "calculation": { "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r466" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r716" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred taxes, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r716" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences", "terseLabel": "Accruals, reserves, and other expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Reserve for bad debts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r467" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails", "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs classified as other.", "label": "Deferred Tax Liabilities, Deferred Expense, Other Capitalized Costs", "negatedTerseLabel": "Deferred contract acquisition costs" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedTerseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r119", "r717" ], "calculation": { "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesCompanysdeferredtaxassetsanddeferredtaxliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Company contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RetirementsavingsplanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r45", "r77" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r45", "r264" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.", "label": "Depreciation, Depletion, and Amortization [Policy Text Block]", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r410", "r443", "r444", "r448", "r453", "r614" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Equitybasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r101", "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of stock based compensation by type of award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r203", "r317", "r318", "r319", "r323", "r324", "r325", "r537", "r588", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from related parties, current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesNoncurrent": { "auth_ref": [ "r194", "r317", "r318", "r319", "r323", "r324", "r325", "r537", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which are usually due after one year (or one business cycle).", "label": "Due from Related Parties, Noncurrent", "terseLabel": "Due from related parties, noncurrent" } } }, "localname": "DueFromRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r215", "r234", "r235", "r236", "r237", "r238", "r242", "r244", "r246", "r247", "r248", "r252", "r493", "r494", "r566", "r568", "r593" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r215", "r234", "r235", "r236", "r237", "r238", "r244", "r246", "r247", "r248", "r252", "r493", "r494", "r566", "r568", "r593" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r249", "r250", "r251", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share attributable to common stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Netlosspershareattributabletocommonstockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r461" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)", "totalLabel": "Effective income tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails", "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r226", "r461", "r476" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income tax benefit at statutory rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r714", "r721" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "auth_ref": [ "r714", "r721" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "negatedLabel": "Permanent differences (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r714", "r721" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign taxes (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r714", "r721" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "terseLabel": "Equity compensation (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r714", "r721" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r714", "r721" ], "calculation": { "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local tax, net of federal benefit (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesEffectivetaxratereconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll-related expenses and taxes" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r442" ], "calculation": { "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails": { "order": 1.0, "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Less stock-based compensation expense capitalized as internal-use software", "verboseLabel": "Capitalized stock based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.", "label": "Share-Based Payment Arrangement, Cash Used to Settle Award", "terseLabel": "Cash settled stock based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average term for recognition (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r713" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r713" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost to stock option" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP", "verboseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails", "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r90", "r189", "r210", "r211", "r212", "r229", "r230", "r231", "r233", "r239", "r241", "r254", "r291", "r371", "r449", "r450", "r451", "r472", "r473", "r492", "r503", "r504", "r505", "r506", "r507", "r508", "r533", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r495", "r496", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of measurement inputs and valuation techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r340", "r389", "r390", "r391", "r392", "r393", "r394", "r496", "r543", "r544", "r545", "r599", "r600", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r495", "r496", "r497", "r498", "r501" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Fairvaluemeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r340", "r389", "r394", "r496", "r543", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r340", "r389", "r394", "r496", "r544", "r599", "r600", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r340", "r389", "r390", "r391", "r392", "r393", "r394", "r496", "r545", "r599", "r600", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r340", "r389", "r390", "r391", "r392", "r393", "r394", "r543", "r544", "r545", "r599", "r600", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r499", "r501" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value, recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r517", "r522", "r618" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails": { "order": 1.0, "parentTag": "phr_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r519", "r525" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails": { "order": 1.0, "parentTag": "phr_LeasePayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash used for finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid [Abstract]", "netLabel": "Finance", "verboseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails", "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r515", "r529" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails_1": { "order": 2.0, "parentTag": "phr_LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount", "weight": 1.0 }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 }, "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance leases", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails", "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r515" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of maturing lease commitments of finance leases" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r515" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r518", "r525" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 }, "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails": { "order": 2.0, "parentTag": "phr_LeasePayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Finance lease payments", "terseLabel": "Financing cash used for finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r514" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "totalLabel": "Property and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r725", "r727" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "negatedTerseLabel": "Accumulated depreciation", "verboseLabel": "Assets under finance lease, accumulated amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r517", "r522", "r618" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails": { "order": 2.0, "parentTag": "phr_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r724" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Property and equipment, at cost" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r528", "r618" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance lease, weighted average discount rate (as a percent)" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r527", "r618" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance lease, weighted average remaining lease term (in years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "netLabel": "Useful life (in years)", "terseLabel": "Estimated Useful Life (in Years)", "verboseLabel": "Estimated useful life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r196", "r305" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Less accumulated amortization", "terseLabel": "Accumulated amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r72" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r72" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r72" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r72" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r303", "r304", "r305", "r306", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r70", "r552" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Total intangible assets, gross carrying value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r66", "r69" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r70", "r551" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net of accumulated amortization of $2,549 and $1,178 as of January\u00a031, 2023 and 2022, respectively", "totalLabel": "Net carrying value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleoffutureamortizationexpenseDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-lived intangible assets, remaining amortization period (in years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiscalPeriod": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.", "label": "Fiscal Period, Policy [Policy Text Block]", "terseLabel": "Fiscal year" } } }, "localname": "FiscalPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r45", "r84", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r195", "r298", "r565", "r597", "r619", "r658", "r665" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill balance at end of period", "periodStartLabel": "Goodwill balance at beginning of period", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofgoodwillrollforwardDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r300", "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill additions during the year" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofgoodwillrollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r64", "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r45", "r299", "r301", "r302", "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r123", "r664" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill adjustments during the year", "verboseLabel": "Measurement period adjustments to goodwill during the year" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofgoodwillrollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofgoodwillrollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAccumulatedAmortization": { "auth_ref": [ "r307", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of capitalized implementation cost from hosting arrangement that is service contract.", "label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Accumulated Amortization", "terseLabel": "Capitalized implementation costs, accumulated amortization" } } }, "localname": "HostingArrangementServiceContractImplementationCostCapitalizedAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedBeforeAccumulatedAmortization": { "auth_ref": [ "r671", "r672" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of capitalized implementation cost from hosting arrangement that is service contract.", "label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, before Accumulated Amortization", "terseLabel": "Capitalized implementation costs" } } }, "localname": "HostingArrangementServiceContractImplementationCostCapitalizedBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r75", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r26", "r157", "r165", "r180", "r266", "r274", "r278", "r280", "r567", "r595" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r226", "r462", "r463", "r470", "r474", "r477", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r715" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Tax examination, penalties and interest accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r227", "r240", "r241", "r265", "r460", "r475", "r478", "r569" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes", "totalLabel": "Total provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/IncometaxesComponentsoftaxbenefitDetails", "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r209", "r456", "r457", "r463", "r464", "r469", "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r42", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r44" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r44" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r44" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "terseLabel": "Increases in contract assets due to acquisitions" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsRollforwardofcontractassetsandcontractliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r548", "r637" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "auth_ref": [ "r44" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.", "label": "Increase (Decrease) in Deferred Charges", "negatedLabel": "Deferred contract acquisition costs" } } }, "localname": "IncreaseDecreaseInDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r44" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r152", "r168", "r213", "r263", "r511" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of components of interest income (expense)" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r167" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income (expense), net", "totalLabel": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r29" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofinterestincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract]", "terseLabel": "Cash paid for:" } } }, "localname": "InterestPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r218", "r220", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalUseSoftwarePolicy": { "auth_ref": [ "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.", "label": "Internal Use Software, Policy [Policy Text Block]", "terseLabel": "Capitalized internal-use software" } } }, "localname": "InternalUseSoftwarePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease expense and cash flow information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseIncome": { "auth_ref": [ "r531" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.", "label": "Lease Income", "terseLabel": "Lease income" } } }, "localname": "LeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails", "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Finance Lease, Description [Abstract]", "terseLabel": "Finance leases:", "verboseLabel": "Finance leases:" } } }, "localname": "LesseeFinanceLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Finance lease, term of contract (in years)" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Operating leases:", "verboseLabel": "Operating leases:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of maturing lease commitments of operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r529" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r225", "r290", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r488", "r489", "r490", "r502", "r594", "r679", "r734", "r735" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r163", "r177", "r619", "r641", "r653", "r723" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r192", "r225", "r290", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r488", "r489", "r490", "r502", "r619", "r679", "r734", "r735" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofintangibleassetacquiredrelatedtoInsigniaHealthacquisitionDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "Line of Credit Facility, Interest Rate During Period", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused capacity, commitment fee (as a percent)" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r162", "r175", "r339", "r354", "r599", "r600" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails_1": { "order": 1.0, "parentTag": "phr_LongTermDebtAndLeaseObligationsGrossIncludingOriginalIssueDiscount", "weight": 1.0 }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total long-term debt maturities" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r3" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term finance leases and other debt", "verboseLabel": "Long-term finance lease liabilities and other debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-Term Debt and Lease Obligation, Current", "negatedTerseLabel": "Less - current portion of finance lease liabilities and other debt", "verboseLabel": "Current portion of finance lease liabilities and other debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "totalLabel": "Total finance lease liabilities and other debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "verboseLabel": "Other Debt" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r82", "r228", "r344" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r82", "r228", "r344" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r82", "r228", "r344" ], "calculation": { "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleoflongtermdebtmaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r20", "r83" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtScheduleofoutstandingloanbalancesDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r219" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r219" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r41", "r43", "r46" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r46", "r166", "r179", "r190", "r207", "r208", "r212", "r225", "r232", "r234", "r235", "r236", "r237", "r240", "r241", "r245", "r266", "r274", "r278", "r280", "r290", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r494", "r502", "r595", "r679" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r266", "r274", "r278", "r280", "r595" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r523", "r618" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "totalLabel": "Total operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r515" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofmaturingleasepaymentsDetails", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r515" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities, current", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r515" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, non-current", "verboseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r520", "r525" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails": { "order": 3.0, "parentTag": "phr_LeasePayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash used for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofsupplementalcashflowinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r514" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/LeasesScheduleofoperatingandfinanceleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r528", "r618" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted average discount rate (as a percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r527", "r618" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessor's operating leases.", "label": "Lessor, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Accumulated federal net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Background and liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Backgroundandliquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r140", "r142" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r197" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r39" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Financing payments of acquisition-related liabilities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "auth_ref": [ "r36" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails": { "order": 1.0, "parentTag": "phr_PaymentsToAcquireBusinessesIncludingContingentConsiderationNetOfCashAcquired", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.", "label": "Payment for Contingent Consideration Liability, Investing Activities", "terseLabel": "Payments of acquisition date fair value of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r40" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Debt issuance costs and facility fees" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r40" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r217" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Treasury stock to satisfy tax withholdings on stock compensation awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r34", "r484" ], "calculation": { "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 }, "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails": { "order": 2.0, "parentTag": "phr_PaymentsToAcquireBusinessesIncludingContingentConsiderationNetOfCashAcquired", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration paid on acquisition date", "verboseLabel": "Cash consideration paid on acquisition date" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r35" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r35" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Develop Software", "negatedLabel": "Capitalized internal-use software" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r387", "r388", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r610" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement savings plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Retirementsavingsplan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r634" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r589", "r596", "r655" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofprepaidandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r37" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r37", "r109" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r37" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r673", "r725", "r727" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Less accumulated depreciation", "terseLabel": "Accumulated depreciation and amortization, property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r674", "r727" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January\u00a031, 2023 and 2022, respectively", "totalLabel": "Property and equipment \u2014 net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r633", "r672", "r724" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r79", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life (in years)", "verboseLabel": "Useful life (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r216", "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofallowancefordoubtfulaccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "totalLabel": "Total" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "PurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Two", "terseLabel": "2025", "verboseLabel": "Purchase obligation" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails", "http://www.phreesia.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "PurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CommitmentsandcontingenciesScheduleofaggregateminimumpurchasecommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r396", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r188", "r536", "r537", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "General and administrative expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r396", "r536", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r534", "r535", "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Relatedpartytransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r38" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-Term Lines of Credit", "negatedLabel": "Payments of revolving line of credit" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r38" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Principal payments on financing agreements" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r113", "r183", "r742" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r97", "r176", "r574", "r575", "r619" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r189", "r229", "r230", "r231", "r233", "r239", "r241", "r291", "r449", "r450", "r451", "r472", "r473", "r492", "r571", "r573" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue and Contract Costs" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCosts" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r29", "r181", "r317", "r318", "r319", "r323", "r324", "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Recognized revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r214", "r225", "r261", "r262", "r273", "r276", "r277", "r281", "r282", "r283", "r290", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r502", "r567", "r679" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r526", "r618" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets recorded in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r283", "r650" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of intangible assets acquired" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of shares excluded from computation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r126", "r127", "r482" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsNarrativeDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofInsigniaHealthLLCandQueueDrpurchasepriceconsiderationDetails", "http://www.phreesia.com/role/AcquisitionsScheduleofconsiderationpaidDetails", "http://www.phreesia.com/role/AcquisitionsScheduleoffinalallocationofInsigniaHealthpurchasepriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of purchase price considerations at acquisition date" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax (benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r20", "r91", "r94", "r95", "r96", "r150", "r151", "r153", "r169", "r599", "r601", "r644" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock based compensation in financial statements" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RevenueandContractCostsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value, assets and liabilities measured on recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FairvaluemeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r66", "r69", "r551" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r66", "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r597", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of long-term debt and finance lease maturities" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofpropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of allocation of purchase price of assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r407", "r409", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r436", "r437", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails", "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r103", "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of ESPP valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r87", "r88", "r89", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r199", "r200", "r201", "r255", "r355", "r356", "r357", "r359", "r363", "r368", "r370", "r603", "r632", "r639" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated amortization expense for intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r272", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SettlementAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.", "label": "Settlement Assets, Current", "terseLabel": "Settlement assets" } } }, "localname": "SettlementAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SettlementLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.", "label": "Settlement Liabilities, Current", "terseLabel": "Settlement obligations" } } }, "localname": "SettlementLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r44" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Non-cash stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "ESPP offering period (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited and expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Unit Activity:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid to settle liability for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid", "terseLabel": "Share settled bonuses" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "terseLabel": "Awards vested during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Valuation date stock price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield (as a percent)", "verboseLabel": "Expected dividends (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)", "verboseLabel": "Risk-free rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails", "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r430" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited and expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited and expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair market value of grants (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise\u00a0price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value outstanding and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Number of options outstanding at end of period (in shares)", "periodStartLabel": "Number of options outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted- average exercise price outstanding at end of period (in dollars per share)", "periodStartLabel": "Weighted- average exercise price outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental expense associated with the modification of stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r436", "r437", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/EquitybasedcompensationPerformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Share-based Payment Arrangement, Year 1" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Share-based Payment Arrangement, Year 3" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Share-based Payment Arrangement, Year 2" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r414", "r433", "r434", "r435", "r436", "r439", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Schedule of market-based performance stock unit activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of vest option (as a percent)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r440" ], "calculation": { "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Total stock based compensation", "totalLabel": "Total stock-based compensation" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationDetails", "http://www.phreesia.com/role/EquitybasedcompensationStockbasedcompensationinourfinancialstatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period / maximum term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "verboseLabel": "Simulation term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationValuationallowanceofperformancebasedrestrictedstockunitsDetails", "http://www.phreesia.com/role/EquitybasedcompensationWeightedaverageassumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life of options exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life of options outstanding and expected to vest (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Amount vested at the end of the period (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Employee purchase price of common stock (as a percent)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails", "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance, stockholders' equity (in shares)", "periodStartLabel": "Beginning balance, stockholders' equity (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Issue price per share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Summaryofsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r90", "r189", "r210", "r211", "r212", "r229", "r230", "r231", "r233", "r239", "r241", "r254", "r291", "r371", "r449", "r450", "r451", "r472", "r473", "r492", "r503", "r504", "r505", "r506", "r507", "r508", "r533", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r229", "r230", "r231", "r254", "r550" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r649" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Stock options to purchase common stock, restricted stock units and performance stock awards" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r50", "r51", "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of stock to settle liabilities for stock-based compensation" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r6", "r7", "r90", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase of ESPP settlement (in shares)", "verboseLabel": "Issuance of common stock for employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of stock for share-settled bonus awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r90", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r6", "r7", "r90", "r97", "r420" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options and vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.phreesia.com/role/EquitybasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r6", "r7", "r90", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock for employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of stock for share-settled bonus awards" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r90", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r24", "r90", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options and vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r63", "r619", "r641", "r653", "r723" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, stockholders' equity", "periodStartLabel": "Beginning balance, stockholders' equity", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets", "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r100", "r224", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r371", "r491" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r509", "r541" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r509", "r541" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r509", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r509", "r541" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/BackgroundandliquidityDetails", "http://www.phreesia.com/role/SubsequenteventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r540", "r542" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/Subsequentevent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental information of non-cash investing and financing activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Acquired technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsNarrativeDetails", "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r185", "r186", "r187", "r286", "r287", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r23", "r98" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r23", "r98", "r99" ], "calculation": { "http://www.phreesia.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 971,236 and 301,003 shares as of January\u00a031, 2023 and 2022, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnbilledContractsReceivable": { "auth_ref": [ "r549" ], "calculation": { "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.", "label": "Unbilled Contracts Receivable", "terseLabel": "Unbilled" } } }, "localname": "UnbilledContractsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/CompositionofcertainfinancialstatementcaptionsScheduleofaccountsreceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r59", "r60", "r61", "r256", "r257", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/IncometaxesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r524", "r618" ], "calculation": { "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/LeasesScheduleofleaseexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/FinanceleasesandotherdebtAmendedandrestatedloanandsecurityagreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/EquitybasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r243", "r248" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r242", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/ConsolidatedStatementsofOperations", "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.phreesia.com/role/NetlosspershareattributabletocommonstockholdersScheduleofcomputationDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118198657&loc=SL118198666-228104", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(k)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888252", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r623": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r624": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r625": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r626": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r627": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r628": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r629": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r631": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131251-203054", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118198657&loc=SL118198666-228104", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 107 0001412408-23-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001412408-23-000023-xbrl.zip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

+>18[^Y6U,6J#Z]QJ-=BN6;S$5Z+G9B.RG/[ M@X_F;XT8^Z 39%K)::B[HZKZL58+J6JV?/)H4,A_^9WYVVQ3PCO&'F:O-V6Q M4&5Y+?ZV*80")XY_4?%VV/X'V)]6'>$[*3WNC?+UJ+6 K<680 MFBM^$DOC(SVLX9/QL#ZEEZGKI=<+4@-L5/@=6*ZD6AD?^( Y>R_MAX4P_F^I MWJKZ_Q\67]=+\==OR[EY1OG.B%H_?EG.Y^^7J]_82LZX5EH@PB#1F2$)JBFD MB"20*88UCM*,Z-R')#SE3XT\NLK^X^])C/)_ JI2VH\[?(?!C5,&!'=@KFDU M!Z]:W?\ B@7HJO\_06T ^-6: !H; E)13_0"492O]%&IJRJ8D4D(( CG1,<294I E,8<<)XPF M!.E(IC[4=D;>U*BLT=./M\YAZL93 9$:F)<:34&C*C"Z@D99\*I1]P_A*,@1 MF$"4H#?KS4J!^V)1W&_NP;R:V1\:K?T(QWD$W)AG"%P'IJ!:Y2NP51I4 M6E^!K=Y78+T$7('/K)#AN,@7JD"DY"QV5';R!>,Y37G?WX^O&AJL25$\WJ[8 MHF3"+AW+ZX6L_CFO=N_+S\MY82Y0/]:OC9U_G:%,IBE)JMR43=)" :2_SHJ_^ N/'9*# /3' MPJT1H&L%8 L)NG: MVA#P:_-_:Q&H3 JX%+P8UD!DV%^/4=GQ8KB>T^7E#^S'GY]7R^^%/5$V"KQ= M;OA:;^;70BPWAIUGFB-.**&&'?/(^'B&':DFF:%(E@I$F?$!O?;+3PF;&@N^ M9A)(Q== U>ZU'PN>A-6-Z$*!-3"7M2J!+TJHXCOC<^.HO5DI6:S!QV59[A:/ M7Y0-7F#S@*M'%XP"$=-)4:-RCXO1S^G%Z9Y^#/)%S:NC5;9:/Z4M7JY7YN^S M-,&Y3G4$1:H1Q+EQN6@<*<@R2A'-$AK%RH=%S@F<&I,T^H)*X:=3_:^MSIX' M<6A-+*[(!"*7L^)&)1A7XY^3C/-]_8CFK=+*>$?RPT(L M[]4M^W%M5ICK\I-:SW2FHLP>US'$C7L2I3$D6<9@G.B,8IRDF?*BF..BID8N MK:9@S7X 9K7T8Y(3H+IQ2!BH!F:/+4JUEM6F=JWG%?AT C)OWCB/1B#&."%H M5*XX;_!SEG"XHR\_\/6'A:&:*NKU#5NM'HO%W?6]=7)F2J09EAF&BE%F]W@8 M)-0PA,PYSA3'J4R)'T,<%S8UCOBX7-P!(^B^6M#X\L,)4%T9(@Q40^\Z&Y3@ MK47)*GP%_FUE5B\AF>$\"L&XX82HD=GAO-'[_.!PCQ]#/'Q;S9[N1+]9ENMW M/\1\8Z/G_\Q6A5VW;G\S4Y@GN9()Y)E=LE D($F46;?D@E.:XR1BR(4M? 5/ MC3EV)S#UB98P.KKQAS?DI[ED2" 'YI5GIUC JG<%MJJ#5O?.KP>"6#8)(=4^ MXHM _42#OP_(G8F^+VXUZ9N[+9$G$:IS0G[O_;A1B+VOD2W)][[?C_"E*F;O M%NMB_7@MI7FSRL_F66S^?XN'-TNI9C37F2":0)QS!7&,)221B&"D!=(90SK" M3L[@:3%3(_-:4]"H>@5J98'1%EAUW4CG#+*G63P<7@-S=E^HG,G"#8D#_F"I MQ!_OEM]_,@^H74'SEYT'>.:QHU"$FVDM(3A>[>_OM;I>FD5ALSDB M&NT!ZZ0_6)?/,8+)"?;S?EY(,,?:5VIU?9(Y\B8P=.[^6T@(1_+9+H'2RT=S MQ>:$7W;V$:/Y8J[&=/TOYWMZ1F05"YM!7;EP7VPZ^8W^I535)M\LQ9K%3&BH ML8J-XZ4(I%HD,,UEDB?8@)PCGZ#1$[*\*'>$.-'/JZ7Q>XU38<-[; +-@_VH MKL#"=\?^%+YN&W*!4!N86QLMV]C/2E&XU-"H6N_=7P&FS61I>,(0U*8^'KR^ M7Z[6Q7]77!4P..H\8*'"GTY(&C? Z;S)>R%,#K?X^W%OEOG MW*EY=[:6A=S,%5AJ8%0NU@I^++Y7IU]K237T!WO,!YB#[1..(L^3QO-;^QA M8M>%['-[W^QMPYBJ7->GQ=NMPQG"BN5<$A@QBB&FJ8(\-LR?X2QC.I=2<:_H M_2-RID;MK9J@J/3T3<$^C*6;UQ@ H8%Y>0M.K6(G@2ADRO1)%(*E1A^6,G(* M]$E3]U.=3U\>*.CK:;:C7<,6BXV1TPCL!D&*-))YA DD'"N(188AR^(8YH@9 MOL!QJC6]*"K,79>I\4@W;.S"@#&/ 7$CFI%@'FMKL!-RMI='?05VUH"=.8.$ MM : =:C8-0]-7C:XS1^RL]%O/1[9,[-[N;BSX4TVON9GMMZLC/NFRB^JS5*^ MT9]7QJLH'MC\P^(_%5O=_K:<::1CG'-LUM$BASB1%#)&,Y@:[N0494F:.1V2 M7*+$U+C3O,^I9TIW'^C=R')H0 =FR>=!=XT)CU? Z@J,L@'3NR^ *E2J=Q\5 MQDW[O@"DO13P2Y[5C^3:$F)F@K23,#E#A$0I51KR2*=FQ2@22)!A-DYC M9!Q!JA36?8K_[8N:&F%MR]J)CJK]*O\=P-6-I\*@-3 ;;8'J:CE*^O5Y> +7 M!3P@Z$5* QXW^%AUP!-WA,@;J I:4I[H)$L3J#B1$'/+%3+6D%+C!I$\1<3M M(.&XB*EQA-40[%3L51[T )"N*[Y+X!E\(>>%S(6) 0.4 CT@X 63 $X5 #UQ MY>6Q"-OB,S.I,AIKNY01B$&L>01I%.8HQ^,XY7[ZH()YHVR M11A)RMA#8(!XC)V,%XO$V#/S5 S&_L4]-XZ,VW6C MZY(>[YFH'ODS^V$+W;U>KE;+WXK%W1MF7@/[\@J58X$3#GG&C.>4$P$)5PG, M5[F"K/'AS#FK_;:0>F(7:/O(1/>ZV40]0]K:+^CRC=TWX>O?] M;5&*^;+^SD\PM5F/RII[#KLYTP^4'/]["V7'Z%= M+Z0AH\*N.*RS=<<,/]&-'97M^K%Q@LMTY?H2LQ ]A4@IW

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ⅅ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�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end